
<html lang="en"     class="pb-page"  data-request-id="eafaf7f2-9e2e-43f4-973d-ed556264b383"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2017.60.issue-11;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.7b00363;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D2R Agonists" /></meta><meta name="dc.Creator" content="Barbara  Männel" /></meta><meta name="dc.Creator" content="Daniela  Dengler" /></meta><meta name="dc.Creator" content="Jeremy  Shonberg" /></meta><meta name="dc.Creator" content="Harald  Hübner" /></meta><meta name="dc.Creator" content="Dorothee  Möller" /></meta><meta name="dc.Creator" content="Peter  Gmeiner" /></meta><meta name="dc.Description" content="By means of a formal structural hybridization of the antipsychotic drug aripiprazole and the heterocyclic catecholamine surrogates present in the β2-adrenoceptor agonists procaterol and BI-167107 (..." /></meta><meta name="Description" content="By means of a formal structural hybridization of the antipsychotic drug aripiprazole and the heterocyclic catecholamine surrogates present in the β2-adrenoceptor agonists procaterol and BI-167107 (..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 18, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00363" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00363" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00363" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00363" /></link>
        
    
    

<title>Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D2R Agonists | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00363" /></meta><meta property="og:title" content="Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D2R Agonists" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0002.jpeg" /></meta><meta property="og:description" content="By means of a formal structural hybridization of the antipsychotic drug aripiprazole and the heterocyclic catecholamine surrogates present in the β2-adrenoceptor agonists procaterol and BI-167107 (4), we designed and synthesized a collection of novel hydroxy-substituted heteroarylpiperazines and heteroarylhomopiperazines with high dopamine D2 receptor (D2R) affinity. In contrast to the weak agonistic behavior of aripiprazole, these ligands are capable of effectively mimicking those interactions of dopamine and the D2R that are crucial for an active state, leading to the recruitment of β-arrestin-2. Interestingly, some ligands show considerably lower intrinsic activity in guanine nucleotide exchange experiments at D2R and consequently represent biased agonists favoring β-arrestin-2 recruitment over canonical G protein activation. The ligands’ agonistic properties are substantially driven by the presence of an endocyclic H-bond donor." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="By means of a formal structural hybridization of the antipsychotic drug aripiprazole and the heterocyclic catecholamine surrogates present in the β2-adrenoceptor agonists procaterol and BI-167107 (4), we designed and synthesized a collection of novel hydroxy-substituted heteroarylpiperazines and heteroarylhomopiperazines with high dopamine D2 receptor (D2R) affinity. In contrast to the weak agonistic behavior of aripiprazole, these ligands are capable of effectively mimicking those interactions of dopamine and the D2R that are crucial for an active state, leading to the recruitment of β-arrestin-2. Interestingly, some ligands show considerably lower intrinsic activity in guanine nucleotide exchange experiments at D2R and consequently represent biased agonists favoring β-arrestin-2 recruitment over canonical G protein activation. The ligands’ agonistic properties are substantially driven by the presence of an endocyclic H-bond donor." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0002.jpeg" /></meta><meta name="twitter:title" content="Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D2R Agonists" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00363"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00363">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00363&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00363&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00363&amp;href=/doi/10.1021/acs.jmedchem.7b00363" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 4693-4713</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00304" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00533" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D<sub>2</sub>R Agonists</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Barbara++M%C3%A4nnel">Barbara Männel</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniela++Dengler">Daniela Dengler</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeremy++Shonberg">Jeremy Shonberg</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Harald++H%C3%BCbner">Harald Hübner</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dorothee++M%C3%B6ller">Dorothee Möller</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Gmeiner">Peter Gmeiner</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-4127-197X" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Department of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander University Erlangen-Nuernberg, Schuhstraße 19, 91052 Erlangen, Germany</span></div><div class="corresp-info"><strong>*</strong>Phone: +49 9131 85-29383. Fax: +49 9131 85-22585. E-mail: <a href="/cdn-cgi/l/email-protection#90e0f5e4f5e2bef7fdf5f9fef5e2d0f6f1e5bef4f5"><span class="__cf_email__" data-cfemail="7e0e1b0a1b0c5019131b17101b0c3e181f0b501a1b">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00363&amp;href=/doi/10.1021%2Facs.jmedchem.7b00363" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 4693–4713</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 10, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>7 March 2017</li><li><span class="item_label"><b>Published</b> online</span>18 May 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 June 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00363" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00363</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4693%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBarbara%2BM%25C3%25A4nnel%252C%2BDaniela%2BDengler%252C%2BJeremy%2BShonberg%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D11%26contentID%3Dacs.jmedchem.7b00363%26title%3DHydroxy-Substituted%2BHeteroarylpiperazines%253A%2BNovel%2BScaffolds%2Bfor%2B%25CE%25B2-Arrestin-Biased%2BD2R%2BAgonists%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4713%26publicationDate%3DJune%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00363"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1419</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">15</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00363" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D2R Agonists&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Barbara&quot;,&quot;last_name&quot;:&quot;Männel&quot;},{&quot;first_name&quot;:&quot;Daniela&quot;,&quot;last_name&quot;:&quot;Dengler&quot;},{&quot;first_name&quot;:&quot;Jeremy&quot;,&quot;last_name&quot;:&quot;Shonberg&quot;},{&quot;first_name&quot;:&quot;Harald&quot;,&quot;last_name&quot;:&quot;Hübner&quot;},{&quot;first_name&quot;:&quot;Dorothee&quot;,&quot;last_name&quot;:&quot;Möller&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Gmeiner&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;18&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;4693-4713&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00363&quot;},&quot;abstract&quot;:&quot;By means of a formal structural hybridization of the antipsychotic drug aripiprazole and the heterocyclic catecholamine surrogates present in the β2-adrenoceptor agonists procaterol and BI-167107 (4), we designed and synthesized a collection of novel hydroxy-substituted heteroarylpiperazines and heteroarylhomopiperazines with high dopamine D2 receptor (D2R) affinity. In contrast to the weak agonistic behavior of aripiprazole, these ligands are capable of effectively mimicking those interactions of dopamine and the D2R that are crucial for an active state, leading to the recruitment of β-arrestin-2. Interestingly, some ligands show considerably lower intrinsic activity in guanine nucleotide exchange experiments at D2R and consequently represent biased agonists favoring β-arrestin-2 recruitment over canonical G protein activation. The ligands’ agonistic properties are substantially driven by the presence of an endocyclic H-bond donor.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00363&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00363" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00363&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00363" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00363&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00363" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00363&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00363&amp;href=/doi/10.1021/acs.jmedchem.7b00363" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00363" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00363" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00363%26sid%3Dliteratum%253Aachs%26pmid%3D28489379%26genre%3Darticle%26aulast%3DM%25C3%25A4nnel%26date%3D2017%26atitle%3DHydroxy-Substituted%2BHeteroarylpiperazines%253A%2BNovel%2BScaffolds%2Bfor%2B%25CE%25B2-Arrestin-Biased%2BD2R%2BAgonists%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D11%26spage%3D4693%26epage%3D4713%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291074" title="Purification">Purification</a>,</li><li><a href="/action/doSearch?ConceptID=291011" title="High-performance liquid chromatography">High-performance liquid chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=292234" title="Chromatography">Chromatography</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/11" title="Go to Volume 60, Issue 11"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/jmcmar.2017.60.issue-11/20170608/jmcmar.2017.60.issue-11.largecover.jpg" alt="Go to Volume 60, Issue 11"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/medium/jm-2017-003633_0002.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00363&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">By means of a formal structural hybridization of the antipsychotic drug aripiprazole and the heterocyclic catecholamine surrogates present in the β<sub>2</sub>-adrenoceptor agonists procaterol and BI-167107 (<b>4</b>), we designed and synthesized a collection of novel hydroxy-substituted heteroarylpiperazines and heteroarylhomopiperazines with high dopamine D<sub>2</sub> receptor (D<sub>2</sub>R) affinity. In contrast to the weak agonistic behavior of aripiprazole, these ligands are capable of effectively mimicking those interactions of dopamine and the D<sub>2</sub>R that are crucial for an active state, leading to the recruitment of β-arrestin-2. Interestingly, some ligands show considerably lower intrinsic activity in guanine nucleotide exchange experiments at D<sub>2</sub>R and consequently represent biased agonists favoring β-arrestin-2 recruitment over canonical G protein activation. The ligands’ agonistic properties are substantially driven by the presence of an endocyclic H-bond donor.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04346" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04346" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The five different dopamine receptor subtypes (D<sub>1</sub>R–D<sub>5</sub>R) are widely distributed throughout the body, especially within the central nervous system (CNS). These G protein-coupled receptors (GPCRs) mediate the physiological functions of dopamine, a neurotransmitter and hormone with a catecholamine structure.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Not surprisingly, malfunctions of the dopaminergic neurotransmission are involved in a number of pathophysiological conditions including schizophrenia, addiction, and Parkinson’s disease (PD). PD is characterized by severe locomotor deficits, which are mainly caused by the loss of dopaminergic neurons in the substantia nigra pars compacta. Besides the cardinal symptoms akinesia, rigidity, and tremor at rest, patients also exhibit cognitive and other nonmotor symptoms in both advanced and early stages of the disease.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Despite considerable efforts to develop novel therapeutic agents, L-DOPA (<span class="smallcaps smallerCapital">l</span>-3,4-dihydroxyphenylalanine) applied together with a peripheral decarboxylase inhibitor remains the “gold standard” in symptomatic antiparkinsonian therapy. However, the prolonged use of this dopamine precursor results in a loss of efficacy over time, resulting first in “off-phases” and concomitantly occurring L-DOPA-induced dyskinesias (LID) during the “on-phases” at later stages of the disease.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Attempts to improve fluctuations or to delay the onset of fluctuations and LIDs with D<sub>2</sub>R agonists as monotherapy or in combination with a lower L-DOPA dose did not prove successful, as the onset of LID is not dependent on the duration of therapy but rather the duration of the disease.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> The exact mechanisms underlying LIDs remain a matter of debate and probably depend on the overall context of denervation and compensatory processes in the CNS. However, animal models of PD suggest LIDs may be associated with uncontrolled neuronal excitability and dopamine receptor supersensitivity.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6, 7)</a></div><div class="NLM_p">Activation of D<sub>2</sub>Rs, as for a plethora of other GPCRs, leads to conformational changes transmitted from the ligand-binding pocket toward intracellular receptor domains. Distinct receptor conformations are thought to guide the intracellular signaling events by interaction of the receptor with different signal transducers, namely G proteins and β-arrestins.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Using evolutionary trace for the generation of D<sub>2</sub>R mutants specifically interacting with the G protein or β-arrestin signaling pathway, it was demonstrated that G protein- and β-arrestin-mediated signaling at the D<sub>2</sub>R is dissociable and has distinct physiological outcomes. Although the generated mutant receptors differed in only two residues compared to wild-type, only the β-arrestin-specific D<sub>2</sub>R mutant was able to promote significant amphetamine-induced forward locomotion in mice.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Preferential activation of one signaling pathway over the other does not only occur in response to genetically modified receptors but also in a ligand-dependent fashion. This ligand-directed signaling is known as “functional selectivity”, “ligand bias”, or “biased agonism” and has gained considerable interest over the past decades.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a></div><div class="NLM_p">Very recently, it was demonstrated in various animal models of PD, that dopamine receptor-mediated activation of β-arrestin-2 is required for the therapeutic effects of L-DOPA. In contrast, genetic deletion of the signal transducer molecule markedly enhanced dyskinesia-like effects of both acute and chronic L-DOPA treatment and significantly reduced forward locomotion.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Similar results were obtained when GRK6, a kinase upstream in the β-arrestin-2 signaling cascade, was deleted.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Noteworthy, overexpression of β-arrestin-2 in PD animal models enhanced the therapeutic effects of L-DOPA while alleviating dyskinesia.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Specifically targeting the D<sub>2</sub>R-mediated activation of β-arrestin-2 might therefore be a valuable approach for the design of novel antiparkinsonian drugs. Here we report on structural modifications of aripiprazole, a weak D<sub>2</sub>R partial agonist, leading to novel β-arrestin-biased D<sub>2</sub>R agonists. Previously, a number of β-arrestin-2 biased partial agonists for D<sub>2</sub>Rs including prototypic ligands <b>1</b> (UNC0006),<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a><b>2</b> (UNC9975).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and <b>3</b> (UNC9994)<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> have been described as putative novel antipsychotics (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>). However, these ligands displayed relatively weak intrinsic activities and none of them exhibited dopamine-like properties for the recruitment of β-arrestin-2. Unlike these partial agonists, our results show hydroxy-substituted heteroarylpiperazines capable to fully activate the D<sub>2</sub>R-promoted recruitment of β-arrestin-2 while displaying considerably lower tendency to stimulate G protein mediated signaling.</div><figure id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/medium/jm-2017-003633_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Previously Described β-Arrestin-Biased Agonists <b>1</b>–<b>3</b> with Partial Agonist Characteristics at D<sub>2</sub>R</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00363&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25433" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25433" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Ligand Design</h3><div class="NLM_p">When aiming to develop functionally selective agonists, a ligand-based strategy suggests starting from a balanced agonist and trying to replace or remove molecule parts associated with receptor activation. If such a modification disrupts one or the other signaling pathway more effectively, ligand bias will be observed. A complementary design embarks on an antagonist scaffold and depends on the inclusion of agonist-type structural moieties. Thus, biased agonists may be accessed by designing hybrid structures containing agonist and antagonist moieties. Starting from the typical 1,4-disubstituted aromatic piperazine (1,4-DAP) aripiprazole, a typical weak D<sub>2</sub>R partial agonist, we envisioned incorporation of typical catechol-like agonist substructures in order to generate putatively biased D<sub>2</sub>R agonists. The head groups of typical 1,4-DAPs are not appropriately substituted to form hydrogen bonds with the side chains of Ser<sup>5.42</sup>, Ser<sup>5.43</sup>, and Ser<sup>5.46</sup> within transmembrane helix 5, which are crucial for the activation of aminergic GPCRs by catecholamines and heterocyclic bioisosteres thereof.<a onclick="showRef(event, 'ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17 ref18">(15-18)</a> Inspired by such H-bond forming head groups,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> we conceived a formal structural hybridization of the 1,4-DAP substructure of aripiprazole and the heterocyclic neurotransmitter surrogates present in the high affinity β<sub>2</sub>-AR agonists indacaterol,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> procaterol,<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21, 22)</a> olodaterol,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and BI-167107 (<b>4</b>),<a onclick="showRef(event, 'ref17 ref24'); return false;" href="javascript:void(0);" class="ref ref17 ref24">(17, 24)</a> leading to a novel chemotype of dopaminergics (<a class="ref internalNav" href="#cht2" aria-label="Chart 2">Chart 2</a>). Both, the 8-hydroxyquinolin-2(1<i>H</i>)-one and the 5-hydroxy-2<i>H</i>-benzo[<i>b</i>][1,4]oxazin-3(4<i>H</i>)-one substructures have been shown to mimic the phenolic hydroxyls of the endogenous β<sub>2</sub>-AR agonists norepinephrine.<a onclick="showRef(event, 'ref17 ref25'); return false;" href="javascript:void(0);" class="ref ref17 ref25">(17, 25)</a> Besides these two heterocycles, we included the respective oxygen-analogue 8-hydroxycoumarine, an 8-hydroxy-substituted quinoline and a formally reduced 1,4-benzodioxane. Although benzodioxane substructures have been employed previously within heterocyclic 1,4-DAPs,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> these ligands were lacking the additional hydroxyl functionality. In addition to the variation of the aromatic head group, we intended to replace the typical 1,4-piperazine by a homologous 1,4-diazepane (1,4-homopiperazine) because this modification has been previously reported to foster D<sub>2</sub>R activation in a putatively β-arrestin-biased manner.<a onclick="showRef(event, 'ref14 ref27'); return false;" href="javascript:void(0);" class="ref ref14 ref27">(14, 27)</a> As lipophilic appendages, we either employed the 3,4-dihydroquinolin-2(1<i>H</i>)-one substructure of aripiprazole or used a pyrazolo[1,5-<i>a</i>]pyridine, a moiety that has been previously shown to convey high dopamine receptor affinity.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28, 29)</a> In both cases, we connected the lipophilic moiety to the piperazine in analogy to the lead structure aripiprazole by using a flexible butoxy-spacer.</div><figure id="cht2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/medium/jm-2017-003633_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 2. Formal Structural Hybridization of the D<sub>2</sub>R Partial Agonist Aripiprazole and the Known β<sub>2</sub>-AR Agonists Procaterol and <b>4</b>, Leading to Novel Dopaminergics</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00363&amp;id=cht2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Synthesis</h3><div class="NLM_p">Synthesis of heteroarylpiperazines comprising a 3,4-dihydroquinolin-2(1<i>H</i>)-one or pyrazolo[1,5-<i>a</i>]pyridine moiety and a butoxy spacer was established based on a convergent synthesis strategy. In general, heteroarylpiperazines and their homopiperazine analogues were synthesized starting from the unsaturated heterocycles, which were benzyl-protected and brominated to allow introduction of <i>N</i>-boc-protected 1,4-piperazine or 1,4-diazepane building blocks by Buchwald–Hartwig amination reactions (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). These head groups were then reacted with the 4-bromobutoxy-substituted 3,4-dihydroquinolin-2(1<i>H</i>)-one or pyrazolo[1,5-<i>a</i>]pyridine moieties to give the target compounds (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). In detail, the synthesis of the 8-(benzyloxy)-5-bromoquinolin-2(1<i>H</i>)-one building block <b>5c</b><a onclick="showRef(event, 'ref25 ref30'); return false;" href="javascript:void(0);" class="ref ref25 ref30">(25, 30)</a> was performed starting from commercially available 8-hydroxyquinolin-2-(1<i>H</i>)-one which was reacted with benzyl bromide using DBU as a base followed by bromination of the aromatic core in the <i>para</i>-position of the benzyl-protected hydroxy group, yielding the intermediates <b>5b</b> and <b>5c</b>, respectively. Unfortunately, reaction of <b>5c</b> and boc-protected piperazine was not successful. Therefore, a second <i>O</i>-benzylation was performed, yielding the 2,8-bis(benzyloxy)-5-bromoquinoline <b>5d</b>. The synthesis of 8-hydroxycoumarine-based ligands was established in analogy to described procedures,<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31, 32)</a> starting from 2,3-dihydroxybenzaldehyde, which was subjected to a Wittig reaction and intramolecular cyclization with carbethoxycarbonylmethylene triphenylphosphorane in diethylaniline. The phenol <b>6a</b> was subsequently converted into the benzyl ether <b>6b</b>, and reaction with bromine in THF yielded the central building block 8-(benzyloxy)-5-bromo-2<i>H</i>-chromen-2-one (<b>6c</b>). The 5-hydroxy-2<i>H</i>-1,4-benzoxazin-3(4<i>H</i>)-one <b>7a</b> was prepared by following a previously described three step procedure. First, 2-nitroresorcinol was converted to 2-aminoresorcinol by catalytic hydrogenation. The primary aromatic amine was reacted with chloroacetyl chloride before the final cyclization under basic conditions afforded <b>7a</b>.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Subsequently, the phenol group was reacted with benzyl bromide using DBU as a base and the aromatic core was brominated in the <i>para</i>-position of the benzyl-protected hydroxyl, giving access to the intermediates <b>7b</b> and <b>7c</b>.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The lactam nitrogen required protection by addition of a second benzyl group, which was introduced by reaction with benzyl bromide, using elevated temperatures and potassium carbonate as a base to afford the intermediate <b>7d</b>. Synthesis of the 8-hydroxybenzo-1,4-dioxane head group started from pyrogallol, which was converted to 8-hydroxybenzo-1,4-dioxane (<b>8a</b>) by reaction with 1,2-dibromoethane following a previously described protocol.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Subsequently, the phenolic hydroxyl group was benzyl-protected (<b>8b</b>) and a bromine residue was introduced into the <i>para</i>-position of the benzyl-protected hydroxyl, yielding intermediate <b>8c</b>. Benzyl protection<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> followed by bromination of commercially available 8-hydroxyquinoline afforded <b>9c</b>,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> which served as precursor for 8-hydroxyquinoline-derived ligands. The five different bromo-substituted heterocycles were subsequently reacted with boc-protected 1,4-piperazine in Buchwald–Hartwig cross-coupling reactions, using conditions described for the reaction of <b>9c</b> with piperidine.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> All reactions were carried out in toluene using either Cs<sub>2</sub>CO<sub>3</sub> or NaO<sup><i>t</i></sup>Bu as a base. As palladium species, Pd(OAc)<sub>2</sub> or Pd<sub>2</sub>(dba)<sub>3</sub> together with racemic BINAP were used. Using the reaction sequence elaborated for the preparation of the arylpiperazines <b>5e</b>, <b>6d</b>, <b>7e</b>, <b>8d</b>, and <b>9d</b>, reaction of the bromo-substituted precursors <b>5d</b>, <b>6c</b>, and <b>7d</b> with boc-protected 1,4-diazepane yielded the homopiperazine analogues <b>5f</b>, <b>6e</b>, and <b>7f</b>. Finally, cleavage of the <i>tert</i>-butyloxycarbonyl groups with TFA in dichloromethane resulted in formation of five 1,4-heteroarylpiperazines (<b>5g</b>, <b>6f</b>, <b>7g</b>, <b>8e</b>, <b>9e</b>) and three 1,4-heteroarylhomopiperazines (<b>5h</b>, <b>6g</b>, <b>7h</b>). For the synthesis of the final compounds, the secondary amines of the heteroarylpiperazines (<b>5g</b>, <b>6f</b>, <b>7g</b>, <b>8e</b>, <b>9e</b>) and -homopiperazines (<b>5h</b>, <b>6g</b>, <b>7h</b>) were subjected to nucleophilic displacement reactions with 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> or 5-(4-bromobutoxy)pyrazolo[1,5-<i>a</i>]pyridine<a onclick="showRef(event, 'ref28 ref37'); return false;" href="javascript:void(0);" class="ref ref28 ref37">(28, 37)</a> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). In both cases, the alkyl bromides were activated by refluxing with sodium iodide.<a onclick="showRef(event, 'ref28 ref36'); return false;" href="javascript:void(0);" class="ref ref28 ref36">(28, 36)</a> Finally, the remaining benzyl protecting groups were cleaved by hydrogenation or under acidic conditions, affording the heteroarylpiperazines <b>12a</b>–<b>e</b>, <b>16a</b>–<b>e</b>, and heteroarylhomopiperazines <b>13a</b>–<b>c</b> and <b>17a</b>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/medium/jm-2017-003633_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0006.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Heterocyclic Aromatic Piperazine and Homopiperazine Head Groups<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00363&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) DBU, benzyl bromide, isopropyl alcohol, rt, 1.5 h (70–88%); (b) Br<sub>2</sub>, AcOH, rt, 4 h (53–84%); (c) K<sub>2</sub>CO<sub>3</sub>, benzyl bromide, DMF, 50 °C, 24 h or rt, 2 h (57–91%); (d) Pd<sub>2</sub>(dba)<sub>3</sub> or Pd(OAc)<sub>2</sub>, <i>rac</i>-BINAP, NaO<sup><i>t</i></sup>Bu, 1-boc-piperazine or 1-boc-homopiperazine, toluene, 85 °C, 115 °C or reflux, 24–48 h (63–73%); (e) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h (51–97%); (f) Br<sub>2</sub>, THF, 0 °C, 2 h, then rt, 16 h (47%); (g) Pd<sub>2</sub>(dba)<sub>3</sub> or Pd(OAc)<sub>2</sub>, <i>rac</i>-BINAP, Cs<sub>2</sub>CO<sub>3</sub>, 1-boc-piperazine or 1-boc-homopiperazine, toluene, 85 °C or reflux, 24–72 h (38–66%); (h) Br<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 5 h (55–75%).</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/medium/jm-2017-003633_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0007.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Full-Length Dopaminergics<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00363&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one, NaI, acetonitrile, reflux 30 min, then addition of triethylamine in acetonitrile, 80 °C, 16 h (45–74%); (b) 5-(4-bromobutoxy)-pyrazolo[1,5-<i>a</i>]pyridine, NaI, acetonitrile, reflux 30 min, then addition of triethylamine in acetonitrile, 80 °C, 16 h (65–77%); (c) 10% Pd/C in acetic acid/methanol, rt, 4 h (63–79%) or TFA in toluene, reflux, 8 h (57–79%) or MsOH in toluene, reflux, 3 h (48–59%).</p></p></figure><div class="NLM_p">In addition to the collection of ligands bearing a secondary moiety attached via a butoxy spacer, we intended to complement our investigations with a different lipophilic appendage (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Very recently, we have developed a vanillin-derived scaffold linked to an amidopropyl or amidobutyl spacer as a useful moiety for specific molecular tools,<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38, 39)</a> and functionally selective D<sub>2</sub>R ligands.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Thus, we ligated the homopiperazine-8-hydroxyquinolin-2(1<i>H</i>)-one <b>5h</b> as a representative head group with the carbaldehyde function of the vanillin-type appendages by reductive amination.<a onclick="showRef(event, 'ref30 ref38'); return false;" href="javascript:void(0);" class="ref ref30 ref38">(30, 38)</a> The intermediates <b>18a</b>,<b>b</b> were converted to the final compounds <b>19a</b>,<b>b</b> by cleavage of the benzyl protection groups with methanesulfonic acid in toluene.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/medium/jm-2017-003633_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0008.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Heteroarylpiperazines with Alternate Appendages<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00363&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 4-(3-(1-butyl-1<i>H</i>-1,2,3-triazol-4-yl)propoxy)-<i>N</i>-(3-oxopropyl)-3-methoxybenzamide or 4-(3-(1-butyl-1<i>H</i>-1,2,3-triazol-4-yl)propoxy)-<i>N</i>-(4-oxobutyl)-3-methoxybenzamide, NaBH(OAc)<sub>3</sub>, dichloroethane, rt, 6 h (80–89%); (b) MsOH in toluene, reflux, 3 h (43–74%).</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Binding Affinities</h3><div class="NLM_p">To determine the impact of the structural modifications on dopamine receptor recognition, we performed radioligand displacement studies with the dopamine receptor subtypes D<sub>1</sub>R, D<sub>2L</sub>R, D<sub>2S</sub>R, D<sub>3</sub>R, D<sub>4</sub>R, and D<sub>5</sub>R. The resulting affinity and selectivity profiles were compared to those of the chemically similar reference ligands aripiprazole and <b>1</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Binding affinities were obtained by measuring the ability of the target compounds to compete with the radioligands [<sup>3</sup>H]SCH23990 or [<sup>3</sup>H]spiperone and membranes from cells expressing the respective receptor subtypes. In general, the series of target compounds showed only weak affinity for the D<sub>1</sub>R and D<sub>5</sub>R subtypes, while they bound to the D<sub>2</sub>R-like family with low nanomolar to even subnanomolar <i>K</i><sub>i</sub> values. Indeed, heteroarylpiperazines comprising a 3,4-dihydroquinolin-2(1<i>H</i>)-one appendage (<b>12a</b>–<b>e</b>) were highly similar to the reference agents and displayed binding affinities ranging from 0.87 to 4.8, 0.67–2.2, and 1.0–12 nM at D<sub>2L</sub>R, D<sub>2S</sub>R and D<sub>3</sub>R, respectively. Interestingly, the incorporation of a methylene unit into the six-membered cyclic diamine (piperazine vs homopiperazine) did not significantly alter the binding affinities for ligands with 8-hydroxyquinolinone (<b>13a</b>) and 5-hydroxybenzoxazinone (<b>13c</b>) head groups (<i>K</i><sub>i</sub> 0.81–2.0 nM for D<sub>2S/L</sub>R and D<sub>3</sub>R) but induced a 15- to 40-fold loss of affinity for the homopiperazine <b>13b</b> (<i>K</i><sub>i</sub> 37–240 nM) comprising an 8-hydroxycoumarine head group. When the 3,4-dihydroquinolin-2(1<i>H</i>)-one appendage was replaced by a pyrazolo[1,5-<i>a</i>]pyridine moiety (<b>16a</b>–<b>e</b>), binding affinities for D<sub>2L</sub>R and D<sub>2S</sub>R were decreased. Interestingly, the extent of this effect was found to depend on the employed heteroaryl pharmacophore. While the quinolinone <b>16a</b> and the benzoxazine <b>16c</b> still showed high affinity toward D<sub>2L</sub>R and D<sub>2S</sub>R (<i>K</i><sub>i</sub> 0.86–8.3 nM), derivatives lacking an the endocyclic hydrogen bond donor at the heterocyclic head group showed substantially lower binding affinities for D<sub>2L</sub>R/D<sub>2S</sub>R (<i>K</i><sub>i</sub> 19–110 nM). The homopiperazine <b>17a</b> showed lower D<sub>2</sub>R binding affinity (<i>K</i><sub>i</sub> 78 and 46 nM for D<sub>2L</sub>R and D<sub>2S</sub>R, respectively). Notably, affinities for the closely related D<sub>3</sub>R subtype did not follow the same trend, as the pyrazolo[1,5-<i>a</i>]pyridine derivatives <b>16a</b>–<b>c</b> and <b>17a</b> displayed low nanomolar or even subnanomolar binding affinities (<i>K</i><sub>i</sub> 0.71–8.5 nM) that were highly similar to those of the reference agents aripiprazole and <b>1</b> (<i>K</i><sub>i</sub> 1.9 and 2.9 nM). At the D<sub>4</sub>R subtype, only the heteroarylpiperazines <b>12c</b> and <b>16c</b> sharing the benzoxazinone head group displayed low nanomolar affinity (8.3 and 4.8 nM).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Binding Affinities of the Heteroarylpiperazines Towards Dopaminergic, Serotonergic, and α-Adrenergic Receptors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/medium/jm-2017-003633_0001.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Data represent mean ± SD of 2–15 independent experiments, each performed in triplicate.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Radioligand: [<sup>3</sup>H]SCH23390.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Radioligand: [<sup>3</sup>H]spiperone.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">Radioligand: [<sup>3</sup>H]WAY100635.</p></div><div class="footnote" id="t1fn5"><sup>Table e</sup><p class="last">Radioligand: [<sup>3</sup>H]ketanserin.</p></div><div class="footnote" id="t1fn6"><sup>Table f</sup><p class="last">Radioligand: [<sup>3</sup>H]prazosin.</p></div></div><div></div></div><div class="NLM_p last">Additional radioligand binding studies were performed to determine the compounds’ affinities toward related serotonergic (5-HT<sub>1A</sub>R, 5-HT<sub>2A</sub>R) and adrenergic (α<sub>1</sub>-AR) receptors using the radioligands [<sup>3</sup>H]WAY100635, [<sup>3</sup>H]ketanserin, or [<sup>3</sup>H]prazosin. In comparison to the reference agents aripiprazole and <b>1</b>, our newly developed compounds showed substantially altered binding properties. At the 5-HT<sub>1A</sub>R, the test compounds’ affinities ranged from 12 to 1200 nM, with the highest binding affinities observed for <b>12d</b>, <b>12e</b>, and <b>16d</b>, containing an 8-hydroxybenzo-1,4-dioxane or an 8-hydroxyquinoline head group. 5-HT<sub>2A</sub>R affinities were substantially lower than for aripiprazole or <b>1</b>, with the highest affinities observed for the 8-hydroxyquinolines <b>12e</b> and <b>16e</b> and the 8-hydroxybenzo-1,4-dioxane <b>12d</b>. Thus, the vast majority of novel target compounds displayed high selectivity for D<sub>2</sub>R over 5-HT<sub>2A</sub>R while maintaining moderate affinity for the 5-HT<sub>1A</sub>R, a receptor that has been identified as additional target in the treatment of PD.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Compared to the typical 1,4-DAP structures, inclusion of a propylamido- or butyramido-vanillin-type appendage (<b>19a</b>,<b>b</b>) led to decreased binding affinities at D<sub>2L</sub>R, D<sub>2S</sub>R, and D<sub>4</sub>R. Notably, <b>19a</b>,<b>b</b> displayed one-digit nanomolar <i>K</i><sub>i</sub> values at D<sub>3</sub>R (1.6 and 3.2 nM), leading to an approximately 100-fold selectivity for D<sub>3</sub>R over D<sub>2</sub>R.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Functional Activity at D<sub>2</sub>R</h3><div class="NLM_p">The influence of the individual structural modifications on the ligands’ ability to activate D<sub>2</sub>R was evaluated in a β-arrestin-2 recruitment assay. The arrestin receptor interaction was initially discovered to attenuate or terminate G protein-mediated signaling.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> There is now broad consensus that β-arrestins also represent signal transducers on their own.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> D<sub>2</sub>R activation mediated through β-arrestin-2 leads to the G protein-independent activation of GSK3β, an enzyme which has been implicated in hyperdopaminergic pathophysiological conditions of neuropsychiatric disorders such as schizophrenia.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> In contrast, studies with animal models of PD suggest that enhanced stimulation of β-arrestin-2 signaling may have beneficial effects on the control of locomotion while reducing dyskinesia frequently occurring in PD treatment.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> We measured the recruitment of β-arrestin-2 to ligand-activated D<sub>2S</sub>R by employing the DiscoverX PathHunter technology in HEK293 cells as described previously<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and compared the results of our target compounds to those of known D<sub>2</sub>R agonists and the 1,4-DAPs aripiprazole and <b>1</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). When the reference agonist quinpirole, the endogenous agonist dopamine and the antiparkinsonian drugs rotigotine, pramipexole, and ropinirole were examined for their ability to induce β-arrestin-2 recruitment, sigmoid dose response curves were observed in all cases (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00363/suppl_file/jm7b00363_si_001.pdf" class="ext-link">Figure S1</a>). The ligands displayed similar efficacies ranging from full agonist behavior to very strong partial agonism observed for ropinirole (<i>E</i><sub>max</sub> 83%). The highest potency was observed for rotigotine (EC<sub>50</sub> 4.1 nM), while about 100-fold higher concentrations were necessary to activate D<sub>2S</sub>R with the endogenous agonist dopamine (EC<sub>50</sub> 390 nM). In comparison to these relatively similar effects of the reference ligands, the novel heteroarylpiperazines and their homopiperazine analogues sampled a wide range of efficacies (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00363/suppl_file/jm7b00363_si_001.pdf" class="ext-link">Figure S2</a>). Indeed, the maximum efficacy was found to depend on two main factors: the nature of the orthosteric heteroaryl moiety and the ring size of the central diamine. More specifically, piperazines <b>12b</b>,<b>d</b>,<b>e</b> and <b>16b</b>,<b>d</b>,<b>e</b> comprising an 8-hydroxybenzo-1,4-dioxane, an 8-hydroxyquinoline, or an 8-hydroxycoumarine head group were devoid of agonistic properties in the β-arrestin-2 recruitment assay, similar to the results obtained for the antipsychotic drug aripiprazole. In contrast, ligands <b>12a</b>,<b>c</b> and <b>16a</b>,<b>c</b> sharing an 5-hydroxybenzoxazin-3-one or 8-hydroxyquinolin-2(1<i>H</i>)-one substructure showed partial agonist activities with <i>E</i><sub>max</sub> values between 21% and 44% and potencies comparable to quinpirole and dopamine (EC<sub>50</sub> 62–240 nM). Notably, enlargement of the cyclic diamine moiety from a six-membered (piperazine) to a seven-membered ring (homopiperazine) increased the intrinsic efficacy of the compounds. Thus, the β-arrestin-2 recruitment assay revealed an <i>E</i><sub>max</sub> value of 75% for the homopiperazine <b>13c</b> comprising a 5-hydroxybenzoxazin-3-one head group. Moreover, the 8-hydroxyquinolin-2(1<i>H</i>)-one-homopiperazines <b>13a</b> and <b>17a</b> behaved as full agonists (<i>E</i><sub>max</sub> 90–102%, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>a,c). These findings are in accordance with earlier reports on an increase in intrinsic efficacy for the diazepane/piperazine replacement in classical 1,4-DAP scaffolds.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> However, the presence of the homopiperazine subunit does not lead to pronounced recruitment of β-arrestin-2 on its own because the reference ligand <b>1</b> only induced marginal recruitment of β-arrestin-2 under these assay conditions (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00363/suppl_file/jm7b00363_si_001.pdf" class="ext-link">Figure S1</a>). The main difference between <b>1</b>, its closely related analogues <b>2</b> and <b>3</b> (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>),<a onclick="showRef(event, 'ref14 ref27'); return false;" href="javascript:void(0);" class="ref ref14 ref27">(14, 27)</a> and our newly synthesized ligands can be found in the heterocyclic moiety were these ligands lack functional groups capable of interacting with the polar serine residues in the orthosteric binding pocket of the receptor. Similar to the rank-order in efficacies observed among the piperazines <b>12a</b>–<b>e</b>, the 8-hydroxycoumarine-homopiperazine <b>13b</b> was less effective (<i>E</i><sub>max</sub> 21%, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>b) than <b>13a</b> or <b>13c</b>. These findings underline the importance of the presence of an additional hydrogen bond donor rather than an H-bond acceptor within the aromatic heterocycle because <b>13b</b> results from <b>13a</b> in a formal NH to O exchange. These results are in excellent agreement with the binding pose of the high-affinity agonist <b>4</b> within the active-state structure of the β<sub>2</sub>-AR.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Moreover, studies on the β<sub>1</sub>-AR in complex with different agonists<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and the β<sub>2</sub>-AR crystal structure in complex with a covalent agonist<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> highlighted the importance of the hydrogen bond network stabilized by catecholamine surrogates for receptor activation. All homopiperazines investigated (<b>13a</b>–<b>c</b>, <b>17a</b>) displayed potencies similar to the endogenous agonist dopamine (EC<sub>50</sub> 190–470 nM). In agreement with previous results pointing toward a profitable effect of the vanillin-type appendage for the recruitment of β-arrestin-2,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> incorporation of this lipophilic moiety in combination with the 8-hydroxyquinolin-2(1<i>H</i>)-one-substituted homopiperazine head group led to pronounced partial agonist properties for the recruitment of β-arrestin-2 at D<sub>2S</sub>R. However, in accordance with the reduced D<sub>2</sub>R affinities, ligands <b>19a</b>,<b>b</b> displayed relatively weak potencies (EC<sub>50</sub> 680 and 1600 nM).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Ligand-Induced Recruitment of β-Arrestin-2 at D<sub>2S</sub>R</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">β-arrrestin-2 recruitment at D<sub>2S</sub>R<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> ± SEM [nM]</th><th class="colsep0 rowsep0" align="center"><i>E</i><sub>max</sub> ± SEM [%]<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">quinpirole</td><td class="colsep0 rowsep0" align="center">52 ± 6</td><td class="colsep0 rowsep0" align="center">100 ± 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dopamine</td><td class="colsep0 rowsep0" align="center">390 ± 20</td><td class="colsep0 rowsep0" align="center">96 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rotigotine</td><td class="colsep0 rowsep0" align="center">4.1 ± 1.0</td><td class="colsep0 rowsep0" align="center">101 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ropinirole</td><td class="colsep0 rowsep0" align="center">89 ± 5</td><td class="colsep0 rowsep0" align="center">83 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pramipexole</td><td class="colsep0 rowsep0" align="center">27 ± 4</td><td class="colsep0 rowsep0" align="center">90 ± 6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aripiprazole</td><td class="colsep0 rowsep0" align="center">1100 ± 600</td><td class="colsep0 rowsep0" align="center">13 ± 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="center">nd<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">≤10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12a</b></td><td class="colsep0 rowsep0" align="center">93 ± 44</td><td class="colsep0 rowsep0" align="center">31 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12b</b></td><td class="colsep0 rowsep0" align="center">nd<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">≤10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12c</b></td><td class="colsep0 rowsep0" align="center">92 ± 36</td><td class="colsep0 rowsep0" align="center">44 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12d</b></td><td class="colsep0 rowsep0" align="center">nd<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">≤10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12e</b></td><td class="colsep0 rowsep0" align="center">nd<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">≤10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13a</b></td><td class="colsep0 rowsep0" align="center">190 ± 40</td><td class="colsep0 rowsep0" align="center">102 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13b</b></td><td class="colsep0 rowsep0" align="center">220 ± 30</td><td class="colsep0 rowsep0" align="center">21 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13c</b></td><td class="colsep0 rowsep0" align="center">470 ± 80</td><td class="colsep0 rowsep0" align="center">75 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16a</b></td><td class="colsep0 rowsep0" align="center">240 ± 60</td><td class="colsep0 rowsep0" align="center">21 ± 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16b</b></td><td class="colsep0 rowsep0" align="center">nd<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">≤10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16c</b></td><td class="colsep0 rowsep0" align="center">62 ± 9</td><td class="colsep0 rowsep0" align="center">43 ± 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16d</b></td><td class="colsep0 rowsep0" align="center">nd<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">≤10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16e</b></td><td class="colsep0 rowsep0" align="center">nd<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">≤10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17a</b></td><td class="colsep0 rowsep0" align="center">370 ± 100</td><td class="colsep0 rowsep0" align="center">90 ± 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19a</b></td><td class="colsep0 rowsep0" align="center">680 ± 70</td><td class="colsep0 rowsep0" align="center">90 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19b</b></td><td class="colsep0 rowsep0" align="center">1600 ± 600</td><td class="colsep0 rowsep0" align="center">76 ± 5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Data represent mean ± SEM of 4–10 independent experiments, each performed in duplicate.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last"><i>E</i><sub>max</sub> relative to the effect of the reference agonist quinpirole.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">nd, not determined</p></div></div></div><figure id="fig1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/medium/jm-2017-003633_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Dose–response curves at D<sub>2S</sub>R and metabolic stability of target compounds <b>13a</b>,<b>b</b> and <b>17a</b>. (a–c) Dose–response curves for D<sub><b>2S</b></sub>R-mediated activation of Gα<sub>o1</sub> (gray) and the recruitment of β-arrestin-2 in absence (blue) or presence (orange) of GRK2. (d) Bias factors for D<sub>2S</sub>R activation were calculated using the operational model of agonism. Positive values for ΔΔlog(τ/<i>K</i><sub>A</sub>) indicate a preference for β-arrestin-2 recruitment. (e) Metabolic stability of <b>13a</b> and <b>17a</b> assessed in rat liver microsomes: distribution between metabolized substrate, substrate nonspecifically bound to matrix, and the remaining fraction after 60 min of incubation. (f) Inhibition of hERG tail currents by <b>13a</b> was measured to estimate susceptibility of cardiotoxicity. Data represent mean ± SEM of at least three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00363&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In an attempt to identify β-arrestin-biased D<sub>2</sub>R agonists, a subset of the target compounds was investigated for their intrinsic activity toward the activation of canonical signaling at D<sub>2S</sub>R. Thus, we studied ligand-promoted nucleotide exchange in membrane preparations from HEK293T cells coexpressing D<sub>2S</sub>R and a pertussis toxin insensitive variant of the Gα<sub>o1</sub> subunit<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> as a proximal measure of G protein activation.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Although D<sub>2</sub>R is known to promiscuously couple to all members of the Gα<sub>i/o</sub> family,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Gα<sub>o</sub> proteins have been identified as predominant mediators of D<sub>2</sub>R signaling in the central nervous system (CNS).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Incubation of the membranes with the endogenous agonist dopamine and the antiparkinsonian drugs rotigotine, ropinirole, and pramipexole led to a similar degree of nucleotide exchange compared to the reference agonist quinpirole (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). While quinpirole, dopamine, pramipexole, and ropinirole showed relatively similar potencies (EC<sub>50</sub> 100–330 nM), rotigotine was effective at 30–100-fold lower concentration (EC<sub>50</sub> 3.2 nM). These results are in good agreement with the recruitment of β-arrestin-2, when rotigotine was also found to be the most potent agonist (EC<sub>50</sub> 4.1 nM). Relative to these high intrinsic efficacies, aripiprazole and <b>1</b> were relatively weak partial agonists (<i>E</i><sub>max</sub> 14–17%). In particular, very high concentrations of <b>1</b> were necessary to elicit guanine nucleotide exchange at D<sub>2S</sub>R. These findings are in good agreement with literature reports indicating a low tendency of <b>1</b> to inhibit cAMP formation.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Compared to 2,3-dichlorophenyl-substituted piperazines or homopiperazines, hydroxylated heteroarylhomopiperazines <b>13a</b>–<b>c</b> and <b>17a</b> showed substantially higher intrinsic efficacies for the induction of canonical D<sub>2S</sub>R signaling (<i>E</i><sub>max</sub> 26–55%). Potencies of <b>13a</b>, <b>13c</b>, and <b>17a</b> were found to be slightly higher than those of dopamine or quinpirole (EC<sub>50</sub> 67–90 nM), while <b>13b</b> only elicited significant G protein activation at concentrations above 1 μM (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>b). The target compounds <b>13a</b>,<b>c</b> and <b>17a</b> were about 50% less efficacious in promoting nucleotide exchange compared to the recruitment of β-arrestin-2 (<i>E</i><sub>max</sub> 26–55% and 75–102%, respectively). Although relative efficacies suggest a preferential engagement β-arrestins over G proteins, a quantitative bias analysis employing the operational model of agonism did not reveal significantly biased agonists among these target compounds, most likely due to the increased potencies for G protein activation. In contrast, the lactone <b>13b</b>, renouncing an endocyclic hydrogen bond donor at the heterocyclic head group, was identified as a β-arrestin-biased ligand when the endogenous agonist dopamine was used as a reference (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00363/suppl_file/jm7b00363_si_001.pdf" class="ext-link">Figure S3a</a>). Bias was also detected for the very weak partial agonist <b>1</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Ligand-Induced Nucleotide Exchange Determined with Membranes from HEK293T Cells Coexpressing D<sub>2S</sub>R and Gα<sub>o1</sub> and β-Arrestin-2 Recruitment Promoted by D<sub>2S</sub>R in the Presence of GRK2</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">[<sup>35</sup>S]GTPγS (D<sub>2S</sub>R + Gα<sub>o1</sub>)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">β-arrrestin-2 recruitment (D<sub>2S</sub>R + GRK2)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" align="center" char="±">bias factor<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a> (D<sub>2S</sub>R)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> ± SEM [nM]</th><th class="colsep0 rowsep0" align="center" char="±"><i>E</i><sub>max</sub> ± SEM [%]<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±">EC<sub>50</sub> ± SEM [nM]</th><th class="colsep0 rowsep0" align="center" char="±"><i>E</i><sub>max</sub> ± SEM [%]<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±">ΔΔlog(<i>t</i>/K<sub>A</sub>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">quinpirole</td><td class="colsep0 rowsep0" align="center">270 ± 30</td><td class="colsep0 rowsep0" align="char" char="±">100 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">16 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">100 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">1.00 ± 0.07<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dopamine</td><td class="colsep0 rowsep0" align="center">200 ± 20</td><td class="colsep0 rowsep0" align="char" char="±">93 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">160 ± 20</td><td class="colsep0 rowsep0" align="char" char="±">97 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">0.00 ± 0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rotigotine</td><td class="colsep0 rowsep0" align="center">3.2 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">91 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">4.4 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">106 ± 4</td><td class="colsep0 rowsep0" align="char" char="±">0.15 ± 0.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ropinirole</td><td class="colsep0 rowsep0" align="center">330 ± 60</td><td class="colsep0 rowsep0" align="char" char="±">92 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">30 ± 6</td><td class="colsep0 rowsep0" align="char" char="±">104 ± 3</td><td class="colsep0 rowsep0" align="char" char="±">0.99 ± 0.08<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pramipexole</td><td class="colsep0 rowsep0" align="center">100 ± 30</td><td class="colsep0 rowsep0" align="char" char="±">102 ± 3</td><td class="colsep0 rowsep0" align="char" char="±">9.6 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">100 ± 3</td><td class="colsep0 rowsep0" align="char" char="±">0.79 ± 0.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aripiprazole</td><td class="colsep0 rowsep0" align="center">130 ± 60</td><td class="colsep0 rowsep0" align="char" char="±">14 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">740 ± 180</td><td class="colsep0 rowsep0" align="char" char="±">43 ± 5</td><td class="colsep0 rowsep0" align="char" char="±">–0.14 ± 0.35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="center">>5 μM<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="±">17 ± 7<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="±">270 ± 80</td><td class="colsep0 rowsep0" align="char" char="±">19 ± 3</td><td class="colsep0 rowsep0" align="char" char="±">2.42 ± 0.48<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13a</b></td><td class="colsep0 rowsep0" align="center">67 ± 20</td><td class="colsep0 rowsep0" align="char" char="±">55 ± 4</td><td class="colsep0 rowsep0" align="char" char="±">200 ± 20</td><td class="colsep0 rowsep0" align="char" char="±">110 ± 6</td><td class="colsep0 rowsep0" align="char" char="±">–0.48 ± 0.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13b</b></td><td class="colsep0 rowsep0" align="center">>5 μM<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="±">36 ± 6<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="±">130 ± 20</td><td class="colsep0 rowsep0" align="char" char="±">51 ± 5</td><td class="colsep0 rowsep0" align="char" char="±">1.91 ± 0.19<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13c</b></td><td class="colsep0 rowsep0" align="center">78 ± 25</td><td class="colsep0 rowsep0" align="char" char="±">26 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">630 ± 110</td><td class="colsep0 rowsep0" align="char" char="±">94 ± 5</td><td class="colsep0 rowsep0" align="char" char="±">–0.58 ± 0.20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17a</b></td><td class="colsep0 rowsep0" align="center">90 ± 16</td><td class="colsep0 rowsep0" align="char" char="±">56 ± 4</td><td class="colsep0 rowsep0" align="char" char="±">250 ± 40</td><td class="colsep0 rowsep0" align="char" char="±">103 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">–0.19 ± 0.10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Data represent mean ± SEM of 5–15 independent experiments, each performed in triplicate.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last"><i>E</i><sub>max</sub> relative to the effect of the reference agonist quinpirole.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">No complete dose response curves obtained, <i>E</i><sub>max</sub> determined at 30 μM.</p></div><div class="footnote" id="t3fn4"><sup>d</sup><p class="last">Ligand bias quantified by the operational model, values <0 indicate preference for GTP binding, values >0 preferential recruitment of β-arrestin-2.</p></div><div class="footnote" id="t3fn5"><sup>e</sup><p class="last">Significant bias determined by one-way ANOVA, followed by Dunnet’s post hoc test, <i>p</i> < 0.05.</p></div></div></div><div class="NLM_p last">Because it is known that recruitment of β-arrestins is greatly facilitated upon adequate receptor phosphorylation,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> we performed additional β-arrestin-2 recruitment assays in the presence of GRK2, a kinase that has been reported to be relevant for the interaction of β-arrestin-2 and D<sub>2</sub>R.<a onclick="showRef(event, 'ref26 ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref26 ref49 ref50">(26, 49, 50)</a> Dose response curves of the endogenous agonist dopamine and the reference agonists quinpirole, rotigotine, ropinirole, and pramipexole revealed highly similar maximum efficacies (<i>E</i><sub>max</sub> 97–104%) under these conditions. While the potency of rotigotine was unaffected by the presence of GRK2 (EC<sub>50</sub> 4.4 nM), a 2–3-fold increase was observed for the four other agonists including the endogenous neurotransmitter dopamine (EC<sub>50</sub> 9.6–160 nM). In good agreement with earlier reports, an increase in efficacy was observed for the weak partial agonists aripiprazole and <b>1</b> (<i>E</i><sub>max</sub> 43 and 19%, respectively). Among our newly developed hydroxylated heterocyclic homopiperazines, coexpression of GRK2 substantially increased the efficacy of <b>13b</b> (<i>E</i><sub>max</sub> 51%, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>b) and <b>13c</b> (<i>E</i><sub>max</sub> 94%), comprising an 8-hydroxycoumarine or a 5-hydroxybenzoxazin-3-one head group, respectively. For the 8-hydroxyquinolin-2(1<i>H</i>)-ones <b>13a</b> and <b>17a</b> only minor changes in efficacy or potency were observed (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>a,c), probably indicating a minor contribution of GRK2 to the signaling panorama of these two ligands. A quantitative comparison of the signaling profiles confirmed the preference for β-arrestin-2 recruitment for the 8-hydroxycoumarine <b>13b</b> and the reference agent <b>1</b> (ΔΔlog(τ/K<sub>A</sub>) 1.91 and 2.42, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>d). No such bias was observed for the ligands <b>13a</b>,<b>c</b> and <b>17a</b>, although the signaling profiles of these two ligands are substantially different from those of typical antiparkinsonian drugs (e.g., rotigotine) or the endogenous agonist dopamine (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00363/suppl_file/jm7b00363_si_001.pdf" class="ext-link">Figures S1–3</a>). These results are most likely caused by the detrimental changes of potency and efficacy observed for <b>13a</b>,<b>c</b> and <b>17a</b> between the different test systems and the relative importance attributed to these influencing factors in the operational model of agonism. To relate these distinct signaling profiles to pharmacological outcomes, and thus to estimate the therapeutic value of such compounds future studies, potentially also involving β-arrestin knockout animals, will be required.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Metabolism and Inhibition of hERG Tail Currents</h3><div class="NLM_p">To assess the drug-like properties of our target compounds, we calculated octanol/water partition coefficients as described previously (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00363/suppl_file/jm7b00363_si_001.pdf" class="ext-link">Table S1</a>).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Compared to the typical 1,4-DAP aripiprazole, hydroxy-substituted heteroarylpiperazines and their homopiperazine analogues were predicted to be less lipophilic. With the exception of the most hydrophilic compounds <b>12c</b>, <b>13c</b>, and <b>16c</b> sharing the 5-hydroxybenzoxazinone head group, the ligands’ lipophilicity was predicted to be similar to the range covered by the approved D<sub>2</sub>R agonists ropinirole, pramipexole, and rotigotine. Furthermore, with the exception of <b>19a</b>,<b>b</b>, none of the compounds hit constraints predicting poor solubility or permeability as indicated by Lipinski’s rule of five.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Metal chelating properties for various divalent cations are well-known characteristics of 8-hydroxyquinoline substructures and have been associated with undesired side effects.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Although chelating properties are likely for some of the presented ligands, no toxic effects were observed under the conditions of our functional experiments.</div><div class="NLM_p">Besides adequate physicochemical properties, sufficient metabolic stability is a general requirement in drug development. Thus, to determine the metabolic stability of the novel heteroarylpiperazines, we explored the representative ligands <b>13a</b> and <b>17a</b> for their propensity to undergo phase I transformations using rat liver microsomes in comparison to the antiparkinsonian drug rotigotine. In agreement with previous findings,<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> rotigotine was extensively metabolized within 15 min of incubation, and a number of known metabolites were identified using mass spectrometry (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00363/suppl_file/jm7b00363_si_001.pdf" class="ext-link">Figures S4, S5</a>). The half-life and intrinsic clearance for rotigotine were determined to be 5.8 min and 240 μL/min/mg protein, respectively (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00363/suppl_file/jm7b00363_si_001.pdf" class="ext-link">Figure S4</a>).<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54, 55)</a> In contrast, only minor metabolization of the pyrazolo[1,5-<i>a</i>]pyridine <b>17a</b> was observed (<i>T</i><sub>1/2</sub> 51 min, CL<sub>int</sub> 27 μL/min/mg protein), while the 3,4-dihydroquinolin-2(1<i>H</i>)-one <b>13a</b> was hardly metabolized at all (<i>T</i><sub>1/2</sub> 130 min, CL<sub>int</sub> 11 μL/min/mg protein). On the basis of the intrinsic clearance, <b>17a</b> can be regarded as intermediately metabolized, while <b>13a</b> falls into the low clearance category.<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54, 55)</a> Both ligands revealed binding to matrix protein (∼27%) in control experiments when the enzymatic transformation was prevented by the absence of the cofactor NADPH (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>e, Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00363/suppl_file/jm7b00363_si_001.pdf" class="ext-link">Figures S4, S5</a>).</div><div class="NLM_p last">QTc-interval prolongation leading to the very rare but potentially lethal Torsades de Pointes (TdP) arrhythmia is a serious complication associated with pharmacotherapy.<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56, 57)</a> Although not the only cause, inhibition of the delayed rectifier potassium <i>I</i><sub>Kr</sub> current mediated by hERG (human-ether-à-go-go related gene) channels is predictive for QTc prolongation and the liability of a drug-like molecule to cause TdP.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Drug-induced arrhythmia has been observed for a number of dopaminergic drugs, including the phenylpiperidine haloperidol and the aromatic piperazine ziprasidone.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> To assess the susceptibility to induce arrhythmia, and hence estimate cardiotoxicity, the influence of a representative hydroxy-substituted heterocyclic phenylpiperazine (<b>13a</b>) on the inhibition of hERG tail currents was examined in vitro. Automated patch-clamp showed that no effect on hERG tail currents was observed at concentrations up to 1 μM (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>f). At higher concentration, a slight inhibition was observed (10 μM, 71.7% current remaining), which was dose-dependently increased (50 μM, 21.5% remaining). However, the inhibitory potency (IC<sub>50</sub>) of <b>13a</b> was determined to be 19.7 μM, a concentration that is 100-fold higher than the EC<sub>50</sub> required for β-arrestin-2 recruitment at D<sub>2S</sub>R and even 24000-fold higher than the binding affinity of <b>13a</b> at D<sub>2S</sub>R (<i>K</i><sub>i</sub> 0.81 nM).</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25001" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25001" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Applied in combination with a peripheral decarboxylase inhibitor, L-DOPA remains the “gold standard” in antiparkinsonian drug therapy. However, its use is limited by wearing off and the occurrence of L-DOPA induced dyskinesia (LID) over the course of time.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Very recently, it has been demonstrated that dopamine receptor-mediated activation of β-arrestin-2 is required for the beneficial locomotor effects of L-DOPA and not involved in the pathogenesis of LIDs. Selective targeting of this signal transducer, e.g., by biased ligands, may therefore represent a valuable novel concept in the treatment of PD.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Aiming to develop novel dopaminergics that activate β-arrestin-2 in a functionally selective manner via the interaction with D<sub>2</sub>R, we performed a formal structural hybridization of typical 1,4-DAPs and heterocyclic catecholamine surrogates leading to hydroxy-substituted heteroaryl-1,4-disubstituted piperazines and homopiperazines. In contrast to previously described β-arrestin-2 biased ligands for D<sub>2</sub>R,<a onclick="showRef(event, 'ref14 ref27'); return false;" href="javascript:void(0);" class="ref ref14 ref27">(14, 27)</a> these compounds are designed to mimic the interactions of the catechol substructure of the endogenous ligand dopamine with crucial serine residues in the orthosteric binding pocket. We found that two major factors determined the intrinsic efficacy of the ligands with this novel scaffold: the presence of an additional endocyclic H-bond donor rather than an H-bond acceptor and the ring-size of the cyclic diamine. Notably, ligands <b>13a</b>,<b>c</b> and <b>17a</b> comprising an 8-hydroxyquinolin-2(1<i>H</i>)-one or a 5-hydroxy-2<i>H</i>-benzo[<i>b</i>][1,4]oxazin-3(4<i>H</i>)-one heterocycle and a homopiperazine substructure showed full agonist properties for the recruitment of β-arrestin-2 while they were substantially less efficacious for the induction of D<sub>2S</sub>R-promoted guanine nucleotide exchange as a measure of canonical Gα<sub>o</sub> protein activation. Although the 8-hydroxycoumarine-substituted homopiperazine <b>13b</b> induced submaximal activation of both signaling pathways, this compound was identified as highly β-arrestin-biased using the operational model of agonism. A further evaluation of representative homopiperazines <b>13a</b> and <b>17a</b> comprising a 3,4-dihydroquinolin-2(1<i>H</i>)-one or pyrazolo[1,5-<i>a</i>]pyridine appendage revealed a low tendency to undergo metabolic transformation reactions in rat liver microsomes and identified a minor liability to inhibit hERG channels, an important off-target in the course of drug development. The combination of typical agonist-type elements from known β<sub>2</sub>-AR agonists such as procaterol<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21, 22)</a> and <b>4</b><a onclick="showRef(event, 'ref17 ref24'); return false;" href="javascript:void(0);" class="ref ref17 ref24">(17, 24)</a> with 1,4-DAP substructures known for their weak partial agonist characteristics<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> proved successful for the design of novel β-arrestin-biased D<sub>2</sub>R agonists with unprecedented intrinsic efficacy. This novel scaffold might serve as a starting point for the development of functionally selective PD therapeutics with a lower propensity to induce LID. Nevertheless, the contribution of other dopamine receptor subtypes, especially the D<sub>1</sub>R, to the efficacy and side effects associated with L-DOPA therapy should also be addressed in drug discovery.<a onclick="showRef(event, 'ref6 ref12'); return false;" href="javascript:void(0);" class="ref ref6 ref12">(6, 12)</a> Medicinal chemistry specifically targeting D<sub>1</sub>R-promoted β-arrestin-2 recruitment may lead to further promising innovations.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08732" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08732" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Chemistry</h3><div class="NLM_p">Reagents and dry solvents were of commercial quality and used as purchased. If not stated otherwise, reactions were carried out under nitrogen atmosphere. MS was run on a BRUKER ESQUIRE 2000 or on a BRUKER amaZon SL mass spectrometer using ESI ionization. HRMS was run on a AB Sciex Triple TOF660 SCiex, source type ESI, or at the Chair of Organic Chemistry, Friedrich Alexander University Erlangen–Nuernberg on a Bruker Daltonik micrOTOF II focus or Bruker Daltonik maXis 4G, source type ESI or APPI. NMR spectra were recorded on a Bruker Avance 400, Bruker Avance 360, or a Bruker Avance 600 spectrometer at 300 K in the solvents indicated. Chemical shifts are given in ppm (δ) relative to TMS. IR spectra were obtained on a Jasco FT/IR 4100 spectrometer using a substance film on a NaCl crystal. Purification by column chromatography was performed with silica gel 60. TLC analyses were performed using Merck 60 F254 aluminum plates in combination with UV detection (254 nm) or ninhydrin staining. Analytical HPLC was conducted on an Agilent 1200 HPLC system employing a DAD detector and a Zorbax Eclipse XDB-C8 (4.6 mm × 150 mm, 5 μm) column with the following binary solvent systems: System 1, eluent, methanol/0.1% aq trifluoroacetic acid, 10% methanol for 3 min, to 100% in 15 min, 100% for 6 min, to 10% in 3 min, then 10% for 3 min, flow rate 5 mL/min, λ = 210 or 254 nm; System 2, CH<sub>3</sub>CN/0.1% aq trifluoroacetic acid, 10% CH<sub>3</sub>CN for 3 min, to 100% in 15 min, 100% for 6 min, to 10% in 3 min, then 10% for 3 min, flow rate 5 mL/min, λ = 210 or 254 nm. Preparative HPLC was performed on an Agilent 1100 Preparative series, using a Macherey-Nagel Varioprep VP 250/32 Nucleodur C18 HTec (32 mm × 250 mm, 5 μm, flow rate 32 mL/min), a Zorbax Eclipse XDB-C8 PrepHT (21.5 mm × 150 mm, 5 μm, flow rate 10 mL/min) or a Macherey-Nagel Varioprep VP 250/10 Nucleodur C18 HTec (10 mm × 250 mm, 5 μm, flow rate 3 mL/min) column with the solvent systems indicated.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 2,8-Bis(benzyloxy)-5-bromoquinoline (<b>5d</b>)</h4><div class="NLM_p last">To a solution of <b>5c</b> (863 mg, 2.6 mmol) and K<sub>2</sub>CO<sub>3</sub> (1.08 g, 2.6 mmol) in DMF (26 mL) was added dropwise benzyl bromide (0.5 mL, 3.9 mmol). The mixture was stirred at room temperature for 2 h. The solvent was evaporated, and the residue was diluted with water. The product was extracted with EtOAc, and the combined organic layers were washed with 0.5 M HCl, water, and brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and evaporated. Purification by flash chromatography (hexanes/EtOAc 30:1) yielded <b>5d</b> (990 mg, 91%) as a colorless solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 5.31 (s, 2H), 5.58 (s, 2H), 6.96 (d, <i>J</i> = 8.4 Hz, 1H), 7.05 (d, <i>J</i> = 9.1 Hz, 1H), 7.28–7.36 (m, 4H), 7.37–7.42 (m, 2H), 7.50 (d, <i>J</i> = 8.4 Hz, 1H), 7.52–7.58 (m, 4H), 8.33 (d, <i>J</i> = 9.1 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 151 MHz) δ 68.16, 71.55, 112.9, 113.0, 114.7, 125.4, 127.4, 127.5, 128.0, 128.1, 128.5, 128.7, 128.8, 137.2, 137.2, 138.7, 139.5, 153.2, 161.6. IR (NaCl) ν 3030, 1610, 1597, 1502, 1404, 1272, 1253, 1095, 1006, 914, 826, 732, 695 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 23.1 min, purity >99%; (system 2) <i>t</i><sub>R</sub> = 22.6 min, purity >99%. ESI-MS <i>m</i>/<i>z</i> 420.0</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> <i>tert</i>-Butyl 4-[2,8-Bis(benzyloxy)quinolin-5-yl]piperazine-1-carboxylate (<b>5e</b>)</h4><div class="NLM_p last">To a solution of 1-boc-piperazine (1.3 g, 7.2 mmol) in toluene (51 mL) were added Pd(OAc)<sub>2</sub> (32 mg, 0.14 mmol) and <i>rac</i>-BINAP (286 mg, 0.43 mmol) under N<sub>2</sub> atmosphere. After stirring for 15 min at room temperature, <b>5d</b> (1.5 g, 3.6 mmol) and NaO<sup><i>t</i></sup>Bu (0.5 g, 5.0 mmol) were added and the resulting mixture was stirred under reflux for 24 h. After cooling down to room temperature, EtOAc was added and the organic layer was washed with 0.5 M HCl, water, and brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and evaporated. Purification by flash chromatography (hexanes/EtOAC 20:1 to 2:1) yielded <b>5e</b> (1.2 g, 63%) as a colorless solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 1.50 (s, 9H), 2.79–3.08 (m, 4H), 3.37–3.77 (m, 4H), 5.30 (s, 2H), 5.58 (s, 2H), 6.88 (d, <i>J</i> = 8.3 Hz, 1H), 6.98 (d, <i>J</i> = 9.0 Hz, 1H), 7.05 (d, <i>J</i> = 8.3 Hz, 1H), 7.28–7.33 (m, 2H), 7.33–7.40 (m, 4H), 7.47–7.67 (m, 4H), 8.39 (d, <i>J</i> = 9.0 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 91 MHz) δ 28.62, 53.47, 67.85, 71.98, 79.99, 112.8, 113.0, 113.5, 122.2, 127.4, 127.8, 128.0, 128.5, 128.6, 128.7, 135.2, 137.6, 137.9, 139.7, 143.6, 150.3, 155.0, 161.3. IR (NaCl) ν 2924, 2854, 1695, 1610, 1411, 1261, 1246, 1169, 1003, 734, 696 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 23.1 min, purity >99%; (system 2) <i>t</i><sub>R</sub> = 22.5 min, purity >99%. ESI-MS <i>m</i>/<i>z</i> 526.7 [M + H<sup>+</sup>].</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> <i>tert</i>-Butyl 4-[2,8-Bis(benzyloxy)quinolin-5-yl]-1,4-diazepane-1-carboxylate (<b>5f</b>)</h4><div class="NLM_p last">To a solution of <i>N</i>-(<i>tert</i>-butyl-oxycarbonyl)-homopiperazine (380 mg, 1.9 mmol) in toluene (15 mL), Pd(OAc)<sub>2</sub> (8.5 mg, 0.04 mmol) and <i>rac</i>-BINAP (71 mg, 0.11 mmol) were added. After stirring for 15 min, <b>5d</b> (400 mg, 0.95 mmol) and NaO<sup><i>t</i></sup>Bu (128 mg, 1.3 mmol) were added. The tube was sealed, and the reaction mixture was stirred at 115 °C for 1 d. After cooling down to room temperature, and the reaction mixture was diluted with EtOAc, the organic layer was washed with 0.5 M HCl, water, and brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and evaporated. Purification by flash chromatography (hexanes/EtOAc 40:1 to 10:1 to 2:1) yielded <b>1f</b> (350 mg, 68%) as a colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 1.50 (d, <i>J</i> = 9.8 Hz, 9H), 1.86–2.13 (m, 2H), 3.02–3.27 (m, 4H), 3.55–3.73 (m, 4H), 5.30 (s, 2H), 5.58 (s, 2H), 6.94 (dd, <i>J</i> = 8.2, 2.6 Hz, 1H), 6.98 (d, <i>J</i> = 9.0 Hz, 1H), 7.00–7.06 (m, <i>J</i> = 8.2, 2.0 Hz, 1H), 7.28–7.33 (m, 2H), 7.33–7.41 (m, 4H), 7.55 (dd, <i>J</i> = 11.8, 7.4 Hz, 4H), 8.44 (d, <i>J</i> = 8.8 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 151 MHz) δ 28.69, (29.19), 29.35, (45.69), 46.48, (47.79), 48.14, (56.57), 56.97, (57.40), 57.46, 67.80, 71.98, (79.60), 79,64, (112.7), 113.1, (115.2), 115.2, 122.8, 127.4, 127.8, 128.0, 128.5, 128.6, 128.7, 135.6, (137.6), 137.6, 137.9, 139.5, (146.0), 146.1, (150.0), 150.0, (155.7), 155.8, 161.3 (signals in brackets represent resonances caused by rotamers). IR (NaCl) ν 3432, 2974, 1645, 1481, 1453, 1408, 1366, 1312, 1261, 1154, 736, 699 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 23.0 min, purity >98%; (system 2) <i>t</i><sub>R</sub> = 22.7 min, purity >99%. ESI-MS <i>m</i>/<i>z</i> 540.2 [M + H<sup>+</sup>].</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 4-[2,8-Bis(benzyloxy)quinolin-5-yl]piperazine (<b>5g</b>)</h4><div class="NLM_p last">To a solution of <b>5e</b> (550 mg, 0.95 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (13 mL) was added TFA (1.3 mL). The mixture was stirred at room temperature for 2 h. The reaction was stopped by adjusting the pH to 9 by addition of 1 M NaOH. The product was extracted with CH<sub>2</sub>Cl<sub>2</sub>, and the combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. Purification by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 15:1) yielded <b>5g</b> (220 mg, 51%) as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 360 MHz) δ 3.11 (m, 4H), 3.26 (m, 4H), 3.45 (s, 1H), 5.31 (s, 2H), 5.58 (s, 2H), 6.94 (d, <i>J</i> = 8.3 Hz, 1H), 6.99 (d, <i>J</i> = 9.0 Hz, 1H), 7.06 (d, <i>J</i> = 8.4 Hz, 1H), 7.43–7.27 (m, 6H), 7.55 (t, <i>J</i> = 7.3 Hz, 4H), 8.36 (d, <i>J</i> = 9.1 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 91 MHz) δ 45.54, 52.64, 67.89, 71.89, 112.8, 113.0, 114.0, 122.1, 127.4, 127.9, 128.0, 128.5, 128.6, 128.7, 135.0, 137.5, 137.8, 139.7, 143.0, 150.6, 161.3. IR (NaCl) ν 3439, 3031, 2946, 1610, 1411, 1264, 1005, 742, 693 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 19.9 min, purity 99%; (system 2) <i>t</i><sub>R</sub> = 16.5 min, purity 93%. ESI-MS <i>m</i>/<i>z</i> 426.1 [M + H<sup>+</sup>].</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 4-[2,8-Bis(benzyloxy)quinolin-5-yl]-1,4-diazepane (<b>5h</b>)</h4><div class="NLM_p last">Compound <b>5h</b> was prepared as described for <b>5g</b>, using a mixture of <b>5f</b> (200 mg, 0.37 mmol) and TFA (0.5 mL) in CH<sub>2</sub>Cl<sub>2</sub> (5.0 mL). Purification by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 15:1) yielded <b>5h</b> (129 mg, 79%) as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 1.95–2.12 (m, 2H), 3.09–3.40 (m, 8H), 5.30 (s, 2H), 5.58 (s, 2H), 6.94–7.01 (m, 2H), 7.04 (d, <i>J</i> = 8.4 Hz, 1H), 7.27–7.32 (m, 2H), 7.33–7.40 (m, 4H), 7.49–7.58 (m, 4H), 8.46 (d, <i>J</i> = 9.0 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 91 MHz) δ 29.97, 46.92, 49.40, 56.66, 57.79, 67.82, 72.02, 112.8, 113.1, 115.4, 122.8, 127.4, 127.8, 127.9, 128.5, 128.6, 128.7, 135.6, 137.6, 137.9, 139.6, 145.9, 150.1, 161.3. IR (NaCl) ν 3432, 3034, 2937, 2848, 1650, 1559, 1506, 1411, 1260, 1093, 733, 697 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 20.0 min, purity 87%; (system 2) <i>t</i><sub>R</sub> = 16.8 min, purity 91%. ESI-MS <i>m</i>/<i>z</i> 440.2 [M + H<sup>+</sup>].</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>tert</i>-Butyl 4-[8-(Benzyloxy)-2-oxo-2<i>H</i>-chromen-5-yl]piperazine-1-carboxylate (<b>6d</b>)</h4><div class="NLM_p last">Pd<sub>2</sub>(dba)<sub>3</sub> (24 mg, 0.03 mmol) and <i>rac</i>-BINAP (49 mg, 0.08 mmol) were dissolved in toluene (9 mL) and stirred for 5 min under nitrogen atmosphere. Then Cs<sub>2</sub>CO<sub>3</sub> (300 mg, 0.92 mmol), 1-boc-piperazine (307 mg, 1.6 mmol), and <b>6c</b> (220 mg, 0.66 mmol) were added, and the reaction mixture was stirred in a sealed microwave reaction tube at 85 °C for 1 d. After cooling down to room temperature, the reaction was diluted and EtOAc was added. The combined organic layer was washed with 0.5 M HCl, water, and brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated. Purification by flash chromatography (hexanes/EtOAc 20:1 to 5:1) yielded <b>6d</b> (172 mg, 59%) as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 1.49 (s, 9H), 2.75–3.08 (m, 4H), 3.45–3.88 (m, 4H), 5.20 (s, 2H), 6.43 (d, <i>J</i> = 9.8 Hz, 1H), 6.80 (d, <i>J</i> = 8.7 Hz, 1H), 7.03 (d, <i>J</i> = 8.7 Hz, 1H), 7.32 (t, <i>J</i> = 7.3 Hz, 1H), 7.38 (t, <i>J</i> = 7.5 Hz, 2H), 7.47 (d, <i>J</i> = 7.4 Hz, 2H), 8.07 (d, <i>J</i> = 9.8 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 91 MHz) δ 28.58, 44.16, 53.55, 71.85, 80.20, 114.7, 115.4, 116.0, 116.9, 127.5, 128.2, 128.8, 136.6, 140.1, 143.0, 143.9, 145.5, 154.9, 160.3. IR (NaCl) ν 2975, 2917, 2857, 1727, 1690, 1487, 1454, 1424, 1267, 1250, 1170, 1127, 1069, 1011, 908, 810 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 21.2 min, purity 94%; (system 2) <i>t</i><sub>R</sub> = 19.8 min, purity 99%. ESI-MS <i>m</i>/<i>z</i> 459.2 [M + Na<sup>+</sup>].</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>tert</i>-Butyl 4-[8-(Benzyloxy)-2-oxo-2<i>H</i>-chromen-5-yl]-1,4-diazepane-1-carboxylate (<b>6e</b>)</h4><div class="NLM_p last">Compound <b>6e</b> was prepared according to the protocol of <b>6d</b>, using a solution of Pd<sub>2</sub>(dba)<sub>3</sub> (24 mg, 0.03 mmol), <i>rac</i>-BINAP (49 mg, 0.08 mmol), Cs<sub>2</sub>CO<sub>3</sub> (300 mg, 0.92 mmol), <i>N</i>-(<i>tert</i>-butyl-oxycarbonyl)-homopiperazine (307 mg, 1.6 mmol), and <b>6c</b> (220 mg, 0.66 mmol) in toluene (9 mL). Purification by flash chromatography (hexanes/EtOAc 20:1 to 5:1) yielded <b>6e</b> (172 mg, 59%) as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 1.46–1.53 (m, 9H), 1.88–2.04 (m, 2H), 3.03–3.16 (m, 4H), 3.52–3.59 (m, 2H), 3.59–3.70 (m, 2H), 5.20 (s, 2H), 6.41 (d, <i>J</i> = 9.7 Hz, 1H), 6.85 (dd, <i>J</i> = 8.7, 4.0 Hz, 1H), 7.00 (dd, <i>J</i> = 8.6, 3.6 Hz, 1H), 7.31–7.33 (m, 1H), 7.36–7.40 (m, 2H), 7.45–7.48 (m, 2H), 8.07–8.14 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 101 MHz) δ 28.50, (28.85), 29.08, (45.46), 46.33, (47.25), 47.66, (56.34), 56.75, 57.19, 71.67, 115.6, 116.3, 116.8, 127.4, 128.0, 128.6, 129.5, 134.0, 136.5, 140.5 (signals in brackets represent resonances caused by rotamers) IR (NaCl) ν 3416, 2974, 2927, 1730, 1655, 1487, 1264, 1070 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 21.5 min, purity 96%; (system 2) <i>t</i><sub>R</sub> = 20.1 min, purity 96%. ESI-MS <i>m</i>/<i>z</i> 451.1 [M + H<sup>+</sup>].</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 4-[8-(Benzyloxy)-2-oxo-2<i>H</i>-chromen-5-yl]piperazine (<b>6f</b>)</h4><div class="NLM_p last">Compound <b>6f</b> was prepared as described for <b>6g</b>, using a mixture of <b>6d</b> (170 mg, 0.39 mmol) and TFA (0.3 mL) in CH<sub>2</sub>Cl<sub>2</sub> (5.3 mL). Purification by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 15:1) yielded <b>6f</b> (85 mg, 65%) as a yellow solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 360 MHz) δ 2.71–2.87 (m, 4H), 2.87–3.03 (m, 4H), 5.20 (s, 2H), 6.46 (d, <i>J</i> = 9.8 Hz, 1H), 6.93 (d, <i>J</i> = 8.8 Hz, 1H), 7.30 (d, <i>J</i> = 8.8 Hz, 1H), 7.34–7.38 (m, 1H), 7.38–7.45 (m, 2H), 7.46–7.52 (m, 2H), 8.11 (d, <i>J</i> = 9.8 Hz, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 151 MHz) δ 45.53, 54.00, 70.45, 114.2, 114.3, 115.1, 116.3, 127.8, 128.0, 128.5, 136.7, 140.7, 141.6, 144.2, 159.5. IR (NaCl) ν 3432, 1684, 1377, 1272, 1204, 1131, 1060 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 16.9 min, purity 99%; (system 2) <i>t</i><sub>R</sub> = 14.0 min, purity 99%. ESI-MS <i>m</i>/<i>z</i> 337.2 [M + H<sup>+</sup>].</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 4-[8-(Benzyloxy)-2-oxo-2<i>H</i>-chromen-5-yl]-1,4-diazepane (<b>6g</b>)</h4><div class="NLM_p last">Compound <b>6g</b> was prepared as described for <b>5g</b>, using a mixture of <b>6e</b> (87 mg, 0.19 mmol) and TFA (0.25 mL) in CH<sub>2</sub>Cl<sub>2</sub> (2.50 mL). Purification by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 15:1) yielded <b>6g</b> (38 mg, 57%) as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 1.91–2.02 (m, 2H). 3.08–3.13 (m, 2H), 3.13–3.21 (m, 2H), 3.22–3.28 (m, 2H), 3.29–3.41 (m, 2H), 5.19 (d, <i>J</i> = 8.3 Hz, 1H), 6.48 (d, <i>J</i> = 9.8 Hz, 1H), 7.04 (d, <i>J</i> = 8.8 Hz, 1H), 7.31 (d, <i>J</i> = 8.9 Hz, 1H), 7.34–7.38 (m, 1H), 7.39–7.45 (m, 2H), 7.46–7.52 (m, 2H), 8.24 (d, <i>J</i> = 9.8 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 101 MHz) δ 27.33, 45.12, 47.02, 54.48, 55.86, 70.42, 115.0, 115.2, 116.3, 116.5, 127.8, 128.0, 128.5, 136.6, 141.2, 141.7, 143.9, 145.3, 159.5. IR (NaCl) ν 3421, 2959, 2922, 2850, 1722, 1651, 1488, 1454, 1270, 1192, 1134, 1067, 806, 699 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 17.1 min, purity 91%; (system 2) <i>t</i><sub>R</sub> = 14.2 min, purity 88%. ESI-MS <i>m</i>/<i>z</i> 351.1 [M + H<sup>+</sup>].</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 4-Benzyl-5-(benzyloxy)-8-bromo-2<i>H</i>-benzo[<i>b</i>][1,4]oxazin-3(4<i>H</i>)-one (<b>7d</b>)</h4><div class="NLM_p last">To a solution of <b>7c</b> (3.7 g, 11.0 mmol) and K<sub>2</sub>CO<sub>3</sub> (4.5 g, 33.0 mmol) in DMF (110 mL) was added dropwise benzyl bromide (1.9 mL, 16.5 mmol). The mixture was stirred at room temperature for 2 h. The solvent was evaporated, and the residue was diluted with water. The product was extracted with EtOAc, and the combined organic layers were washed with 0.5 M HCl, water, and brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and evaporated. Purification by flash chromatography (hexanes/EtOAc 12:1 to 1:1) yielded <b>7d</b> (2.67 g, 57%) as a colorless solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz) δ 4.65 (s, 2H), 4.95 (s, 2H), 5.37 (s, 2H), 6.50 (d, <i>J</i> = 9.0 Hz, 1H), 6.99 (d, <i>J</i> = 7.1 Hz, 2H), 7.13 (d, <i>J</i> = 9.0 Hz, 1H), 7.14–7.20 (m, 3H), 7.28–7.32 (m, 2H), 7.34–7.41 (m, 3H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 151 MHz) δ 46.89, 69.24, 71.63, 102.8, 109.2, 120.2, 127.0, 127.1, 127.7, 128.2, 128.4, 128.6, 128.9, 135.8, 137.0, 146.7, 148.8, 166.2. IR (NaCl) ν 1692, 1485, 1456, 1386, 1279, 1103, 1016, 739, 702 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 21.7 min, purity 89% (system 2) <i>t</i><sub>R</sub> = 20.2 min, purity 87%. ESI-MS <i>m</i>/<i>z</i> 425.9 [M + H<sup>+</sup>].</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>tert-</i>Butyl 4-[4-Benzyl-5-(benzyloxy)-2<i>H</i>-benzo[<i>b</i>][1,4]oxazin-3(4<i>H</i>)-one-8-yl]piperazin-1-carboxylate (<b>7e</b>)</h4><div class="NLM_p last">To a solution of 1-boc-piperazine (385 mg, 2.1 mmol) in toluene (13 mL) were added Pd(OAc)<sub>2</sub> (8.5 mg, 0.04 mmol) and <i>rac</i>-BINAP (70 mg, 0.13 mmol) under nitrogen atmosphere. After stirring for 15 min, <b>7d</b> (400 mg, 0.94 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (1.1 g, 3.3 mmol) were added. The resulting mixture heated to reflux for 72 h. After cooling down to room temperature, the reaction mixture was diluted with EtOAc, and the organic layer was washed with 0.5 M HCl, water, and brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and evaporated. Purification by flash chromatography (H/EtOAC 12:1 to 2:1) yielded <b>7e</b> (313 mg, 66%) as a light-brown solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 360 MHz) δ 1.48 (s, 9H), 2.80–2.95 (m, 4H), 3.49–3.65 (m, 4H), 4.57 (s, 2H), 4.92 (s, 2H), 5.39 (s, 2H), 6.52 (d, 1H, <i>J</i> = 9.0 Hz), 6.57 (d, 1H, <i>J</i> = 9.0 Hz), 6.95–7.05 (m, 2H), 7.08–7.21 (m, 3H), 7.28–7.51 (m, 5H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 91 MHz) δ 28.60, 46.90, 51.25, 68.95, 71.61, 79.94, 107.8, 114.5, 120.2, 127.0, 127.0, 127.7, 128.3, 128.4, 128.8, 135.9, 136.4, 137.40, 142.9, 145.4, 154.9, 166.6. IR (NaCl) ν 2923, 2852, 1688, 1502, 1390, 1245, 1169, 1101, 1023, 911, 732 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 21.8 min, purity 89% (system 2) <i>t</i><sub>R</sub> = 19.9 min, purity 91%. ESI-MS <i>m</i>/<i>z</i> 530.1 [M + H<sup>+</sup>].</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>tert</i>-Butyl 4-[4-Benzyl-5-(benzyloxy)-3-oxo-3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazin-8-yl]-1,4-diazepane-1-carboxylate (<b>7f</b>)</h4><div class="NLM_p last">Compound <b>7f</b> was prepared as described for <b>7e</b>, using a solution of <i>N</i>-(<i>tert</i>-butyl-oxycarbonyl)-homopiperazine (467 mg, 2.3 mmol), Pd(OAc)<sub>2</sub> (9.5 mg, 0.04 mmol), <i>rac</i>-BINAP (74 mg, 0.12 mmol), <b>7d</b> (450 mg, 1.1 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (1.21 g, 3.7 mmol) in toluene (15 mL), allowing a reaction time of 48 h. Purification by flash chromatography (hexanes/EtOAc 12:1 to 2:1) yielded <b>7f</b> (218 mg, 38%) as a light-brown solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz, incl rotamers) δ 1.45 (d, <i>J</i> = 10.8 Hz, 9H), 2.01–1.81 (m, 2H), 3.32–3.02 (m, 4H), 3.67–3.36 (m, 4H), 4.53 (s, 2H), 4.90 (d, <i>J</i> = 3.6 Hz, 2H), 5.38 (s, 2H), 6.48 (dd, <i>J</i> = 8.8, 4.9 Hz, 1H), 6.59 (d, <i>J</i> = 9.0 Hz, 1H), 7.07–6.99 (m, 2H), 7.19–7.10 (m, 3H), 7.32–7.29 (m, 2H), 7.39–7.32 (m, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 91 MHz) δ 21.17, 28.65, 45.92, 46.92, 48.06, 53.65, 54.17, 68.92, 71.71, 79.48, 108.0, 115.1, 120.3, 126.9, 127.1, 127.7, 128.3, 128.8, 136.6, 136.7, 137.5, 142.4, 144.4, 155.6, 166.8. IR (NaCl) ν 3026, 2946, 2830, 1686, 1503, 1454, 1385, 1267, 1023, 738, 695 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 21.8 min, purity 74%. ESI-MS <i>m</i>/<i>z</i> 544.2 [M + H<sup>+</sup>].</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 4-[4-Benzyl-5-(benzyloxy)-2<i>H</i>-benzo[<i>b</i>][1,4]oxazin-3(4<i>H</i>)-one-8-yl]piperazine (<b>7g</b>)</h4><div class="NLM_p last">Compound <b>7g</b> was prepared as described for <b>5g</b>, using a mixture of <b>7e</b> (255 mg, 0.48 mmol) and TFA (0.6 mL) in CH<sub>2</sub>Cl<sub>2</sub> (6.4 mL). Purification by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 15:1) yielded <b>7g</b> (161 mg, 87%) as a light-yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 3.00–2.95 (m, 4H), 3.13–3.03 (m, 4H), 4.57 (s, 2H), 4.92 (s, 2H), 5.39 (s, 2H), 6.53 (d, <i>J</i> = 9.0 Hz, 1H), 6.60 (d, <i>J</i> = 9.0 Hz, 1H), 7.03–6.99 (m, 2H), 7.18–7.10 (m, 3H), 7.32–7.29 (m, 2H), 7.39–7.33 (m, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 151 MHz) δ 46.08, 46.85, 52.15, 68.89, 71.54, 107.8, 114.4, 120.1, 126.9, 127.0, 127.7, 128.3, 128.3, 128.8, 136.4, 136.4, 137.4, 142.8, 145.2, 166.7. IR (NaCl) ν 3432, 2851, 1655, 1504, 1457, 1389, 1258, 1101, 1262 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 19.0 min, purity 99% (system 2) <i>t</i><sub>R</sub> = 15.2 min, purity 96%. ESI-MS <i>m</i>/<i>z</i> 430.0 [M + H<sup>+</sup>].</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 4-[4-Benzyl-5-(benzyloxy)-2<i>H</i>-benzo[<i>b</i>][1,4]oxazin-3(4<i>H</i>)-one-8-yl]-1,4-diazepane (<b>7h</b>)</h4><div class="NLM_p last">Compound <b>7h</b> was prepared according to the protocol of <b>5g</b>, using a mixture of <b>7f</b> (156 mg, 0.29 mmol) and TFA (0.4 mL) in CH<sub>2</sub>Cl<sub>2</sub> (4.0 mL). Purification by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 15:1) yielded <b>7h</b> (78 mg, 61%) as a light-yellow solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz) δ 1.82–1. 89 (m, 2H). 2.93–2.97 (m, 2H), 2.97–3.02 (m, 2H), 3.14–3.21 (m, 4H), 4.58 (s, 2H), 5.00 (s, 2H), 5.29 (s, 2H), 6.63 (d, <i>J</i> = 9.1 Hz, 1H), 6.67 (d, <i>J</i> = 9.2 Hz, 1H), 6.99–7.04 (m, 2H), 7.11–719 (m, 1H), 7.19–7.26 (m, 2H), 7.30–7.45 (m, 5H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 151 MHz) δ 28.74, 45.56, 46.07, 48.40, 51.31, 53.55, 68.23, 70.75, 108.0, 113.9, 119.6, 126.5, 126.8, 127.7, 127.9, 128.2, 128.5, 136.4, 136.6, 137.4, 141.2, 143.1, 166.3. IR (NaCl) ν 3026, 2946, 2830, 1686, 1503, 1454, 1385, 1267, 1023, 738, 695 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 19.3 min, purity 94%. ESI-MS <i>m</i>/<i>z</i> 444.1 [M + H<sup>+</sup>].</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>tert</i>-Butyl 4-[8-(Benzyloxy)-2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-5-yl]piperazine-1-carboxylate (<b>8d</b>)</h4><div class="NLM_p last">Pd<sub>2</sub>(dba)<sub>3</sub> (23 mg, 0.025 mmol) and <i>rac</i>-BINAP (46 mg, 0.07 mmol) were dissolved in toluene (9 mL) and stirred for 5 min under nitrogen atmosphere. Then NaO<sup><i>t</i></sup>Bu (83 mg, 0.87 mmol), 1-boc-piperazin (290 mg, 1.56 mmol), and <b>8c</b> (200 mg, 0.62 mmol) were added and the reaction mixture was stirred in a sealed microwave reaction tube at 85 °C for 1 d. After cooling down to room temperature, the reaction was diluted with EtOAc was added. The combined organic layer was washed with 0.5 M HCl, water, and brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and evaporated. Purification by flash chromatography (hexanes/EtOAc 10:1 to 1:1) yielded <b>8d</b> (185 mg, 70%) as orange solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz) δ 1.48 (s, 9H), 2.89–2.94 (m, 4H), 3.53–3.63 (m, 4H), 4.29–4.33 (m, 2H), 4.33–4.40 (m, 2H), 5.09 (s, 2H), 6.38 (d, <i>J</i> = 8.9 Hz, 1H), 6.45 (d, <i>J</i> = 8.9 Hz, 1H), 7.27–7.32 (m, 1H), 7.33–7.38 (m, 2H), 7.42–7.45 (m, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 151 MHz) δ 28.61, 44.13, 51.29, 64.21, 64.39, 71.61, 79.83, 105.8, 109.2, 127.5, 128.0, 128.6, 134.9, 135.8, 137.4, 137.7, 144.5, 154.9. IR (NaCl) ν 2922, 2852, 1689, 1500, 1453, 1422, 1364, 1282, 1239, 1170, 1116, 998 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 20.2 min, purity 92%; (system 2) <i>t</i><sub>R</sub> = 16.7 min, purity 91%. ESI-MS <i>m</i>/<i>z</i> 427.1 [M + H<sup>+</sup>].</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 1-[8-(Benzyloxy)-2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-5-yl]piperazine (<b>8e</b>)</h4><div class="NLM_p last">Compound <b>8e</b> was prepared according to the protocol of <b>5g</b>, using a solution of <b>8d</b> (450 mg, 1.05 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (12 mL) and TFA (1.2 mL). Purification by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 15:1) yielded <b>8e</b> (214 mg, 66%) as a colorless solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 2.99–2.96 (m, 4H), 3.10–3.06 (m, 4H), 4.33–4.30 (m, 2H), 4.35–4.33 (m, 2H), 5.09 (s, 2H), 6.41 (d, <i>J</i> = 8.9 Hz, 1H), 6.45 (d, <i>J</i> = 8.9 Hz, 1H), 7.29 (t, <i>J</i> = 7.3 Hz, 1H), 7.36 (dd, <i>J</i> = 10.3, 4.7 Hz, 2H), 7.43 (d, <i>J</i> = 7.5 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 91 MHz) δ 46.18, 52.19, 64.21, 64.36, 71.61, 105.8, 109.2, 127.6, 128.0, 128.6, 134.9, 136.2, 137.4, 137.7, 144.3. IR(NaCl) ν 3396, 2926, 2873, 1501, 1471, 1278, 1239, 1112, 996, 789 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 16.6 min, purity 93%; (system 2) <i>t</i><sub>R</sub> = 13.5 min, purity 95%. ESI-MS <i>m</i>/<i>z</i> 327.1 [M + H<sup>+</sup>].</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>tert</i>-Butyl 4-[8-(Benzyloxy)quinolin-5-yl]piperazine-1-carboxylate (<b>9d</b>)</h4><div class="NLM_p last">To a solution of 1-boc-piperazine (391 mg, 2.1 mmol) in toluene (15 mL), Pd(OAc)<sub>2</sub> (9 mg, 0.04 mmol) and <i>rac</i>-BINAP (0.13 mmol, 86 mg) were added. After stirring for 15 min, <b>9c</b> (330 mg, 1.0 mmol) and NaO<sup><i>t</i></sup>Bu (141 mg, 1.47 mmol) were added. The tube was sealed, and the reaction mixture was stirred at 115 °C for 1 d. After cooling down to room temperature, the reaction mixture was diluted with EtOAc, and the organic layer was washed with 0.5 M HCl, water, and brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and evaporated. Purification of the crude product by flash chromatography (H/EtOAc 20:1 to 2:1) yielded <b>9d</b> (320 mg, 73%) as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 1.50 (s, 9H), 2.72–3.18 (m, 4H), 3.31–4.22 (m, 4H), 5.42 (s, 2H), 6.94 (d, <i>J</i> = 8.3 Hz, 1H), 6.98 (d, <i>J</i> = 8.3 Hz, 1H), 7.30 (t, <i>J</i> = 7.4 Hz, 1H), 7.37 (dd, <i>J</i> = 10.4, 4.7 Hz, 2H), 7.46 (dd, <i>J</i> = 8.5, 4.2 Hz, 1H), 7.49–7.55 (m, 2H), 8.55 (dd, <i>J</i> = 8.5, 1.7 Hz, 1H), 8.99 (dd, <i>J</i> = 4.2, 1.7 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 151 MHz) δ 28.59, 44.43, 53.37, 70.98, 80.01, 109.7, 115.8, 121.2, 125.5, 127.2, 127.9, 128.7, 132.0, 137.3, 141.3, 142.4, 149.4, 151.2, 155.0. IR (NaCl) ν 2974, 2928, 2858, 2815, 1691, 1608, 1454, 1365, 1247, 1170, 1103, 1008, 912, 734 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 19.1 min, purity 99% (system 2) <i>t</i><sub>R</sub> = 16.3 min, purity 99%. ESI-MS <i>m</i>/<i>z</i> 420.4 [M + H<sup>+</sup>].</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 4-[8-(Benzyloxy)quinolin-5-yl]piperazine (<b>9e</b>)</h4><div class="NLM_p last">Compound <b>9e</b> was prepared following the protocol of <b>5g</b>, using a mixture of <b>9d</b> (600 mg, 1.43 mmol) and TFA (1.8 mL) in CH<sub>2</sub>Cl<sub>2</sub> (18 mL). Purification by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 15:1) yielded <b>9e</b> (443 mg, 97%) as a light-yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 2.97–3.08 (m, 4H), 3.16 (t, <i>J</i> = 4.8 Hz, 4H), 5.42 (s, 2H), 6.94 (d, <i>J</i> = 8.3 Hz, 1H), 7.00 (d, <i>J</i> = 8.3 Hz, 1H), 7.29 (t, <i>J</i> = 7.4 Hz, 1H), 7.33–7.38 (m, 2H), 7.45 (dd, <i>J</i> = 8.5, 4.1 Hz, 1H), 7.51 (d, <i>J</i> = 7.2 Hz, 2H), 8.53 (dd, <i>J</i> = 8.5, 1.7 Hz, 1H), 8.98 (dd, <i>J</i> = 4.1, 1.7 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 151 MHz) δ 46.42, 54.23, 71.00, 109.7, 115.7, 121.1, 125.5, 127.2, 127.9, 128.7, 132.1, 137.4, 141.4, 142.9, 149.4, 151.1. IR (NaCl) ν 3416, 3062, 2943, 2821, 1607, 1472, 1364, 1304, 1253, 1099, 911, 816, 792, 734 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 14.2 min, purity 99% (system 1) <i>t</i><sub>R</sub> = 11.5 min, purity 99%. ESI-MS <i>m</i>/<i>z</i> 320.3 [M + H<sup>+</sup>], 342.2 [M + Na<sup>+</sup>].</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 7-(4-{4-[2,8-Bis(benzyloxy)quinolin-5-yl]piperazin-1-yl}butoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (<b>10a</b>)</h4><div class="NLM_p last">A solution of 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (214 mg, 0.72 mmol) and NaI (162 mg, 1.08 mmol) in acetonitrile (3.6 mL) was heated to for 0.5 h before a solution <b>5g</b> (400 mg, 0.94 mmol) and triethylamine (150 μL, 1.08 mmol) in acetonitrile (1.8 mL) was added. The reaction mixture was stirred at 80 °C for further 16 h. After cooling down to room temperature, saturated NaHCO<sub>3</sub> solution was added and the product was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated. Purification by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 40:1 to15:1) yielded <b>10a</b> (263 mg, 57%) as a colorless solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 1.68–1.78 (m, 2H), 1.78–1. 90 (m, 2H), 2.49–2.56 (m, 2H), 2.61 (dd, <i>J</i> = 8.2, 6.8 Hz, 2H), 2.65–2.86 (m, 4H), 2.83–2.94 (m, 2H), 2.96–3.12 (m, 4H), 3.97 (t, <i>J</i> = 6.3 Hz, 2H), 5.30 (s, 2H), 5.58 (s, 2H), 6.33 (d, <i>J</i> = 2.4 Hz, 1H), 6.53 (dd, <i>J</i> = 8.3, 2.4 Hz, 1H), 6.91 (d, <i>J</i> = 8.3 Hz, 1H), 6.97 (d, <i>J</i> = 9.0 Hz, 1H), 7.02–7.08 (m, 2H), 7.27–7.33 (m, 2H), 7.33–7.43 (m, 4H), 7.50–7.60 (m, 4H), 8.07 (s, 1H), 8.38 (d, <i>J</i> = 9.0 Hz, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 151 MHz) δ 23.58, 24.75, 27.43, 31.25, 53.48, 53.89, 58.45, 67.80, 68.06, 71.99, 102.3, 108.8, 112.5, 113.1, 113.2, 115.9, 122.1, 127.4, 127.8, 127.9, 128.5, 128.5, 128.7, 128.8, 135.5, 137.6, 138.0, 138.3, 139.7, 143.9, 150.0, 158.8, 161.2, 171.8. IR (NaCl) ν 3416, 2918, 2850, 2090, 1633, 1268 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 19.4 min, purity 96%; (system 2) <i>t</i><sub>R</sub> = 16.3 min, purity 99%. ESI-MS <i>m</i>/<i>z</i> 644.1 [M + H<sup>+</sup>].</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 7-(4-{4-[8-(Benzyloxy)-2-oxo-2<i>H</i>-chromen-5-yl]piperazin-1-yl}butoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (<b>10b</b>)</h4><div class="NLM_p last">Compound <b>10b</b> was prepared as described for <b>10a</b>, using a solution of 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (27 mg, 0.092 mmol) and NaI (25 mg, 0.166 mmol) in acetonitrile (0.4 mL) and a solution of <b>6f</b> (34 mg, 0.101 mmol) and triethylamine (23 μL, 0.166 mmol) in acetonitrile (0.2 mL). Purification by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 40:1 to15:1) yielded <b>10b</b> (37 mg, 74%) as a yellow solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz) δ 1.54–1.63 (m, 2H), 1.69–1.76 (m, 2H), 2.36–2.45 (m, 4H), 2.55–2.63 (m, 4H), 2.77 (t, <i>J</i> = 7.5 Hz, 2H), 2.88 (s, 4H), 3.92 (t, <i>J</i> = 6.4 Hz, 2H), 5.20 (s, 2H), 6.43 (d, <i>J</i> = 2.5 Hz, 1H), 6.47 (d, <i>J</i> = 9.8 Hz, 1H), 6.49 (dd, <i>J</i> = 8.3, 2.5 Hz, 1H), 6.95 (d, <i>J</i> = 8.8 Hz, 1H), 7.04 (d, <i>J</i> = 8.3 Hz, 1H), 7.30 (d, <i>J</i> = 8.8 Hz, 1H), 7.35 (t, <i>J</i> = 7.3 Hz, 1H), 7.42 (dd, <i>J</i> = 10.3, 4.7 Hz, 2H), 7.49 (d, <i>J</i> = 7.2 Hz, 2H), 8.08 (d, <i>J</i> = 9.8 Hz, 1H), 9.96 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 151 MHz) δ 22.73, 23.98, 26.60, 30.74, 52.90, 53.14, 57.31, 67.28, 70.43, 101.7, 107.5, 114.2, 114.3, 115.2, 115.4, 116.3, 127.8, 128.0, 128.4, 128.5, 136.7, 139.2, 140.6, 141.6, 143.7, 144.1, 157.9, 159.5, 170.2. IR (NaCl) ν 3406, 1645, 1269, 1196, 1066 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 17.8 min, purity 99%; (system 2) <i>t</i><sub>R</sub> = 15.3 min, purity 99%. ESI-MS <i>m</i>/<i>z</i> 554.4 [M + H<sup>+</sup>].</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 7-(4-{4-[4-Benzyl-5-(benzyloxy)-2<i>H</i>-benzo[b][1,4]oxazin-3(4<i>H</i>)-one-8-yl]piperazin-1-yl}butoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (<b>10c</b>)</h4><div class="NLM_p last">Compound <b>10c</b> was prepared following the protocol for <b>10a</b> using a solution of 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (27 mg, 0.09 mmol) and NaI (24 mg, 0.16 mmol) in acetonitrile (0.9 mL) and a solution of <b>7g</b> (47 mg, 0.11 mmol) and triethylamine (20 μL, 0.16 mmol) in acetonitrile (0.4 mL). Purification by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 40:1 to 15:1) yielded <b>10c</b> (40 mg, 68%) as a colorless solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 1.73–1.77 (m, 2H), 1.78–1.98 (m, 2H), 2.53–2.58 (m, 2H), 2.57–2.68 (m, 2H), 2.72–2.82 (m, 4H), 2.85–2.96 (m, 2H), 3.02–3.11 (m, 4H), 3.96 (t, <i>J</i> = 6.1 Hz, 2H), 4.57 (s, 2H), 4.91 (s, 2H), 5.38 (s, 2H), 6.30 (d, <i>J</i> = 2.4 Hz, 1H), 6.50–6.53 (m, 1H), 6.53 (d, <i>J</i> = 9.0 Hz, 1H), 6.61 (d, <i>J</i> = 9.0 Hz, 1H), 6.97–7.03 (m, 2H), 7.04 (d, <i>J</i> = 8.3 Hz, 1H), 7.10–7.18 (m, 3H), 7.29–7.33 (m, 2H), 7.33–7.40 (m, 3H), 7.77 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 151 MHz) δ 22.96, 24.59, 27.13, 31.09, 46.73, 50.47, 53.08, 58.04, 67.76, 68.77, 71.40, 102.2, 107.7, 108.7, 114.2, 115.8, 119.9, 126.8, 126.9, 127.6, 128.2, 128.2, 128.6, 128.6, 135.5, 136.2, 137.2, 138.1, 142.6, 145.1, 158.6, 166.5, 171.7. IR (NaCl) ν 3437, 2948, 2823, 1650, 1387, 1272, 1187, 1097 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 19.3 min, purity 99%; (system 2) <i>t</i><sub>R</sub> = 16.3 min, purity 99%. ESI-MS <i>m</i>/<i>z</i> 647.5 [M + H<sup>+</sup>].</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 7-(4-{4-[8-(Benzyloxy)-2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-5-yl]piperazin-1-yl}butoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (<b>10d</b>)</h4><div class="NLM_p last">Compound <b>10d</b> was prepared following the protocol for <b>10a</b> using a solution of 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (23 mg, 0.08 mmol) and NaI (20 mg, 0.14 mmol) in acetonitrile (0.5 mL) and a solution of <b>8e</b> (34 mg, 0.10 mmol) and triethylamine (19 μL, 0.14 mmol) in acetonitrile (0.3 mL). Purification by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 40:1 to 15:1) yielded <b>10d</b> (27 mg, 64%) as a colorless solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 1.68–1.77 (m, 2H), 1.78–1.87 (m, 2H), 2.41–2.53 (m, 2H), 2.54–2.65 (m, 2H), 2.67–2.74 (m, 4H), 2.86–2.93 (m, 2H), 2.95–3.16 (m, 4H), 3.96 (t, <i>J</i> = 6.3 Hz, 2H), 4.30–4.32 (m, 2H), 4.32–4.35 (m, 2H), 5.09 (s, 2H), 6.27 (d, <i>J</i> = 2.4 Hz, 1H), 6.41 (d, <i>J</i> = 8.9 Hz, 1H), 6.45 (d, <i>J</i> = 8.9 Hz, 1H), 6.52 (dd, <i>J</i> = 8.3, 2.4 Hz, 1H), 7.04 (d, <i>J</i> = 8.3 Hz, 1H), 7.32–7.28 (m, 1H), 7.33–7.39 (m, 2H), 7.42–7.44 (m, 2H), 7.45 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 91 MHz) δ 23.45, 24.78, 27.41, 31.27, 51.08, 53.51, 58.38, 64.20, 64.38, 68.09, 71.62, 102.3, 105.8, 108.8, 109.1, 115.9, 127.6, 128.0, 128.7, 128.9, 134.8, 137.5, 137.7, 138.2, 144.3, 158.8, 171.4. IR (NaCl) ν 3432, 2817, 1645, 1510, 1265, 1108 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 17.9 min, purity 98%; (system 2) <i>t</i><sub>R</sub> = 15.2 min, purity 98%. ESI-MS <i>m</i>/<i>z</i> 544.8 [M + H<sup>+</sup>].</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 7-(4-{4-[8-(Benzyloxy)quinolin-5-yl]piperazin-1-yl}butoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (<b>10e</b>)</h4><div class="NLM_p last">Compound <b>10e</b> was prepared as described for <b>10a</b> using a solution of 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (80 mg, 0.267 mmol) and NaI (72 mg, 0.480 mmol) in acetonitrile (1.4 mL) and a solution of <b>9e</b> (102 mg, 0.320 mmol) and triethylamine (62 μL, 0.480 mmol) in acetonitrile (0.7 mL). Purification by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 40:1 to 15:1) yielded <b>10e</b> (107 mg, 74%) as a light-yellow solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz) δ 1.59–1.68 (m, 2H), 1.71–1.81 (m, 2H), 2.37–2.46 (m, 4H), 2.52–2.73 (m, 4H), 2.78 (t, <i>J</i> = 7.5 Hz, 2H), 2.87–3.05 (m, 4H), 3.94 (t, <i>J</i> = 6.4 Hz, 2H), 5.27 (s, 2H), 6.45 (d, <i>J</i> = 2.5 Hz, 1H), 6.50 (dd, <i>J</i> = 8.2, 2.5 Hz, 1H), 7.04 (d, <i>J</i> = 8.3 Hz, 1H), 7.12 (d, <i>J</i> = 8.3 Hz, 1H), 7.18 (d, <i>J</i> = 8.4 Hz, 1H), 7.35 (t, <i>J</i> = 7.4 Hz, 1H), 7.40–7.44 (m, 2H), 7.52–7.58 (m, 3H), 8.47 (dd, <i>J</i> = 8.5, 1.7 Hz, 1H), 8.86 (dd, <i>J</i> = 4.1, 1.7 Hz, 1H), 9.97 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 91 MHz) δ 23.34, 24.75, 27.37, 31.24, 53.12, 53.75, 58.33, 68.01, 71.04, 102.3, 108.8, 109.8, 115.7, 115.9, 121.1, 125.5, 127.3, 127.9, 128.7, 128.8, 132.1, 137.4, 138.3, 141.5, 142.5, 149.4, 151.1, 158.8, 171.7. IR (NaCl) ν 3432, 1640, 1453, 1369, 1266, 1191, 1097 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 16.1 min, purity 99%; (system 2) <i>t</i><sub>R</sub> = 13.1 min, purity 99%. ESI-MS <i>m</i>/<i>z</i> 537.6 [M + H<sup>+</sup>].</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 7-(4-{4-[2,8-Bis(benzyloxy)quinolin-5-yl]-1,4-diazepan-1-yl}butoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (<b>11a</b>)</h4><div class="NLM_p last">Compound <b>11a</b> was prepared as described for <b>10a</b> using a solution of 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (60 mg, 0.20 mmol) and NaI (55 mg, 0.36 mmol) in acetonitrile (1.0 mL) and a solution of <b>5h</b> (98 mg, 0.22 mmol) and triethylamine (50 μL, 0.36 mmol) in acetonitrile (0.5 mL). Purification by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 40:1 to 15:1) yielded <b>11a</b> (91 mg, 68%) as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 360 MHz) δ 1.77–1.89 (m, 4H), 2.01–2.21 (m, 2H), 2.45–2.74 (m, 2H), 2.78–2.99 (m, 4H), 3.04–3.17 (m, 4H), 3.23 (t, <i>J</i> = 6.0 Hz, 2H), 3.30–3.46 (m, 2H), 3.89–4.15 (m, 2H), 5.30 (s, 2H), 5.58 (s, 2H), 6.33 (d, <i>J</i> = 2.4 Hz, 1H), 6.52 (dd, <i>J</i> = 8.3, 2.4 Hz, 1H), 6.94–6.99 (m, 2H), 7.00–7.09 (m, 2H), 7.27–7.47 (m, 6H), 7.50–7.64 (m, 4H), 7.83 (s, 1H), 8.35–8.47 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 91 MHz) δ 23.21, 24.76, 27.09, 31.24, 54.18, 55.89, 56.50, 58.06, 67.79, 67.84, 71.97, 102.4, 108.8, 112.8, 113.1, 115.6, 116.1, 122.6, 127.4, 127.8, 128.0, 128.5, 128.6, 128.7, 128.9, 135.5, 137.6, 137.9, 138.3, 139.6, 150.2, 158.0, 161.3, 171.5. IR (NaCl) ν 3442, 3057, 2989, 1645, 1266, 736 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 20.2 min, purity 97%; (system 2) <i>t</i><sub>R</sub> = 17.6 min, purity 97%. ESI-MS <i>m</i>/<i>z</i> 657.4 [M + H<sup>+</sup>].</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 7-(4-{4-[8-(Benzyloxy)-2-oxo-2<i>H</i>-chromen-5-yl]-1,4-diazepan-1-yl}butoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (<b>11b</b>)</h4><div class="NLM_p last">Compound <b>11b</b> was prepared as described for <b>10a</b> using a solution of 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (23 mg, 0.078 mmol) and NaI (17 mg, 0.117 mmol) in acetonitrile (0.8 mL) and a solution of <b>6g</b> (30 mg, 0.086 mmol) and triethylamine (20 μL) in acetonitrile (0.4 mL). Purification by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 40:1 to 15:1) yielded <b>11b</b> (20 mg, 45%) as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 1.74–1.95 (m, 4H), 2.15–2.04 (m, 2H), 2.58 (dd, <i>J</i> = 8.2, 6.8 Hz, 2H), 2.81–2.95 (m, 4H), 3.09–3.23 (m, 6H), 3.31–3.42 (m, 2H), 3.97 (t, <i>J</i> = 5.9 Hz, 2H), 5.17 (s, 2H), 6.39 (d, <i>J</i> = 9.8 Hz, 1H), 6.43 (d, <i>J</i> = 2.4 Hz, 1H), 6.50 (dd, <i>J</i> = 8.3, 2.4 Hz, 1H), 6.87 (d, <i>J</i> = 8.7 Hz, 1H), 7.01 (dd, <i>J</i> = 8.5, 5.0 Hz, 2H), 7.28–7.34 (m, 1H), 7.34–7.39 (m, 2H), 7.45 (dd, <i>J</i> = 7.9, 0.8 Hz, 2H), 8.12 (d, <i>J</i> = 9.8 Hz, 1H), 8.54 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 91 MHz) δ 23.02, 24.69, 26.88, 26.96, 31.21, 54.22, 55.99, 58.10, 67.74, 71.83, 102.5, 108.8, 115.7, 115.7, 116.0, 116.6, 117.1, 127.6, 128.2, 128.7, 136.6, 138.4, 140.7, 142.6, 145.2, 145.4, 158.5, 160.3, 171.9. IR (NaCl) ν 3406, 1645, 1270, 1191 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 18.0 min, purity 99%; (system 2) <i>t</i><sub>R</sub> = 15.5 min, purity 99%. ESI-MS <i>m</i>/<i>z</i> 568.2 [M + H<sup>+</sup>].</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 7-(4-{4-[4-Benzyl-5-(benzyloxy)-2<i>H</i>-benzo[<i>b</i>][1,4]oxazin-3(4<i>H</i>)-one-8-yl]-1,4-diazepan-1-yl}butoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (<b>11c</b>)</h4><div class="NLM_p last">Compound <b>11c</b> was prepared as described for <b>10a</b>, using a solution of 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(<i>1H</i>)-one (31 mg, 0.10 mmol) and NaI (23 mg, 0.15 mmol) in acetonitrile (1.0 mL) and a solution of <b>7h</b> (50 mg, 0.11 mmol) and triethylamine (20 μL, 0.15 mmol) in acetonitrile (0.5 mL). Purification by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 50:1 to 15:1) yielded <b>11c</b> (46 mg, 68%) as a colorless solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 1.80–1.91 (m, 2H), 1.94–2.06 (m, 2H), 2.24–2.32 (m, 2H), 2.53–2.63 (m, 2H), 2.88 (t, <i>J</i> = 7.5 Hz, 2H), 2.93–3.06 (m, 2H), 3.12–3.31 (m, 6H), 3.34–3.46 (m, 2H), 3.97 (t, <i>J</i> = 6.0 Hz, 2H), 4.52 (s, 2H), 4.92 (s, 2H), 5.38 (s, 2H), 6.35 (d, <i>J</i> = 2.3 Hz, 1H), 6.48–6.55 (m, 2H), 6.57 (d, <i>J</i> = 9.1 Hz, 1H), 7.00–7.05 (m, 3H), 7.10–7.20 (m, 3H), 7.28–7.32 (m, 2H), 7.32–7.40 (m, 3H), 8.00 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 91 MHz) δ 22.38, 24.77, 26.95, 29.84, 31.24, 39.31, 46.93, 50.61, 53.39, 56.67, 57.70, 67.57, 68.94, 71.74, 102.4, 108.0, 108.7, 114.5, 116.2, 120.3, 127.0, 127.1, 127.7, 128.3, 128.4, 128.8, 128.9, 136.4, 137.4, 138.4, 142.1, 144.6, 158.5, 166.5, 171.5. IR (NaCl) ν 3429, 1642, 1390, 1267, 1098 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 19.7 min, purity 96%; (system 2) <i>t</i><sub>R</sub> = 16.8 min, purity 97%. ESI-MS <i>m</i>/<i>z</i> 661.3 [M + H<sup>+</sup>].</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 7-{4-[4-(8-Hydroxyquinolin-2(1<i>H</i>)-one-5-yl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1<i>H</i>)-one·TFA (<b>12a</b>)</h4><div class="NLM_p last">To a solution of <b>10a</b> (85 mg, 0.13 mmol) in acetic acid (1.8 mL) under nitrogen atmosphere, a catalytic amount of 10% Pd/C was added. The flask was flushed with hydrogen, and the reaction mixture was stirred at room temperature for 4 h. After filtering over Celite and washing with MeOH, the solvent was evaporated. Purification of the crude product by preparative HPLC yielded the TFA-salt of <b>12a</b> (38 mg, 63%) as a brown solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz) δ 1.44–1.63 (m, 2H), 1.64–1.81 (m, 2H), 2.32–2.45 (m, 4H), 2.53–2.63 (m, 4H), 2.69–2.80 (m, 2H), 2.80–2.89 (m, 4H), 3.91 (t, <i>J</i> = 6.3 Hz, 2H), 6.40–6.44 (m, 1H), 6.44–6.52 (m, 2H), 6.70 (d, <i>J</i> = 8.4 Hz, 1H), 6.86 (d, <i>J</i> = 8.4 Hz, 1H), 7.02 (d, <i>J</i> = 8.2 Hz, 1H), 7.99 (d, <i>J</i> = 9.8 Hz, 1H), 9.94 (s, 1H), 10.37 (s, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 91 MHz) δ 22.73, 23.98, 26.62, 30.73, 53.10, 53.16, 57.37, 67.30, 101.7, 107.6, 111.7, 114.5, 114.6, 115.4, 121.1, 128.3, 129.1, 136.2, 139.2, 139.7, 142.0, 157.7, 161.0, 170.2. IR (NaCl) ν 3427,2895, 2786, 1635, 1541, 1338, 1249, 1088, 889, 754, 680, 603 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 15.3 min, purity 97%; (system 2) <i>t</i><sub>R</sub> = 12.3 min, purity 96%. ESI-MS <i>m</i>/<i>z</i> 463.2 [M + H<sup>+</sup>]. HRMS-ESI calcd 463.2340; found 463.2339 [M + H<sup>+</sup>].</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 7-{4-[4-(8-Hydroxy-2-oxo-2<i>H</i>-chromen-5-yl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1<i>H</i>)-one (<b>12b</b>)</h4><div class="NLM_p last">To a solution of <b>10b</b> (32 mg, 0.058 mmol) in toluene (0.56 mL) was added TFA (0.24 mL). The reaction mixture was stirred under reflux for 8 h. After cooling down to room temperature, the pH was adjusted to 7–8 with NaHCO<sub>3</sub> solution and the product was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated. Purification of the crude product by preparative HPLC yielded the TFA-salt of <b>12b</b> (22 mg, 66%) as a yellow solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 360 MHz) δ 1.67–1.98 (m, 4H), 2.37–2.44 (m, 2H), 2.77 (t, <i>J</i> = 7.5 Hz, 2H), 2.94–3.09 (m, 2H), 3.12–3.36 (m, 6H), 3.52–3.61 (m, 2H), 3.94 (t, <i>J</i> = 5.7 Hz, 2H), 6.43 (d, <i>J</i> = 2.6 Hz, 1H), 6.45 (d, <i>J</i> = 9.9 Hz, 1H), 6.49 (dd, <i>J</i> = 8.2, 2.5 Hz, 1H), 6.94 (d, <i>J</i> = 8.6 Hz, 1H), 7.05 (d, <i>J</i> = 8.2 Hz, 1H), 7.06 (d, <i>J</i> = 8.6 Hz, 1H), 8.16 (d, <i>J</i> = 9.8 Hz, 1H), 9.67 (s, 1H), 9.98 (s, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 151 MHz) δ 20.78, 24.45, 26.27, 31.21, 50.46, 51.82, 55.73, 67.11, 102.2, 107.9, 115.2, 115.7, 115.8, 116.2, 118.6, 128.9, 139.7, 140.7, 141.1, 142.0, 143.4, 158.1, 160.0, 170.7. IR (NaCl) ν 3432, 2958, 2848, 1675, 1478, 1376, 1275, 1200, 1139, 1025, 994, 832, 721 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 15.4 min, purity 97%; (system 2) <i>t</i><sub>R</sub> = 12.8 min, purity 97%. ESI-MS <i>m</i>/<i>z</i> 464.3 [M + H<sup>+</sup>]. HRMS-ESI calcd 464.2180; found 464.2174 [M + H<sup>+</sup>].</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 7-{4-[4-(5-Hydroxy-2<i>H</i>-benzo[<i>b</i>][1,4]oxazin-3(4<i>H</i>)-one-8-yl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1<i>H</i>)-one (<b>12c</b>)</h4><div class="NLM_p last">To a suspension of <b>10c</b> (9 mg, 0.01 mmol) in toluene (0.1 mL) was added MsOH (50 μL, 0.07 mmol). The reaction mixture was stirred under reflux for 3 h. After cooling down to room temperature, the solvent was removed. Purification of the crude product by flash chromatography yielded <b>12c</b> (5 mg, 77%) as a colorless solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz) δ 1.69–1.79 (m, 2H), 1.79–1.89 (m, 2H), 2.38–2.47 (m, 2H), 2.76–2.85 (m, 2H), 2.89–3.00 (m, 2H), 3.11–3.18 (m, 2H), 3.18–3.24 (m, 2H), 3.30–3.35 (m, 2H), 3.48–3.61 (m, 2H), 3.94 (t, <i>J</i> = 6.0 Hz, 2H), 4.50 (s, 2H), 6.44–6.46 (m, 1H), 6.46–6.47 (m, 1H), 6.48–6.49 (m, 1H), 6.49–6.51 (m, 1H), 7.06 (d, <i>J</i> = 8.3 Hz, 1H), 9.66 (s, 1H), 9.80 (s, 1H), 9.87 (s, 1H), 10.01 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 151 MHz) δ 20.59, 24.32, 26.16, 31.07, 48.00, 51.60, 55.57, 67.00, 67.11, 102.1, 107.8, 108.8, 112.7, 116.0, 117.1, 128.7, 132.0, 137.8, 139.5, 141.7, 158.0, 164.7, 170.6. IR (NaCl) ν 3341, 3030, 2921, 2851, 1611, 1598, 1478, 1280, 1250, 826, 725, 692 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 15.4 min, purity 96%; (system 2) <i>t</i><sub>R</sub> = 12.4 min, purity 96%. ESI-MS <i>m</i>/<i>z</i> 467.1 [M + H<sup>+</sup>].</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 7-(4-[4-(8-Hydroxy-2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-5-yl)piperazin-1-yl]butoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one (<b>12d</b>)</h4><div class="NLM_p last">To a solution of <b>10d</b> (73 mg, 0.12 mmol) in acetic acid/methanol (0.17 mL, 1.7 mL) under nitrogen atmosphere, a catalytic amount of 10% Pd/C was added. The flask was flushed with hydrogen, and the reaction mixture was stirred at room temperature for 4 h. After filtering over Celite and washing with MeOH, the solvent was evaporated. Purification of the crude product by column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 20:1) yielded <b>12d</b> (32 mg, 61%) as a colorless solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 360 MHz) δ 1.50–1.64 (m, 2H), 1.66–1.79 (m, 2H), 2.36–2.46 (m, 4H), 2.73–2.82 (m, 2H), 2.83–2.92 (m, 4H), 3.17 (d, <i>J</i> = 4.7 Hz, 2H), 3.91 (t, <i>J</i> = 6.3 Hz, 2H), 4.17–4.24 (m, 4H), 6.27 (s, 2H), 6.43 (d, <i>J</i> = 2.5 Hz, 1H), 6.48 (dd, <i>J</i> = 8.2, 2.5 Hz, 1H), 7.04 (d, <i>J</i> = 8.2 Hz, 1H), 8.60 (s, 1H), 9.95 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 151 MHz) δ 21.03, 23.98, 26.58, 30.74, 48.58, 50.65, 52.98, 57.34, 63.41, 63.65, 67.26, 101.7, 106.5, 107.6, 108.9, 115.4, 128.3, 132.9, 137.4, 139.2, 157.8, 170.2. IR (NaCl) ν 3419, 2944, 1674, 1503, 1475, 1376, 1271, 1190, 1099, 988, 798, 734 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 15.1 min, purity 96%; (system 2) <i>t</i><sub>R</sub> = 12.5 min, purity 99%. ESI-MS <i>m</i>/<i>z</i> 454.1 [M + H<sup>+</sup>]. HRMS-ESI calcd 454.2336; found 454.2338 [M + H<sup>+</sup>].</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 7-{4-[4-(8-Hydroxyquinolin-5-yl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1<i>H</i>)-one·TFA (<b>12e</b>)</h4><div class="NLM_p last">Compound <b>12e</b> was prepared as described for <b>12b</b>, using a solution <b>10e</b> (59 mg, 0.11 mmol) and TFA (0.8 mL) in toluene (0.8 mL). Purification of the crude product by preparative HPLC yielded the TFA-salt of <b>12e</b> (38 mg, 62%) as an orange solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 360 MHz) δ 1.70–1.96 (m, 4H), 2.42 (dd, <i>J</i> = 8.3, 6.7 Hz, 2H), 2.79 (t, <i>J</i> = 7.5 Hz, 2H), 3.03–3.20 (m, 2H), 3.21–3.50 (m, 6H), 3.61–3.72 (m, 2H), 3.97 (t, <i>J</i> = 5.7 Hz, 2H), 6.45 (d, <i>J</i> = 2.4 Hz, 1H), 6.51 (dd, <i>J</i> = 8.2, 2.5 Hz, 1H), 7.07 (d, <i>J</i> = 8.3 Hz, 1H), 7.12 (d, <i>J</i> = 8.0 Hz, 1H), 7.26 (d, <i>J</i> = 7.5 Hz, 1H), 7.63–7.77 (m, 1H), 8.70 (d, <i>J</i> = 7.4 Hz, 1H), 8.90–9.20 (m, 1H), 9.72 (bs, 1H), 10.00 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 151 MHz) δ 20.24, 23.91, 25.76, 30.66, 49.78, 51.43, 55.24, 66.61, 101.7, 107.4, 111.5, 115.6, 117.7, 121.5, 124.3, 128.3, 134.1, 138.9, 139.1, 147.3, 149.1, 157.6, 170.2. IR (NaCl) ν 3411, 3245, 2953, 2854, 1679, 1593, 1522, 1374, 1272, 1201, 1130, 1029, 832, 801, 721 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 14.5 min, purity 99%; (system 2) <i>t</i><sub>R</sub> = 11.7 min, purity 99%. ESI-MS <i>m</i>/<i>z</i> 447.4 [M + H<sup>+</sup>]. HRMS-ESI calcd 447.2391; found 447.2386 [M + H<sup>+</sup>].</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 7-{4-[4-(8-Hydroxyquinolin-2(1<i>H</i>)-one-5-yl)-1,4-diazepan-1-yl]butoxy}-3,4-dihydroquinolin-2(1<i>H</i>)-one·TFA (<b>13a</b>)</h4><div class="NLM_p last">Compound <b>13a</b> was prepared according to the protocol of <b>12c</b>, using a solution of <b>11a</b> (77 mg, 0.177 mmol) and MsOH (0.7 mL) in toluene (2 mL). Purification of the crude product by preparative HPLC yielded the TFA-salt of <b>13a</b> (41 mg, 59%) as a brown solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz) δ 1.70–1.80 (m, 2H), 1.81–1.95 (m, 2H), 2.12 (m, 2H), 2.38–2.45 (m, 2H), 2.79 (t, <i>J</i> = 7.5 Hz, 2H), 3.06 (t, <i>J</i> = 5.9 Hz, 2H), 3.23–3.31 (m, 3H), 3.31–3.42 (m, 2H), 3.46 (dd, <i>J</i> = 14.5, 7.0 Hz, 1H), 3.54–3.63 (m, 2H), 3.95 (t, <i>J</i> = 6.1 Hz, 2H), 6.44 (d, <i>J</i> = 2.5 Hz, 1H), 6.48–6.53 (m, 2H), 6.83 (d, <i>J</i> = 8.4 Hz, 1H), 6.91 (d, <i>J</i> = 8.4 Hz, 1H), 7.06 (d, <i>J</i> = 8.3 Hz, 1H), 8.16 (d, <i>J</i> = 9.8 Hz, 1H), 9.72 (bs, 1H), 10.01 (bs, 1H), 10.11 (bs, 1H), 10.39 (bs, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 151 MHz) δ 20.76, 23.97, 24.34, 25.83, 30.72, 50.72, 52.49, 54.68, 55.02, 55.39, 56.22, 66.69, 101.7, 107.4, 114.5, 114.5, 115.5, 115.7, 121.4, 128.4, 128.8, 136.6, 139.2, 140.2, 141.7, 142.8, 157.7, 161.1, 170.2. IR (NaCl) ν 3432, 1640, 1202, 1145, 1025, 986 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 15.4 min, purity 96%; (system 2) <i>t</i><sub>R</sub> = 12.4 min, purity 96%. HRMS-ESI calcd 447.2496; found 447.2491 [M + H<sup>+</sup>].</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 7-{4-[4-(8-Hydroxy-2-oxo-2<i>H</i>-chromen-5-yl)-1,4-diazepan-1-yl]butoxy}-3,4-dihydroquinolin-2(1<i>H</i>)-one·TFA (<b>13b</b>)</h4><div class="NLM_p last">Compound <b>13b</b> was prepared as described for <b>12b</b>, using a solution of <b>11b</b> (12 mg, 0.02 mmol) and TFA (0.1 mL) in toluene (0.2 mL). Purification of the crude product by preparative HPLC yielded the TFA-salt of <b>13b</b> (9.5 mg, 79%) as a yellow solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz) δ 1.70–1.80 (m, 2H). 1.80–1.89 (m, 2H), 2.02–2.16 (m, 2H), 2.38–2.44 (m, 2H), 2.78 (t, <i>J</i> = 7.5 Hz, 2H), 3.05–3.12 (m, 2H), 3.16–3.26 (m, 2H), 3.42–3.54 (m, 4H), 3.94 (t, <i>J</i> = 6.0 Hz, 2H), 6.41–6.47 (m, 2H), 6.50 (dd, <i>J</i> = 8.2, 2.5 Hz, 1H), 6.99 (d, <i>J</i> = 8.6 Hz, 1H), 7.03–7.09 (m, 2H), 8.25 (d, <i>J</i> = 9.8 Hz, 1H), 10.01 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 151 MHz) δ 20.77, 23.89, 24.35, 25.81, 30.64, 52.41, 54.46, 55.36, 56.14, 66.66, 101.6, 107.4, 114.9, 115.2, 115.6, 117.3, 118.2, 128.3, 139.1, 141.1, 141.1, 142.5, 142.9, 157.6, 159.6, 170.2. IR (NaCl) ν 3427, 1640, 1267, 1196, 1147 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 15.6 min, purity 99%. ESI-MS <i>m</i>/<i>z</i> 478.1 [M + H<sup>+</sup>]. HRMS-ESI calcd 478.2336; found 478.2337 [M + H<sup>+</sup>].</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 7-{4-[4-(5-Hydroxy-2<i>H</i>-benzo[<i>b</i>][1,4]oxazin-3(4<i>H</i>)-one-8-yl)-1,4-diazepan-1-yl]butoxy}-3,4-dihydroquinolin-2(1<i>H</i>)-one·TFA (<b>13c</b>)</h4><div class="NLM_p last">Compound <b>13c</b> was prepared as described for <b>12c</b>, using a solution of <b>7c</b> (25 mg, 0.038 mmol) and MsOH (70 μL) in toluene (0.54 mL). Purification of the crude product by preparative HPLC yielded the TFA-salt of <b>13c</b> (12 mg, 53%) as a light-brown solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz) δ 1.67–1.77 (m, 2H), 1.78–1.94 (m, 2H), 2.12 (s, 2H), 2.36–2.46 (m, 2H), 2.78 (t, <i>J</i> = 7.5 Hz, 2H), 2.97–3.14 (m, 1H), 3.16–3.26 (m, 3H), 3.44–3.58 (m, 2H), 3.94 (t, <i>J</i> = 6.0 Hz, 2H), 4.50 (d, <i>J</i> = 3.7 Hz, 2H), 6.42 (d, <i>J</i> = 8.7 Hz, 1H), 6.44 (d, <i>J</i> = 2.4 Hz, 1H), 6.46 (d, <i>J</i> = 8.8 Hz, 1H), 6.50 (dd, <i>J</i> = 8.2, 2.5 Hz, 1H), 7.05 (d, <i>J</i> = 8.3 Hz, 1H), 9.50 (s, 1H), 9.67 (s, 1H), 9.82 (s, 1H), 10.00 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 151 MHz) δ 20.77, 23.99, 25.85, 30.74, 48.69, 49.97, 52.40, 55.15, 55.88, 66.71, 66.79, 101.7, 107.5, 108.3, 112.5, 115.7, 116.8, 128.4, 133.7, 136.9, 139.2, 140.1, 157.7, 164.5, 170.3. IR (NaCl) ν 3427, 2920, 2850, 1645, 1520, 1645, 1520, 1474, 1375, 1197, 1147, 1082 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 15.2 min, purity 99%. ESI-MS <i>m</i>/<i>z</i> 481.1 [M + H<sup>+</sup>]. HRMS-ESI calcd 481.2445; found 481.2432 [M + H<sup>+</sup>].</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 5-(4-{4-[2,8-Bis(benzyloxy)quinolin-5-yl]piperazin-1-yl}butoxy)pyrazolo[1,5-<i>a</i>]pyridine (<b>14a</b>)</h4><div class="NLM_p last">A solution of 5-(4-bromobutoxy)pyrazolo[1,5-<i>a</i>]pyridine (253 mg, 0.94 mmol) and NaI (253 mg, 1.69 mmol) in acetonitrile (4.7 mL) was stirred under reflux for 0.5 h before a solution of <b>5g</b> (439 mg, 1.03 mmol) and triethylamine (200 μL, 1.54 mmol) in acetonitrile (2.3 mL) was added. Stirring was continued at 80 °C for 16 h. After cooling down to room temperature, saturated NaHCO<sub>3</sub> solution was added and the product was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated. Purification by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 50:1 to 30:1) afforded <b>14a</b> (382 mg, 66%) as a yellow solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 360 MHz) δ 1.59–1.69 (m, 2H), 1.75–1.87 (m, 2H), 2.40–2.47 (m, 2H), 2.57–2.76 (m, 4H), 2.87–3.01 (m, 4H), 4.07 (t, <i>J</i> = 6.3 Hz, 2H), 5.27 (s, 2H), 5.53 (s, 2H), 6.36 (dd, <i>J</i> = 2.1, 0.6 Hz, 1H), 6.54 (dd, <i>J</i> = 7.5, 2.6 Hz, 1H), 6.96 (d, <i>J</i> = 8.4 Hz, 1H), 7.02 (d, <i>J</i> = 2.6 Hz, 1H), 7.07 (d, <i>J</i> = 9.1 Hz, 1H), 7.17 (d, <i>J</i> = 8.4 Hz, 1H), 7.28–7.36 (m, 4H), 7.40 (t, <i>J</i> = 7.4 Hz, 2H), 7.50–7.61 (m, 4H), 7.86 (d, <i>J</i> = 2.1 Hz, 1H), 8.37 (d, <i>J</i> = 9.1 Hz, 1H), 8.50 (d, <i>J</i> = 7.6 Hz, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 151 MHz) δ 22.71, 26.24, 53.07, 53.13, 54.89, 66.78, 67.78, 70.50, 95.29, 95.63, 106.5, 112.1, 112.6, 113.1, 121.1, 127.2, 127.6, 127.7, 128.2, 128.3, 128.6, 129.6, 135.5, 137.2, 137.8, 138.6, 140.6, 142.4, 155.0, 160.2. IR (NaCl) ν 3442, 3050, 2951, 2822, 1648, 1610, 1445, 1409, 1264, 1191, 1009, 897 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 20.1 min, purity 99%; (system 2) <i>t</i><sub>R</sub> = 17.6 min, purity 99%. ESI-MS <i>m</i>/<i>z</i> 615.0 [M + H<sup>+</sup>].</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 5-(4-{4-[8-(Benzyloxy)-2-oxo-2<i>H</i>-chromen-5-yl]piperazin-1-yl}butoxy)pyrazolo[1,5-<i>a</i>]pyridine (<b>14b</b>)</h4><div class="NLM_p last">Compound <b>14b</b> was prepared as described for <b>14a</b>, using a solution 5-(4-bromobutoxy)-pyrazolo[1,5-<i>a</i>]pyridine (33 mg, 0.122 mmol) and NaI (33 mg, 0.220 mmol) in acetonitrile (0.6 mL) and a solution of <b>6f</b> (45 mg, 0.134 mmol) and triethylamine (30 μL, 0.220 mmol) in acetonitrile (0.2 mL). Purification by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 40:1) yielded <b>14b</b> (42 mg, 65%) as a colorless solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz) δ 1.55–1.70 (m, 2H), 1.70–1.92 (m, 2H), 2.39–2.47 (m, 2H), 2.55–2.74 (m, 4H), 2.80–2.97 (m, 4H), 4.06 (t, <i>J</i> = 6.5 Hz, 2H), 5.20 (s, 2H), 6.33–6.40 (m, 1H), 6.47 (d, <i>J</i> = 9.8 Hz, 1H), 6.54 (dd, <i>J</i> = 7.5, 2.7 Hz, 1H), 6.93 (d, <i>J</i> = 8.8 Hz, 1H), 7.02 (d, <i>J</i> = 2.6 Hz, 1H), 7.29 (d, <i>J</i> = 8.8 Hz, 1H), 7.35 (t, <i>J</i> = 7.3 Hz, 1H), 7.42 (dd, <i>J</i> = 10.3, 4.7 Hz, 2H), 7.49 (d, <i>J</i> = 7.3 Hz, 2H), 7.86 (d, <i>J</i> = 2.1 Hz, 1H), 8.08 (d, <i>J</i> = 9.8 Hz, 1H), 8.50 (d, <i>J</i> = 7.5 Hz, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 151 MHz) δ 22.57, 26.14, 52.80, 53.05, 57.10, 67.67, 70.34, 95.20, 95.53, 106.4, 114.1, 114.2, 115.1, 116.2, 127.7, 127.9, 128.7, 130.0, 136.6, 140.2, 140.5, 141.6, 142.3, 143.6, 144.0, 155.0, 159.4. IR (NaCl) ν 2255, 2135, 1655, 1025, 995, 822 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 17.8 min, purity 96%; (system 2) <i>t</i><sub>R</sub> = 15.2 min, purity 92%. ESI-MS <i>m</i>/<i>z</i> 525.3 [M + H<sup>+</sup>].</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 5-(4-{4-[4-Benzyl-5-(benzyloxy)-2<i>H</i>-benzo[<i>b</i>][1,4]oxazin-3(4<i>H</i>)-one-8-yl]piperazin-1-yl}butoxy)pyrazolo[1,5-<i>a</i>]pyridine (<b>14c</b>)</h4><div class="NLM_p last">Compound <b>14c</b> was prepared as described for <b>14a</b>, using a solution 5-(4-bromobutoxy)-pyrazolo[1,5-<i>a</i>]pyridine (100 mg, 0.37 mmol) and NaI (84 mg, 0.56 mmol) in acetonitrile (4.8 mL) and a solution of <b>7g</b> (176 mg, 0.41 mmol) and triethylamine (80 μL, 0.56 mmol) in acetonitrile (0.4 mL). Purification by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 60:1 to 40:1) yielded <b>14c</b> (170 mg, 74%) as a colorless solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz) δ 1.55–1.66 (m, 2H), 1.74–1.81 (m, 2H), 2.38 (t, <i>J</i> = 7.1 Hz, 2H), 2.49–2.50 (m, 4H), 2.84–2.91 (m, 4H), 4.04 (t, <i>J</i> = 6.5 Hz, 2H), 4.59 (s, 2H), 5.01 (s, 2H), 5.29 (s, 2H), 6.35 (dd, <i>J</i> = 2.1, 0.6 Hz, 1H), 6.54 (dd, <i>J</i> = 7.5, 2.7 Hz, 1H), 6.62 (d, <i>J</i> = 9.1 Hz, 1H), 6.70 (d, <i>J</i> = 9.1 Hz, 1H), 6.99 (d, <i>J</i> = 7.2 Hz, 2H), 7.01 (d, <i>J</i> = 2.6 Hz, 1H), 7.15 (dd, <i>J</i> = 8.3, 6.3 Hz, 1H), 7.19–7.24 (m, <i>J</i> = 7.4 Hz, 2H), 7.32–7.40 (m, 5H), 7.86 (d, <i>J</i> = 2.1 Hz, 1H), 8.50 (d, <i>J</i> = 7.6 Hz, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 151 MHz) δ 22.64, 26.24, 45.62, 50.57, 52.82, 57.28, 67.77, 68.22, 70.63, 95.28, 95.61, 106.5, 107.8, 113.9, 119.4, 126.4, 126.8, 127.7, 128.0, 128.1, 128.2, 128.5, 129.6, 135.6, 136.5, 137.4, 140.6, 142.2, 142.4, 144.2, 155.0, 166.3. IR (NaCl) ν 3227, 291, 2812, 16861650, 1501, 1441, 1388, 1267, 1192, 1101, 1025, 792, 737, 698 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 19.3 min, purity 95%; (system 2) <i>t</i><sub>R</sub> = 16.5 min, purity 92%. ESI-MS <i>m</i>/<i>z</i> 618.2 [M + H<sup>+</sup>].</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 5-(4-{4-[8-(Benzyloxy)-2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-5-yl]piperazin-1-yl}butoxy)pyrazolo[1,5-<i>a</i>]pyridine (<b>14d</b>)</h4><div class="NLM_p last">Compound <b>14d</b> was prepared as described for <b>14a</b>, using a solution 5-(4-bromobutoxy)-pyrazolo[1,5-<i>a</i>]pyridine (81 mg, 0.30 mmol) and NaI (81 mg, 0.54 mmol) in acetonitrile (4.3 mL) and a solution of <b>8e</b> (118 mg, 0.36 mmol) and triethylamine (70 μL) in acetonitrile (0.4 mL). Purification by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 50:1) yielded <b>14d</b> (118 mg, 77%) as a colorless solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz) δ 1.54–1.71 (m, 2H), 1.73–1.81 (m, 2H), 2.35–2.40 (m, 2H), 2.84–2.93 (m, 4H), 4.05 (t, <i>J</i> = 6.5 Hz, 2H), 4.20–4.22 (m, 2H), 4.22–4.24 (m, 2H), 4.99 (s, 2H), 6.38–6.31 (m, 2H), 6.51 (d, <i>J</i> = 8.9 Hz, 1H), 6.54 (dd, <i>J</i> = 7.5, 2.7 Hz, 1H), 7.02 (d, <i>J</i> = 2.6 Hz, 1H), 7.32 (ddd, <i>J</i> = 7.2, 3.9, 1.3 Hz, 1H), 7.36–7.40 (m, 2H), 7.41–7.44 (m, 2H), 7.86 (d, <i>J</i> = 2.1 Hz, 1H), 8.50 (d, <i>J</i> = 7.6 Hz, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 91 MHz) δ 22.64, 26.23, 50.53, 52.95, 57.30, 63.43, 63.61, 67.77, 70.31, 95.26, 95.61, 105.3, 106.5, 108.3, 127.6, 127.7, 128.3, 129.5, 134.3, 135.6, 137.2, 137.4, 140.6, 142.4, 143.3, 155.0. IR (NaCl) ν 2872, 2818, 1646, 1496, 1441, 1337, 1275, 1193, 1116, 999 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 17.9 min, purity 98%; (system 2) <i>t</i><sub>R</sub> = 15.3 min, purity 95%. ESI-MS <i>m</i>/<i>z</i> 515.4 [M + H<sup>+</sup>].</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 5-(4-{4-[8-(Benzyloxy)quinolin-5-yl]piperazin-1-yl}butoxy)pyrazolo[1,5-<i>a</i>]pyridine (<b>14e</b>)</h4><div class="NLM_p last">Compound <b>14e</b> was prepared according to the protocol of <b>14a</b>, using a solution 5-(4-bromobutoxy)-pyrazolo[1,5-<i>a</i>]pyridine (80 mg, 0.30 mmol) and NaI (80 mg, 0.53 mmol) in acetonitrile (1.5 mL) and a solution of <b>9e</b> (114 mg, 0.36 mmol) and triethylamine (75 μL, 0.53 mmol) in acetonitrile. Purification by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 60:1 to 40:1) afforded <b>14e</b> (103 mg, 68%) as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 1.61–1.80 (m, 2H), 1.82–1.95 (m, 2H), 2.47–2.61 (m, 2H), 2.66–2.80 (m, 4H), 2.99–3.17 (m, 4H), 4.03 (t, <i>J</i> = 6.3 Hz, 2H), 5.41 (s, 2H), 6.30 (d, <i>J</i> = 1.7 Hz, 1H), 6.44 (dd, <i>J</i> = 7.5, 2.6 Hz, 1H), 6.74 (d, <i>J</i> = 2.5 Hz, 1H), 6.93 (d, <i>J</i> = 8.3 Hz, 1H), 6.99 (d, <i>J</i> = 8.3 Hz, 1H), 7.29 (t, <i>J</i> = 7.4 Hz, 1H), 7.36 (t, <i>J</i> = 7.5 Hz, 2H), 7.43 (dd, <i>J</i> = 8.5, 4.2 Hz, 1H), 7.47–7.55 (m, 2H), 7.85 (d, <i>J</i> = 2.1 Hz, 1H), 8.28 (d, <i>J</i> = 7.6 Hz, 1H), 8.53 (dd, <i>J</i> = 8.5, 1.5 Hz, 1H), 8.97 (dd, <i>J</i> = 4.1, 1.7 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 91 MHz) δ 23.57, 27.10, 53.36, 53.87, 58.33, 68.10, 71.04, 95.51, 95.55, 106.8, 109.8, 115.6, 121.0, 125.5, 127.2, 127.9, 128.7, 129.5, 132.1, 137.5, 141.2, 141.5, 142.9, 149.4, 151.1, 155.8. IR (NaCl) ν 2942, 2823, 1646, 1444, 1365, 1254, 1191, 1101 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 15.4 min, purity 95%; (system 2) <i>t</i><sub>R</sub> = 13.1 min, purity 96%. ESI-MS <i>m</i>/<i>z</i> 508.7 [M + H<sup>+</sup>].</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 7-(4-{4-[2,8-Bis(benzyloxy)quinolin-5-yl]-1,4-diazepan-1-yl}butoxy)pyrazolo[1,5-<i>a</i>]pyridine (<b>15a</b>)</h4><div class="NLM_p last">Compound <b>15a</b> was prepared as described for <b>14a</b> using a solution of 5-(4-bromobutoxy)-pyrazolo[1,5-<i>a</i>]pyridine (25 mg, 0.095 mmol) and NaI (21 mg, 0.142 mmol) in acetonitrile (0.95 mL) and a solution of <b>5h</b> (176 mg, 0.409 mmol) and triethylamine (80 μL, 0.558 mmol) in acetonitrile (0.4 mL). Purification by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 60:1 to 40:1) yielded <b>15a</b> (170 mg,74%) as a colorless solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 360 MHz) δ 1.85–1.98 (m, 4H), 2.07–2.19 (m, 2H), 2.77–2.94 (m, 2H), 3.06–3.19 (m, 4H), 3.24 (t, <i>J</i> = 6.0 Hz, 2H), 3.39 (m, 2H), 4.03 (t, <i>J</i> = 5.7 Hz, 2H), 5.30 (s, 2H), 5.58 (s, 2H), 6.30 (dd, <i>J</i> = 2.2, 0.7 Hz, 1H), 6.43 (dd, <i>J</i> = 7.6, 2.6 Hz, 1H), 6.73 (d, <i>J</i> = 2.5 Hz, 1H), 6.90–7.00 (m, 2H), 7.04 (d, <i>J</i> = 8.4 Hz, 1H), 7.28–7.43 (m, 6H), 7.50–7.62 (m, 4H), 7.85 (d, <i>J</i> = 2.2 Hz, 1H), 8.28 (d, <i>J</i> = 7.6 Hz, 1H), 8.40 (d, <i>J</i> = 9.1 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 91 MHz) δ 22.07, 26.64, 55.85, 56.55, 57.78, 67.38, 67.91, 71.80, 95.71, 95.81, 106.6, 112.8, 113.2, 116.3, 122.5, 127.4, 127.9, 128.0, 128.5, 128.6, 128.7, 129.6, 135.0, 137.4, 137.7, 139.5, 141.1, 143.0, 150.7, 155.4, 161.3. IR (NaCl) ν 3031, 2927, 2849, 2599, 1646, 1443, 1410, 1265, 1191, 1095, 1002 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 20.3 min, purity 83%; (system 2) <i>t</i><sub>R</sub> = 17.9 min, purity 83%. ESI-MS <i>m</i>/<i>z</i> 628.2 [M + H<sup>+</sup>].</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 5-{4-[4-(8-Hydroxyquinolin-2(1<i>H</i>)-one-5-yl)piperazin-1-yl]butoxy}pyrazolo[1,5-<i>a</i>]pyridine (<b>16a</b>)</h4><div class="NLM_p last">Compound <b>16a</b> was prepared as described for <b>12a</b>, using a solution of <b>14a</b> (378 mg, 0.62 mmol) and a catalytic amount of 10% Pd/C in AcOH/MeOH 1:1 (8.8 mL). Purification of the crude product flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 25:1 + 1% NH<sub>3</sub>) yielded <b>16a</b> (185 mg, 70%) as a yellow solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz) δ 1.57–1.71 (m, 2H), 1.76–1.86 (m, 2H), 2.43 (t, <i>J</i> = 7.2 Hz, 2H), 2.55–2.64 (m, 4H), 2.82–2.90 (m, 4H), 4.06 (t, <i>J</i> = 6.5 Hz, 2H), 6.36 (d, <i>J</i> = 1.5 Hz, 1H), 6.48 (d, <i>J</i> = 9.8 Hz, 1H), 6.54 (dd, <i>J</i> = 7.5, 2.7 Hz, 1H), 6.70 (d, <i>J</i> = 8.4 Hz, 1H), 6.86 (d, <i>J</i> = 8.3 Hz, 1H), 7.02 (d, <i>J</i> = 2.6 Hz, 1H), 7.86 (d, <i>J</i> = 2.1 Hz, 1H), 8.00 (d, <i>J</i> = 9.8 Hz, 1H) 8.50 (d, <i>J</i> = 7.5 Hz, 1H), 10.21 (s, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 101 MHz) δ 22.60, 26.16, 53.02, 53.09, 57.18, 67.68, 95.19, 95.50, 106.4, 111.6, 114.3, 114.5, 121.0, 129.0, 129.5, 136.1, 139.7, 140.5, 141.9, 142.3, 155.0, 161.0. IR (NaCl) ν 3421, 2949, 2819, 1643, 1485, 1442, 1369, 1345, 1442, 1276, 1190, 1145 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 15.1 min, purity 99%; (system 2) <i>t</i><sub>R</sub> = 12.3 min, purity 97%. HRMS-ESI calcd 434.2187; found 434.2183 [M + H<sup>+</sup>].</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 5-{4-[4-(8-Hydroxy-2-oxo-2<i>H</i>-chromen-5-yl)piperazin-1-yl]butoxy}pyrazolo[1,5-<i>a</i>]pyridine·TFA (<b>16b</b>)</h4><div class="NLM_p last">Compound <b>16b</b> was prepared as described for <b>12b</b>, using a solution of <b>14b</b> (35 mg, 0.067 mmol) and TFA (0.29 mL) in toluene (0.67 mL). Purification of the crude product by preparative HPLC yielded the TFA-salt of <b>16b</b> (21 mg, 57%) as a yellow solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz) δ 1.79–1.91 (m, 4H), 3.0–3.12 (m, 2H), 3.12–3.39 (m, 6H), 3.53–3.69 (m, 2H), 4.09 (t, <i>J</i> = 5.5 Hz, 2H), 6.38 (d, <i>J</i> = 1.8 Hz, 1H), 6.47 (d, <i>J</i> = 9.8 Hz, 1H), 6.55 (dd, <i>J</i> = 7.5, 2.7 Hz, 1H), 6.95 (d, <i>J</i> = 8.6 Hz, 1H), 7.04 (d, <i>J</i> = 2.6 Hz, 1H), 7.08 (d, <i>J</i> = 8.6 Hz, 1H), 7.88 (d, <i>J</i> = 2.1 Hz, 1H), 8.18 (d, <i>J</i> = 9.8 Hz, 1H), 8.53 (d, <i>J</i> = 7.6 Hz, 1H), 9.71 (s, 1H), 10. 00 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 151 MHz) δ 20.28, 25.47, 49.99, 51.37, 55.20, 67.16, 95.40, 95.74, 106.4, 114.8, 115.3, 115.3, 118.1, 129.7, 140.2, 140.5, 140.6, 141.6, 142.5, 142.9, 154.9, 159.5. IR (NaCl) ν 3406, 3077, 2941, 2845, 1715, 1648, 1439, 1198, 1128, 1047, 1024, 826, 718, 668 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 15.3 min, purity 99%; (system 2) <i>t</i><sub>R</sub> = 12.9 min, purity 99%. HRMS-ESI calcd 435.2027; found 435.2031 [M + H<sup>+</sup>].</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 5-{4-[4-(5-Hydroxy-2<i>H</i>-benzo[<i>b</i>][1,4]oxazin-3(4<i>H</i>)-one-8-yl)piperazin-1-yl]butoxy}pyrazolo[1,5-<i>a</i>]pyridine·TFA (<b>16c</b>)</h4><div class="NLM_p last">Compound <b>16c</b> was prepared as described for <b>12c</b>, using a solution <b>14c</b> (99 mg, 0.16 mmol) and MsOH (0.31 mL) in toluene (2.3 mL). Purification of the crude product by preparative HPLC yielded the TFA-salt of <b>16c</b> (24 mg, 28%) as colorless solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz) δ 1.73–1.94 (m, 4H), 2.91 (t, <i>J</i> = 11.8 Hz, 2H), 3.13–3.21 (m, 2H), 3.21–3.27 (m, 2H), 3.33–3.42 (m, 2H), 3.54–3.61 (m, 2H), 4.07 (t, <i>J</i> = 5.9 Hz, 2H), 4.51 (s, 2H), 6.38 (dd, <i>J</i> = 2.1, 0.7 Hz, 1H), 6.46 (d, <i>J</i> = 8.7 Hz, 1H), 6.50 (d, <i>J</i> = 8.8 Hz, 1H), 6.55 (dd, <i>J</i> = 7.5, 2.7 Hz, 1H), 7.03 (d, <i>J</i> = 2.6 Hz, 1H), 7.88 (d, <i>J</i> = 2.1 Hz, 1H), 8.53 (d, <i>J</i> = 7.6 Hz, 1H), 9.64–9.76 (m, 2H), 9.87 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 91 MHz) δ 20.18, 25.38, 47.63, 51.23, 55.13, 66.69, 67.08, 95.29, 95.67, 106.3, 108.3, 112.4, 116.7, 129.6, 131.6, 137.4, 140.4, 141.3, 142.4, 154.8, 164.2. IR (NaCl) ν 3432, 2964, 2925, 2851, 1650, 1261, 1193, 1075 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 14.7 min, purity 95%; (system 2) <i>t</i><sub>R</sub> = 12.1 min, purity 97%. ESI-MS <i>m</i>/<i>z</i> 438.1 [M + H<sup>+</sup>]. HRMS-ESI calcd 438.2136; found 438.2135 [M + H<sup>+</sup>].</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 5-(4-[4-(8-Hydroxy-2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-5-yl)piperazin-1-yl]butoxy)pyrazolo[1,5-<i>a</i>]pyridine (<b>16d</b>)</h4><div class="NLM_p last">Compound <b>16d</b> was prepared as described for <b>12a</b>, using a solution of <b>14d</b> (112 mg, 0.22 mmol) and a catalytic amount of 10% Pd/C in AcOH/MeOH 1:1 (2.2 mL). Purification of the crude product by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 60:1 to 30:1) yielded <b>16d</b> (74 mg, 79%) as a colorless solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz) δ 1.56–1.64 (m, 2H), 1.75–1.82 (m, 2H), 2.37 (t, <i>J</i> = 7.2 Hz, 2H), 2.46–2.49 (m, 4H), 2.77–2.94 (m, 4H), 4.04 (t, <i>J</i> = 6.5 Hz, 2H), 4.19 (dd, <i>J</i> = 3.4, 1.6 Hz, 2H), 4.21 (dd, <i>J</i> = 3.5, 1.5 Hz, 2H), 6.26 (s, 2H), 6.35 (dd, <i>J</i> = 2.2, 0.8 Hz, 1H), 6.54 (dd, <i>J</i> = 7.5, 2.6 Hz, 1H), 7.02 (d, <i>J</i> = 2.6 Hz, 1H), 7.86 (d, <i>J</i> = 2.1 Hz, 1H), 8.49 (d, <i>J</i> = 7.6 Hz, 1H), 8.62 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 151 MHz) δ 22.69, 26.27, 50.77, 53.07, 57.38, 63.44, 63.67, 67.81, 95.31, 95.63, 106.5, 106.5, 108.9, 129.6, 132.9, 133.7, 137.4, 140.6, 141.8, 142.4, 155.1. IR (NaCl) ν 3406, 2952, 2879, 2825, 1645, 1445, 1343, 1267, 1189, 1093, 990 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 15.0 min, purity 93%; (system 2) <i>t</i><sub>R</sub> = 12.5 min, purity 94%. HRMS-ESI calcd 425.2184; found 425.2188 [M + H<sup>+</sup>].</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 5-{4-[4-(8-Hydroxyquinolin-5-yl)piperazin-1-yl]butoxy}pyrazolo[1,5-<i>a</i>]pyridine·TFA (<b>16e</b>)</h4><div class="NLM_p last">Compound <b>16e</b> was prepared according to the protocol of <b>12b</b>, using a solution of <b>14e</b> (70 mg, 0.14 mmol) and TFA (1.0 mL) in toluene (1.0 mL). Purification of the crude product by preparative HPLC yielded the TFA-salt of <b>16e</b> (48 mg, 66%) as a yellow solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 360 MHz) δ 1.80–1.95 (m, 4H), 3.00–3.19 (m, 2H), 3.26–3.47 (m, 6H), 3.71–3.57 (m, 2H), 4.09 (t, <i>J</i> = 5.7 Hz, 2H), 6.37 (d, <i>J</i> = 1.7 Hz, 1H), 6.54 (dd, <i>J</i> = 7.5, 2.7 Hz, 1H), 7.03 (d, <i>J</i> = 2.6 Hz, 1H), 7.17 (d, <i>J</i> = 8.2 Hz, 1H), 7.29 (d, <i>J</i> = 8.2 Hz, 1H), 7.76 (dd, <i>J</i> = 8.0, 4.4 Hz, 1H), 7.86 (d, <i>J</i> = 2.1 Hz, 1H), 8.52 (d, <i>J</i> = 7.6 Hz, 1H), 8.80 (d, <i>J</i> = 8.4 Hz, 1H), 8.95 (d, <i>J</i> = 3.5 Hz, 1H), 9.91 (bs, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 91 MHz) δ 20.81, 26.02, 50.38, 52.04, 55.77, 67.70, 95.91, 96.29, 106.9, 112.8, 118.8, 122.2, 125.1, 130.2, 136.3, 141.1, 143.0, 147.3, 155.4, 158.9. IR (NaCl) ν 3401, 3096, 2921, 2851, 1680, 1445, 1385, 1198, 1132, 1027, 837, 799, 723 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 14.3 min, purity 98%; (system 2) <i>t</i><sub>R</sub> = 11.6 min, purity 99%. HRMS-ESI calcd 418.2238; found 418.2229 [M + H<sup>+</sup>].</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 5-{4-[4-(8-Hydroxyquinolin-2(1<i>H</i>)-one-5-yl)-1,4-diazepan-1-yl]butoxy}pyrazolo[1,5-<i>a</i>]pyridine·TFA (<b>17a</b>)</h4><div class="NLM_p last">Compound <b>17a</b> was prepared as described for <b>12c</b>, using a solution of <b>15a</b> (16 mg, 0.025 mmol) and MsOH (0.02 mL) in toluene (0.4 mL). Purification of the crude product by preparative HPLC yielded the TFA-salt of <b>17a</b> (6.7 mg, 48%) as a light-brown solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 360 MHz) δ 1.75–1.96 (m, 4H), 2.11–2.18 (m, 2H), 3.07 (t, <i>J</i> = 5.7 Hz, 2H), 3.22–3.33 (m, 2H), 3.55–3.66 (m, 2H), 4.08 (t, <i>J</i> = 5.8 Hz, 2H), 6.38 (d, <i>J</i> = 1.3 Hz, 1H), 6.50 (d, <i>J</i> = 9.8 Hz, 1H), 6.54 (dd, <i>J</i> = 7.5, 2.6 Hz, 1H), 6.84 (d, <i>J</i> = 8.4 Hz, 1H), 6.92 (d, <i>J</i> = 8.4 Hz, 1H), 7.04 (d, <i>J</i> = 2.4 Hz, 1H), 7.87 (d, <i>J</i> = 1.8 Hz, 1H), 8.17 (d, <i>J</i> = 9.8 Hz, 1H), 8.52 (d, <i>J</i> = 7.6 Hz, 1H), 10.04 (s, 1H), 10.14 (s, 1H), 10.38 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 151 MHz) δ 21.17, 24.75, 26.00, 51.15, 52.92, 55.12, 55.90, 56.60, 67.70, 95.85, 96.21, 106.9, 115.0, 115.0, 116.0, 116.7, 121.8, 129.2, 130.1, 137.1, 140.7, 141.0, 142.9, 143.3, 155.3, 158.3, 158.7, 161.6. IR (NaCl) ν 3427, 2927, 2854, 1653, 1560, 1445, 1193 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 15.4 min, purity 99%; (system 2) <i>t</i><sub>R</sub> = 12.5 min, purity 96%. ESI-MS <i>m</i>/<i>z</i> 448.2 [M + H<sup>+</sup>]. HRMS-ESI calcd 448.2330; found 448.2335 [M + H<sup>+</sup>].</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> <i>N</i>-(3-(4-(2,8-Bis(benzyloxy)quinolin-5-yl)-1,4-diazepan-1-yl)propyl)-4-(3-(1-butyl-1<i>H</i>-1,2,3-triazol-4-yl)propoxy)-3-methoxybenzamide (<b>18a</b>)</h4><div class="NLM_p last">Compound <b>5h</b> (25 mg, 0.06 mmol) and 4-(3-(1-butyl-1<i>H</i>-1,2,3-triazol-4-yl)propoxy)-<i>N</i>-(3-oxopropyl)-3-methoxybenzamide (44 mg, 0.11 mmol) were dissolved in dichloroethane (2.8 mL), and NaBH(OAc)<sub>3</sub> (48 mg, 0.23 mmol) was added. The mixture was stirred at room temperature for 6 h. After addition of 1 M NaOH, the product was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated. After column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 20:1) <b>18a</b> was obtained as crude yellow solid. <b>18a</b> was used in further reactions without a final purification step. ESI-MS <i>m</i>/<i>z</i> 812.4 [M + H<sup>+</sup>]</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> <i>N</i>-(4-(4-(2,8-Bis(benzyloxy)quinolin-5-yl)-1,4-diazepan-1-yl)butyl)-4-(3-(1-butyl-1<i>H</i>-1,2,3-triazol-4-yl)propoxy)-3-methoxybenzamide (<b>18b</b>)</h4><div class="NLM_p last">Compound <b>18b</b> was prepared as described for <b>18a</b>, using a solution of <b>5h</b> (10 mg, 0.02 mmol) and 4-[3-(1-butyl-1<i>H</i>-1,2,3-triazol-4-yl)propoxy]-<i>N</i>-(4-oxobutyl)-3-methoxybenzamide<a onclick="showRef(event, 'ref38 ref61'); return false;" href="javascript:void(0);" class="ref ref38 ref61">(38, 61)</a> (18 mg, 0.04 mmol) and NaBH(OAc)<sub>3</sub> (19 mg, 0.09 mmol) in DCE (1.1 mL). Purification of the crude product by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 40:1) yielded <b>18b</b> (15 mg, 80%) as light-yellow solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz) δ 0.87 (t, <i>J</i> = 7.4 Hz, 3H), 1.22 (dq, <i>J</i> = 14.7, 7.3 Hz, 2H), 1.58 (dt, <i>J</i> = 14.1, 6.9 Hz, 2H), 1.69–1.80 (m, 4H), 1.98–2.11 (m, 2H), 2.15 (s, 2H), 2.77 (t, <i>J</i> = 7.5 Hz, 2H), 3.14 (t, <i>J</i> = 5.6 Hz, 2H), 3.24 (s, 2H), 3.29–3.33 (m, 2H), 3.41–3.52 (m, 4H), 3.59 (s, 2H), 3.81 (s, 3H), 4.05 (t, <i>J</i> = 6.3 Hz, 2H), 4.29 (t, <i>J</i> = 7.0 Hz, 2H), 5.29 (s, 2H), 5.53 (s, 2H), 6.99 (d, <i>J</i> = 8.9 Hz, 1H), 7.10 (t, <i>J</i> = 8.9 Hz, 2H), 7.21 (d, <i>J</i> = 8.5 Hz, 1H), 7.27–7.36 (m, 3H), 7.41 (dd, <i>J</i> = 17.7, 10.2 Hz, 2H), 7.44–7.51 (m, 2H), 7.53–7.59 (m, 3H), 7.90 (s, 1H), 8.45 (t, <i>J</i> = 5.6 Hz, 1H), 8.50 (d, <i>J</i> = 9.0 Hz, 1H), 10.06 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 91 MHz) δ 13.23, 19.04, 21.30, 21.56, 24.32, 26.43, 28.44, 30.62, 31.66, 38.40, 48.83, 50.64, 52.50, 54.57, 55.17, 55.63, 56.22, 66.79, 67.48, 70.44, 110.9, 112.0, 112.4, 112.5, 115.8, 120.3, 121.8, 121.8, 126.8, 127.2, 127.6, 127.7, 128.2, 128.3, 128.5, 135.9, 137.2, 137.7, 138.4, 143.9, 146.0, 148.4, 149.5, 150.5, 157.8, 158.1, 160.3, 165.7. IR (NaCl) ν 3421, 2948, 2864, 1681, 1506, 1471, 1410, 1320, 1267, 1201, 1130, 1026 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 20.6 min, purity 94%; (system 2) <i>t</i><sub>R</sub> = 18.0 min, purity 95%. ESI-MS <i>m</i>/<i>z</i> 826.4 [M + H<sup>+</sup>]</div></div><div id="sec4_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> <i>N</i>-(3-(4-(8-Hydroxyquinolin-2(1<i>H</i>)-one-5-yl)-1,4-diazepan-1-yl)propyl)-4-(3-(1-butyl-1<i>H</i>-1,2,3-triazol-4-yl)propoxy)-3-methoxybenzamide (<b>19a</b>)</h4><div class="NLM_p last">To a solution of <b>18a</b> (25 mg, 0.03 mmol) in toluene (0.44 mL) was added MsOH (20 μL), and the mixture was stirred at 80 °C for 1 h. After cooling down to room temperature, the solvent was evaporated. The residue was purified by preparative HPLC to yield the TFA salt of <b>19a</b> (10 mg, 43%) as a yellow solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz) δ 0.88 (t, <i>J</i> = 7.4 Hz, 3H), 1.18–1.28 (m, 2H), 1.69–1.83 (m, 2H), 1.92–2.02 (m, 2H), 2.0–2.09 (m, 2H), 2.09–2.16 (m, 2H), 2.78 (t, <i>J</i> = 7.6 Hz, 2H), 3.06 (t, <i>J</i> = 5.9 Hz, 2H), 3.20–3.31 (m, 3H), 3.32–3.43 (m, 4H), 3.43–3.52 (m, 2H), 3.54–3.65 (m, 3H), 3.82 (s, 3H), 4.06 (t, <i>J</i> = 6.4 Hz, 2H), 4.29 (t, <i>J</i> = 7.1 Hz, 2H), 6.49 (d, <i>J</i> = 9.8 Hz, 1H), 6.83 (d, <i>J</i> = 8.4 Hz, 1H), 6.91 (d, <i>J</i> = 8.4 Hz, 1H), 7.01 (d, <i>J</i> = 8.9 Hz, 1H), 7.43–7.49 (m, 2H), 7.91 (s, 1H), 8.18 (d, <i>J</i> = 9.8 Hz, 1H), 8.56 (t, <i>J</i> = 5.7 Hz, 1H), 9.82 (s, 1H), 10.12 (s, 1H), 10.39 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 151 MHz) δ 13.19, 18.98, 21.49, 24.34, 24.43, 28.36, 31.61, 36.34, 48.77, 50.68, 52.42, 54.53, 54.61, 55.30, 55.56, 67.40, 110.8, 111.8, 114.5, 115.4, 115.6, 117.6, 120.4, 121.3, 121.7, 126.4, 128.7, 136.5, 140.2, 142.7, 145.9, 148.3, 150.5, 157.8, 158.0, 161.0, 166.0. IR (NaCl) ν 3437, 2958, 2854, 1650, 1510, 1428, 1374, 1327, 1277, 1202, 1142, 1019, 843, 802, 720 cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 16.7 min, purity >99%. ESI-MS <i>m</i>/<i>z</i> 623.3 [M + H<sup>+</sup>]. HRMS-ESI calcd 316.6815; found 316.6815 [M + H<sup>+</sup>].</div></div><div id="sec4_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> <i>N</i>-(4-(4-(8-Hydroxyquinolin-2(1<i>H</i>)-one-5-yl)-1,4-diazepan-1-yl)butyl)-4-(3-(1-butyl-1<i>H</i>-1,2,3-triazol-4-yl)propoxy)-3-methoxybenzamide (<b>19b</b>)</h4><div class="NLM_p last">To a solution of <b>18b</b> (19 mg, 0.02 mmol) in TFA/toluene (1:1, 0.4 mL) two drops of MsOH were added before the mixture was stirred at 80 °C for 1 h. After cooling down to room temperature, the solvent was evaporated and the crude residue was purified by preparative HPLC to yield the TFA-salt <b>19b</b> (11 mg, 74%) as a yellow solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz) δ 0.87 (t, <i>J</i> = 7.4 Hz, 3H), 1.14–1.35 (m, 2H), 1.66–1.51 (m, 2H), 1.84–1.69 (m, 4H), 2.10–2.02 (m, 2H), 2.21–2.10 (m, 2H), 2.77 (t, <i>J</i> = 7.5 Hz, 2H), 3.09–2.99 (m, 2H), 3.24–3.19 (m, 2H), 3.32–3.24 (m, 4H), 3.60–3.51 (m, 2H), 3.82 (s, 3H), 4.05 (t, <i>J</i> = 6.3 Hz, 2H), 4.29 (t, <i>J</i> = 7.1 Hz, 2H), 6.49 (d, <i>J</i> = 9.8 Hz, 1H), 6.83 (d, <i>J</i> = 8.4 Hz, 1H), 6.93 (d, <i>J</i> = 8.4 Hz, 1H), 6.99 (d, <i>J</i> = 9.0 Hz, 1H), 7.51–7.43 (m, 2H), 7.91 (s, 1H), 8.17 (d, <i>J</i> = 9.5 Hz, 1H), 8.48 (t, <i>J</i> = 5.6 Hz, 1H), 10.23 (s, 1H), 10.33 (s, 1H), 10.42 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 151 MHz) δ 13.19, 18.98, 21.13, 21.50, 24.11, 26.33, 28.37, 31.60, 38.30, 48.48, 48.76, 50.53, 52.27, 54.45, 55.36, 55.56, 56.03, 67.38, 110.8, 111.8, 114.4, 114.5, 115.4, 116.2, 120.3, 121.2, 121.7, 126.7, 128.7, 136.6, 140.2, 142.7, 145.9, 148.3, 150.4, 157.8, 158.0, 161.1, 165.6. IR (NaCl) ν 3421, 1644, 1562, 1490, 1421, 1371, 1275, 1205, 1144, 1025, 982, 802, 719. cm<sup>–1</sup>. HPLC: (system 1) <i>t</i><sub>R</sub> = 16.7 min, purity >98%. ESI-MS <i>m</i>/<i>z</i> 646.3 [M + H<sup>+</sup>]. HRMS-ESI calcd 323.6892; found 323.6890 [M/2 + 2H<sup>+</sup>].</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Membrane Preparation</h3><div class="NLM_p last">Membranes were obtained using a previously described protocol.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Briefly, HEK293T cells were grown to a confluence of 70% and transiently transfected with the receptor of interest with or without cotransfection of a PTX insensitive Gα<sub>o1</sub> subunit using Mirus TransIT-293 transfection reagent (MoBiTec, Goettingen, Germany), CaHPO<sub>4</sub> precipitation, or a solution of linear polyethylenimine in PBS as described previously.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28, 29)</a> After 24 h of incubation with the transfection complex, the medium was replaced. 48 h after transfection, cells were washed with ice-cold phosphate buffered saline (PBS, pH 7.4) and detached with homogenate buffer (10 mM Tris-HCl, 0.5 mM EDTA, 5.4 mM KCl, 140 mM NaCl, pH 7.4). After centrifugation (8 min, 220<i>g</i>), the pellet was resuspended in 10 mL of ice-cold homogenate buffer and cells were lysed with an ultraturrax. After ultracentrifugation (30 min 50000<i>g</i>), membranes were resuspended in binding buffer (50 mM Tris-HCl, 1 mM EDTA, 5 mM MgCl<sub>2</sub>, 100 μg/mL bacitracin, 5 μg/mL soybean trypsin inhibitor, pH 7.4) and homogenized with a glass–Teflon homogenizer at 4 °C. Membrane preparations were shock-frozen in liquid nitrogen and stored at −80 °C. The protein concentration was determined with the method of Lowry<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> and bovine serum albumin as standard. Membranes from stably transfected CHO cells were obtained analogously.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Competition Binding Experiments</h3><div class="NLM_p last">Affinities of the test compounds toward the human D<sub>1</sub>R, D<sub>2L</sub>R, D<sub>2S</sub>R, D<sub>3</sub>R, D<sub>4</sub>R, D<sub>5</sub>R, 5-HT<sub>2A</sub>R, and porcine α<sub>1</sub>-AR and 5-HT<sub>1A</sub>R were determined as described previously.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> In brief, membranes containing human D<sub>2L</sub>R, D<sub>2S</sub>R, D<sub>3</sub>R, or D<sub>4</sub>R obtained from CHO cells stably expressing the corresponding receptors were used together with the radioligand [<sup>3</sup>H]spiperone (specific activity of 73 Ci/mmol, PerkinElmer, Rodgau, Germany) at a final concentration of 0.10–0.20 nM (<i>K</i><sub>D</sub> 0.035–0.10, <i>B</i><sub>max</sub> 610–1100 fmol/mg, protein concentration 4–6 μg/test tube), 0.15–0.20 nM (<i>K</i><sub>D</sub> 0.032–0.11, <i>B</i><sub>max</sub> 1500–8500 fmol/mg, protein concentration 1–4 μg/test tube), 0.20–0.50 nM (<i>K</i><sub>D</sub> 0.08–0.55, <i>B</i><sub>max</sub> 3300–8500 fmol/mg, protein concentration 1–2 μg/test tube), and 0.20–0.50 nM (<i>K</i><sub>D</sub> 0.14–0.35, <i>B</i><sub>max</sub> 600–4500 fmol/mg, protein concentration 5–14 μg/test tube) for D<sub>2L</sub>R, D<sub>2S</sub>R, D<sub>3</sub>R, and D<sub>4</sub>R, respectively. Competition binding experiments with the human D<sub>1</sub>R, D<sub>5</sub>R, and 5-HT<sub>2A</sub>R were performed in an analogous manner with membranes from transiently transfected HEK293T cells together with [<sup>3</sup>H]SCH23390 (80 Ci/mmol, Biotrend, Cologne, Germany, final concentration 0.20–0.50 nM, <i>K</i><sub>D</sub> 0.14–0.45 nM, <i>B</i><sub>max</sub> 2200–8900 fmol/mg, protein concentration 2–4 μg/test tube for D<sub>1</sub>R and 0.40–0.60 nM, K<sub>D</sub> 0.34–0.71 nM, <i>B</i><sub>max</sub> 450–2750 fmol/mg, 5–10 μg/test tube for D<sub>5</sub>R) or [<sup>3</sup>H]ketanserin (47 Ci/mmol, PerkinElmer, final concentration 0.30–0.50 nM, <i>K</i><sub>D</sub> 0.20–0.40 nM, <i>B</i><sub>max</sub> 1400–2400 fmol/mg, protein concentration 3–6 μg/test tube for 5-HT<sub>2A</sub>R). Binding studies with α<sub>1</sub>R or 5-HT<sub>1A</sub>R were carried out as described previously with homogenates derived from porcine cerebral cortex<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> in the presence of the radioligands [<sup>3</sup>H]prazosin (84 Ci/mmol, PerkinElmer, 0.15–0.20 nM final concentration, <i>K</i><sub>D</sub> 0.060–0.170 nM, <i>B</i><sub>max</sub> 150–350 fmol/mg, protein concentration 20–40 μg/test tube for α<sub>1</sub>R) or [<sup>3</sup>H]WAY100635 (80 Ci/mmol, Biotrend, 0.20–0.35 nM final concentration, <i>K</i><sub>D</sub> 0.035–0.065 nM, <i>B</i><sub>max</sub> 40–120 fmol/mg, protein concentration 60–80 μg/test tube for 5-HT<sub>1A</sub>R). Unspecific binding was determined in the presence of haloperidol (10 μM for D<sub>1</sub>R-D<sub>5</sub>R), WAY100635 (10 μM for 5-HT<sub>1A</sub>R), ketanserin (10 μM for 5-HT<sub>2A</sub>R), or prazosin (10 μM for α<sub>1</sub>R).<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Resulting competition curves were analyzed by nonlinear regression using the algorithms for one-site competition of PRISM 6.0 (GraphPad, San Diego, CA).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> β-Arrestin-2 Recruitment</h3><div class="NLM_p last">The PathHunter assay (DiscoverX, Birmingham, U.K.) was employed to determine β-arrestin-2 recruitment at D<sub>2S</sub>R as described previously.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> In brief, (EA)-β-arrestin-2-HEK293 cells were transiently transfected with D<sub>2S</sub>R–ARMS2–PK2 employing Mirus TransIT-293 (MoBiTec, Göttingen, Germany). Experiments in the presence of GRK2 were performed analogously, using the cDNAs of D<sub>2S</sub>R–ARMS2–PK2 and hGRK2 in a 2:1 ratio for transfection. Then 24 h after transfection, cells were detached with Versene (Life Technologies, Darmstadt, Germany), seeded into white 384-well plates (Greiner, Frickenhausen, Germany) in assay medium at a density of 5000 cells/well, and maintained for 24 h at 37 °C, 5% CO<sub>2</sub>. After incubation with the test compounds dissolved in PBS for 5 h at 37 °C, the detection mix was added and incubation was continued for 60 min at room temperature. Chemiluminescence was determined using the CLARIOstar plate reader (BMG LabTech, Ortenberg, Germany). Then 3–8 experiments per compound were performed with each concentration in duplicate. All responses were normalized to the effect of 10 μM quinpirole (100%) and buffer conditions (0%) and analyzed using the algorithms for nonlinear regression in PRISM 6.0.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> [<sup>35</sup>S]GTPγS Binding Experiments</h3><div class="NLM_p last">[<sup>35</sup>S]GTPγS incorporation assays were performed in analogy to previously described protocols.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Membranes from HEK293T cells transiently transfected with D<sub>2S</sub>R and a pertussis toxin insensitive variant of Gα<sub>o1</sub> (protein concentration 15 μg/mL, final volume 200 μL, <i>B</i><sub>max</sub> 9900 ± 140 fmol/mg) were incubated with 10 μM GDP and the test compounds in assay buffer (20 mM HEPES, 10 mM MgCl<sub>2</sub>·6H<sub>2</sub>O, 100 mM NaCl, 70 mg/L saponin) for 30 min at 37 °C. After the addition of [<sup>35</sup>S]GTPγS (0.1 nM final concentration, specific activity 1250 Ci/mmol, PerkinElmer), incubation was continued for 30 min at 37 °C before the reaction was terminated by filtration through Whatman GF/B filters. Bound radioactivity was determined as described previously.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Then 4–6 experiments per compound were performed with each concentration (0.1 pM to 100 μM) in triplicate. Responses were normalized to the maximum effect of the full agonist quinpirole (100%) and buffer conditions (0%). Analysis of dose response curves was performed using the algorithms for nonlinear regression in PRISM 6.0.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Operational Model of Agonism</h3><div class="NLM_p last">Quantification of ligand bias was performed using the operational model of agonism<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> following recently published protocols.<a onclick="showRef(event, 'ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref66 ref67">(66, 67)</a> Using the algorithms implemented in PRISM6.0 (Graphpad), transduction ratios (τ/K<sub>A</sub>) were obtained in their logarithmic form. Thus, normalized data from the functional experiments was analyzed using the following equation:<span class="NLM_disp-formula" id="ueq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/jm-2017-003633_m001.gif" alt="" /></img></span>with basal being the response of a the system in absence of an agonist, <i>E</i><sub>m</sub> the maximal response, [<i>X</i>] the concentration of the agonist, and <i>n</i> the transducer slope. Parameter <i>n</i> was globally shared, while basal and <i>E</i><sub>m</sub> were constrained to 0 and 100%, respectively. Transduction coefficients (τ/<i>K</i><sub>A</sub>) were then normalized to the response of endogenous agonist dopamine:<span class="NLM_disp-formula" id="ueq2"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/jm-2017-003633_m002.gif" alt="" /></img></span>Determination of bias was performed by calculation of the difference for two investigated pathways:<span class="NLM_disp-formula" id="ueq3"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/jm-2017-003633_m003.gif" alt="" /></img></span>Standard errors were estimated as described previously<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> using the following equation:<span class="NLM_disp-formula" id="ueq4"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/jm-2017-003633_m004.gif" alt="" /></img></span>Statistical significance was calculated using one-way ANOVA followed by Dunnett’s post hoc test at the level of ΔΔlog(τ/<i>K</i><sub>A</sub>) and accepting <i>p</i> < 0.05 as level of significance.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Metabolic Stability</h3><div class="NLM_p last">Metabolic stability of the test compounds was assessed in rat liver microsomes in analogy to previously described procedures.<a onclick="showRef(event, 'ref61 ref68'); return false;" href="javascript:void(0);" class="ref ref61 ref68">(61, 68)</a> Each incubation mixture (total volume 500 μL) contained the test compounds (concentration 20 μM from a 10 mM stock solution in DMSO) or a positive control (rotigotine, 20 μM from a 10 mM stock solution in DMSO) and pooled male rat liver microsomes (Sprague–Dawley, Sigma-Aldrich, Germany) at a concentration of 0.5 mg microsomal protein/mL in Tris-MgCl<sub>2</sub> buffer (48 mM Tris, 4.8 mM MgCl<sub>2</sub>, pH 7.4). Microsomal reactions were initiated by addition of 50 μL of a cofactor solution (NADPH, final concentration 1 mM, Carl Roth, Germany) and carried out in polyethylene caps (Eppendorf, 1.5 mL) at 37 °C. At 0, 15, 30, and 60 min, the enzymatic reactions were terminated by addition of 500 μL of ice-cold acetonitrile (containing 8 μM internal standard), and precipitated protein was removed by centrifugation (15000<i>g</i>, 3 min). The supernatant was analyzed by HPLC (binary solvent system, eluent methanol in 0.1% aqueous formic acid, 10–90% methanol in 18 min, 90–95% methanol in 2 min, 95% methanol for 2 min, flow rate of 0.5 mL/min) using a Zorbax Eclipse XDB-C8 (4.6 mm × 150 mm, 5 μm) column. For each time point, three independent experiments were performed and parallel control incubations in the absence of cofactor solution were used to determine unspecific binding to the matrix. Substrate remaining was calculated as a mean value ± SEM by comparing the AUC substrate after predetermined incubation time to the AUC of substrate at time 0, corrected by a factor calculated from the AUC of internal standard at each time point. For each compound, the concentration of the substrate remaining was plotted in its logarithmic form as a function of time to calculate an elimination rate constant (<i>k</i>), the half-life (<i>T</i><sub>1/2</sub>), and the intrinsic clearance (CL<sub>int</sub>) according to the following two equations as described previously:<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54, 55)</a><span class="NLM_disp-formula" id="ueq5"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/jm-2017-003633_m005.gif" alt="" /></img></span></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> hERG Inhibition</h3><div class="NLM_p last">Inhibition of hERG (human-ether-à-go-go related gene) tail currents was examined using automated whole cell patch clamp and CHO cells stably transfected with the human <i>KCNH2</i> gene at B’SYS Analytics, Switzerland. All experiments were conducted at room temperature using a bath solution containing 140 mM NaCl, 4 mM KCl, 2 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 10 mM HEPES, and 10 mM <span class="smallcaps smallerCapital">d</span>-glucose adjusted to pH 7.4 with NaOH. A solution of 130 mM KCl, 2 mM CaCl<sub>2</sub>, 4 mM MgCl<sub>2</sub>, 4 mM Na<sub>2</sub>-ATP, 10 mM HEPES, and 5 mM EGTA adjusted to pH 7.2 with KOH was used as intracellular solution. Outward tail currents were measured upon depolarization of the cell membrane from a holding potential of −80 mV to +20 mV for 2 s (activation of channels) and upon subsequent repolarization to −40 mV for 3 s. After a waiting time of 5 s, the next pulse followed. The application protocol consisted of five periods, during which vehicle (DMSO 0.5%) and <b>13a</b> were applied in increasing concentrations. The voltage protocol was executed 20 times during each application period. As reference, the selective <i>I</i><sub>Kr</sub> inhibitor E-4031 (Sigma, Germany) was employed (final concentration 100 nM). The tail current amplitudes at the end of each period were used in further evaluation steps. The amount of current block was calculated as percentage of control, and the data was analyzed with the following equation to generate a dose–response curve and to determine an IC<sub>50</sub>, when <i>n</i> is the hill slope and [<i>X</i>] the concentration of the test compound: <span class="NLM_disp-formula" id="ueq6"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/jm-2017-003633_m006.gif" alt="" /></img></span></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i76"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00363">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05232" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05232" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00363" class="ext-link">10.1021/acs.jmedchem.7b00363</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Supplementary figures, data from functional assays, <sup>1</sup>H and <sup>13</sup>C NMR spectra (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00363/suppl_file/jm7b00363_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00363/suppl_file/jm7b00363_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00363/suppl_file/jm7b00363_si_001.pdf">jm7b00363_si_001.pdf (2.92 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00363/suppl_file/jm7b00363_si_002.csv">jm7b00363_si_002.csv (1.42 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00363" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56506" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56506" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Gmeiner</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry and
Pharmacy, Medicinal Chemistry, Friedrich-Alexander
University Erlangen-Nuernberg, Schuhstraße 19, 91052 Erlangen, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4127-197X" title="Orcid link">http://orcid.org/0000-0002-4127-197X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d8a8bdacbdaaf6bfb5bdb1b6bdaa98beb9adf6bcbd"><span class="__cf_email__" data-cfemail="b3c3d6c7d6c19dd4ded6daddd6c1f3d5d2c69dd7d6">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Barbara Männel</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry and
Pharmacy, Medicinal Chemistry, Friedrich-Alexander
University Erlangen-Nuernberg, Schuhstraße 19, 91052 Erlangen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniela Dengler</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry and
Pharmacy, Medicinal Chemistry, Friedrich-Alexander
University Erlangen-Nuernberg, Schuhstraße 19, 91052 Erlangen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeremy Shonberg</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry and
Pharmacy, Medicinal Chemistry, Friedrich-Alexander
University Erlangen-Nuernberg, Schuhstraße 19, 91052 Erlangen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Harald Hübner</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry and
Pharmacy, Medicinal Chemistry, Friedrich-Alexander
University Erlangen-Nuernberg, Schuhstraße 19, 91052 Erlangen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dorothee Möller</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry and
Pharmacy, Medicinal Chemistry, Friedrich-Alexander
University Erlangen-Nuernberg, Schuhstraße 19, 91052 Erlangen, Germany</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ACK-d130e8308-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i77">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52885" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52885" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the Deutsche Forschungsgemeinschaft (DFG) grant GRK 1910. We thank Prof. Graeme Milligan (University of Glasgow, U.K.) and Prof. Michel Bouvier (IRIC, University of Montreal) for providing the cDNAs for Gα<sub>o1</sub> and GRK2, respectively. We thank Dr. Stefan Löber (FAU Erlangen-Nuernberg) for helpful discussions.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i78" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i78"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i79" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i79"> Abbreviations Used</h2><tr><td class="NLM_term">APPI</td><td class="NLM_def"><p class="first last">atmospheric pressure photoionization</p></td></tr><tr><td class="NLM_term">β<sub>x</sub>-AR</td><td class="NLM_def"><p class="first last">β adrenergic receptor, subtype x</p></td></tr><tr><td class="NLM_term">CHO</td><td class="NLM_def"><p class="first last">Chinese hamster ovary</p></td></tr><tr><td class="NLM_term">CL<sub>int</sub></td><td class="NLM_def"><p class="first last">intrinsic clearance</p></td></tr><tr><td class="NLM_term">1,4-DAP</td><td class="NLM_def"><p class="first last">1,4-disubstituted-aromatic piperazine</p></td></tr><tr><td class="NLM_term">D<sub>x</sub>R</td><td class="NLM_def"><p class="first last">dopamine D<sub>x</sub> receptor</p></td></tr><tr><td class="NLM_term">EGTA</td><td class="NLM_def"><p class="first last">ethylene glycol-bis(β-aminoethyl ether)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetraacetic acid</p></td></tr><tr><td class="NLM_term">Gα<sub>x</sub></td><td class="NLM_def"><p class="first last">G protein α subunit subtype x</p></td></tr><tr><td class="NLM_term">GRK2</td><td class="NLM_def"><p class="first last">G protein-coupled receptor kinase subtype 2</p></td></tr><tr><td class="NLM_term">GTPγS</td><td class="NLM_def"><p class="first last">guanosine 5′-<i>O</i>-(thiotriphosphate)</p></td></tr><tr><td class="NLM_term">hD<sub>x</sub>R</td><td class="NLM_def"><p class="first last">human dopamine D<sub>x</sub> receptor</p></td></tr><tr><td class="NLM_term">h5-HT<sub>x</sub>R</td><td class="NLM_def"><p class="first last">human serotonin 5-HT<sub>x</sub> receptor</p></td></tr><tr><td class="NLM_term"><i>I</i><sub>Kr</sub></td><td class="NLM_def"><p class="first last">rectifying potassium current</p></td></tr><tr><td class="NLM_term">L-DOPA</td><td class="NLM_def"><p class="first last"><span class="smallcaps smallerCapital">l</span>-3,4-dihydroxyphenylalanine</p></td></tr><tr><td class="NLM_term">LID</td><td class="NLM_def"><p class="first last">L-DOPA-induced dyskinesia</p></td></tr><tr><td class="NLM_term">pα<sub>x</sub>R</td><td class="NLM_def"><p class="first last">porcine adrenergic α<sub>x</sub> receptor</p></td></tr><tr><td class="NLM_term">p5-HT<sub>x</sub>R</td><td class="NLM_def"><p class="first last">porcine serotonin 5-HT<sub>x</sub> receptor</p></td></tr><tr><td class="NLM_term">PTX</td><td class="NLM_def"><p class="first last">pertussis toxin</p></td></tr><tr><td class="NLM_term">QTc</td><td class="NLM_def"><p class="first last">corrected QT interval</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">standard deviation</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">standard error of mean</p></td></tr><tr><td class="NLM_term">TdP</td><td class="NLM_def"><p class="first last">Torsade de Pointes arrhythmia</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i80">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64166" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64166" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 68 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Beaulieu, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espinoza, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainetdinov, R. R.</span><span> </span><span class="NLM_article-title">Dopamine Receptors – Iuphar Review 13</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">172</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span><span class="refDoi"> DOI: 10.1111/bph.12906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1111%2Fbph.12906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=25671228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWlsLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=1-23&author=J.-M.+Beaulieuauthor=S.+Espinozaauthor=R.+R.+Gainetdinov&title=Dopamine+Receptors+%E2%80%93+Iuphar+Review+13&doi=10.1111%2Fbph.12906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine receptors - IUPHAR Review 13</span></div><div class="casAuthors">Beaulieu, Jean-Martin; Espinoza, Stefano; Gainetdinov, Raul R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-23</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The variety of physiol. functions controlled by dopamine in the brain and periphery is mediated by the D1, D2, D3, D4 and D5 dopamine GPCRs.  Drugs acting on dopamine receptors are significant tools for the management of several neuropsychiatric disorders including schizophrenia, bipolar disorder, depression and Parkinson's disease.  Recent investigations of dopamine receptor signalling have shown that dopamine receptors, apart from their canonical action on cAMP-mediated signalling, can regulate a myriad of cellular responses to fine-tune the expression of dopamine-assocd. behaviors and functions.  Such signalling mechanisms may involve alternate G protein coupling or non-G protein mechanisms involving ion channels, receptor tyrosine kinases or proteins such as β-arrestins that are classically involved in GPCR desensitization.  Another level of complexity is the growing appreciation of the physiol. roles played by dopamine receptor heteromers.  Applications of new in vivo techniques have significantly furthered the understanding of the physiol. functions played by dopamine receptors.  Here we provide an update of the current knowledge regarding the complex biol., signalling, physiol. and pharmacol. of dopamine receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1fpdKAWrR5rVg90H21EOLACvtfcHk0ljJjeXmG7ZRSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWlsLjJ&md5=7f15533abc8fb6aa76a4ec41072b6219</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1111%2Fbph.12906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12906%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DJ.-M.%26aulast%3DEspinoza%26aufirst%3DS.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26atitle%3DDopamine%2520Receptors%2520%25E2%2580%2593%2520Iuphar%2520Review%252013%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D1%26epage%3D23%26doi%3D10.1111%2Fbph.12906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Chaudhuri, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schapira, A. H. V.</span><span> </span><span class="NLM_article-title">Non-Motor Symptoms of Parkinson’s Disease: Dopaminergic Pathophysiology and Treatment</span> <span class="citation_source-journal">Lancet Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">464</span><span class="NLM_x">–</span> <span class="NLM_lpage">474</span><span class="refDoi"> DOI: 10.1016/S1474-4422(09)70068-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1016%2FS1474-4422%2809%2970068-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=19375664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVajsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=464-474&author=K.+R.+Chaudhuriauthor=A.+H.+V.+Schapira&title=Non-Motor+Symptoms+of+Parkinson%E2%80%99s+Disease%3A+Dopaminergic+Pathophysiology+and+Treatment&doi=10.1016%2FS1474-4422%2809%2970068-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment</span></div><div class="casAuthors">Chaudhuri, K. Ray; Schapira, Anthony H. V.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">464-474</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Several studies, including work from the Parkinson's disease (PD) non-motor group and others, have established that the non-motor symptoms of PD are common, occur across all stages of PD, are under-reported, and are a key determinant of quality of life.  Research suggests that the non-motor symptoms of the disease are frequently unrecognized by clinicians and remain untreated.  Even when identified, there is a common perception that many of these symptoms are untreatable.  The role of dopaminergic drugs in treating the various non-motor problems of PD, although clin. recognized, has received little attention.  In this Review, we investigate the dopaminergic basis of the range of non-motor symptoms that occur in PD such as depression, apathy, sleep disorders (including rapid-eye movement sleep behavior disorder), and erectile dysfunction.  We discuss the evidence that these symptoms are treatable, at least in part, with various dopaminergic strategies and, where relevant, we also refer to the use of deep-brain stimulation of appropriate targets in the brain.  This Review provides a comprehensive overview of the management of this challenging aspect of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH0aCFNtuE7rVg90H21EOLACvtfcHk0ljO3RoQEdmR3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVajsb0%253D&md5=30e08b16ec451f1240d43101601388da</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2809%2970068-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252809%252970068-7%26sid%3Dliteratum%253Aachs%26aulast%3DChaudhuri%26aufirst%3DK.%2BR.%26aulast%3DSchapira%26aufirst%3DA.%2BH.%2BV.%26atitle%3DNon-Motor%2520Symptoms%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%253A%2520Dopaminergic%2520Pathophysiology%2520and%2520Treatment%26jtitle%3DLancet%2520Neurol.%26date%3D2009%26volume%3D8%26spage%3D464%26epage%3D474%26doi%3D10.1016%2FS1474-4422%2809%2970068-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Oertel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulz, J. B.</span><span> </span><span class="NLM_article-title">Current and Experimental Treatments of Parkinson Disease: A Guide for Neuroscientists</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">139</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">337</span><span class="refDoi"> DOI: 10.1111/jnc.13750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1111%2Fjnc.13750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=27577098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVaku7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2016&pages=325-337&author=W.+Oertelauthor=J.+B.+Schulz&title=Current+and+Experimental+Treatments+of+Parkinson+Disease%3A+A+Guide+for+Neuroscientists&doi=10.1111%2Fjnc.13750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Current and experimental treatments of Parkinson disease: A guide for neuroscientists</span></div><div class="casAuthors">Oertel, Wolfgang; Schulz, Joerg B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">S1</span>),
    <span class="NLM_cas:pages">325-337</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Over a period of more than 50 years, the symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been optimized using pharmacotherapy, deep brain stimulation, and physiotherapy.  The arsenal of pharmacotherapies includes L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine.  In the later course of the disease, motor complications occur, at which stage different oral formulations of L-Dopa or dopamine agonists with long half-life, a transdermal application or parenteral pumps for continuous drug supply can be subscribed.  Alternatively, the patient is offered deep brain stimulation of the subthalamic nucleus (STN) or the internal part of the globus pallidus (GPi).  For a more efficacious treatment of motor complications, new formulations of L-Dopa, dopamine agonists, and amantadine as well as new MAO-B and COMT inhibitors are currently tested in clin. trials, and some of them already yielding pos. results in phase 3 trials.  In addn., nondopaminergic agents have been tested in the early clin. phase for the treatment of motor fluctuations and dyskinesia, including adenosine A2A antagonists (istradefylline, preladenant, and tozadenant) and modulators of the metabolic glutamate receptor 5 (mGluR5 - mavoglurant) and serotonin (eltoprazine) receptors.  Recent clin. trials testing coenzyme Q10, the dopamine agonist pramipexole, creatine monohydrate, pioglitazone, or AAV-mediated gene therapy aimed at increasing expression of neurturin, did not prove efficacious.  Treatment with nicotine, caffeine, inosine (a precursor of urate), and isradipine (a dihydropyridine calcium channel blocker), as well as active and passive immunization against α-synuclein and inhibitors or modulators of α-synuclein-aggregation are currently studied in clin. trials.  However, to date, no disease-modifying treatment is available.  The authors here review the current status of treatment options for motor and nonmotor symptoms, and discuss current investigative strategies for disease modification.  This review provides basic insights, mainly addressing basic scientists and nonspecialists.  It stresses the need to intensify therapeutic PD research and points out reasons why the translation of basic research to disease-modifying therapies has been unsuccessful so far.  The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy.  For a more efficacious treatment of motor complications, new formulations of L-Dopa, dopamine agonists, and amantadine as well as new MAO-B and COMT inhibitors are currently tested in clin. trials.  Nondopaminergic agents have been tested in the early clin. phase for the treatment of motor fluctuations and dyskinesia.  Recent clin. trials testing coenzyme Q10, the dopamine agonist pramipexole, creatine monohydrate, pioglitazone, or AAV-mediated gene therapy aimed at increasing expression of neurturin, did not prove efficacious.  Treatment with nicotine, caffeine, and isradipine - a dihydropyridine calcium channel blocker - as well as active and passive immunization against α-synuclein and inhibitors of α-synuclein-aggregation are currently studied in clin. trials.  However, to date, no disease-modifying treatment is available for PD.  The authors here review the current status of treatment options and investigative strategies for both motor and nonmotor symptoms.  This review stresses the need to intensify therapeutic PD research and points out reasons why the translation of basic research to disease-modifying therapies has been unsuccessful so far.  This article is part of a.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOoeI0DPzjZ7Vg90H21EOLACvtfcHk0ljO3RoQEdmR3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVaku7vI&md5=da131e76891960bf56133449592627c7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fjnc.13750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.13750%26sid%3Dliteratum%253Aachs%26aulast%3DOertel%26aufirst%3DW.%26aulast%3DSchulz%26aufirst%3DJ.%2BB.%26atitle%3DCurrent%2520and%2520Experimental%2520Treatments%2520of%2520Parkinson%2520Disease%253A%2520A%2520Guide%2520for%2520Neuroscientists%26jtitle%3DJ.%2520Neurochem.%26date%3D2016%26volume%3D139%26spage%3D325%26epage%3D337%26doi%3D10.1111%2Fjnc.13750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Cilia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akpalu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarfo, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cham, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amboni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cereda, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akassi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pezzoli, G.</span><span> </span><span class="NLM_article-title">The Modern Pre-Levodopa Era of Parkinson’s Disease: Insights into Motor Complications from Sub-Saharan Africa</span> <span class="citation_source-journal">Brain</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">2731</span><span class="NLM_x">–</span> <span class="NLM_lpage">2742</span><span class="refDoi"> DOI: 10.1093/brain/awu195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1093%2Fbrain%2Fawu195" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2014&pages=2731-2742&author=R.+Ciliaauthor=A.+Akpaluauthor=F.+S.+Sarfoauthor=M.+Chamauthor=M.+Amboniauthor=E.+Ceredaauthor=M.+Fabbriauthor=P.+Adjeiauthor=J.+Akassiauthor=A.+Bonettiauthor=G.+Pezzoli&title=The+Modern+Pre-Levodopa+Era+of+Parkinson%E2%80%99s+Disease%3A+Insights+into+Motor+Complications+from+Sub-Saharan+Africa&doi=10.1093%2Fbrain%2Fawu195"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawu195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawu195%26sid%3Dliteratum%253Aachs%26aulast%3DCilia%26aufirst%3DR.%26aulast%3DAkpalu%26aufirst%3DA.%26aulast%3DSarfo%26aufirst%3DF.%2BS.%26aulast%3DCham%26aufirst%3DM.%26aulast%3DAmboni%26aufirst%3DM.%26aulast%3DCereda%26aufirst%3DE.%26aulast%3DFabbri%26aufirst%3DM.%26aulast%3DAdjei%26aufirst%3DP.%26aulast%3DAkassi%26aufirst%3DJ.%26aulast%3DBonetti%26aufirst%3DA.%26aulast%3DPezzoli%26aufirst%3DG.%26atitle%3DThe%2520Modern%2520Pre-Levodopa%2520Era%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%253A%2520Insights%2520into%2520Motor%2520Complications%2520from%2520Sub-Saharan%2520Africa%26jtitle%3DBrain%26date%3D2014%26volume%3D137%26spage%3D2731%26epage%3D2742%26doi%3D10.1093%2Fbrain%2Fawu195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Fahn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oakes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoulson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieburtz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olanow, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanner, C.</span><span> </span><span class="NLM_article-title">Levodopa and the Progression of Parkinson’s Disease</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">351</span><span class="NLM_x">, </span> <span class="NLM_fpage">2498</span><span class="NLM_x">–</span> <span class="NLM_lpage">2508</span><span class="refDoi"> DOI: 10.1056/NEJMoa033447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1056%2FNEJMoa033447" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=15590952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVGksbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2004&pages=2498-2508&author=S.+Fahnauthor=D.+Oakesauthor=I.+Shoulsonauthor=K.+Kieburtzauthor=A.+Rudolphauthor=A.+Langauthor=C.+W.+Olanowauthor=C.+Tanner&title=Levodopa+and+the+Progression+of+Parkinson%E2%80%99s+Disease&doi=10.1056%2FNEJMoa033447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Levodopa and the progression of Parkinson's disease</span></div><div class="casAuthors">Fahn, S.; Oakes, D.; Shoulson, I.; Kieburtz, K.; Rudolph, A.; Marek, K.; Seibyl, J.; Lang, A.; Olanow, C. W.; Tanner, C.; Schifitto, G.; Zhao, H.; Reyes, L.; Shinaman, A.; Comella, C.; Goetz, C.; Blasucci, L.; Samanta, J.; Stacy, M.; Williamson, K.; Harringan, M.; Greene, P.; Ford, B.; Moskowitz, C.; Truong, D.; Pathak, M.; Jankovic, J.; Ondo, W.; Atassi, F.; Hunter, C.; Jacques, C.; Friedman, J. H.; Lannon, M.; Russell, D. S.; Jennings, D.; Fussell, B.; Standaert, D.; Schwarzschild, M. A.; Growdon, J.; Tennis, M.; Gauthier, S.; Panisset, M.; Hall, J.; Gancher, S.; Hammerstad, J.; Stone, C.; Alexander-Brown, B.; Factor, S.; Molho, E.; Brown, D.; Evans, S.; Clark, J.; Manyam, B.; Simpson, P.; Wulbrecht, B.; Whetteckey, J.; Martin, W.; Roberts, T.; King, P.; Hauser, R.; Zesiewicz, T.; Gauger, L.; Trugman, J.; Wooten, G. F.; Rost-Ruffner, E.; Perlmutter, J.; Racette, B.; Suchowersky, O.; Ranawaya, R.; Wood, S.; Pantella, C.; Kurlan, R.; Richard, I.; Pearson, N.; Caviness, J.; Adler, C.; Lind, M.; Simuni, T.; Siderowf, A.; Colcher, A.; Lloyd, M.; Weiner, W.; Shulman, L.; Koller, W.; Lyons, K.; Feldman, R.; St.-Halaire, M.-H.; Ellias, S.; Thomas, C.-A.; Juncos, J.; Watts, R.; Partlow, A.; Tetrud, J.; Togasaki, D. M.; Welsh, M.; Stewart, T.; Mark, M. H.; Sage, J. I.; Caputo, D.; Gould, H.; Rao, J.; McKendrick, A.; Brin, M.; Danisi, F.; Benabou, R.; Hubble, J.; Paulson, G.; Reider, C.; Birnbaum, A.; Miyasaki, J.; Johnston, L.; So, J.; Pahwa, R.; Dubinsky, R.; Wszolek, Z.; Uitti, R.; Turk, M.; Tuite, P.; Rottenberg, D.; Hansen, J.; Serrano Ramos, C.; Waters, C.; Lews, M.; Welsh, M.; Kawai, C.; O'Brien, C.; Kumar, R.; Seeberger, L.; Judd, D.; Mendis, T.; Barclay, C. L.; Grimes, D. A.; Sutherland, L.; Dawson, T.; Reich, S.; Dunlop, R.; Albin, R.; Frey, K.; Wernette, K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2498-2508</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Despite the known benefit of levodopa in reducing the symptoms of Parkinson's disease, concern has been expressed that its use might hasten neurodegeneration.  This study assessed the effect of levodopa on the rate of progression of Parkinson's disease.  In this randomized, double-blind, placebo-controlled trial, we evaluated 361 patients with early Parkinson's disease who were assigned to receive carbidopa-levodopa at a daily dose of 37.5 and 150 mg, 75 and 300 mg, or 150 and 600 mg, resp., or a matching placebo for a period of 40 wk, and then to undergo withdrawal of treatment for 2 wk.  The primary outcome was a change in scores on the Unified Parkinson's Disease Rating Scale (UPDRS) between baseline and 42 wk.  Neuroimaging studies of 142 subjects were performed at baseline and at week 40 to assess striatal dopamine-transporter d. with the use of iodine-123-labeled 2-β3-carboxymethoxy-3-β-(4-iodophenyl)tropane ([123I]β-CIT) uptake.  The severity of parkinsonism increased more in the placebo group than in all the groups receiving levodopa: the mean difference between the total score on the UPDRS at baseline and at 42 wk was 7.8 units in the placebo group, 1.9 units in the group receiving levodopa at a dose of 150 mg daily, 1.9 in those receiving 300 mg daily, and -1.4 in those receiving 600 mg daily (P<0.001).  In contrast, in a substudy of 116 patients the mean percent decline in the [123I]β-CIT uptake was significantly greater with levodopa than placebo (-6 percent among those receiving levodopa at 150 mg daily, -4 percent in those receiving it at 300 mg daily, and-7.2 percent among those receiving it at 600 mg daily, as compared with -1.4 percent among those receiving placebo; 19 patients with no dopaminergic deficits on the baseline scans were excluded from the anal.) (P=0.036).  The subjects receiving the highest dose of levodopa had significantly more dyskinesia, hypertonia, infection, headache, and nausea than those receiving placebo.  The clin. data suggest that levodopa either slows the progression of Parkinson's disease or has a prolonged effect on the symptoms of the disease.  In contrast, the neuroimaging data suggest either that levodopa accelerates the loss of nigrostriatal dopamine nerve terminals or that its pharmacol. effects modify the dopamine transporter.  The potential long-term effects of levodopa on Parkinson's disease remain uncertain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3aL483WQB3bVg90H21EOLACvtfcHk0ljRIl7jLZbb2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVGksbnE&md5=812566c1dec6affaf62025942c23b516</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa033447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa033447%26sid%3Dliteratum%253Aachs%26aulast%3DFahn%26aufirst%3DS.%26aulast%3DOakes%26aufirst%3DD.%26aulast%3DShoulson%26aufirst%3DI.%26aulast%3DKieburtz%26aufirst%3DK.%26aulast%3DRudolph%26aufirst%3DA.%26aulast%3DLang%26aufirst%3DA.%26aulast%3DOlanow%26aufirst%3DC.%2BW.%26aulast%3DTanner%26aufirst%3DC.%26atitle%3DLevodopa%2520and%2520the%2520Progression%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D351%26spage%3D2498%26epage%3D2508%26doi%3D10.1056%2FNEJMoa033447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Jenner, P.</span><span> </span><span class="NLM_article-title">Molecular Mechanisms of L-DOPA-Induced Dyskinesia</span> <span class="citation_source-journal">Nat. Rev. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">665</span><span class="NLM_x">–</span> <span class="NLM_lpage">677</span><span class="refDoi"> DOI: 10.1038/nrn2471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1038%2Fnrn2471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=18714325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVSjurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=665-677&author=P.+Jenner&title=Molecular+Mechanisms+of+L-DOPA-Induced+Dyskinesia&doi=10.1038%2Fnrn2471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of L-DOPA-induced dyskinesia</span></div><div class="casAuthors">Jenner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">665-677</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Dyskinesia is a treatment-limiting side effect of dopaminergic replacement therapies in Parkinson's disease.  Here Jenner discusses what we know about the mol. causes of dyskinesia induction and expression, highlighting recent findings that suggest that altered glutamatergic transmission might be important.  L-DOPA (L-3,4-dihydroxyphenylalanine) remains the most effective drug for the treatment of Parkinson's disease.  However, chronic use causes dyskinesia, a complex motor phenomenon that consists of two components: the execution of involuntary movements in response to drug administration, and the 'priming' phenomenon that underlies these movements' establishment and persistence.  A reinterpretation of recent data suggests that priming for dyskinesia results from nigral denervation and the loss of striatal dopamine input, which alters glutamatergic synaptic connectivity in the striatum.  The subsequent response of the abnormal basal ganglia to dopaminergic drugs dets. the manner and timing of dyskinesia expression.  The combination of nigral denervation and drug treatment establishes inappropriate signaling between the motor cortex and the striatum, leading to persistent dyskinesia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-pdXwQI94e7Vg90H21EOLACvtfcHk0ljRIl7jLZbb2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVSjurvP&md5=5dac15ce126371908eef79c093420b67</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrn2471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn2471%26sid%3Dliteratum%253Aachs%26aulast%3DJenner%26aufirst%3DP.%26atitle%3DMolecular%2520Mechanisms%2520of%2520L-DOPA-Induced%2520Dyskinesia%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2008%26volume%3D9%26spage%3D665%26epage%3D677%26doi%3D10.1038%2Fnrn2471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Bezard, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brotchie, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, C. E.</span><span> </span><span class="NLM_article-title">Pathophysiology of Levodopa-Induced Dyskinesia: Potential for New Therapies</span> <span class="citation_source-journal">Nat. Rev. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">588</span><span class="refDoi"> DOI: 10.1038/35086062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1038%2F35086062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=11484001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmtVaqtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=577-588&author=E.+Bezardauthor=J.+M.+Brotchieauthor=C.+E.+Gross&title=Pathophysiology+of+Levodopa-Induced+Dyskinesia%3A+Potential+for+New+Therapies&doi=10.1038%2F35086062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Pathophysiology of levodopa-induced dyskinesia: potential for new therapies</span></div><div class="casAuthors">Bezard, Erwan; Brotchie, Jonathan M.; Gross, Christian E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">577-588</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  Involuntary movements - or dyskinesias - are a debilitating complication of levodopa therapy for Parkinson's disease, and is experienced in most patients.  Despite the importance of this problem, little was known about the cause of dyskinesia until recently; however, this situation has changed significantly in the past few years.  Our increased understanding of levodopa-induced dyskinesia is not only valuable for improving patient care, but also in providing us with new insights into the functional organization of the basal ganglia and motor systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWYg9R_A809LVg90H21EOLACvtfcHk0ljRIl7jLZbb2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmtVaqtbY%253D&md5=bafffabb855b5a952871105b38a84e91</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2F35086062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35086062%26sid%3Dliteratum%253Aachs%26aulast%3DBezard%26aufirst%3DE.%26aulast%3DBrotchie%26aufirst%3DJ.%2BM.%26aulast%3DGross%26aufirst%3DC.%2BE.%26atitle%3DPathophysiology%2520of%2520Levodopa-Induced%2520Dyskinesia%253A%2520Potential%2520for%2520New%2520Therapies%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2001%26volume%3D2%26spage%3D577%26epage%3D588%26doi%3D10.1038%2F35086062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Reiter, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shukla, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefkowitz, R. J.</span><span> </span><span class="NLM_article-title">Molecular Mechanism of Beta-Arrestin-Biased Agonism at Seven-Transmembrane Receptors</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span><span class="refDoi"> DOI: 10.1146/annurev.pharmtox.010909.105800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1146%2Fannurev.pharmtox.010909.105800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=21942629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsV2nt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=179-197&author=E.+Reiterauthor=S.+Ahnauthor=A.+K.+Shuklaauthor=R.+J.+Lefkowitz&title=Molecular+Mechanism+of+Beta-Arrestin-Biased+Agonism+at+Seven-Transmembrane+Receptors&doi=10.1146%2Fannurev.pharmtox.010909.105800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors</span></div><div class="casAuthors">Reiter, Eric; Ahn, Seungkirl; Shukla, Arun K.; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">179-197</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The concept of biased agonism has recently come to the fore with the realization that seven-transmembrane receptors (7TMRs, also known as G protein-coupled receptors, or GPCRs) activate complex signaling networks and can adopt multiple active conformations upon agonist binding.  As a consequence, the "efficacy" of receptors, which was classically considered linear, is now recognized as pluridimensional.  Biased agonists selectively stabilize only a subset of receptor conformations induced by the natural "unbiased" ligand, thus preferentially activating certain signaling mechanisms.  Such agonists thus reveal the intriguing possibility that one can direct cellular signaling with unprecedented precision and specificity and support the notion that biased agonists may identify new classes of therapeutic agents that have fewer side effects.  This review focuses on one particular class of biased ligands that has the ability to alter the balance between G protein-dependent and β-arrestin-dependent signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB-dMKnViGurVg90H21EOLACvtfcHk0lhd57ZuWUIOzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsV2nt74%253D&md5=05065a33108ddeebc36923b3cc821037</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.010909.105800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.010909.105800%26sid%3Dliteratum%253Aachs%26aulast%3DReiter%26aufirst%3DE.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DShukla%26aufirst%3DA.%2BK.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DMolecular%2520Mechanism%2520of%2520Beta-Arrestin-Biased%2520Agonism%2520at%2520Seven-Transmembrane%2520Receptors%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2012%26volume%3D52%26spage%3D179%26epage%3D197%26doi%3D10.1146%2Fannurev.pharmtox.010909.105800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Peterson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pack, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkins, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urs, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bass, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lichtarge, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span> </span><span class="NLM_article-title">Elucidation of G-Protein and B-Arrestin Functional Selectivity at the Dopamine D2 Receptor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">7097</span><span class="NLM_x">–</span> <span class="NLM_lpage">7102</span><span class="refDoi"> DOI: 10.1073/pnas.1502742112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1073%2Fpnas.1502742112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=7097-7102&author=S.+M.+Petersonauthor=T.+F.+Packauthor=A.+D.+Wilkinsauthor=N.+M.+Ursauthor=D.+J.+Urbanauthor=C.+E.+Bassauthor=O.+Lichtargeauthor=M.+G.+Caron&title=Elucidation+of+G-Protein+and+B-Arrestin+Functional+Selectivity+at+the+Dopamine+D2+Receptor&doi=10.1073%2Fpnas.1502742112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1502742112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1502742112%26sid%3Dliteratum%253Aachs%26aulast%3DPeterson%26aufirst%3DS.%2BM.%26aulast%3DPack%26aufirst%3DT.%2BF.%26aulast%3DWilkins%26aufirst%3DA.%2BD.%26aulast%3DUrs%26aufirst%3DN.%2BM.%26aulast%3DUrban%26aufirst%3DD.%2BJ.%26aulast%3DBass%26aufirst%3DC.%2BE.%26aulast%3DLichtarge%26aufirst%3DO.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26atitle%3DElucidation%2520of%2520G-Protein%2520and%2520B-Arrestin%2520Functional%2520Selectivity%2520at%2520the%2520Dopamine%2520D2%2520Receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D7097%26epage%3D7102%26doi%3D10.1073%2Fpnas.1502742112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Urban, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Zastrow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spedding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailman, R. B.</span><span> </span><span class="NLM_article-title">Functional Selectivity and Classical Concepts of Quantitative Pharmacology</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">320</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span><span class="refDoi"> DOI: 10.1124/jpet.106.104463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1124%2Fjpet.106.104463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=16803859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsFersw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=2007&pages=1-13&author=J.+D.+Urbanauthor=W.+P.+Clarkeauthor=M.+von+Zastrowauthor=D.+E.+Nicholsauthor=B.+Kobilkaauthor=H.+Weinsteinauthor=J.+A.+Javitchauthor=B.+L.+Rothauthor=A.+Christopoulosauthor=P.+M.+Sextonauthor=K.+J.+Millerauthor=M.+Speddingauthor=R.+B.+Mailman&title=Functional+Selectivity+and+Classical+Concepts+of+Quantitative+Pharmacology&doi=10.1124%2Fjpet.106.104463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Functional selectivity and classical concepts of quantitative pharmacology</span></div><div class="casAuthors">Urban, Jonathan D.; Clarke, William P.; von Zastrow, Mark; Nichols, David E.; Kobilka, Brian; Weinstein, Harel; Javitch, Jonathan A.; Roth, Bryan L.; Christopoulos, Arthur; Sexton, Patrick M.; Miller, Keith J.; Spedding, Michael; Mailman, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">320</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The concept of intrinsic efficacy has been enshrined in pharmacol. for half of a century, yet recent data have revealed that many ligands can differentially activate signaling pathways mediated via a single G protein-coupled receptor in a manner that challenges the traditional definition of intrinsic efficacy.  Some terms for this phenomenon include functional selectivity, agonist-directed trafficking, and biased agonism.  At the extreme, functionally selective ligands may be both agonists and antagonists at different functions mediated by the same receptor.  Data illustrating this phenomenon are presented from serotonin, opioid, dopamine, vasopressin, and adrenergic receptor systems.  A variety of mechanisms may influence this apparently ubiquitous phenomenon.  It may be initiated by differences in ligand-induced intermediate conformational states, as shown for the β2-adrenergic receptor.  Subsequent mechanisms that may play a role include diversity of G proteins, scaffolding and signaling partners, and receptor oligomers.  Clearly, expanded research is needed to elucidate the proximal (e.g., how functionally selective ligands cause conformational changes that initiate differential signaling), intermediate (mechanisms that translate conformation changes into differential signaling), and distal mechanisms (differential effects on target tissue or organism).  Besides the heuristically interesting nature of functional selectivity, there is a clear impact on drug discovery, because this mechanism raises the possibility of selecting or designing novel ligands that differentially activate only a subset of functions of a single receptor, thereby optimizing therapeutic action.  It also may be timely to revise classic concepts in quant. pharmacol. and relevant pharmacol. conventions to incorporate these new concepts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5GzdtvWZRkbVg90H21EOLACvtfcHk0lhd57ZuWUIOzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsFersw%253D%253D&md5=54465473b5996d0755baeee89eeb0ba9</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.104463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.104463%26sid%3Dliteratum%253Aachs%26aulast%3DUrban%26aufirst%3DJ.%2BD.%26aulast%3DClarke%26aufirst%3DW.%2BP.%26aulast%3Dvon%2BZastrow%26aufirst%3DM.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DKobilka%26aufirst%3DB.%26aulast%3DWeinstein%26aufirst%3DH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DMiller%26aufirst%3DK.%2BJ.%26aulast%3DSpedding%26aufirst%3DM.%26aulast%3DMailman%26aufirst%3DR.%2BB.%26atitle%3DFunctional%2520Selectivity%2520and%2520Classical%2520Concepts%2520of%2520Quantitative%2520Pharmacology%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D320%26spage%3D1%26epage%3D13%26doi%3D10.1124%2Fjpet.106.104463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Neve, K. A.</span><span> </span><span class="NLM_article-title">Functional Selectivity of G Protein-Coupled Receptor Ligands—New Opportunities for Drug Discovery</span>. In  <span class="citation_source-book">The Receptors</span>, <span class="NLM_edition">1st</span> ed.; <span class="NLM_contrib-group">Neve, K. A.</span>, Ed.; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">Totowa, NJ</span>;<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=25-40&author=K.+A.+Neveauthor=K.+A.+Neve&title=The+Receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DNeve%26aufirst%3DK.%2BA.%26atitle%3DFunctional%2520Selectivity%2520of%2520G%2520Protein-Coupled%2520Receptor%2520Ligands%25E2%2580%2594New%2520Opportunities%2520for%2520Drug%2520Discovery%26btitle%3DThe%2520Receptors%26aulast%3DNeve%26aufirst%3DK.%2BA.%26pub%3DHumana%2520Press%26date%3D2009%26spage%3D25%26epage%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Urs, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bido, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daigle, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bass, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainetdinov, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bezard, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span> </span><span class="NLM_article-title">Targeting B-Arrestin2 in the Treatment of L-DOPA–Induced Dyskinesia in Parkinson’s Disease</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">E2517</span><span class="NLM_x">–</span> <span class="NLM_lpage">E2526</span><span class="refDoi"> DOI: 10.1073/pnas.1502740112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1073%2Fpnas.1502740112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=E2517-E2526&author=N.+M.+Ursauthor=S.+Bidoauthor=S.+M.+Petersonauthor=T.+L.+Daigleauthor=C.+E.+Bassauthor=R.+R.+Gainetdinovauthor=E.+Bezardauthor=M.+G.+Caron&title=Targeting+B-Arrestin2+in+the+Treatment+of+L-DOPA%E2%80%93Induced+Dyskinesia+in+Parkinson%E2%80%99s+Disease&doi=10.1073%2Fpnas.1502740112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1502740112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1502740112%26sid%3Dliteratum%253Aachs%26aulast%3DUrs%26aufirst%3DN.%2BM.%26aulast%3DBido%26aufirst%3DS.%26aulast%3DPeterson%26aufirst%3DS.%2BM.%26aulast%3DDaigle%26aufirst%3DT.%2BL.%26aulast%3DBass%26aufirst%3DC.%2BE.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26aulast%3DBezard%26aufirst%3DE.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26atitle%3DTargeting%2520B-Arrestin2%2520in%2520the%2520Treatment%2520of%2520L-DOPA%25E2%2580%2593Induced%2520Dyskinesia%2520in%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3DE2517%26epage%3DE2526%26doi%3D10.1073%2Fpnas.1502740112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Ahmed, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berthet, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bychkov, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porras, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bioulac, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carl, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloch, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kook, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubert, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dovero, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doudnikoff, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurevich, V. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurevich, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bezard, E.</span><span> </span><span class="NLM_article-title">Lentiviral Overexpression of GRK6 Alleviates L-DOPA–Induced Dyskinesia in Experimental Parkinson’s Disease</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">28ra28</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3000664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1126%2Fscitranslmed.3000664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=20410529" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=28ra28&author=M.+R.+Ahmedauthor=A.+Berthetauthor=E.+Bychkovauthor=G.+Porrasauthor=Q.+Liauthor=B.+H.+Bioulacauthor=Y.+T.+Carlauthor=B.+Blochauthor=S.+Kookauthor=I.+Aubertauthor=S.+Doveroauthor=E.+Doudnikoffauthor=V.+V.+Gurevichauthor=E.+V.+Gurevichauthor=E.+Bezard&title=Lentiviral+Overexpression+of+GRK6+Alleviates+L-DOPA%E2%80%93Induced+Dyskinesia+in+Experimental+Parkinson%E2%80%99s+Disease&doi=10.1126%2Fscitranslmed.3000664"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3000664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3000664%26sid%3Dliteratum%253Aachs%26aulast%3DAhmed%26aufirst%3DM.%2BR.%26aulast%3DBerthet%26aufirst%3DA.%26aulast%3DBychkov%26aufirst%3DE.%26aulast%3DPorras%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DBioulac%26aufirst%3DB.%2BH.%26aulast%3DCarl%26aufirst%3DY.%2BT.%26aulast%3DBloch%26aufirst%3DB.%26aulast%3DKook%26aufirst%3DS.%26aulast%3DAubert%26aufirst%3DI.%26aulast%3DDovero%26aufirst%3DS.%26aulast%3DDoudnikoff%26aufirst%3DE.%26aulast%3DGurevich%26aufirst%3DV.%2BV.%26aulast%3DGurevich%26aufirst%3DE.%2BV.%26aulast%3DBezard%26aufirst%3DE.%26atitle%3DLentiviral%2520Overexpression%2520of%2520GRK6%2520Alleviates%2520L-DOPA%25E2%2580%2593Induced%2520Dyskinesia%2520in%2520Experimental%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2010%26volume%3D2%26spage%3D28ra28%26doi%3D10.1126%2Fscitranslmed.3000664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Allen, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yost, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sassano, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yadav, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span> </span><span class="NLM_article-title">Discovery of Beta-Arrestin-Biased Dopamine D2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">18488</span><span class="NLM_x">–</span> <span class="NLM_lpage">18493</span><span class="refDoi"> DOI: 10.1073/pnas.1104807108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1073%2Fpnas.1104807108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=22025698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFymtLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=18488-18493&author=J.+A.+Allenauthor=J.+M.+Yostauthor=V.+Setolaauthor=X.+Chenauthor=M.+F.+Sassanoauthor=M.+Chenauthor=S.+Petersonauthor=P.+N.+Yadavauthor=X.+P.+Huangauthor=B.+Fengauthor=N.+H.+Jensenauthor=X.+Cheauthor=X.+Baiauthor=S.+V.+Fryeauthor=W.+C.+Wetselauthor=M.+G.+Caronauthor=J.+A.+Javitchauthor=B.+L.+Rothauthor=J.+Jin&title=Discovery+of+Beta-Arrestin-Biased+Dopamine+D2+Ligands+for+Probing+Signal+Transduction+Pathways+Essential+for+Antipsychotic+Efficacy&doi=10.1073%2Fpnas.1104807108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy</span></div><div class="casAuthors">Allen, John A.; Yost, Julianne M.; Setola, Vincent; Chen, Xin; Sassano, Maria F.; Chen, Meng; Peterson, Sean; Yadav, Prem N.; Huang, Xi-Ping; Feng, Bo; Jensen, Niels H.; Che, Xin; Bai, Xu; Frye, Stephen V.; Wetsel, William C.; Caron, Marc G.; Javitch, Jonathan A.; Roth, Bryan L.; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">18488-18493, S18488/1-S18488/15</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Elucidating the key signal transduction pathways essential for both antipsychotic efficacy and side-effect profiles is essential for developing safer and more effective therapies.  Recent work has highlighted noncanonical modes of dopamine D2 receptor (D2R) signaling via β-arrestins as being important for the therapeutic actions of both antipsychotic and antimanic agents.  We thus sought to create unique D2R agonists that display signaling bias via β-arrestinergic signaling.  Through a robust diversity-oriented modification of the scaffold represented by aripiprazole (1), we discovered UNC9975 (2), UNC0006 (3); and UNC9994 (4) as unprecedented β-arrestin-biased D2R ligands.  These compds. also represent unprecedented β-arrestin-biased ligands for a Gi-coupled G protein-coupled receptor (GPCR).  Significantly, UNC9975, UNC0006, and UNC9994 are simultaneously antagonists of Gi-regulated cAMP prodn. and partial agonists for D2R/β-arrestin-2 interactions.  Importantly, VNC9975 displayed potent antipsychotic-like activity without inducing motoric side effects in inbred C57BL/6 mice in vivo.  Genetic deletion of β-arrestin-2 simultaneously attenuated the antipsychotic actions of UNC9975 and transformed it into a typical antipsychotic .drug with a high propensity to induce catalepsy.  Similarly, the antipsychotic-like activity displayed by UNC9994, an extremely β-arrestin-biased D2R agonist, in wild-type mice was completely abolished in β-arrestin-2 knockout mice.  Taken together, our results suggest that β-arrestin signaling and recruitment can be simultaneously a significant contributor to antipsychotic efficacy and protective against motoric side effects.  These functionally selective, β-arrestin-biased D2R ligands represent valuable chem. probes for further investigations of D2R signaling in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr87mjP6jm447Vg90H21EOLACvtfcHk0lhySulehB-jYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFymtLzK&md5=d5b06e4ac4d2cc4cd04fd1de760ec628</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1104807108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1104807108%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26aulast%3DYost%26aufirst%3DJ.%2BM.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DPeterson%26aufirst%3DS.%26aulast%3DYadav%26aufirst%3DP.%2BN.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DChe%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DX.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520Beta-Arrestin-Biased%2520Dopamine%2520D2%2520Ligands%2520for%2520Probing%2520Signal%2520Transduction%2520Pathways%2520Essential%2520for%2520Antipsychotic%2520Efficacy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D18488%26epage%3D18493%26doi%3D10.1073%2Fpnas.1104807108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Weichert, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruse, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manglik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Covalent Agonists for Studying G Protein-Coupled Receptor Activation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">10744</span><span class="NLM_x">–</span> <span class="NLM_lpage">10748</span><span class="refDoi"> DOI: 10.1073/pnas.1410415111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1073%2Fpnas.1410415111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=25006259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyqtbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=10744-10748&author=D.+Weichertauthor=A.+C.+Kruseauthor=A.+Manglikauthor=C.+Hillerauthor=C.+Zhangauthor=H.+H%C3%BCbnerauthor=B.+K.+Kobilkaauthor=P.+Gmeiner&title=Covalent+Agonists+for+Studying+G+Protein-Coupled+Receptor+Activation&doi=10.1073%2Fpnas.1410415111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent agonists for studying G protein-coupled receptor activation</span></div><div class="casAuthors">Weichert, Dietmar; Kruse, Andrew C.; Manglik, Aashish; Hiller, Christine; Zhang, Cheng; Huebner, Harald; Kobilka, Brian K.; Gmeiner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">10744-10748</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Structural studies on G protein-coupled receptors (GPCRs) provide important insights into the architecture and function of these important drug targets.  However, the crystn. of GPCRs in active states is particularly challenging, requiring the formation of stable and conformationally homogeneous ligand-receptor complexes.  Native hormones, neurotransmitters, and synthetic agonists that bind with low affinity are ineffective at stabilizing an active state for crystallogenesis.  To promote structural studies on the pharmacol. highly relevant class of aminergic GPCRs, the authors here present the development of covalently binding mol. tools activating Gs-, Gi-, and Gq-coupled receptors.  The covalent agonists are derived from the monoamine neurotransmitters noradrenaline, dopamine, serotonin, and histamine, and they were accessed using a general and versatile synthetic strategy.  The authors demonstrate that the tool compds. presented herein display an efficient covalent binding mode and that the resp. covalent ligand-receptor complexes activate G proteins comparable to the natural neurotransmitters.  A crystal structure of the β2-adrenoreceptor in complex with a covalent noradrenaline analog and a conformationally selective antibody (nanobody) verified that these agonists can be used to facilitate crystallogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqbJHK2UMj1rVg90H21EOLACvtfcHk0liUP95mYnC3Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyqtbnN&md5=a131bb7711d9a1826c77c3b598dee470</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1410415111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1410415111%26sid%3Dliteratum%253Aachs%26aulast%3DWeichert%26aufirst%3DD.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DHiller%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DCovalent%2520Agonists%2520for%2520Studying%2520G%2520Protein-Coupled%2520Receptor%2520Activation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D10744%26epage%3D10748%26doi%3D10.1073%2Fpnas.1410415111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Ring, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manglik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruse, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enos, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span> </span><span class="NLM_article-title">Adrenaline-Activated Structure of Beta2-Adrenoceptor Stabilized by an Engineered Nanobody</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">502</span><span class="NLM_x">, </span> <span class="NLM_fpage">575</span><span class="NLM_x">–</span> <span class="NLM_lpage">579</span><span class="refDoi"> DOI: 10.1038/nature12572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1038%2Fnature12572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=24056936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFSlsLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=502&publication_year=2013&pages=575-579&author=A.+M.+Ringauthor=A.+Manglikauthor=A.+C.+Kruseauthor=M.+D.+Enosauthor=W.+I.+Weisauthor=K.+C.+Garciaauthor=B.+K.+Kobilka&title=Adrenaline-Activated+Structure+of+Beta2-Adrenoceptor+Stabilized+by+an+Engineered+Nanobody&doi=10.1038%2Fnature12572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Adrenaline-activated structure of β2-adrenoceptor stabilized by an engineered nanobody</span></div><div class="casAuthors">Ring, Aaron M.; Manglik, Aashish; Kruse, Andrew C.; Enos, Michael D.; Weis, William I.; Garcia, K. Christopher; Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">502</span>
        (<span class="NLM_cas:issue">7472</span>),
    <span class="NLM_cas:pages">575-579</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) are integral membrane proteins that play an essential role in human physiol., yet the mol. processes through which they bind to their endogenous agonists and activate effector proteins remain poorly understood.  So far, it has not been possible to capture an active-state GPCR bound to its native neurotransmitter.  Crystal structures of agonist-bound GPCRs have relied on the use of either exceptionally high-affinity agonists or receptor stabilization by mutagenesis.  Many natural agonists such as adrenaline, which activates the β2-adrenoceptor (β2AR), bind with relatively low affinity, and they are often chem. unstable.  Here, using directed evolution, the authors engineered a high-affinity conformationally selective single-domain camelid antibody fragment (nanobody; Nb6B9) that stabilized the active state of human β2AR, and used this to obtain crystal structures of the activated receptor bound to multiple ligands.  The authors present structures of the active-state human β2AR bound to 3 chem. distinct agonists: (1) the ultrahigh-affinity agonist BI167107; (2) the high-affinity catecholamine agonist, hydroxybenzylisoproterenol; and (3) the low-affinity endogenous agonist, adrenaline.  The crystal structures revealed a highly conserved overall ligand recognition and activation mode despite diverse ligand chem. structures and affinities that ranged from 100 nM to ∼80 pM.  Overall, the adrenaline-bound receptor structure was similar to the others, but it had substantial rearrangements in extracellular loop 3 and the extracellular tip of transmembrane helix 6.  These structures also revealed a water-mediated H-bond between 2 conserved Tyr residues, which appeared to stabilize the active state of the β2AR and related GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAp0VskflwWbVg90H21EOLACvtfcHk0liUP95mYnC3Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFSlsLzP&md5=c5b844a0a86ee0a74843588a4a363592</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnature12572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12572%26sid%3Dliteratum%253Aachs%26aulast%3DRing%26aufirst%3DA.%2BM.%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26aulast%3DEnos%26aufirst%3DM.%2BD.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DGarcia%26aufirst%3DK.%2BC.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DAdrenaline-Activated%2520Structure%2520of%2520Beta2-Adrenoceptor%2520Stabilized%2520by%2520an%2520Engineered%2520Nanobody%26jtitle%3DNature%26date%3D2013%26volume%3D502%26spage%3D575%26epage%3D579%26doi%3D10.1038%2Fnature12572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Rasmussen, S. G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fung, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casarosa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chae, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVree, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbaum, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thian, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konetzki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunahara, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gellman, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pautsch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyaert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span> </span><span class="NLM_article-title">Structure of a Nanobody-Stabilized Active State of the B2 Adrenoceptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">469</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span><span class="refDoi"> DOI: 10.1038/nature09648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1038%2Fnature09648" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=469&publication_year=2011&pages=175-180&author=S.+G.+F.+Rasmussenauthor=H.-J.+Choiauthor=J.+J.+Fungauthor=E.+Pardonauthor=P.+Casarosaauthor=P.+S.+Chaeauthor=B.+T.+DeVreeauthor=D.+M.+Rosenbaumauthor=F.+S.+Thianauthor=T.+S.+Kobilkaauthor=A.+Schnappauthor=I.+Konetzkiauthor=R.+K.+Sunaharaauthor=S.+H.+Gellmanauthor=A.+Pautschauthor=J.+Steyaertauthor=W.+I.+Weisauthor=B.+K.+Kobilka&title=Structure+of+a+Nanobody-Stabilized+Active+State+of+the+B2+Adrenoceptor&doi=10.1038%2Fnature09648"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnature09648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09648%26sid%3Dliteratum%253Aachs%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%2BF.%26aulast%3DChoi%26aufirst%3DH.-J.%26aulast%3DFung%26aufirst%3DJ.%2BJ.%26aulast%3DPardon%26aufirst%3DE.%26aulast%3DCasarosa%26aufirst%3DP.%26aulast%3DChae%26aufirst%3DP.%2BS.%26aulast%3DDeVree%26aufirst%3DB.%2BT.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DKonetzki%26aufirst%3DI.%26aulast%3DSunahara%26aufirst%3DR.%2BK.%26aulast%3DGellman%26aufirst%3DS.%2BH.%26aulast%3DPautsch%26aufirst%3DA.%26aulast%3DSteyaert%26aufirst%3DJ.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DStructure%2520of%2520a%2520Nanobody-Stabilized%2520Active%2520State%2520of%2520the%2520B2%2520Adrenoceptor%26jtitle%3DNature%26date%3D2011%26volume%3D469%26spage%3D175%26epage%3D180%26doi%3D10.1038%2Fnature09648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Warne, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moukhametzianov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nehme, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leslie, A. G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schertler, G. F. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tate, C. G.</span><span> </span><span class="NLM_article-title">The Structural Basis for Agonist and Partial Agonist Action on a B1-Adrenergic Receptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">469</span><span class="NLM_x">, </span> <span class="NLM_fpage">241</span><span class="NLM_x">–</span> <span class="NLM_lpage">244</span><span class="refDoi"> DOI: 10.1038/nature09746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1038%2Fnature09746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=21228877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvFelsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=469&publication_year=2011&pages=241-244&author=T.+Warneauthor=R.+Moukhametzianovauthor=J.+G.+Bakerauthor=R.+Nehmeauthor=P.+C.+Edwardsauthor=A.+G.+W.+Leslieauthor=G.+F.+X.+Schertlerauthor=C.+G.+Tate&title=The+Structural+Basis+for+Agonist+and+Partial+Agonist+Action+on+a+B1-Adrenergic+Receptor&doi=10.1038%2Fnature09746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis for agonist and partial agonist action on a β1-adrenergic receptor</span></div><div class="casAuthors">Warne, Tony; Moukhametzianov, Rouslan; Baker, Jillian G.; Nehme, Rony; Edwards, Patricia C.; Leslie, Andrew G. W.; Schertler, Gebhard F. X.; Tate, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">469</span>
        (<span class="NLM_cas:issue">7329</span>),
    <span class="NLM_cas:pages">241-244</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">β-Adrenergic receptors (βARs) are G-protein-coupled receptors (GPCRs) that activate intracellular G proteins upon binding catecholamine agonist ligands such as adrenaline and noradrenaline.  Synthetic ligands have been developed that either activate or inhibit βARs for the treatment of asthma, hypertension or cardiac dysfunction.  These ligands are classified as either full agonists, partial agonists or antagonists, depending on whether the cellular response is similar to that of the native ligand, reduced or inhibited, resp.  However, the structural basis for these different ligand efficacies is unknown.  Here we present four crystal structures of the thermostabilized turkey (Meleagris gallopavo) β1-adrenergic receptor (β1AR-m23) bound to the full agonists carmoterol and isoprenaline and the partial agonists salbutamol and dobutamine.  In each case, agonist binding induces a 1 Å contraction of the catecholamine-binding pocket relative to the antagonist bound receptor.  Full agonists can form hydrogen bonds with two conserved serine residues in transmembrane helix 5 (Ser5.42 and Ser5.46), but partial agonists only interact with Ser5.42 (superscripts refer to Ballesteros-Weinstein numbering).  The structures provide an understanding of the pharmacol. differences between different ligand classes, illuminating how GPCRs function and providing a solid foundation for the structure-based design of novel ligands with predictable efficacies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2EWXHDM88tLVg90H21EOLACvtfcHk0liUP95mYnC3Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvFelsw%253D%253D&md5=aa7fa20ff770ea13d97f0cf39311a1ea</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnature09746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09746%26sid%3Dliteratum%253Aachs%26aulast%3DWarne%26aufirst%3DT.%26aulast%3DMoukhametzianov%26aufirst%3DR.%26aulast%3DBaker%26aufirst%3DJ.%2BG.%26aulast%3DNehme%26aufirst%3DR.%26aulast%3DEdwards%26aufirst%3DP.%2BC.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DSchertler%26aufirst%3DG.%2BF.%2BX.%26aulast%3DTate%26aufirst%3DC.%2BG.%26atitle%3DThe%2520Structural%2520Basis%2520for%2520Agonist%2520and%2520Partial%2520Agonist%2520Action%2520on%2520a%2520B1-Adrenergic%2520Receptor%26jtitle%3DNature%26date%3D2011%26volume%3D469%26spage%3D241%26epage%3D244%26doi%3D10.1038%2Fnature09746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Weichert, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Structure-Guided Development of Dual B2 Adrenergic/Dopamine D2 Receptor Agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2641</span><span class="NLM_x">–</span> <span class="NLM_lpage">2653</span><span class="refDoi"> DOI: 10.1016/j.bmc.2016.04.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1016%2Fj.bmc.2016.04.028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=2641-2653&author=D.+Weichertauthor=M.+Stanekauthor=H.+H%C3%BCbnerauthor=P.+Gmeiner&title=Structure-Guided+Development+of+Dual+B2+Adrenergic%2FDopamine+D2+Receptor+Agonists&doi=10.1016%2Fj.bmc.2016.04.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.04.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.04.028%26sid%3Dliteratum%253Aachs%26aulast%3DWeichert%26aufirst%3DD.%26aulast%3DStanek%26aufirst%3DM.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DStructure-Guided%2520Development%2520of%2520Dual%2520B2%2520Adrenergic%252FDopamine%2520D2%2520Receptor%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D2641%26epage%3D2653%26doi%3D10.1016%2Fj.bmc.2016.04.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Beattie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruce, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlton, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuenoud, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairhurst, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fozard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janus, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosethorne, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandham, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sykes, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trifilieff, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissler, E.</span><span> </span><span class="NLM_article-title">An Investigation into the Structure–Activity Relationships Associated with the Systematic Modification of the B2-Adrenoceptor Agonist Indacaterol</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">6280</span><span class="NLM_x">–</span> <span class="NLM_lpage">6285</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.07.096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1016%2Fj.bmcl.2012.07.096" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6280-6285&author=D.+Beattieauthor=D.+Beerauthor=M.+E.+Bradleyauthor=I.+Bruceauthor=S.+J.+Charltonauthor=B.+M.+Cuenoudauthor=R.+A.+Fairhurstauthor=D.+Farrauthor=J.+R.+Fozardauthor=D.+Janusauthor=E.+M.+Rosethorneauthor=D.+A.+Sandhamauthor=D.+A.+Sykesauthor=A.+Trifilieffauthor=K.+L.+Turnerauthor=E.+Wissler&title=An+Investigation+into+the+Structure%E2%80%93Activity+Relationships+Associated+with+the+Systematic+Modification+of+the+B2-Adrenoceptor+Agonist+Indacaterol&doi=10.1016%2Fj.bmcl.2012.07.096"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.07.096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.07.096%26sid%3Dliteratum%253Aachs%26aulast%3DBeattie%26aufirst%3DD.%26aulast%3DBeer%26aufirst%3DD.%26aulast%3DBradley%26aufirst%3DM.%2BE.%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DCuenoud%26aufirst%3DB.%2BM.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DFarr%26aufirst%3DD.%26aulast%3DFozard%26aufirst%3DJ.%2BR.%26aulast%3DJanus%26aufirst%3DD.%26aulast%3DRosethorne%26aufirst%3DE.%2BM.%26aulast%3DSandham%26aufirst%3DD.%2BA.%26aulast%3DSykes%26aufirst%3DD.%2BA.%26aulast%3DTrifilieff%26aufirst%3DA.%26aulast%3DTurner%26aufirst%3DK.%2BL.%26aulast%3DWissler%26aufirst%3DE.%26atitle%3DAn%2520Investigation%2520into%2520the%2520Structure%25E2%2580%2593Activity%2520Relationships%2520Associated%2520with%2520the%2520Systematic%2520Modification%2520of%2520the%2520B2-Adrenoceptor%2520Agonist%2520Indacaterol%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6280%26epage%3D6285%26doi%3D10.1016%2Fj.bmcl.2012.07.096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Yoshizaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanimura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yabuuchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span> </span><span class="NLM_article-title">Sympathomimetic Amines Having a Carbostyril Nucleus</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1138</span><span class="NLM_x">–</span> <span class="NLM_lpage">1142</span><span class="refDoi"> DOI: 10.1021/jm00231a011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00231a011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1976&pages=1138-1142&author=S.+Yoshizakiauthor=K.+Tanimuraauthor=S.+Tamadaauthor=Y.+Yabuuchiauthor=K.+Nakagawa&title=Sympathomimetic+Amines+Having+a+Carbostyril+Nucleus&doi=10.1021%2Fjm00231a011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm00231a011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00231a011%26sid%3Dliteratum%253Aachs%26aulast%3DYoshizaki%26aufirst%3DS.%26aulast%3DTanimura%26aufirst%3DK.%26aulast%3DTamada%26aufirst%3DS.%26aulast%3DYabuuchi%26aufirst%3DY.%26aulast%3DNakagawa%26aufirst%3DK.%26atitle%3DSympathomimetic%2520Amines%2520Having%2520a%2520Carbostyril%2520Nucleus%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1976%26volume%3D19%26spage%3D1138%26epage%3D1142%26doi%3D10.1021%2Fjm00231a011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Yoshizaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manabe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tei, S.</span><span> </span><span class="NLM_article-title">Isomers of Erythro-5-(1-Hydroxy-2-Isopropylaminobutyl)-8-Hydroxycarbostyril, a New Bronchodilator</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1103</span><span class="NLM_x">–</span> <span class="NLM_lpage">1104</span><span class="refDoi"> DOI: 10.1021/jm00218a024</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00218a024" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1977&pages=1103-1104&author=S.+Yoshizakiauthor=Y.+Manabeauthor=S.+Tamadaauthor=K.+Nakagawaauthor=S.+Tei&title=Isomers+of+Erythro-5-%281-Hydroxy-2-Isopropylaminobutyl%29-8-Hydroxycarbostyril%2C+a+New+Bronchodilator&doi=10.1021%2Fjm00218a024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm00218a024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00218a024%26sid%3Dliteratum%253Aachs%26aulast%3DYoshizaki%26aufirst%3DS.%26aulast%3DManabe%26aufirst%3DY.%26aulast%3DTamada%26aufirst%3DS.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DTei%26aufirst%3DS.%26atitle%3DIsomers%2520of%2520Erythro-5-%25281-Hydroxy-2-Isopropylaminobutyl%2529-8-Hydroxycarbostyril%252C%2520a%2520New%2520Bronchodilator%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1977%26volume%3D20%26spage%3D1103%26epage%3D1104%26doi%3D10.1021%2Fjm00218a024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Bouyssou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoenke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolf, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lustenberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pestel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sieger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lotz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heine, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Büttner, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konetzki, I.</span><span> </span><span class="NLM_article-title">Discovery of Olodaterol, a Novel Inhaled B2-Adrenoceptor Agonist with a 24 H Bronchodilatory Efficacy</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1410</span><span class="NLM_x">–</span> <span class="NLM_lpage">1414</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.12.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1016%2Fj.bmcl.2009.12.087" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1410-1414&author=T.+Bouyssouauthor=C.+Hoenkeauthor=K.+Rudolfauthor=P.+Lustenbergerauthor=S.+Pestelauthor=P.+Siegerauthor=R.+Lotzauthor=C.+Heineauthor=F.+H.+B%C3%BCttnerauthor=A.+Schnappauthor=I.+Konetzki&title=Discovery+of+Olodaterol%2C+a+Novel+Inhaled+B2-Adrenoceptor+Agonist+with+a+24+H+Bronchodilatory+Efficacy&doi=10.1016%2Fj.bmcl.2009.12.087"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.12.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.12.087%26sid%3Dliteratum%253Aachs%26aulast%3DBouyssou%26aufirst%3DT.%26aulast%3DHoenke%26aufirst%3DC.%26aulast%3DRudolf%26aufirst%3DK.%26aulast%3DLustenberger%26aufirst%3DP.%26aulast%3DPestel%26aufirst%3DS.%26aulast%3DSieger%26aufirst%3DP.%26aulast%3DLotz%26aufirst%3DR.%26aulast%3DHeine%26aufirst%3DC.%26aulast%3DB%25C3%25BCttner%26aufirst%3DF.%2BH.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DKonetzki%26aufirst%3DI.%26atitle%3DDiscovery%2520of%2520Olodaterol%252C%2520a%2520Novel%2520Inhaled%2520B2-Adrenoceptor%2520Agonist%2520with%2520a%252024%2520H%2520Bronchodilatory%2520Efficacy%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1410%26epage%3D1414%26doi%3D10.1016%2Fj.bmcl.2009.12.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Hoenke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouyssou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tautermann, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolf, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konetzki, I.</span><span> </span><span class="NLM_article-title">Use of 5-Hydroxy-4H-Benzo[1,4]Oxazin-3-Ones as Beta2-Adrenoceptor Agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6640</span><span class="NLM_x">–</span> <span class="NLM_lpage">6644</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1016%2Fj.bmcl.2009.10.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6640-6644&author=C.+Hoenkeauthor=T.+Bouyssouauthor=C.+S.+Tautermannauthor=K.+Rudolfauthor=A.+Schnappauthor=I.+Konetzki&title=Use+of+5-Hydroxy-4H-Benzo%5B1%2C4%5DOxazin-3-Ones+as+Beta2-Adrenoceptor+Agonists&doi=10.1016%2Fj.bmcl.2009.10.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DHoenke%26aufirst%3DC.%26aulast%3DBouyssou%26aufirst%3DT.%26aulast%3DTautermann%26aufirst%3DC.%2BS.%26aulast%3DRudolf%26aufirst%3DK.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DKonetzki%26aufirst%3DI.%26atitle%3DUse%2520of%25205-Hydroxy-4H-Benzo%255B1%252C4%255DOxazin-3-Ones%2520as%2520Beta2-Adrenoceptor%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6640%26epage%3D6644%26doi%3D10.1016%2Fj.bmcl.2009.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Rosenbaum, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aragao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arlow, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devree, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunahara, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chae, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gellman, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dror, R. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caffrey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span> </span><span class="NLM_article-title">Structure and Function of an Irreversible Agonist-Beta(2) Adrenoceptor Complex</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">469</span><span class="NLM_x">, </span> <span class="NLM_fpage">236</span><span class="NLM_x">–</span> <span class="NLM_lpage">240</span><span class="refDoi"> DOI: 10.1038/nature09665</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1038%2Fnature09665" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=21228876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvFehsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=469&publication_year=2011&pages=236-240&author=D.+M.+Rosenbaumauthor=C.+Zhangauthor=J.+A.+Lyonsauthor=R.+Hollauthor=D.+Aragaoauthor=D.+H.+Arlowauthor=S.+G.+Rasmussenauthor=H.+J.+Choiauthor=B.+T.+Devreeauthor=R.+K.+Sunaharaauthor=P.+S.+Chaeauthor=S.+H.+Gellmanauthor=R.+O.+Drorauthor=D.+E.+Shawauthor=W.+I.+Weisauthor=M.+Caffreyauthor=P.+Gmeinerauthor=B.+K.+Kobilka&title=Structure+and+Function+of+an+Irreversible+Agonist-Beta%282%29+Adrenoceptor+Complex&doi=10.1038%2Fnature09665"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and function of an irreversible agonist-β2 adrenoceptor complex</span></div><div class="casAuthors">Rosenbaum, Daniel M.; Zhang, Cheng; Lyons, Joseph A.; Holl, Ralph; Aragao, David; Arlow, Daniel H.; Rasmussen, Soren G. F.; Choi, Hee-Jung; DeVree, Brian T.; Sunahara, Roger K.; Chae, Pil Seok; Gellman, Samuel H.; Dror, Ron O.; Shaw, David E.; Weis, William I.; Caffrey, Martin; Gmeiner, Peter; Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">469</span>
        (<span class="NLM_cas:issue">7329</span>),
    <span class="NLM_cas:pages">236-240</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) are eukaryotic integral membrane proteins that modulate biol. function by initiating cellular signaling in response to chem. diverse agonists.  Despite recent progress in the structural biol. of GPCRs, the mol. basis for agonist binding and allosteric modulation of these proteins is poorly understood.  Structural knowledge of agonist-bound states is essential for deciphering the mechanism of receptor activation, and for structure-guided design and optimization of ligands.  However, the crystn. of agonist-bound GPCRs has been hampered by modest affinities and rapid off-rates of available agonists.  Using the inactive structure of the human β2 adrenergic receptor (β2AR) as a guide, we designed a β2AR agonist that can be covalently tethered to a specific site on the receptor through a disulfide bond.  The covalent β2AR-agonist complex forms efficiently, and is capable of activating a heterotrimeric G protein.  We crystd. a covalent agonist-bound β2AR-T4L fusion protein in lipid bilayers through the use of the lipidic mesophase method, and detd. its structure at 3.5 Å resoln.  A comparison to the inactive structure and an antibody-stabilized active structure (companion paper) shows how binding events at both the extracellular and intracellular surfaces are required to stabilize an active conformation of the receptor.  The structures are in agreement with long-timescale (up to 30 μs) mol. dynamics simulations showing that an agonist-bound active conformation spontaneously relaxes to an inactive-like conformation in the absence of a G protein or stabilizing antibody.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3cxTxwHig_rVg90H21EOLACvtfcHk0li92j3FblOIbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvFehsQ%253D%253D&md5=8629b93e43fb692395e2aa6f8bb011a9</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnature09665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09665%26sid%3Dliteratum%253Aachs%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLyons%26aufirst%3DJ.%2BA.%26aulast%3DHoll%26aufirst%3DR.%26aulast%3DAragao%26aufirst%3DD.%26aulast%3DArlow%26aufirst%3DD.%2BH.%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%26aulast%3DChoi%26aufirst%3DH.%2BJ.%26aulast%3DDevree%26aufirst%3DB.%2BT.%26aulast%3DSunahara%26aufirst%3DR.%2BK.%26aulast%3DChae%26aufirst%3DP.%2BS.%26aulast%3DGellman%26aufirst%3DS.%2BH.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DCaffrey%26aufirst%3DM.%26aulast%3DGmeiner%26aufirst%3DP.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DStructure%2520and%2520Function%2520of%2520an%2520Irreversible%2520Agonist-Beta%25282%2529%2520Adrenoceptor%2520Complex%26jtitle%3DNature%26date%3D2011%26volume%3D469%26spage%3D236%26epage%3D240%26doi%3D10.1038%2Fnature09665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCorvy, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span> </span><span class="NLM_article-title">Discovery of G Protein-Biased D2 Dopamine Receptor Partial Agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">10601</span><span class="NLM_x">–</span> <span class="NLM_lpage">10618</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01208</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01208" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOqs7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10601-10618&author=X.+Chenauthor=J.+D.+McCorvyauthor=M.+G.+Fischerauthor=K.+V.+Butlerauthor=Y.+Shenauthor=B.+L.+Rothauthor=J.+Jin&title=Discovery+of+G+Protein-Biased+D2+Dopamine+Receptor+Partial+Agonists&doi=10.1021%2Facs.jmedchem.6b01208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of G Protein-Biased D2 Dopamine Receptor Partial Agonists</span></div><div class="casAuthors">Chen, Xin; McCorvy, John D.; Fischer, Matthew G.; Butler, Kyle V.; Shen, Yudao; Roth, Bryan L.; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10601-10618</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Biased ligands (also known as functionally selective ligands) of G protein-coupled receptors are valuable tools for dissecting the roles of G protein-dependent and independent signaling pathways in health and disease.  Biased ligands have also been increasingly pursued by the biomedical community as promising therapeutics with improved efficacy and reduced side effects compared with unbiased ligands.  The authors previously discovered first-in-class β-arrestin-biased agonists of dopamine D2 receptor (D2R) by extensively exploring multiple regions of aripiprazole, a balanced D2R agonist.  In the authors' continuing efforts to identify biased agonists of D2R, the authors unexpectedly discovered a G protein-biased agonist of D2R, compd. 1 (5-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-methylbenzo[d]thiazole), which is the first G protein-biased D2R agonist from the aripiprazole scaffold.  The authors designed and synthesized novel analogs to explore two regions of 1 and conducted structure-functional selectivity relationship (SFSR) studies.  Here the authors report the discovery of 1, findings from the authors' SFSR studies, and characterization of novel G protein-biased D2R agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeKlhGCqSPxLVg90H21EOLACvtfcHk0li92j3FblOIbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOqs7vK&md5=81b1435b1ae82438aa3f270f7ee4f853</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01208%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DFischer%26aufirst%3DM.%2BG.%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520G%2520Protein-Biased%2520D2%2520Dopamine%2520Receptor%2520Partial%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10601%26epage%3D10618%26doi%3D10.1021%2Facs.jmedchem.6b01208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sassano, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span> </span><span class="NLM_article-title">Structure-Functional Selectivity Relationship Studies of Beta-Arrestin-Biased Dopamine D(2) Receptor Agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7141</span><span class="NLM_x">–</span> <span class="NLM_lpage">7153</span><span class="refDoi"> DOI: 10.1021/jm300603y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300603y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWhsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7141-7153&author=X.+Chenauthor=M.+F.+Sassanoauthor=L.+Zhengauthor=V.+Setolaauthor=M.+Chenauthor=X.+Baiauthor=S.+V.+Fryeauthor=W.+C.+Wetselauthor=B.+L.+Rothauthor=J.+Jin&title=Structure-Functional+Selectivity+Relationship+Studies+of+Beta-Arrestin-Biased+Dopamine+D%282%29+Receptor+Agonists&doi=10.1021%2Fjm300603y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Functional Selectivity Relationship Studies of β-Arrestin-Biased Dopamine D2 Receptor Agonists</span></div><div class="casAuthors">Chen, Xin; Sassano, Maria F.; Zheng, Lianyou; Setola, Vincent; Chen, Meng; Bai, Xu; Frye, Stephen V.; Wetsel, William C.; Roth, Bryan L.; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7141-7153</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Functionally selective G protein-coupled receptor (GPCR) ligands, which differentially modulate canonical and noncanonical signaling, are extremely useful for elucidating key signal transduction pathways essential for both the therapeutic actions and side effects of drugs.  However, few such ligands have been created, and very little purposeful attention has been devoted to studying what we term: "structure-functional selectivity relationships" (SFSR).  We recently disclosed the first β-arrestin-biased dopamine D2 receptor (D2R) agonists UNC9975 (44) and UNC9994 (36), which have robust in vivo antipsychotic drug-like activities.  Here we report the first comprehensive SFSR studies focused on exploring four regions of the aripiprazole scaffold, which resulted in the discovery of these β-arrestin-biased D2R agonists.  These studies provide a successful proof-of-concept for how functionally selective ligands can be discovered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwoG1fasQ6GLVg90H21EOLACvtfcHk0lgT0gwy3sOVaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWhsbfK&md5=00b0613e62ce7b5a4c98cb5212fea3b5</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm300603y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300603y%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DBai%26aufirst%3DX.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DStructure-Functional%2520Selectivity%2520Relationship%2520Studies%2520of%2520Beta-Arrestin-Biased%2520Dopamine%2520D%25282%2529%2520Receptor%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7141%26epage%3D7153%26doi%3D10.1021%2Fjm300603y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Möller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kling, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skultety, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leuner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Functionally Selective Dopamine D2, D3 Receptor Partial Agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4861</span><span class="NLM_x">–</span> <span class="NLM_lpage">4875</span><span class="refDoi"> DOI: 10.1021/jm5004039</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5004039" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4861-4875&author=D.+M%C3%B6llerauthor=R.+C.+Klingauthor=M.+Skultetyauthor=K.+Leunerauthor=H.+H%C3%BCbnerauthor=P.+Gmeiner&title=Functionally+Selective+Dopamine+D2%2C+D3+Receptor+Partial+Agonists&doi=10.1021%2Fjm5004039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm5004039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5004039%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25B6ller%26aufirst%3DD.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DSkultety%26aufirst%3DM.%26aulast%3DLeuner%26aufirst%3DK.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DFunctionally%2520Selective%2520Dopamine%2520D2%252C%2520D3%2520Receptor%2520Partial%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4861%26epage%3D4875%26doi%3D10.1021%2Fjm5004039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Möller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uzuneser, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skultety, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huth, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plouffe, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alzheimer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedland, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouvier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-<i>a</i>]Pyridine Substructure</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2908</span><span class="NLM_x">–</span> <span class="NLM_lpage">2929</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01857</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01857" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A280%3ADC%252BC1czhs1Ojsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2908-2929&author=D.+M%C3%B6llerauthor=A.+Banerjeeauthor=T.+C.+Uzuneserauthor=M.+Skultetyauthor=T.+Huthauthor=B.+Plouffeauthor=H.+H%C3%BCbnerauthor=C.+Alzheimerauthor=K.+Friedlandauthor=C.+P.+M%C3%BCllerauthor=M.+Bouvierauthor=P.+Gmeiner&title=Discovery+of+G+Protein-Biased+Dopaminergics+with+a+Pyrazolo%5B1%2C5-a%5DPyridine+Substructure&doi=10.1021%2Facs.jmedchem.6b01857"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure</span></div><div class="casAuthors">Moller Dorothee; Banerjee Ashutosh; Skultety Marika; Hubner Harald; Gmeiner Peter; Uzuneser Taygun C; Muller Christian P; Huth Tobias; Alzheimer Christian; Plouffe Bianca; Bouvier Michel; Friedland Kristina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2908-2929</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">1,4-Disubstituted aromatic piperazines are privileged structural motifs recognized by aminergic G protein-coupled receptors.  Connection of a lipophilic moiety to the arylpiperazine core by an appropriate linker represents a promising concept to increase binding affinity and to fine-tune functional properties.  In particular, incorporation of a pyrazolo[1,5-a]pyridine heterocyclic appendage led to a series of high-affinity dopamine receptor partial agonists.  Comprehensive pharmacological characterization involving BRET biosensors, binding studies, electrophysiology, and complementation-based assays revealed compounds favoring activation of G proteins (preferably Go) over β-arrestin recruitment at dopamine D2 receptors.  The feasibility to design G protein-biased partial agonists as putative novel therapeutics was demonstrated for the representative 2-methoxyphenylpiperazine 16c, which unequivocally displayed antipsychotic activity in vivo.  Moreover, combination of the pyrazolo[1,5-a]pyridine appendage with a 5-hydroxy-N-propyl-2-aminotetraline unit led to balanced or G protein-biased dopaminergic ligands depending on the stereochemistry of the headgroup, illustrating the complex structure-functional selectivity relationships at dopamine D2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSsvEaQplNsM25P7XSLhESfW6udTcc2eZaJpdh8PpFpLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czhs1Ojsw%253D%253D&md5=208855de29fed6b821fd6e4a5bfb412f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01857%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25B6ller%26aufirst%3DD.%26aulast%3DBanerjee%26aufirst%3DA.%26aulast%3DUzuneser%26aufirst%3DT.%2BC.%26aulast%3DSkultety%26aufirst%3DM.%26aulast%3DHuth%26aufirst%3DT.%26aulast%3DPlouffe%26aufirst%3DB.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DAlzheimer%26aufirst%3DC.%26aulast%3DFriedland%26aufirst%3DK.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BP.%26aulast%3DBouvier%26aufirst%3DM.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520G%2520Protein-Biased%2520Dopaminergics%2520with%2520a%2520Pyrazolo%255B1%252C5-a%255DPyridine%2520Substructure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2908%26epage%3D2929%26doi%3D10.1021%2Facs.jmedchem.6b01857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Weichert, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kling, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Molecular Determinants of Biased Agonism at the Dopamine D2 Receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">2703</span><span class="NLM_x">–</span> <span class="NLM_lpage">2717</span><span class="refDoi"> DOI: 10.1021/jm501889t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501889t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjslelsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2703-2717&author=D.+Weichertauthor=A.+Banerjeeauthor=C.+Hillerauthor=R.+C.+Klingauthor=H.+H%C3%BCbnerauthor=P.+Gmeiner&title=Molecular+Determinants+of+Biased+Agonism+at+the+Dopamine+D2+Receptor&doi=10.1021%2Fjm501889t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Determinants of Biased Agonism at the Dopamine D2 Receptor</span></div><div class="casAuthors">Weichert, Dietmar; Banerjee, Ashutosh; Hiller, Christine; Kling, Ralf C.; Huebner, Harald; Gmeiner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2703-2717</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of biased (functionally selective) ligands provides a formidable challenge in medicinal chem.  In an effort to learn to design functionally selective mol. tools for the highly therapeutically relevant dopamine D2 receptor, we synthesized a collection of agonists based on structurally distinct head groups derived from canonical or atypical dopaminergic pharmacophores.  The test compds. feature a long lipophilic appendage that was shown to mediate biased signaling.  By employing functional assays and mol. dynamics simulations, we could show that atypical dopamine surrogates of type 1 and 2 promote biased signaling, while ligands built from classical dopaminergic head groups (type 3 and 4) typically elicit more balanced signaling profiles.  Besides this, we found a strong influence of the stereochem. of type 4 aminotetraline-derived agonists on functional selectivity at D2 receptors.  Whereas the (S)-enantiomer behaved as a full agonist, the biased ligand (R)-4 induced poor G protein coupling but substantial β-arrestin recruitment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLUr0k5gvdy7Vg90H21EOLACvtfcHk0lilNhjdouWbDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjslelsrc%253D&md5=cdf8f3ed9dff5f14ae06dbbc227fb14a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm501889t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501889t%26sid%3Dliteratum%253Aachs%26aulast%3DWeichert%26aufirst%3DD.%26aulast%3DBanerjee%26aufirst%3DA.%26aulast%3DHiller%26aufirst%3DC.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DMolecular%2520Determinants%2520of%2520Biased%2520Agonism%2520at%2520the%2520Dopamine%2520D2%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2703%26epage%3D2717%26doi%3D10.1021%2Fjm501889t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Pisani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giangreco, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolotti, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanachi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cellamare, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carotti, A.</span><span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of Coumarin Derivatives Tethered to an Edrophonium-Like Fragment as Highly Potent and Selective Dual Binding Site Acetylcholinesterase Inhibitors</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1616</span><span class="NLM_x">–</span> <span class="NLM_lpage">1630</span><span class="refDoi"> DOI: 10.1002/cmdc.201000210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1002%2Fcmdc.201000210" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=1616-1630&author=L.+Pisaniauthor=M.+Cattoauthor=I.+Giangrecoauthor=F.+Leonettiauthor=O.+Nicolottiauthor=A.+Stefanachiauthor=S.+Cellamareauthor=A.+Carotti&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+Coumarin+Derivatives+Tethered+to+an+Edrophonium-Like+Fragment+as+Highly+Potent+and+Selective+Dual+Binding+Site+Acetylcholinesterase+Inhibitors&doi=10.1002%2Fcmdc.201000210"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000210%26sid%3Dliteratum%253Aachs%26aulast%3DPisani%26aufirst%3DL.%26aulast%3DCatto%26aufirst%3DM.%26aulast%3DGiangreco%26aufirst%3DI.%26aulast%3DLeonetti%26aufirst%3DF.%26aulast%3DNicolotti%26aufirst%3DO.%26aulast%3DStefanachi%26aufirst%3DA.%26aulast%3DCellamare%26aufirst%3DS.%26aulast%3DCarotti%26aufirst%3DA.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520Coumarin%2520Derivatives%2520Tethered%2520to%2520an%2520Edrophonium-Like%2520Fragment%2520as%2520Highly%2520Potent%2520and%2520Selective%2520Dual%2520Binding%2520Site%2520Acetylcholinesterase%2520Inhibitors%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D1616%26epage%3D1630%26doi%3D10.1002%2Fcmdc.201000210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Cerqueira, N. M. F. S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliveira-Campos, A. M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coelho, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Carvalho, L. H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guglielmetti, R.</span><span> </span><span class="NLM_article-title">Synthesis of Photochromic Dyes Based on Annulated Coumarin Systems</span> <span class="citation_source-journal">Helv. Chim. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">442</span><span class="NLM_x">–</span> <span class="NLM_lpage">450</span><span class="refDoi"> DOI: 10.1002/1522-2675(200202)85:2<442::AID-HLCA442>3.0.CO;2-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1002%2F1522-2675%28200202%2985%3A2%3C442%3A%3AAID-HLCA442%3E3.0.CO%3B2-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2002&pages=442-450&author=N.+M.+F.+S.+A.+Cerqueiraauthor=A.+M.+F.+Oliveira-Camposauthor=P.+J.+Coelhoauthor=L.+H.+M.+de+Carvalhoauthor=A.+Samatauthor=R.+Guglielmetti&title=Synthesis+of+Photochromic+Dyes+Based+on+Annulated+Coumarin+Systems&doi=10.1002%2F1522-2675%28200202%2985%3A2%3C442%3A%3AAID-HLCA442%3E3.0.CO%3B2-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2F1522-2675%28200202%2985%3A2%3C442%3A%3AAID-HLCA442%3E3.0.CO%3B2-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1522-2675%2528200202%252985%253A2%253C442%253A%253AAID-HLCA442%253E3.0.CO%253B2-9%26sid%3Dliteratum%253Aachs%26aulast%3DCerqueira%26aufirst%3DN.%2BM.%2BF.%2BS.%2BA.%26aulast%3DOliveira-Campos%26aufirst%3DA.%2BM.%2BF.%26aulast%3DCoelho%26aufirst%3DP.%2BJ.%26aulast%3Dde%2BCarvalho%26aufirst%3DL.%2BH.%2BM.%26aulast%3DSamat%26aufirst%3DA.%26aulast%3DGuglielmetti%26aufirst%3DR.%26atitle%3DSynthesis%2520of%2520Photochromic%2520Dyes%2520Based%2520on%2520Annulated%2520Coumarin%2520Systems%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D2002%26volume%3D85%26spage%3D442%26epage%3D450%26doi%3D10.1002%2F1522-2675%28200202%2985%3A2%3C442%3A%3AAID-HLCA442%3E3.0.CO%3B2-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Mewshaw, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornby, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spangler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scerni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schechter, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andree, T. H.</span><span> </span><span class="NLM_article-title">Studies toward the Discovery of the Next Generation of Antidepressants. 3. Dual 5-HT1A and Serotonin Transporter Affinity within a Class of <i>N</i>-Aryloxyethylindolylalkylamines</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">3823</span><span class="NLM_x">–</span> <span class="NLM_lpage">3842</span><span class="refDoi"> DOI: 10.1021/jm0304010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0304010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=3823-3842&author=R.+E.+Mewshawauthor=D.+Zhouauthor=P.+Zhouauthor=X.+Shiauthor=G.+Hornbyauthor=T.+Spanglerauthor=R.+Scerniauthor=D.+Smithauthor=L.+E.+Schechterauthor=T.+H.+Andree&title=Studies+toward+the+Discovery+of+the+Next+Generation+of+Antidepressants.+3.+Dual+5-HT1A+and+Serotonin+Transporter+Affinity+within+a+Class+of+N-Aryloxyethylindolylalkylamines&doi=10.1021%2Fjm0304010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm0304010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0304010%26sid%3Dliteratum%253Aachs%26aulast%3DMewshaw%26aufirst%3DR.%2BE.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DHornby%26aufirst%3DG.%26aulast%3DSpangler%26aufirst%3DT.%26aulast%3DScerni%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DSchechter%26aufirst%3DL.%2BE.%26aulast%3DAndree%26aufirst%3DT.%2BH.%26atitle%3DStudies%2520toward%2520the%2520Discovery%2520of%2520the%2520Next%2520Generation%2520of%2520Antidepressants.%25203.%2520Dual%25205-HT1A%2520and%2520Serotonin%2520Transporter%2520Affinity%2520within%2520a%2520Class%2520of%2520N-Aryloxyethylindolylalkylamines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D3823%26epage%3D3842%26doi%3D10.1021%2Fjm0304010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Chung, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bian, Z.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A. S.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J. C.-O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, P. H.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chui, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, K.-H.</span><span> </span><span class="NLM_article-title">Development of 8-Benzyloxy-Substituted Quinoline Ethers and Evaluation of Their Antimicrobial Activities</span> <span class="citation_source-journal">Med. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1568</span><span class="NLM_x">–</span> <span class="NLM_lpage">1577</span><span class="refDoi"> DOI: 10.1007/s00044-014-1217-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1007%2Fs00044-014-1217-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVKmt7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=1568-1577&author=P.-Y.+Chungauthor=R.+Gambariauthor=Y.-X.+Chenauthor=C.-H.+Chengauthor=Z.-X.+Bianauthor=A.+S.-C.+Chanauthor=J.+C.-O.+Tangauthor=P.+H.-M.+Leungauthor=C.-H.+Chuiauthor=K.-H.+Lam&title=Development+of+8-Benzyloxy-Substituted+Quinoline+Ethers+and+Evaluation+of+Their+Antimicrobial+Activities&doi=10.1007%2Fs00044-014-1217-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Development of 8-benzyloxy-substituted quinoline ethers and evaluation of their antimicrobial activities</span></div><div class="casAuthors">Chung, Po-Yee; Gambari, Roberto; Chen, Yi-Xin; Cheng, Chor-Hing; Bian, Zhao-Xiang; Chan, Albert Sun-Chi; Tang, Johnny Cheuk-On; Leung, Polly Hang-Mei; Chui, Chung-Hin; Lam, Kim-Hung</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1568-1577</span>CODEN:
                <span class="NLM_cas:coden">MCREEB</span>;
        ISSN:<span class="NLM_cas:issn">1054-2523</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Boston</span>)
        </div><div class="casAbstract">FR OLA series of 8-benzyloxy-substituted quinoline ethers (2a-n) compds. was synthesized.  All synthesized compds. were screened in vitro for their preliminary antimicrobial activities against two Gram-neg. bacteria (Pseudomonas aeruginosa and Escherichia coli), two Gram-pos. bacteria (Staphylococcus aureus and Staphylococcus epidermidis), and a fungal species (Aspergillus niger).  Among all the synthesized compds., compd. 2e showed a significant growth inhibitory activity with an MIC value 3.125 μg/mL which was comparable to 8-hydroxyquinoline (2.5 μg/mL) and terbinafine (1.25 μg/mL) against A. niger.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok3erKcuEWL7Vg90H21EOLACvtfcHk0lhRmOpPedH7CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVKmt7bP&md5=5f57cfa77ee5df368525af0c87ca3e34</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs00044-014-1217-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00044-014-1217-4%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DP.-Y.%26aulast%3DGambari%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.-X.%26aulast%3DCheng%26aufirst%3DC.-H.%26aulast%3DBian%26aufirst%3DZ.-X.%26aulast%3DChan%26aufirst%3DA.%2BS.-C.%26aulast%3DTang%26aufirst%3DJ.%2BC.-O.%26aulast%3DLeung%26aufirst%3DP.%2BH.-M.%26aulast%3DChui%26aufirst%3DC.-H.%26aulast%3DLam%26aufirst%3DK.-H.%26atitle%3DDevelopment%2520of%25208-Benzyloxy-Substituted%2520Quinoline%2520Ethers%2520and%2520Evaluation%2520of%2520Their%2520Antimicrobial%2520Activities%26jtitle%3DMed.%2520Chem.%2520Res.%26date%3D2015%26volume%3D24%26spage%3D1568%26epage%3D1577%26doi%3D10.1007%2Fs00044-014-1217-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Manninen, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omar, W. A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heiskanen, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemmetyinen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hormi, O. E. O.</span><span> </span><span class="NLM_article-title">Synthesis and Characterization of Tris-(5-Amino-8-Hydroxyquinoline)Aluminum Complexes and Their Use as Anode Buffer Layers in Inverted Organic Solar Cells</span> <span class="citation_source-journal">J. Mater. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">22971</span><span class="NLM_x">–</span> <span class="NLM_lpage">22982</span><span class="refDoi"> DOI: 10.1039/c2jm35292c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1039%2Fc2jm35292c" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=22971-22982&author=V.+M.+Manninenauthor=W.+A.+E.+Omarauthor=J.+P.+Heiskanenauthor=H.+J.+Lemmetyinenauthor=O.+E.+O.+Hormi&title=Synthesis+and+Characterization+of+Tris-%285-Amino-8-Hydroxyquinoline%29Aluminum+Complexes+and+Their+Use+as+Anode+Buffer+Layers+in+Inverted+Organic+Solar+Cells&doi=10.1039%2Fc2jm35292c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1039%2Fc2jm35292c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2jm35292c%26sid%3Dliteratum%253Aachs%26aulast%3DManninen%26aufirst%3DV.%2BM.%26aulast%3DOmar%26aufirst%3DW.%2BA.%2BE.%26aulast%3DHeiskanen%26aufirst%3DJ.%2BP.%26aulast%3DLemmetyinen%26aufirst%3DH.%2BJ.%26aulast%3DHormi%26aufirst%3DO.%2BE.%2BO.%26atitle%3DSynthesis%2520and%2520Characterization%2520of%2520Tris-%25285-Amino-8-Hydroxyquinoline%2529Aluminum%2520Complexes%2520and%2520Their%2520Use%2520as%2520Anode%2520Buffer%2520Layers%2520in%2520Inverted%2520Organic%2520Solar%2520Cells%26jtitle%3DJ.%2520Mater.%2520Chem.%26date%3D2012%26volume%3D22%26spage%3D22971%26epage%3D22982%26doi%3D10.1039%2Fc2jm35292c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Oshiro, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurahashi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tottori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uwahodo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishi, T.</span><span> </span><span class="NLM_article-title">Novel Antipsychotic Agents with Dopamine Autoreceptor Agonist Properties: Synthesis and Pharmacology of 7-[4-(4-Phenyl-1-Piperazinyl)Butoxy]-3,4-Dihydro-2(1<i>H</i>)-Quinolinone Derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">658</span><span class="NLM_x">–</span> <span class="NLM_lpage">667</span><span class="refDoi"> DOI: 10.1021/jm940608g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm940608g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADyaK1cXosFaqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=658-667&author=Y.+Oshiroauthor=S.+Satoauthor=N.+Kurahashiauthor=T.+Tanakaauthor=T.+Kikuchiauthor=K.+Tottoriauthor=Y.+Uwahodoauthor=T.+Nishi&title=Novel+Antipsychotic+Agents+with+Dopamine+Autoreceptor+Agonist+Properties%3A+Synthesis+and+Pharmacology+of+7-%5B4-%284-Phenyl-1-Piperazinyl%29Butoxy%5D-3%2C4-Dihydro-2%281H%29-Quinolinone+Derivatives&doi=10.1021%2Fjm940608g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Antipsychotic Agents with Dopamine Autoreceptor Agonist Properties: Synthesis and Pharmacology of 7-[4-(4-Phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone Derivatives</span></div><div class="casAuthors">Oshiro, Yasuo; Sato, Seiji; Kurahashi, Nobuyuki; Tanaka, Tatsuyoshi; Kikuchi, Tetsuro; Tottori, Katsura; Uwahodo, Yasufumi; Nishi, Takao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">658-667</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To develop a novel antipsychotic agent which is an agonist of dopamine (DA) autoreceptors and an antagonist of postsynaptic DA receptors, a series of 7-[4-[4-(substituted phenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinones was synthesized and their dual activities were examd.  The postsynaptic DA receptor antagonistic activities of the compds. were evaluated by their ability to inhibit stereotypy induced by apomorphine in mice, and the autoreceptor agonist activities were detd. by their effects on the γ-butyrolactone (GBL)-induced increase in L-dihydroxyphenylalanine (DOPA) synthesis in the mouse brain.  Many compds. inhibited the stereotypic behavior, and several compds. reversed the GBL-induced increase in the DOPA synthesis.  Among them, 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone (aripiprazole, OPC-14597) (I) had these 2 activities.  This compd. reversed the GBL-induced DOPA synthesis (ED50 values of 5.1 μmol/kg po) and inhibited the APO induced stereotypy (ED50 values of 0.6 mmol/kg po).  I induced catalepsy at 10-fold higher dose than that required for the antagonism of APO-induced stereotypy (ED50 value of 7.8 μmol/kg oral).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnD8-A-QQlZLVg90H21EOLACvtfcHk0lhRmOpPedH7CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXosFaqtw%253D%253D&md5=02ff3a24cc876f68419f60acc4bae45e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm940608g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm940608g%26sid%3Dliteratum%253Aachs%26aulast%3DOshiro%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DKurahashi%26aufirst%3DN.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DKikuchi%26aufirst%3DT.%26aulast%3DTottori%26aufirst%3DK.%26aulast%3DUwahodo%26aufirst%3DY.%26aulast%3DNishi%26aufirst%3DT.%26atitle%3DNovel%2520Antipsychotic%2520Agents%2520with%2520Dopamine%2520Autoreceptor%2520Agonist%2520Properties%253A%2520Synthesis%2520and%2520Pharmacology%2520of%25207-%255B4-%25284-Phenyl-1-Piperazinyl%2529Butoxy%255D-3%252C4-Dihydro-2%25281H%2529-Quinolinone%2520Derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D658%26epage%3D667%26doi%3D10.1021%2Fjm940608g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Gmeiner, P.; Huebner, H.; Skultety, M.</span><span> </span><span class="NLM_article-title">Preparation of Indolizines and Aza-Analog Derivatives Thereof as CNS Active Compounds</span>. WO2008113559A2,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=P.+Gmeiner&author=H.+Huebner&author=M.+Skultety&title=Preparation+of+Indolizines+and+Aza-Analog+Derivatives+Thereof+as+CNS+Active+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DPreparation%2520of%2520Indolizines%2520and%2520Aza-Analog%2520Derivatives%2520Thereof%2520as%2520CNS%2520Active%2520Compounds%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Kühhorn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Götz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whistler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Development of a Bivalent Dopamine D(2) Receptor Agonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7911</span><span class="NLM_x">–</span> <span class="NLM_lpage">7919</span><span class="refDoi"> DOI: 10.1021/jm2009919</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2009919" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlWrs7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7911-7919&author=J.+K%C3%BChhornauthor=A.+G%C3%B6tzauthor=H.+H%C3%BCbnerauthor=D.+Thompsonauthor=J.+Whistlerauthor=P.+Gmeiner&title=Development+of+a+Bivalent+Dopamine+D%282%29+Receptor+Agonist&doi=10.1021%2Fjm2009919"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Bivalent Dopamine D2 Receptor Agonist</span></div><div class="casAuthors">Kuehhorn, Julia; Goetz, Angela; Huebner, Harald; Thompson, Dawn; Whistler, Jennifer; Gmeiner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7911-7919</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bivalent D2 agonists may function as useful mol. probes for the discovery of novel neurol. therapeutics.  On the basis of our recently developed bivalent dopamine D2 receptor antagonists of type 1, the bivalent agonist 2 was synthesized when a spacer built from 22 atoms was employed.  Compared to the monovalent control compd. 6 contg. a capped spacer, the bis-aminoindane deriv. 2 revealed substantial steepening of the competition curve, indicating a bivalent binding mode.  Dimer-specific Hill slopes were not a result of varying functional properties because both the dopaminergic 2 and the monovalent control agent 6 proved to be D2 agonists substantially inhibiting cAMP accumulation and inducing D2 receptor internalization.  Investigation of the heterobivalent ligands 8 and 9, contg. an agonist and a phenylpiperazine-based antagonist pharmacophore, revealed moderate steepening of the displacement curves and antagonist to very weak partial agonist properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKk6sjty41_LVg90H21EOLACvtfcHk0lhRmOpPedH7CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlWrs7fP&md5=c814855234dd17049cfab52f53a85ae7</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm2009919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2009919%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25BChhorn%26aufirst%3DJ.%26aulast%3DG%25C3%25B6tz%26aufirst%3DA.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DThompson%26aufirst%3DD.%26aulast%3DWhistler%26aufirst%3DJ.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DDevelopment%2520of%2520a%2520Bivalent%2520Dopamine%2520D%25282%2529%2520Receptor%2520Agonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7911%26epage%3D7919%26doi%3D10.1021%2Fjm2009919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Tabor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisenburger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purkayastha, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaindl, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grömer, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornhuber, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tschammer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birdsall, N. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mashanov, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandoghdar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Visualization and Ligand-Induced Modulation of Dopamine Receptor Dimerization at the Single Molecule Level</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">33233</span><span class="refDoi"> DOI: 10.1038/srep33233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1038%2Fsrep33233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=27615810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWnu7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=33233&author=A.+Taborauthor=S.+Weisenburgerauthor=A.+Banerjeeauthor=N.+Purkayasthaauthor=J.+M.+Kaindlauthor=H.+H%C3%BCbnerauthor=L.+Weiauthor=T.+W.+Gr%C3%B6merauthor=J.+Kornhuberauthor=N.+Tschammerauthor=N.+J.+M.+Birdsallauthor=G.+I.+Mashanovauthor=V.+Sandoghdarauthor=P.+Gmeiner&title=Visualization+and+Ligand-Induced+Modulation+of+Dopamine+Receptor+Dimerization+at+the+Single+Molecule+Level&doi=10.1038%2Fsrep33233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Visualization and ligand-induced modulation of dopamine receptor dimerization at the single molecule level</span></div><div class="casAuthors">Tabor, Alina; Weisenburger, Siegfried; Banerjee, Ashutosh; Purkayastha, Nirupam; Kaindl, Jonas M.; Huebner, Harald; Wei, Luxi; Groemer, Teja W.; Kornhuber, Johannes; Tschammer, Nuska; Birdsall, Nigel J. M.; Mashanov, Gregory I.; Sandoghdar, Vahid; Gmeiner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">33233</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs), including dopamine receptors, represent a group of important pharmacol. targets.  An increased formation of dopamine receptor D2 homodimers has been suggested to be assocd. with the pathophysiol. of schizophrenia.  Selective labeling and ligand-induced modulation of dimerization may therefore allow the investigation of the pathophysiol. role of these dimers.  Using TIRF microscopy at the single mol. level, transient formation of homodimers of dopamine receptors in the membrane of stably transfected CHO cells has been obsd.  The equil. between dimers and monomers was modulated by the binding of ligands; whereas antagonists showed a ratio that was identical to that of unliganded receptors, agonist-bound D2 receptor-ligand complexes resulted in an increase in dimerization.  Addn. of bivalent D2 receptor ligands also resulted in a large increase in D2 receptor dimers.  A phys. interaction between the protomers was confirmed using high resoln. cryogenic localization microscopy, with ca. 9 nm between the centers of mass.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0U-LA35caB7Vg90H21EOLACvtfcHk0liRCJr-2OHDsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWnu7fJ&md5=03a23cdbee9605ce1fc9cf6bff103713</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fsrep33233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep33233%26sid%3Dliteratum%253Aachs%26aulast%3DTabor%26aufirst%3DA.%26aulast%3DWeisenburger%26aufirst%3DS.%26aulast%3DBanerjee%26aufirst%3DA.%26aulast%3DPurkayastha%26aufirst%3DN.%26aulast%3DKaindl%26aufirst%3DJ.%2BM.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DGr%25C3%25B6mer%26aufirst%3DT.%2BW.%26aulast%3DKornhuber%26aufirst%3DJ.%26aulast%3DTschammer%26aufirst%3DN.%26aulast%3DBirdsall%26aufirst%3DN.%2BJ.%2BM.%26aulast%3DMashanov%26aufirst%3DG.%2BI.%26aulast%3DSandoghdar%26aufirst%3DV.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DVisualization%2520and%2520Ligand-Induced%2520Modulation%2520of%2520Dopamine%2520Receptor%2520Dimerization%2520at%2520the%2520Single%2520Molecule%2520Level%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D33233%26doi%3D10.1038%2Fsrep33233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Ohno, Y.</span><span> </span><span class="NLM_article-title">Therapeutic Role of 5-HT1A Receptors in the Treatment of Schizophrenia and Parkinson’s Disease</span> <span class="citation_source-journal">CNS Neurosci. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">65</span><span class="refDoi"> DOI: 10.1111/j.1755-5949.2010.00211.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1111%2Fj.1755-5949.2010.00211.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=21091640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVCnurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=58-65&author=Y.+Ohno&title=Therapeutic+Role+of+5-HT1A+Receptors+in+the+Treatment+of+Schizophrenia+and+Parkinson%E2%80%99s+Disease&doi=10.1111%2Fj.1755-5949.2010.00211.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease</span></div><div class="casAuthors">Ohno, Yukihiro</div><div class="citationInfo"><span class="NLM_cas:title">CNS Neuroscience & Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-65</span>CODEN:
                <span class="NLM_cas:coden">CNTNAB</span>;
        ISSN:<span class="NLM_cas:issn">1755-5930</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  5-HT1A receptors have long been implicated in the pathogenesis and treatment of anxiety and depressive disorders.  Recently, several lines of studies have revealed new insights into the therapeutic role of 5-HT1A receptors in treating schizophrenia and Parkinson's disease.  Specifically, 5-HT1A receptors seem to be a promising target for alleviating antipsychotic-induced extrapyramidal side effects (EPS) and cognitive/affective disorders in schizophrenia.  In the treatment of patients with Parkinson's disease, 5-HT1A agonists are expected to improve not only affective symptoms (e.g., anxiety and depression), but also the core parkinsonian symptoms as well as antiparkinsonian agents-induced side effects (e.g., L-DOPA-induced dyskinesia).  Here, the therapeutic mechanisms mediated by 5-HT1A receptors in schizophrenia and Parkinson's disease are reviewed.  This evidence should encourage discovery of new 5-HT1A ligands, which can resolve the unmet clin. needs in the current therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMhhzTRrq3R7Vg90H21EOLACvtfcHk0liRCJr-2OHDsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVCnurc%253D&md5=d70ebb228afb20826693e9ed48d287c2</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1111%2Fj.1755-5949.2010.00211.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1755-5949.2010.00211.x%26sid%3Dliteratum%253Aachs%26aulast%3DOhno%26aufirst%3DY.%26atitle%3DTherapeutic%2520Role%2520of%25205-HT1A%2520Receptors%2520in%2520the%2520Treatment%2520of%2520Schizophrenia%2520and%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DCNS%2520Neurosci.%2520Ther.%26date%3D2011%26volume%3D17%26spage%3D58%26epage%3D65%26doi%3D10.1111%2Fj.1755-5949.2010.00211.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Lohse, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benovic, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Codina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefkowitz, R. J.</span><span> </span><span class="NLM_article-title">Beta-Arrestin: A Protein That Regulates Beta-Adrenergic Receptor Function</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">248</span><span class="NLM_x">, </span> <span class="NLM_fpage">1547</span><span class="NLM_x">–</span> <span class="NLM_lpage">1550</span><span class="refDoi"> DOI: 10.1126/science.2163110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1126%2Fscience.2163110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=2163110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADyaK3cXlvVKktLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=248&publication_year=1990&pages=1547-1550&author=M.+J.+Lohseauthor=J.+L.+Benovicauthor=J.+Codinaauthor=M.+G.+Caronauthor=R.+J.+Lefkowitz&title=Beta-Arrestin%3A+A+Protein+That+Regulates+Beta-Adrenergic+Receptor+Function&doi=10.1126%2Fscience.2163110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">β-Arrestin:  a protein that regulates β-adrenergic receptor function</span></div><div class="casAuthors">Lohse, Martin J.; Benovic, Jeffrey L.; Codina, Juan; Caron, Marc G.; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">248</span>
        (<span class="NLM_cas:issue">4962</span>),
    <span class="NLM_cas:pages">1547-50</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Homologous or agonist-specific desensitization of β-adrenergic receptors is thought to be mediated by a specific kinase, the β-adrenergic receptor kinase (βARK).  However, recent data suggest that a cofactor is required for this kinase to inhibit receptor function.  The cDNA for such a cofactor was cloned and found to encode a 418-amino acid protein homologous to the retinal protein arrestin.  The protein, termed β-arrestin, was expressed and partially purified.  It inhibited the signaling function of βARK-phosphorylated β-adrenergic receptors by >75%, but not that of rhodopsin.  It is proposed that β-arrestin in concert with βARK effects homologous desensitization of β-adrenergic receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPkPorBQRSCrVg90H21EOLACvtfcHk0liRCJr-2OHDsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXlvVKktLk%253D&md5=57d5471cdc1ae51a2ba4a83360accc65</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1126%2Fscience.2163110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.2163110%26sid%3Dliteratum%253Aachs%26aulast%3DLohse%26aufirst%3DM.%2BJ.%26aulast%3DBenovic%26aufirst%3DJ.%2BL.%26aulast%3DCodina%26aufirst%3DJ.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DBeta-Arrestin%253A%2520A%2520Protein%2520That%2520Regulates%2520Beta-Adrenergic%2520Receptor%2520Function%26jtitle%3DScience%26date%3D1990%26volume%3D248%26spage%3D1547%26epage%3D1550%26doi%3D10.1126%2Fscience.2163110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Lefkowitz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenoy, S. K.</span><span> </span><span class="NLM_article-title">Transduction of Receptor Signals by Beta-Arrestins</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">308</span><span class="NLM_x">, </span> <span class="NLM_fpage">512</span><span class="NLM_x">–</span> <span class="NLM_lpage">517</span><span class="refDoi"> DOI: 10.1126/science.1109237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1126%2Fscience.1109237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=15845844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtlOjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2005&pages=512-517&author=R.+J.+Lefkowitzauthor=S.+K.+Shenoy&title=Transduction+of+Receptor+Signals+by+Beta-Arrestins&doi=10.1126%2Fscience.1109237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Transduction of Receptor Signals by β-Arrestins</span></div><div class="casAuthors">Lefkowitz, Robert J.; Shenoy, Sudha K.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">5721</span>),
    <span class="NLM_cas:pages">512-517</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  The transmission of extracellular signals to the interior of the cell is a function of plasma membrane receptors, of which the seven transmembrane receptor family is by far the largest and most versatile.  Classically, these receptors stimulate heterotrimeric G proteins, which control rates of generation of diffusible second messengers and entry of ions at the plasma membrane.  Recent evidence, however, indicates another previously unappreciated strategy used by the receptors to regulate intracellular signaling pathways.  They direct the recruitment, activation, and scaffolding of cytoplasmic signaling complexes via two multifunctional adaptor and transducer mols., β-arrestins 1 and 2.  This mechanism regulates aspects of cell motility, chemotaxis, apoptosis, and likely other cellular functions through a rapidly expanding list of signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk2fXdqgYhC7Vg90H21EOLACvtfcHk0lhtN_HfQC6AzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtlOjtLs%253D&md5=ed070237312d050e5d5ec437b3adc76c</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1126%2Fscience.1109237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1109237%26sid%3Dliteratum%253Aachs%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DShenoy%26aufirst%3DS.%2BK.%26atitle%3DTransduction%2520of%2520Receptor%2520Signals%2520by%2520Beta-Arrestins%26jtitle%3DScience%26date%3D2005%26volume%3D308%26spage%3D512%26epage%3D517%26doi%3D10.1126%2Fscience.1109237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Urs, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, J. P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span> </span><span class="NLM_article-title">Deletion of Gsk3β in D2r-Expressing Neurons Reveals Distinct Roles for B-Arrestin Signaling in Antipsychotic and Lithium Action</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">20732</span><span class="NLM_x">–</span> <span class="NLM_lpage">20737</span><span class="refDoi"> DOI: 10.1073/pnas.1215489109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1073%2Fpnas.1215489109" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=20732-20737&author=N.+M.+Ursauthor=J.+C.+Snyderauthor=J.+P.+R.+Jacobsenauthor=S.+M.+Petersonauthor=M.+G.+Caron&title=Deletion+of+Gsk3%CE%B2+in+D2r-Expressing+Neurons+Reveals+Distinct+Roles+for+B-Arrestin+Signaling+in+Antipsychotic+and+Lithium+Action&doi=10.1073%2Fpnas.1215489109"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1215489109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1215489109%26sid%3Dliteratum%253Aachs%26aulast%3DUrs%26aufirst%3DN.%2BM.%26aulast%3DSnyder%26aufirst%3DJ.%2BC.%26aulast%3DJacobsen%26aufirst%3DJ.%2BP.%2BR.%26aulast%3DPeterson%26aufirst%3DS.%2BM.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26atitle%3DDeletion%2520of%2520Gsk3%25CE%25B2%2520in%2520D2r-Expressing%2520Neurons%2520Reveals%2520Distinct%2520Roles%2520for%2520B-Arrestin%2520Signaling%2520in%2520Antipsychotic%2520and%2520Lithium%2520Action%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D20732%26epage%3D20737%26doi%3D10.1073%2Fpnas.1215489109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Lane, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powney, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, G.</span><span> </span><span class="NLM_article-title">G Protein Coupling and Ligand Selectivity of the D2L and D3 Dopamine Receptors</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">325</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">330</span><span class="refDoi"> DOI: 10.1124/jpet.107.134296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1124%2Fjpet.107.134296" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=18218829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktFGjur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=325&publication_year=2008&pages=319-330&author=J.+R.+Laneauthor=B.+Powneyauthor=A.+Wiseauthor=S.+Reesauthor=G.+Milligan&title=G+Protein+Coupling+and+Ligand+Selectivity+of+the+D2L+and+D3+Dopamine+Receptors&doi=10.1124%2Fjpet.107.134296"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">G protein coupling and ligand selectivity of the D2L and D3 dopamine receptors</span></div><div class="casAuthors">Lane, J. Robert; Powney, Ben; Wise, Alan; Rees, Stephen; Milligan, Graeme</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">325</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">319-330</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The human dopamine D2L receptor couples promiscuously to multiple members of the Gαi/o subfamily.  Despite the high homol. of the D2L and D3 receptors, the G protein coupling specificity of the human D3 receptor is less clearly characterized.  The primary aim of this study, then, was the parallel characterization of the G protein coupling specificity of the D2L and D3 receptors.  By using both receptor-G protein fusion proteins and stable cell lines in which pertussis toxin-resistant mutants of individual Gαi-family G proteins were expressed in an inducible fashion, we demonstrated highly selective coupling of the D3 receptor to Gαo1.  Furthermore, by using the fusion proteins to ensure identical stoichiometry of receptor to G protein for each pairing, a range of ligands displayed higher potency and, for partial agonists, higher efficacy at the D3 receptor when coupled to Gαo1 compared with the D2L receptor.  The second aim of this study was to investigate the mol. basis of the above differential G protein coupling specificity.  The importance of a 12-amino acid sequence from the C-terminal end of the third intracellular loop of the D2L receptor in providing promiscuity in G protein coupling was demonstrated using a chimeric D3/D2 receptor in which the equiv. region of the D3 receptor was exchanged for this sequence.  This chimera displayed D3-like affinity for [3H]spiperone and potency for agonists but gained D2-like ability to couple to each of Gαi1-3 as well as Gαo1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxa1ewwkwA2bVg90H21EOLACvtfcHk0lhtN_HfQC6AzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktFGjur0%253D&md5=dd55e53f17554e5fdf1740b788b9028c</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.134296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.134296%26sid%3Dliteratum%253Aachs%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DPowney%26aufirst%3DB.%26aulast%3DWise%26aufirst%3DA.%26aulast%3DRees%26aufirst%3DS.%26aulast%3DMilligan%26aufirst%3DG.%26atitle%3DG%2520Protein%2520Coupling%2520and%2520Ligand%2520Selectivity%2520of%2520the%2520D2L%2520and%2520D3%2520Dopamine%2520Receptors%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D325%26spage%3D319%26epage%3D330%26doi%3D10.1124%2Fjpet.107.134296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Strange, P. G.</span><span> </span><span class="NLM_article-title">Use of the Gtpγs Binding Assay for Analysis of Ligand Potency and Efficacy at G Protein-Coupled Receptors</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">161</span><span class="NLM_x">, </span> <span class="NLM_fpage">1238</span><span class="NLM_x">–</span> <span class="NLM_lpage">1249</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00963.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1111%2Fj.1476-5381.2010.00963.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=20662841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFWhsr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2010&pages=1238-1249&author=P.+G.+Strange&title=Use+of+the+Gtp%CE%B3s+Binding+Assay+for+Analysis+of+Ligand+Potency+and+Efficacy+at+G+Protein-Coupled+Receptors&doi=10.1111%2Fj.1476-5381.2010.00963.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors</span></div><div class="casAuthors">Strange, Philip G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1238-1249</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  In this review I consider assays for G protein-coupled receptor (GPCR) activity based on the binding of labeled analogs of GTPγS ([35S]GTPγS or Eu-GTPγS) to G proteins in tissues (GTPγS binding assays).  Such assays provide convenient measures of GPCR activity close to the receptor in the signaling cascade.  In order to set up a GTPγS binding assay, the requirements of the assay must be considered.  These are tissue source, GTPγS analog, G protein, GDP, Mg2+/Na+ ions, saponin, incubation time.  The assay, once optimized, can be used to generate concn./response curves for GPCRs signaling via Gi/o proteins (or to other G proteins with a modified assay) and actions of agonists, inverse agonists and antagonists may, in principle, be assessed.  For agonists and inverse agonists, data for the maximal agonist effect, the concn. of ligand giving a half-maximal response and the Hill coeff. may be derived.  For antagonists, data for the equil. dissocn. const. can be obtained.  The mechanistic basis of the assay is considered.  Although the assay can be used to profile ligands, under the conditions it is used, it may not be measuring the same event that dets. GPCR action in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonpFh81URvabVg90H21EOLACvtfcHk0lhtN_HfQC6AzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFWhsr3K&md5=8fa11a4e869eec381bae3880f4051dc2</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00963.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00963.x%26sid%3Dliteratum%253Aachs%26aulast%3DStrange%26aufirst%3DP.%2BG.%26atitle%3DUse%2520of%2520the%2520Gtp%25CE%25B3s%2520Binding%2520Assay%2520for%2520Analysis%2520of%2520Ligand%2520Potency%2520and%2520Efficacy%2520at%2520G%2520Protein-Coupled%2520Receptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D161%26spage%3D1238%26epage%3D1249%26doi%3D10.1111%2Fj.1476-5381.2010.00963.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Gazi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickolls, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strange, P. G.</span><span> </span><span class="NLM_article-title">Functional Coupling of the Human Dopamine D2 Receptor with Galphai1, Galphai2, Galphai3, and Galphao G Proteins: Evidence for Agonist Regulation of G Protein Selectivity</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">775</span><span class="NLM_x">–</span> <span class="NLM_lpage">786</span><span class="refDoi"> DOI: 10.1038/sj.bjp.0705116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1038%2Fsj.bjp.0705116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=12642378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisFegs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2003&pages=775-786&author=L.+Gaziauthor=S.+Nickollsauthor=P.+G.+Strange&title=Functional+Coupling+of+the+Human+Dopamine+D2+Receptor+with+Galphai1%2C+Galphai2%2C+Galphai3%2C+and+Galphao+G+Proteins%3A+Evidence+for+Agonist+Regulation+of+G+Protein+Selectivity&doi=10.1038%2Fsj.bjp.0705116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Functional coupling of the human dopamine D2 receptor with Gαi1, Gαi2, Gαi3 and Gαo G proteins: Evidence for agonist regulation of G protein selectivity</span></div><div class="casAuthors">Gazi, Lucien; Nickolls, Sarah A.; Strange, Philip G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">775-786</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The human dopamine D2long (D2L) receptor was expressed with four different G proteins in Sf9 cells using the baculovirus expression system.  When co-expressed with Gi/Go G proteins (Gi1α, Gi2α, Gi3α, or Goα, plus Gβ1 and Gγ2), the receptor displayed a high-affinity binding site for the agonists (dopamine and NPA), which was sensitive to GTP (100 μM), demonstrating interaction between the receptor and the different G proteins.  The receptor to G protein ratio (R:G ratio) was evaluated using [3H]-spiperone satn. binding (R) and [35S]-GTPγS satn. binding (G).  R:G ratios of 1:12, 1:3, 1:14 and 1:5 were found for Gi1, Gi2, Gi3, and Go prepns., resp.  However, when R:G ratios of 1:2 and 1:12 were compared for Gi2 and Go, no difference was found for the stimulation of [35S]-GTPγS binding.  Several agonists were tested for their ability to stimulate [35S]-GTPγS binding to membranes co-expressing the receptor and various G proteins.  All the compds. tested showed agonist activity in prepns. expressing Gi3 and Go.  However, for Gi2 and Gi1 prepns., compds. such as S-(-)-3-PPP and p-tyramine were unable to stimulate [35S]-GTPγS binding.  Most of the compds. showed higher relative efficacies (compared to dopamine) and higher potencies in the prepn. expressing Go.  Comparison of the effects of different agonists in the different prepns. showed that each agonist differentially activates the four G proteins.  We conclude that the degree of selectivity of G protein activation by the D2L receptor can depend on the conformation of the receptor stabilized by an agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSCewgdeU6SbVg90H21EOLACvtfcHk0lhaAi42KdsFng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisFegs7s%253D&md5=f0417b2243b11377ab4df51a98aebaff</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0705116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0705116%26sid%3Dliteratum%253Aachs%26aulast%3DGazi%26aufirst%3DL.%26aulast%3DNickolls%26aufirst%3DS.%26aulast%3DStrange%26aufirst%3DP.%2BG.%26atitle%3DFunctional%2520Coupling%2520of%2520the%2520Human%2520Dopamine%2520D2%2520Receptor%2520with%2520Galphai1%252C%2520Galphai2%252C%2520Galphai3%252C%2520and%2520Galphao%2520G%2520Proteins%253A%2520Evidence%2520for%2520Agonist%2520Regulation%2520of%2520G%2520Protein%2520Selectivity%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2003%26volume%3D138%26spage%3D775%26epage%3D786%26doi%3D10.1038%2Fsj.bjp.0705116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Jiang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spicher, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulay, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birnbaumer, L.</span><span> </span><span class="NLM_article-title">Most Central Nervous System D2 Dopamine Receptors Are Coupled to Their Effectors by Go</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">3577</span><span class="NLM_x">–</span> <span class="NLM_lpage">3582</span><span class="refDoi"> DOI: 10.1073/pnas.051632598</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1073%2Fpnas.051632598" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=3577-3582&author=M.+Jiangauthor=K.+Spicherauthor=G.+Boulayauthor=Y.+Wangauthor=L.+Birnbaumer&title=Most+Central+Nervous+System+D2+Dopamine+Receptors+Are+Coupled+to+Their+Effectors+by+Go&doi=10.1073%2Fpnas.051632598"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1073%2Fpnas.051632598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.051632598%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DM.%26aulast%3DSpicher%26aufirst%3DK.%26aulast%3DBoulay%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DBirnbaumer%26aufirst%3DL.%26atitle%3DMost%2520Central%2520Nervous%2520System%2520D2%2520Dopamine%2520Receptors%2520Are%2520Coupled%2520to%2520Their%2520Effectors%2520by%2520Go%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2001%26volume%3D98%26spage%3D3577%26epage%3D3582%26doi%3D10.1073%2Fpnas.051632598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Lohse, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, C.</span><span> </span><span class="NLM_article-title">Arrestin Interactions with G Protein-Coupled Receptors</span> <span class="citation_source-journal">Handb. Exp. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">219</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">56</span><span class="refDoi"> DOI: 10.1007/978-3-642-41199-1_2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1007%2F978-3-642-41199-1_2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=24292823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFOhurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=219&publication_year=2014&pages=15-56&author=M.+J.+Lohseauthor=C.+Hoffmann&title=Arrestin+Interactions+with+G+Protein-Coupled+Receptors&doi=10.1007%2F978-3-642-41199-1_2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Arrestin Interactions with G Protein-Coupled Receptors</span></div><div class="casAuthors">Lohse, Martin J.; Hoffmann, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">219</span>
        (<span class="NLM_cas:issue">Arrestins</span>),
    <span class="NLM_cas:pages">15-56</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">1865-0325</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) are the primary interaction partners for arrestins.  The visual arrestins, arrestin 1 and arrestin 4, physiol. bind to only very few receptors, i.e., rhodopsin and the color opsins, resp.  In contrast, the ubiquitously expressed nonvisual variants β-arrestin 1 and 2 bind to a large no. of receptors in a fairly nonspecific manner.  This binding requires two triggers, agonist activation and receptor phosphorylation by a G-protein-coupled receptor kinase (GRK).  These two triggers are mediated by two different regions of the arrestins, the "phosphorylation sensor" in the core of the protein and a less well-defined "activation sensor.".  Binding appears to occur mostly in a 1:1 stoichiometry, involving the N-terminal domain of GPCRs, but in addn. a second GPCR may loosely bind to the C-terminal domain when active receptors are abundant.  Arrestin binding initially uncouples GPCRs from their G-proteins.  It stabilizes receptors in an active conformation and also induces a conformational change in the arrestins that involves a rotation of the two domains relative to each other plus changes in the polar core.  This conformational change appears to permit the interaction with further downstream proteins.  The latter interaction, demonstrated mostly for β-arrestins, triggers receptor internalization as well as a no. of nonclassical signaling pathways.  Open questions concern the exact stoichiometry of the interaction, possible specificity with regard to the type of agonist and of GRK involved, selective regulation of downstream signaling (=biased signaling), and the options to use these mechanisms as therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2hOyPIZgUfLVg90H21EOLACvtfcHk0lhaAi42KdsFng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFOhurk%253D&md5=dd72458eea9257ac6fcca239265740d8</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-41199-1_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-41199-1_2%26sid%3Dliteratum%253Aachs%26aulast%3DLohse%26aufirst%3DM.%2BJ.%26aulast%3DHoffmann%26aufirst%3DC.%26atitle%3DArrestin%2520Interactions%2520with%2520G%2520Protein-Coupled%2520Receptors%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2014%26volume%3D219%26spage%3D15%26epage%3D56%26doi%3D10.1007%2F978-3-642-41199-1_2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Urs, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gee, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pack, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCorvy, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evron, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguiz, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borrelli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span> </span><span class="NLM_article-title">Distinct Cortical and Striatal Actions of a B-Arrestin–Biased Dopamine D2 Receptor Ligand Reveal Unique Antipsychotic-Like Properties</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">E8178</span><span class="NLM_x">–</span> <span class="NLM_lpage">E8186</span><span class="refDoi"> DOI: 10.1073/pnas.1614347113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1073%2Fpnas.1614347113" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=E8178-E8186&author=N.+M.+Ursauthor=S.+M.+Geeauthor=T.+F.+Packauthor=J.+D.+McCorvyauthor=T.+Evronauthor=J.+C.+Snyderauthor=X.+Yangauthor=R.+M.+Rodriguizauthor=E.+Borrelliauthor=W.+C.+Wetselauthor=J.+Jinauthor=B.+L.+Rothauthor=P.+O%E2%80%99Donnellauthor=M.+G.+Caron&title=Distinct+Cortical+and+Striatal+Actions+of+a+B-Arrestin%E2%80%93Biased+Dopamine+D2+Receptor+Ligand+Reveal+Unique+Antipsychotic-Like+Properties&doi=10.1073%2Fpnas.1614347113"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1614347113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1614347113%26sid%3Dliteratum%253Aachs%26aulast%3DUrs%26aufirst%3DN.%2BM.%26aulast%3DGee%26aufirst%3DS.%2BM.%26aulast%3DPack%26aufirst%3DT.%2BF.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DEvron%26aufirst%3DT.%26aulast%3DSnyder%26aufirst%3DJ.%2BC.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DBorrelli%26aufirst%3DE.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DP.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26atitle%3DDistinct%2520Cortical%2520and%2520Striatal%2520Actions%2520of%2520a%2520B-Arrestin%25E2%2580%2593Biased%2520Dopamine%2520D2%2520Receptor%2520Ligand%2520Reveal%2520Unique%2520Antipsychotic-Like%2520Properties%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3DE8178%26epage%3DE8186%26doi%3D10.1073%2Fpnas.1614347113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Peterson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pack, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span> </span><span class="NLM_article-title">Receptor, Ligand and Transducer Contributions to Dopamine D2 Receptor Functional Selectivity</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0141637</span><span class="refDoi"> DOI: 10.1371/journal.pone.0141637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1371%2Fjournal.pone.0141637" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0141637&author=S.+M.+Petersonauthor=T.+F.+Packauthor=M.+G.+Caron&title=Receptor%2C+Ligand+and+Transducer+Contributions+to+Dopamine+D2+Receptor+Functional+Selectivity&doi=10.1371%2Fjournal.pone.0141637"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0141637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0141637%26sid%3Dliteratum%253Aachs%26aulast%3DPeterson%26aufirst%3DS.%2BM.%26aulast%3DPack%26aufirst%3DT.%2BF.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26atitle%3DReceptor%252C%2520Ligand%2520and%2520Transducer%2520Contributions%2520to%2520Dopamine%2520D2%2520Receptor%2520Functional%2520Selectivity%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0141637%26doi%3D10.1371%2Fjournal.pone.0141637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Lipinski, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominy, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, P. J.</span><span> </span><span class="NLM_article-title">Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span><span class="refDoi"> DOI: 10.1016/S0169-409X(00)00129-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1016%2FS0169-409X%2800%2900129-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=11259830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2001&pages=3-26&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+Computational+Approaches+to+Estimate+Solubility+and+Permeability+in+Drug+Discovery+and+Development+Settings&doi=10.1016%2FS0169-409X%2800%2900129-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-26</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is greater than 500 and the calcd. Log P (CLogP) is greater than 5 (or MlogP >4.15).  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYDqa02g16urVg90H21EOLACvtfcHk0liuxDATdUGIvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D&md5=c60bb89da68f051c0ee7ac4c0468a0e4</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2800%2900129-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252800%252900129-0%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520Computational%2520Approaches%2520to%2520Estimate%2520Solubility%2520and%2520Permeability%2520in%2520Drug%2520Discovery%2520and%2520Development%2520Settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2001%26volume%3D46%26spage%3D3%26epage%3D26%26doi%3D10.1016%2FS0169-409X%2800%2900129-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Prachayasittikul, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prachayasittikul, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruchirawat, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prachayasittikul, V.</span><span> </span><span class="NLM_article-title">8-Hydroxyquinolines: A Review of Their Metal Chelating Properties and Medicinal Applications</span> <span class="citation_source-journal">Drug Des., Dev. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1157</span><span class="NLM_x">–</span> <span class="NLM_lpage">1178</span><span class="refDoi"> DOI: 10.2147/DDDT.S49763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.2147%2FDDDT.S49763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=24115839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A280%3ADC%252BC2c3hsFGjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=1157-1178&author=V.+Prachayasittikulauthor=S.+Prachayasittikulauthor=S.+Ruchirawatauthor=V.+Prachayasittikul&title=8-Hydroxyquinolines%3A+A+Review+of+Their+Metal+Chelating+Properties+and+Medicinal+Applications&doi=10.2147%2FDDDT.S49763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications</span></div><div class="casAuthors">Prachayasittikul Veda; Prachayasittikul Supaluk; Ruchirawat Somsak; Prachayasittikul Virapong</div><div class="citationInfo"><span class="NLM_cas:title">Drug design, development and therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1157-78</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Metal ions play an important role in biological processes and in metal homeostasis.  Metal imbalance is the leading cause for many neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. 8-Hydroxyquinoline (8HQ) is a small planar molecule with a lipophilic effect and a metal chelating ability.  As a result, 8HQ and its derivatives hold medicinal properties such as antineurodegenerative, anticancer, antioxidant, antimicrobial, anti-inflammatory, and antidiabetic activities.  Herein, diverse bioactivities of 8HQ and newly synthesized 8HQ-based compounds are discussed together with their mechanisms of actions and structure-activity relationships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSIgm-NVygKbTQLBVDQn4bCfW6udTcc2eYod0YBEe68qbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3hsFGjug%253D%253D&md5=f94aea2e89099f930db6b55bfeca418e</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S49763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S49763%26sid%3Dliteratum%253Aachs%26aulast%3DPrachayasittikul%26aufirst%3DV.%26aulast%3DPrachayasittikul%26aufirst%3DS.%26aulast%3DRuchirawat%26aufirst%3DS.%26aulast%3DPrachayasittikul%26aufirst%3DV.%26atitle%3D8-Hydroxyquinolines%253A%2520A%2520Review%2520of%2520Their%2520Metal%2520Chelating%2520Properties%2520and%2520Medicinal%2520Applications%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2013%26volume%3D7%26spage%3D1157%26epage%3D1178%26doi%3D10.2147%2FDDDT.S49763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Swart, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oelen, W. E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruins, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tepper, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Zeeuw, R. A.</span><span> </span><span class="NLM_article-title">Determination of the Dopamine D2 Agonist N-0923 and Its Major Metabolites in Perfused Rat Livers by HPLC-UV-Atmospheric Pressure Ionization Mass Spectrometry</span> <span class="citation_source-journal">J. Anal. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">71</span><span class="NLM_x">–</span> <span class="NLM_lpage">77</span><span class="refDoi"> DOI: 10.1093/jat/18.2.71</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1093%2Fjat%2F18.2.71" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=7911536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADyaK2cXis1Snur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1994&pages=71-77&author=P.+J.+Swartauthor=W.+E.+M.+Oelenauthor=A.+P.+Bruinsauthor=P.+G.+Tepperauthor=R.+A.+de+Zeeuw&title=Determination+of+the+Dopamine+D2+Agonist+N-0923+and+Its+Major+Metabolites+in+Perfused+Rat+Livers+by+HPLC-UV-Atmospheric+Pressure+Ionization+Mass+Spectrometry&doi=10.1093%2Fjat%2F18.2.71"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of the dopamine D2 agonist N-0923 and its major metabolites in perfused rat livers by HPLC-UV-atmospheric pressure ionization mass spectrometry</span></div><div class="casAuthors">Swart, P. J.; Oelen, W. E. M.; Bruins, A. P.; Tepper, P. G.; de Zeeuw, R. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Analytical Toxicology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">71-7</span>CODEN:
                <span class="NLM_cas:coden">JATOD3</span>;
        ISSN:<span class="NLM_cas:issn">0146-4760</span>.
    </div><div class="casAbstract">The metab. of the dopamine D2 agonist N-0923 (I) was investigated by an in vitro isolated liver perfusion.  Detg. the metabolic profile and identity of the different metabolites was achieved by using high-performance liq. chromatog. with UV detection, combined with atm. pressure ionization mass spectrometry.  Using this technique, no extensive sample cleanup is required, and the studies can be performed without radioactivity.  In addn. to previously obsd. metabolites, nine new metabolic products were identified.  All metabolites were exclusively excreted into the bile, except for the despropyl metabolite which was also detectable in the perfusate.  5-O-glucuronidation and N-depropylation followed by 5-O-glucuronidation are the most important metabolic routes.  N-dealkylation of the thienylethyl group followed by 5-O-glucuronidation and sulfation is a second major metabolic pathway.  Catechol formation of the despropyl metabolite with or without subsequent conjugation was not found.  Catechol formation of the desthienylethyl metabolite occurred, but only its glucuronide conjugates were found.  This study complements previous results of in vivo metabolic studies using the radiolabeled racemate N-0437, and it explains differences in bile excretion during isolated liver perfusions using N-0923 and radiolabeled N-0923.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4kyBKN-uXgrVg90H21EOLACvtfcHk0liuxDATdUGIvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1Snur4%253D&md5=28080e2120ab1e129dd35a1b4ea7afb3</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1093%2Fjat%2F18.2.71&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjat%252F18.2.71%26sid%3Dliteratum%253Aachs%26aulast%3DSwart%26aufirst%3DP.%2BJ.%26aulast%3DOelen%26aufirst%3DW.%2BE.%2BM.%26aulast%3DBruins%26aufirst%3DA.%2BP.%26aulast%3DTepper%26aufirst%3DP.%2BG.%26aulast%3Dde%2BZeeuw%26aufirst%3DR.%2BA.%26atitle%3DDetermination%2520of%2520the%2520Dopamine%2520D2%2520Agonist%2520N-0923%2520and%2520Its%2520Major%2520Metabolites%2520in%2520Perfused%2520Rat%2520Livers%2520by%2520HPLC-UV-Atmospheric%2520Pressure%2520Ionization%2520Mass%2520Spectrometry%26jtitle%3DJ.%2520Anal.%2520Toxicol.%26date%3D1994%26volume%3D18%26spage%3D71%26epage%3D77%26doi%3D10.1093%2Fjat%2F18.2.71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of in Vitro Half-Life Approach and Nonspecific Binding to Microsomes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1350</span><span class="NLM_x">–</span> <span class="NLM_lpage">1359</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10534321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=1350-1359&author=R.+S.+Obach&title=Prediction+of+Human+Clearance+of+Twenty-Nine+Drugs+from+Hepatic+Microsomal+Intrinsic+Clearance+Data%3A+An+Examination+of+in+Vitro+Half-Life+Approach+and+Nonspecific+Binding+to+Microsomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1350-1359</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Twenty-nine drugs of disparate structures and physicochem. properties were used in an examn. of the capability of human liver microsomal lability data ("in vitro T1/2" approach) to be useful in the prediction of human clearance.  Addnl., the potential importance of nonspecific binding to microsomes in the in vitro incubation milieu for the accurate prediction of human clearance was investigated.  The compds. examd. demonstrated a wide range of microsomal metabolic labilities with scaled intrinsic clearance values ranging from less than 0.5 mL/min/kg to 189 mL/min/kg.  Microsomal binding was detd. at microsomal protein concns. used in the lability incubations.  For the 29 compds. studied, unbound fractions in microsomes ranged from 0.11 to 1.0.  Generally, basic compds. demonstrated the greatest extent of binding and neutral and acidic compds. the least extent of binding.  In the projection of human clearance values, basic and neutral compds. were well predicted when all binding considerations (blood and microsome) were disregarded, however, including both binding considerations also yielded reasonable predictions.  Including only blood binding yielded very poor projections of human clearance for these two types of compds.  However, for acidic compds., disregarding all binding considerations yielded poor predictions of human clearance.  It was generally most difficult to accurately predict clearance for this class of compds.; however the accuracy was best when all binding considerations were included.  Overall, inclusion of both blood and microsome binding values gave the best agreement between in vivo clearance values and clearance values projected from in vitro intrinsic clearance data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWp2hUTOxyubVg90H21EOLACvtfcHk0lgyZ6CMGe7Vug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D&md5=7804cd4dfb131caac45aff9b7a1df901</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DPrediction%2520of%2520Human%2520Clearance%2520of%2520Twenty-Nine%2520Drugs%2520from%2520Hepatic%2520Microsomal%2520Intrinsic%2520Clearance%2520Data%253A%2520An%2520Examination%2520of%2520in%2520Vitro%2520Half-Life%2520Approach%2520and%2520Nonspecific%2520Binding%2520to%2520Microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1999%26volume%3D27%26spage%3D1350%26epage%3D1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Peters, S. A.</span><span> </span><span class="NLM_article-title">Appendix I</span>. In  <span class="citation_source-book">Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations: Principles, Methods, and Applications in the Pharmaceutical Industry</span>, <span class="NLM_edition">1st</span> ed.; <span class="NLM_publisher-name">John Wiley & Sons</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">421</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1002%2F9781118140291.app1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=407-421&author=S.+A.+Peters&title=Physiologically-Based+Pharmacokinetic+%28PBPK%29+Modeling+and+Simulations%3A+Principles%2C+Methods%2C+and+Applications+in+the+Pharmaceutical+Industry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1002%2F9781118140291.app1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118140291.app1%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DS.%2BA.%26atitle%3DAppendix%2520I%26btitle%3DPhysiologically-Based%2520Pharmacokinetic%2520%2528PBPK%2529%2520Modeling%2520and%2520Simulations%253A%2520Principles%252C%2520Methods%252C%2520and%2520Applications%2520in%2520the%2520Pharmaceutical%2520Industry%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%26date%3D2012%26spage%3D407%26epage%3D421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Recanatini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poluzzi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, F.</span><span> </span><span class="NLM_article-title">Qt Prolongation through hERG K+ Channel Blockade: Current Knowledge and Strategies for the Early Prediction During Drug Development</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">133</span><span class="NLM_x">–</span> <span class="NLM_lpage">166</span><span class="refDoi"> DOI: 10.1002/med.20019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1002%2Fmed.20019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=15389727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitlWhs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=133-166&author=M.+Recanatiniauthor=E.+Poluzziauthor=M.+Masettiauthor=A.+Cavalliauthor=F.+De+Ponti&title=Qt+Prolongation+through+hERG+K%2B+Channel+Blockade%3A+Current+Knowledge+and+Strategies+for+the+Early+Prediction+During+Drug+Development&doi=10.1002%2Fmed.20019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">QT prolongation through hERG K+ channel blockade: current knowledge and strategies for the early prediction during drug development</span></div><div class="casAuthors">Recanatini, Maurizio; Poluzzi, Elisabetta; Masetti, Matteo; Cavalli, Andrea; de Ponti, Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-166</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Prolongation of the QT interval of the ECG is a typical effect of Class III antiarrhythmic drugs, achieved through blockade of potassium channels.  In the past decade, evidence has accrued that several classes of drugs used for non-cardiovascular indications may prolong the QT interval with the same mechanism (namely, human ether-a-go-go-related gene (hERG) K+ channel blockade).  The great interest in QT prolongation is because of several reasons.  First, drug-induced QT prolongation increases the likelihood of a polymorphous ventricular arrhythmia (namely, torsades de pointes, TdP), which may cause syncope and degenerate into ventricular fibrillation and sudden death.  Second, the fact that several classes of drugs, such as antihistamines, fluoroquinolones, macrolides, and neuroleptics may cause the long QT syndrome (LQTS) raises the question whether this is a class effect (e.g., shared by all agents of a given pharmacol. class) or a specific effect of single agents within a class.  There is now consensus that, in most cases, only a few agents within a therapeutic class share the ability to significantly affect hERG K+ channels.  These compds. should be identified as early as possible during drug development.  Third, QT prolongation and interaction with hERG K+ channels have become surrogate markers of cardiotoxicity and have received increasing regulatory attention.  This review briefly outlines the mechanisms leading to QT prolongation and the different strategies that can be followed to predict this unwanted effect.  In particular, it will focus on the approaches recently proposed for the in silico screening of new compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO7B-6DBAFeLVg90H21EOLACvtfcHk0lgyZ6CMGe7Vug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitlWhs7Y%253D&md5=aa5aea37c667b4f35546259cc2593c6d</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1002%2Fmed.20019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20019%26sid%3Dliteratum%253Aachs%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DPoluzzi%26aufirst%3DE.%26aulast%3DMasetti%26aufirst%3DM.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DDe%2BPonti%26aufirst%3DF.%26atitle%3DQt%2520Prolongation%2520through%2520hERG%2520K%252B%2520Channel%2520Blockade%253A%2520Current%2520Knowledge%2520and%2520Strategies%2520for%2520the%2520Early%2520Prediction%2520During%2520Drug%2520Development%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2005%26volume%3D25%26spage%3D133%26epage%3D166%26doi%3D10.1002%2Fmed.20019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Raschi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceccarini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Recanatini, M.</span><span> </span><span class="NLM_article-title">Herg-Related Drug Toxicity and Models for Predicting hERG Liability and QT Prolongation</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1005</span><span class="NLM_x">–</span> <span class="NLM_lpage">1021</span><span class="refDoi"> DOI: 10.1517/17425250903055070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1517%2F17425250903055070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=19572824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVWhsLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=1005-1021&author=E.+Raschiauthor=L.+Ceccariniauthor=F.+De+Pontiauthor=M.+Recanatini&title=Herg-Related+Drug+Toxicity+and+Models+for+Predicting+hERG+Liability+and+QT+Prolongation&doi=10.1517%2F17425250903055070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">hERG-related drug toxicity and models for predicting hERG liability and QT prolongation</span></div><div class="casAuthors">Raschi, Emanuel; Ceccarini, Luisa; De Ponti, Fabrizio; Recanatini, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1005-1021</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: hERG K+ channels have been recognized as a primary antitarget in safety pharmacol.  Their blockade, caused by several drugs with different therapeutic indications, may lead to QT prolongation and, eventually, to potentially fatal arrhythmia, namely torsade de pointes.  Therefore, a no. of preclin. models have been developed to predict hERG liability early in the drug development process.  Objective: The aim of this review is to outline the present state of the art on drug-induced hERG blockade, providing insights on the predictive value of in vitro and in silico models for hERG liability.  Methods: On the basis of latest reports, high-throughput preclin. models have been discussed outlining advantages and limitations.  Conclusion: Although no single model has an abs. value, an integrated risk assessment is recommended to predict the pro-arrhythmic risk of a given drug.  This prediction requires expertise from different areas and should encompass emerging issues such as interference with hERG trafficking and QT shortening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCQa-hX-BiQ7Vg90H21EOLACvtfcHk0lgyZ6CMGe7Vug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVWhsLnK&md5=93e148db825611c7e086f75e50b8953c</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1517%2F17425250903055070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425250903055070%26sid%3Dliteratum%253Aachs%26aulast%3DRaschi%26aufirst%3DE.%26aulast%3DCeccarini%26aufirst%3DL.%26aulast%3DDe%2BPonti%26aufirst%3DF.%26aulast%3DRecanatini%26aufirst%3DM.%26atitle%3DHerg-Related%2520Drug%2520Toxicity%2520and%2520Models%2520for%2520Predicting%2520hERG%2520Liability%2520and%2520QT%2520Prolongation%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2009%26volume%3D5%26spage%3D1005%26epage%3D1021%26doi%3D10.1517%2F17425250903055070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Sanguinetti, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitcheson, J. S.</span><span> </span><span class="NLM_article-title">Predicting Drug–hERG Channel Interactions That Cause Acquired Long QT Syndrome</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span><span class="refDoi"> DOI: 10.1016/j.tips.2005.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1016%2Fj.tips.2005.01.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=119-124&author=M.+C.+Sanguinettiauthor=J.+S.+Mitcheson&title=Predicting+Drug%E2%80%93hERG+Channel+Interactions+That+Cause+Acquired+Long+QT+Syndrome&doi=10.1016%2Fj.tips.2005.01.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2005.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2005.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DSanguinetti%26aufirst%3DM.%2BC.%26aulast%3DMitcheson%26aufirst%3DJ.%2BS.%26atitle%3DPredicting%2520Drug%25E2%2580%2593hERG%2520Channel%2520Interactions%2520That%2520Cause%2520Acquired%2520Long%2520QT%2520Syndrome%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2005%26volume%3D26%26spage%3D119%26epage%3D124%26doi%3D10.1016%2Fj.tips.2005.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Poluzzi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raschi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moretti, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, F.</span><span> </span><span class="NLM_article-title">Drug-Induced Torsades De Pointes: Data Mining of the Public Version of the FDA Adverse Event Reporting System (AERS)</span> <span class="citation_source-journal">Pharmacoepidemiol. Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">512</span><span class="NLM_x">–</span> <span class="NLM_lpage">518</span><span class="refDoi"> DOI: 10.1002/pds.1746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1002%2Fpds.1746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=19358226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFCks7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=512-518&author=E.+Poluzziauthor=E.+Raschiauthor=U.+Morettiauthor=F.+De+Ponti&title=Drug-Induced+Torsades+De+Pointes%3A+Data+Mining+of+the+Public+Version+of+the+FDA+Adverse+Event+Reporting+System+%28AERS%29&doi=10.1002%2Fpds.1746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS)</span></div><div class="casAuthors">Poluzzi, Elisabetta; Raschi, Emanuel; Moretti, Ugo; De Ponti, Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacoepidemiology and Drug Safety</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">512-518</span>CODEN:
                <span class="NLM_cas:coden">PDSAEA</span>;
        ISSN:<span class="NLM_cas:issn">1053-8569</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">To investigate spontaneous reports of TdP present in the public version of the FDA Adverse Event Reporting System (AERS) in the light of what is already known on their TdP-liability.  Reports of TdP from Jan. 2004 through Dec. 2007 were retrieved from the public version of the AERS database.  All reports were selected from REACTION files and the relevant suspected and/or interacting drugs were identified from DRUG files.  Qual. anal. was performed by the case/non-case method.  Cases were represented by TdP reports, whereas non-cases were all reports of adverse drug reactions other than TdP.  Quant. anal. was assessed by calcg. the crude and adjusted reporting odds ratio (ROR), as a measure of disproportionality, with the 95% confidence interval.  Reports of TdP were 1665 over a 4-yr period, involving 376 active substances.  Thirty-five drugs with at least 10 reports were identified: amiodarone and methadone were assocd. with the highest no. of cases (113 and 83 resp.) and most of the other reports were ascribable to antibacterials, antidepressants and antipsychotics; remarkable differences in no. of cases and ROR were present among agents within each therapeutic class.  A disproportionate reporting was also obsd. for other compds. such as donepezil, famotidine and mitoxantrone.  Large spontaneous reporting databases represent an important source for signal detection of rare adverse drug reactions (ADR), such as TdP.  The no. of reports assocd. to donepezil, famotidine and mitoxantrone could be considered unexpected on the basis of current evidence and needs further investigations on their true TdP-liability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcqqV3h5uS37Vg90H21EOLACvtfcHk0lgqPTSQjgo-UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFCks7k%253D&md5=c43280d022cc8bf6f24bde78fad69544</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fpds.1746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpds.1746%26sid%3Dliteratum%253Aachs%26aulast%3DPoluzzi%26aufirst%3DE.%26aulast%3DRaschi%26aufirst%3DE.%26aulast%3DMoretti%26aufirst%3DU.%26aulast%3DDe%2BPonti%26aufirst%3DF.%26atitle%3DDrug-Induced%2520Torsades%2520De%2520Pointes%253A%2520Data%2520Mining%2520of%2520the%2520Public%2520Version%2520of%2520the%2520FDA%2520Adverse%2520Event%2520Reporting%2520System%2520%2528AERS%2529%26jtitle%3DPharmacoepidemiol.%2520Drug%2520Saf.%26date%3D2009%26volume%3D18%26spage%3D512%26epage%3D518%26doi%3D10.1002%2Fpds.1746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Löber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tschammer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Recent Advances in the Search for D3- and D4-Selective Drugs: Probes, Models and Candidates</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">148</span><span class="NLM_x">–</span> <span class="NLM_lpage">157</span><span class="refDoi"> DOI: 10.1016/j.tips.2010.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1016%2Fj.tips.2010.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=21232805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A280%3ADC%252BC3M3ktVWnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=148-157&author=S.+L%C3%B6berauthor=H.+H%C3%BCbnerauthor=N.+Tschammerauthor=P.+Gmeiner&title=Recent+Advances+in+the+Search+for+D3-+and+D4-Selective+Drugs%3A+Probes%2C+Models+and+Candidates&doi=10.1016%2Fj.tips.2010.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the search for D3- and D4-selective drugs: probes, models and candidates</span></div><div class="casAuthors">Lober Stefan; Hubner Harald; Tschammer Nuska; Gmeiner Peter</div><div class="citationInfo"><span class="NLM_cas:title">Trends in pharmacological sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">148-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dopamine D(2)-like receptors (including D(2), D(3) and D(4)) belong to the 'rhodopsin-like' family of G protein-coupled receptors (GPCRs), which represent the largest group of targets for bioactive molecules.  Due to their high sequence similarity, the design of subtype-selective ligands requires rational and effective strategies.  The general formula of 1,4-disubstituted aromatic piperidines and piperazines (1,4-DAPs) was extracted from classical dopaminergic drugs.  The biological properties of this compound family are encoded by an aromatic head group that controls intrinsic activity, an amine moiety and a lipophilic appendage.  D(3)- and D(4)-selective molecular probes and drug candidates were generated from the general formula of 1,4-DAP.  Formal structural rearrangement led to investigational drugs beyond the 1,4-DAP structure.  The very recent publication of the X-ray crystal structure of D(3) should facilitate efficient discovery of unprecedented chemotypes.  However, the development of D(3)-selective agonists, functionally selective ligands and the exploitation of homo- and heteromers remain challenging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJYDidIFGFwMjl5L8hwNX0fW6udTcc2eYTty2ooLmgALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3ktVWnsg%253D%253D&md5=9b688525eaa75c6d965b634617c16d70</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2010.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2010.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6ber%26aufirst%3DS.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DTschammer%26aufirst%3DN.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DRecent%2520Advances%2520in%2520the%2520Search%2520for%2520D3-%2520and%2520D4-Selective%2520Drugs%253A%2520Probes%252C%2520Models%2520and%2520Candidates%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2011%26volume%3D32%26spage%3D148%26epage%3D157%26doi%3D10.1016%2Fj.tips.2010.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Hiller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kling, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinemann, F. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Functionally Selective Dopamine D2/D3 Receptor Agonists Comprising an Enyne Moiety</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5130</span><span class="NLM_x">–</span> <span class="NLM_lpage">5141</span><span class="refDoi"> DOI: 10.1021/jm400520c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400520c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC3sXoslSqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5130-5141&author=C.+Hillerauthor=R.+C.+Klingauthor=F.+W.+Heinemannauthor=K.+Meyerauthor=H.+H%C3%BCbnerauthor=P.+Gmeiner&title=Functionally+Selective+Dopamine+D2%2FD3+Receptor+Agonists+Comprising+an+Enyne+Moiety&doi=10.1021%2Fjm400520c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Functionally Selective Dopamine D2/D3 Receptor Agonists Comprising an Enyne Moiety</span></div><div class="casAuthors">Hiller, Christine; Kling, Ralf C.; Heinemann, Frank W.; Meyer, Karsten; Huebner, Harald; Gmeiner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5130-5141</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonracemic ethynylcyclohexynylamines I and ent-I {R = 1,1'-biphenyl-4-yl, pyrazolo[1,5-a]pyridin-2-yl, pyrazolo[1,5-a]pyridin-3-yl, 4-[3-(1-butyl-1,2,3-triazol-4-yloxy)propoxy]-3-methoxyphenyl, benzo[b]thiophene-2-yl, ferrocenyl} were prepd. as dopamine receptor agonists with atypical catechol isosteres; their selectivities for dopamine receptors and for activating receptors through G-protein subunits Go and Gi and the metabolic stability of rac-I (R = 4-PhC6H4) were detd.  The ethynylcyclohexynylamines bound to D2-like receptors with high affinities.  Ent-I (R = pyrazolo[1,5-a]pyridin-2-yl) selectively activated D2slow-promoted Go activation over Gi coupling; the most significant functional bias obsd. was for ent-I {R = 4-[3-(1-butyl-1,2,3-triazol-4-yloxy)propoxy]-3-methoxyphenyl} which selectively activated Go over Gi coupling at D2long receptors.  Functional selectivity for β-arrestin recruitment over Gi activation was obsd. for I (R = 1,1'-biphenyl-4-yl) and ent-I (R = benzothiophene-2-yl), while ent-I (R = pyrazolo[1,5-a]pyridin-2-yl) preferred β-arrestin recruitment compared to Go coupling.  The structure of a nonracemic N-(ethynylcyclohexenyl)dinitrobenzamide was detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXn2SrS-IBCrVg90H21EOLACvtfcHk0lgqPTSQjgo-UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXoslSqtr4%253D&md5=3855de949f505a83ed3aa561ca182e75</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm400520c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400520c%26sid%3Dliteratum%253Aachs%26aulast%3DHiller%26aufirst%3DC.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DHeinemann%26aufirst%3DF.%2BW.%26aulast%3DMeyer%26aufirst%3DK.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DFunctionally%2520Selective%2520Dopamine%2520D2%252FD3%2520Receptor%2520Agonists%2520Comprising%2520an%2520Enyne%2520Moiety%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5130%26epage%3D5141%26doi%3D10.1021%2Fjm400520c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Tschammer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elsner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehrlich, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuster, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kühhorn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whistler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Highly Potent 5-Aminotetrahydropyrazolopyridines: Enantioselective Dopamine D3 Receptor Binding, Functional Selectivity, and Analysis of Receptor-Ligand Interactions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2477</span><span class="NLM_x">–</span> <span class="NLM_lpage">2491</span><span class="refDoi"> DOI: 10.1021/jm101639t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101639t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2477-2491&author=N.+Tschammerauthor=J.+Elsnerauthor=A.+Goetzauthor=K.+Ehrlichauthor=S.+Schusterauthor=M.+Rubergauthor=J.+K%C3%BChhornauthor=D.+Thompsonauthor=J.+Whistlerauthor=H.+H%C3%BCbnerauthor=P.+Gmeiner&title=Highly+Potent+5-Aminotetrahydropyrazolopyridines%3A+Enantioselective+Dopamine+D3+Receptor+Binding%2C+Functional+Selectivity%2C+and+Analysis+of+Receptor-Ligand+Interactions&doi=10.1021%2Fjm101639t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm101639t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101639t%26sid%3Dliteratum%253Aachs%26aulast%3DTschammer%26aufirst%3DN.%26aulast%3DElsner%26aufirst%3DJ.%26aulast%3DGoetz%26aufirst%3DA.%26aulast%3DEhrlich%26aufirst%3DK.%26aulast%3DSchuster%26aufirst%3DS.%26aulast%3DRuberg%26aufirst%3DM.%26aulast%3DK%25C3%25BChhorn%26aufirst%3DJ.%26aulast%3DThompson%26aufirst%3DD.%26aulast%3DWhistler%26aufirst%3DJ.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DHighly%2520Potent%25205-Aminotetrahydropyrazolopyridines%253A%2520Enantioselective%2520Dopamine%2520D3%2520Receptor%2520Binding%252C%2520Functional%2520Selectivity%252C%2520and%2520Analysis%2520of%2520Receptor-Ligand%2520Interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2477%26epage%3D2491%26doi%3D10.1021%2Fjm101639t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Lowry, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosebrough, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farr, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randall, R. J.</span><span> </span><span class="NLM_article-title">Protein Measurement with the Folin Phenol Reagent</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1951</span><span class="NLM_x">, </span> <span class="NLM_volume">193</span><span class="NLM_x">, </span> <span class="NLM_fpage">265</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1016%2FS0021-9258%2819%2952451-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=14907713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADyaG38XhsVyrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=1951&pages=265-275&author=O.+H.+Lowryauthor=N.+J.+Rosebroughauthor=A.+L.+Farrauthor=R.+J.+Randall&title=Protein+Measurement+with+the+Folin+Phenol+Reagent"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Protein measurement with the Folin phenol reagent</span></div><div class="casAuthors">Lowry, Oliver H.; Rosebrough, Nira J.; Farr, A. Lewis; Randall, Rose J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1951</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">265-75</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">cf. C.A. 41, 1271h.  Proteins were detd. with the Folin phenol reagent after alk. Cu treatment.  The method is as sensitive as with Nessler reagent, yet requires no digestion.  It is 10-20 times more sensitive than detn. of the ultraviolet absorption at λ = 280 mμ and is more specific.  It is several fold more sensitive than the ninhydrin reaction and 100 times more sensitive than the biuret reaction.  Two major disadvantages are: the amt. of color varies with different proteins; the color is not strictly proportional to concn.  Few substances cause serious interference.  Uric acid, guanine, and xanthine react with Folin reagent.  The method is useful for following enzyme fractionation, detg. mixed tissue proteins, detn. of very small amts. of protein, or detg. highly dild. protein, or protein in colored solns. or in the presence of N-contg. material.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHNRKGd34F8LVg90H21EOLACvtfcHk0ljpUdEpZQiepg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG38XhsVyrsw%253D%253D&md5=19d36395fad7dd87661caa3d2b97640d</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2819%2952451-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252819%252952451-6%26sid%3Dliteratum%253Aachs%26aulast%3DLowry%26aufirst%3DO.%2BH.%26aulast%3DRosebrough%26aufirst%3DN.%2BJ.%26aulast%3DFarr%26aufirst%3DA.%2BL.%26aulast%3DRandall%26aufirst%3DR.%2BJ.%26atitle%3DProtein%2520Measurement%2520with%2520the%2520Folin%2520Phenol%2520Reagent%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1951%26volume%3D193%26spage%3D265%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haubmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Utz, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Conjugated Enynes as Nonaromatic Catechol Bioisosteres: Synthesis, Binding Experiments and Computational Studies of Novel Dopamine Receptor Agonists Recognizing Preferentially the D3 Subtype</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">756</span><span class="NLM_x">–</span> <span class="NLM_lpage">762</span><span class="refDoi"> DOI: 10.1021/jm991098z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm991098z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=756-762&author=H.+H%C3%BCbnerauthor=C.+Haubmannauthor=W.+Utzauthor=P.+Gmeiner&title=Conjugated+Enynes+as+Nonaromatic+Catechol+Bioisosteres%3A+Synthesis%2C+Binding+Experiments+and+Computational+Studies+of+Novel+Dopamine+Receptor+Agonists+Recognizing+Preferentially+the+D3+Subtype&doi=10.1021%2Fjm991098z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjm991098z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm991098z%26sid%3Dliteratum%253Aachs%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DHaubmann%26aufirst%3DC.%26aulast%3DUtz%26aufirst%3DW.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DConjugated%2520Enynes%2520as%2520Nonaromatic%2520Catechol%2520Bioisosteres%253A%2520Synthesis%252C%2520Binding%2520Experiments%2520and%2520Computational%2520Studies%2520of%2520Novel%2520Dopamine%2520Receptor%2520Agonists%2520Recognizing%2520Preferentially%2520the%2520D3%2520Subtype%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D756%26epage%3D762%26doi%3D10.1021%2Fjm991098z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Black, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leff, P.</span><span> </span><span class="NLM_article-title">Operational Models of Pharmacological Agonism</span> <span class="citation_source-journal">Proc. R. Soc. London, Ser. B</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">220</span><span class="NLM_x">, </span> <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">162</span><span class="refDoi"> DOI: 10.1098/rspb.1983.0093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1098%2Frspb.1983.0093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=6141562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADyaL2cXmtFaqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=220&publication_year=1983&pages=141-162&author=J.+W.+Blackauthor=P.+Leff&title=Operational+Models+of+Pharmacological+Agonism&doi=10.1098%2Frspb.1983.0093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Operational models of pharmacological agonism</span></div><div class="casAuthors">Black, J. W.; Leff, P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Royal Society of London, Series B:  Biological Sciences</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">220</span>
        (<span class="NLM_cas:issue">1219</span>),
    <span class="NLM_cas:pages">141-62</span>CODEN:
                <span class="NLM_cas:coden">PRLBA4</span>;
        ISSN:<span class="NLM_cas:issn">0080-4649</span>.
    </div><div class="casAbstract">A general, operational model is presented which explicitly describes pharmacol. agonism in terms of 3 parameters: an agonist-receptor dissocn. const., the total receptor concn. [Ro], and a parameter (KE) which defines the transduction of the agonist-receptor complex into pharmacol. effect.  The ratio RO/KE, the transducer ratio (τ), is a logical definition for the efficacy of an agonist in a system.  The model provides a chem. definition of intrinsic efficacy, making this parameter exptl. accessible in principle.  Alternate models are compared and contrasted with regard to their practical and conceptual utilities in exptl. pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonpXVldFQ_nbVg90H21EOLACvtfcHk0ljpUdEpZQiepg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXmtFaqtA%253D%253D&md5=a0421df9c56495d48d076010acf44b65</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1098%2Frspb.1983.0093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frspb.1983.0093%26sid%3Dliteratum%253Aachs%26aulast%3DBlack%26aufirst%3DJ.%2BW.%26aulast%3DLeff%26aufirst%3DP.%26atitle%3DOperational%2520Models%2520of%2520Pharmacological%2520Agonism%26jtitle%3DProc.%2520R.%2520Soc.%2520London%252C%2520Ser.%2520B%26date%3D1983%26volume%3D220%26spage%3D141%26epage%3D162%26doi%3D10.1098%2Frspb.1983.0093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Namkung, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radresa, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armando, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devost, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beautrait, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Gouill, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laporte, S. A.</span><span> </span><span class="NLM_article-title">Quantifying Biased Signaling in GPCRs Using BRET-Based Biosensors</span> <span class="citation_source-journal">Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span><span class="refDoi"> DOI: 10.1016/j.ymeth.2015.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1016%2Fj.ymeth.2015.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=25890247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslehsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2016&pages=5-10&author=Y.+Namkungauthor=O.+Radresaauthor=S.+Armandoauthor=D.+Devostauthor=A.+Beautraitauthor=C.+Le+Gouillauthor=S.+A.+Laporte&title=Quantifying+Biased+Signaling+in+GPCRs+Using+BRET-Based+Biosensors&doi=10.1016%2Fj.ymeth.2015.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Quantifying biased signaling in GPCRs using BRET-based biosensors</span></div><div class="casAuthors">Namkung, Yoon; Radresa, Olivier; Armando, Sylvain; Devost, Dominic; Beautrait, Alexandre; Le Gouill, Christian; Laporte, Stephane A.</div><div class="citationInfo"><span class="NLM_cas:title">Methods (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5-10</span>CODEN:
                <span class="NLM_cas:coden">MTHDE9</span>;
        ISSN:<span class="NLM_cas:issn">1046-2023</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">There has been a growing appreciation that G protein-coupled receptor (GPCR) functional selectivity (viz. biased signaling), in particular between G protein- and β-arrestin-dependent signaling, can be achieved with specific ligands, and that such directed signaling represents a promising avenue for improving drug efficacy and therapy.  Thus, for any given GPCRs it is important to define means to pharmacol. characterize and classify drugs for their propensity to bias signaling.  Here we describe an exptl. protocol and step-by-step approach to assess functional selectivity between Gαq and β-arrestin-dependent responses using the prototypical angiotensin II (AngII) type 1 receptor (AT1R) expressed in HEK 293 cells.  The protocol describes the expression of Bioluminescence Resonance Energy Transfer (BRET) sensors for either Gαq or β-arrestin with AT1R, and the use of the operational model of pharmacol. agonism to quantify ligand bias.  Such methods are equally applicable to other GPCRs and their downstream signaling effectors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoisQm2sSQfUbVg90H21EOLACvtfcHk0lhIf5BXX74ljQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslehsLo%253D&md5=3734d70788ffaa1faeb348d608d2c126</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.ymeth.2015.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymeth.2015.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DNamkung%26aufirst%3DY.%26aulast%3DRadresa%26aufirst%3DO.%26aulast%3DArmando%26aufirst%3DS.%26aulast%3DDevost%26aufirst%3DD.%26aulast%3DBeautrait%26aufirst%3DA.%26aulast%3DLe%2BGouill%26aufirst%3DC.%26aulast%3DLaporte%26aufirst%3DS.%2BA.%26atitle%3DQuantifying%2520Biased%2520Signaling%2520in%2520GPCRs%2520Using%2520BRET-Based%2520Biosensors%26jtitle%3DMethods%26date%3D2016%26volume%3D92%26spage%3D5%26epage%3D10%26doi%3D10.1016%2Fj.ymeth.2015.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">van der Westhuizen, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breton, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouvier, M.</span><span> </span><span class="NLM_article-title">Quantification of Ligand Bias for Clinically Relevant B2-Adrenergic Receptor Ligands: Implications for Drug Taxonomy</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">492</span><span class="NLM_x">–</span> <span class="NLM_lpage">509</span><span class="refDoi"> DOI: 10.1124/mol.113.088880</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1124%2Fmol.113.088880" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2014&pages=492-509&author=E.+T.+van+der+Westhuizenauthor=B.+Bretonauthor=A.+Christopoulosauthor=M.+Bouvier&title=Quantification+of+Ligand+Bias+for+Clinically+Relevant+B2-Adrenergic+Receptor+Ligands%3A+Implications+for+Drug+Taxonomy&doi=10.1124%2Fmol.113.088880"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1124%2Fmol.113.088880&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.113.088880%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BWesthuizen%26aufirst%3DE.%2BT.%26aulast%3DBreton%26aufirst%3DB.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DBouvier%26aufirst%3DM.%26atitle%3DQuantification%2520of%2520Ligand%2520Bias%2520for%2520Clinically%2520Relevant%2520B2-Adrenergic%2520Receptor%2520Ligands%253A%2520Implications%2520for%2520Drug%2520Taxonomy%26jtitle%3DMol.%2520Pharmacol.%26date%3D2014%26volume%3D85%26spage%3D492%26epage%3D509%26doi%3D10.1124%2Fmol.113.088880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Manglik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aryal, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCorvy, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dengler, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corder, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kling, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernat, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sassano, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giguère, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Löber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherrer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span> </span><span class="NLM_article-title">Structure-Based Discovery of Opioid Analgesics with Reduced Side Effects</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">537</span><span class="NLM_x">, </span> <span class="NLM_fpage">185</span><span class="NLM_x">–</span> <span class="NLM_lpage">190</span><span class="refDoi"> DOI: 10.1038/nature19112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1038%2Fnature19112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=27533032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlKmsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=537&publication_year=2016&pages=185-190&author=A.+Manglikauthor=H.+Linauthor=D.+K.+Aryalauthor=J.+D.+McCorvyauthor=D.+Denglerauthor=G.+Corderauthor=A.+Levitauthor=R.+C.+Klingauthor=V.+Bernatauthor=H.+H%C3%BCbnerauthor=X.-P.+Huangauthor=M.+F.+Sassanoauthor=P.+M.+Gigu%C3%A8reauthor=S.+L%C3%B6berauthor=D.+Duanauthor=G.+Scherrerauthor=B.+K.+Kobilkaauthor=P.+Gmeinerauthor=B.+L.+Rothauthor=B.+K.+Shoichet&title=Structure-Based+Discovery+of+Opioid+Analgesics+with+Reduced+Side+Effects&doi=10.1038%2Fnature19112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based discovery of opioid analgesics with reduced side effects</span></div><div class="casAuthors">Manglik, Aashish; Lin, Henry; Aryal, Dipendra K.; McCorvy, John D.; Dengler, Daniela; Corder, Gregory; Levit, Anat; Kling, Ralf C.; Bernat, Viachaslau; Hubner, Harald; Huang, Xi-Ping; Sassano, Maria F.; Giguere, Patrick M.; Lober, Stefan; Da Duan; Scherrer, Gregory; Kobilka, Brian K.; Gmeiner, Peter; Roth, Bryan L.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">537</span>
        (<span class="NLM_cas:issue">7619</span>),
    <span class="NLM_cas:pages">185-190</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Morphine is an alkaloid from the opium poppy used to treat pain.  The potentially lethal side effects of morphine and related opioids-which include fatal respiratory depression-are thought to be mediated by μ-opioid-receptor (μOR) signalling through the β-arrestin pathway or by actions at other receptors.  Conversely, G-protein μOR signalling is thought to confer analgesia.  Here we computationally dock over 3 million mols. against the μOR structure and identify new scaffolds unrelated to known opioids.  Structure-based optimization yields PZM21-a potent Gi activator with exceptional selectivity for μOR and minimal β-arrestin-2 recruitment.  Unlike morphine, PZM21 is more efficacious for the affective component of analgesia vs. the reflexive component and is devoid of both respiratory depression and morphine-like reinforcing activity in mice at equi-analgesic doses.  PZM21 thus serves as both a probe to disentangle μOR signalling and a therapeutic lead that is devoid of many of the side effects of current opioids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiCff2w3U8iLVg90H21EOLACvtfcHk0lhIf5BXX74ljQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlKmsbvI&md5=b8bb2d8575dadf4a6dc74d94c26d2c1a</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fnature19112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19112%26sid%3Dliteratum%253Aachs%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DAryal%26aufirst%3DD.%2BK.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DDengler%26aufirst%3DD.%26aulast%3DCorder%26aufirst%3DG.%26aulast%3DLevit%26aufirst%3DA.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DBernat%26aufirst%3DV.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DGigu%25C3%25A8re%26aufirst%3DP.%2BM.%26aulast%3DL%25C3%25B6ber%26aufirst%3DS.%26aulast%3DDuan%26aufirst%3DD.%26aulast%3DScherrer%26aufirst%3DG.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DGmeiner%26aufirst%3DP.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DStructure-Based%2520Discovery%2520of%2520Opioid%2520Analgesics%2520with%2520Reduced%2520Side%2520Effects%26jtitle%3DNature%26date%3D2016%26volume%3D537%26spage%3D185%26epage%3D190%26doi%3D10.1038%2Fnature19112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 15 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Ana Mallo-Abreu, Irene Reyes-Resina, Jhonny Azuaje, Rafael Franco, Aitor García-Rey, Maria Majellaro, Darío Miranda-Pastoriza, Xerardo García-Mera, Willem Jespers, Hugo Gutiérrez-de-Terán, Gemma Navarro, <span class="NLM_string-name hlFld-ContribAuthor">Eddy Sotelo</span>. </span><span class="cited-content_cbyCitation_article-title">Potent and Subtype-Selective Dopamine D2 Receptor Biased Partial Agonists Discovered via an Ugi-Based Approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8710-8726. <a href="https://doi.org/10.1021/acs.jmedchem.1c00704" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00704</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00704%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPotent%252Band%252BSubtype-Selective%252BDopamine%252BD2%252BReceptor%252BBiased%252BPartial%252BAgonists%252BDiscovered%252Bvia%252Ban%252BUgi-Based%252BApproach%26aulast%3DMallo-Abreu%26aufirst%3DAna%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D19042021%26date%3D10062021%26volume%3D64%26issue%3D12%26spage%3D8710%26epage%3D8726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Julian Ott, Mona M. Spilhaug, Simone Maschauer, Waqas Rafique, Jimmy E. Jakobsson, Karoline Hartvig, Harald Hübner, Peter Gmeiner, Olaf Prante, <span class="NLM_string-name hlFld-ContribAuthor">Patrick J. Riss</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacological Characterization of Low-to-Moderate Affinity Opioid Receptor Agonists and Brain Imaging with 18F-Labeled Derivatives in Rats. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (17)
                                     , 9484-9499. <a href="https://doi.org/10.1021/acs.jmedchem.0c00683" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00683</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00683%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPharmacological%252BCharacterization%252Bof%252BLow-to-Moderate%252BAffinity%252BOpioid%252BReceptor%252BAgonists%252Band%252BBrain%252BImaging%252Bwith%252B18F-Labeled%252BDerivatives%252Bin%252BRats%26aulast%3DOtt%26aufirst%3DJulian%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D24042020%26date%3D17082020%26date%3D31072020%26volume%3D63%26issue%3D17%26spage%3D9484%26epage%3D9499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yudao Shen, John D. McCorvy, Michael L. Martini, Ramona M. Rodriguiz, Vladimir M. Pogorelov, Karen M. Ward, William C. Wetsel, Jing Liu, Bryan L. Roth, <span class="NLM_string-name hlFld-ContribAuthor">Jian Jin</span>. </span><span class="cited-content_cbyCitation_article-title">D2 Dopamine Receptor G Protein-Biased Partial Agonists Based on Cariprazine. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (9)
                                     , 4755-4771. <a href="https://doi.org/10.1021/acs.jmedchem.9b00508" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00508</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00508%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DD2%252BDopamine%252BReceptor%252BG%252BProtein-Biased%252BPartial%252BAgonists%252BBased%252Bon%252BCariprazine%26aulast%3DShen%26aufirst%3DYudao%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22032019%26date%3D18042019%26date%3D09042019%26volume%3D62%26issue%3D9%26spage%3D4755%26epage%3D4771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Alessandro Bonifazi, Hideaki Yano, Adrian M. Guerrero, Vivek Kumar, Alexander F. Hoffman, Carl R. Lupica, Lei Shi, <span class="NLM_string-name hlFld-ContribAuthor">Amy Hauck Newman</span>. </span><span class="cited-content_cbyCitation_article-title">Novel and Potent Dopamine D2 Receptor Go-Protein Biased Agonists. </span><span class="cited-content_cbyCitation_journal-name">ACS Pharmacology & Translational Science</span><span> <strong>2019,</strong> <em>2 </em>
                                    (1)
                                     , 52-65. <a href="https://doi.org/10.1021/acsptsci.8b00060" title="DOI URL">https://doi.org/10.1021/acsptsci.8b00060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsptsci.8b00060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsptsci.8b00060%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Pharmacology%2520%2526%2520Translational%2520Science%26atitle%3DNovel%252Band%252BPotent%252BDopamine%252BD2%252BReceptor%252BGo-Protein%252BBiased%252BAgonists%26aulast%3DBonifazi%26aufirst%3DAlessandro%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D21122018%26date%3D28012019%26date%3D14012019%26volume%3D2%26issue%3D1%26spage%3D52%26epage%3D65" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xudong Cao, Yifang Zhang, Yin Chen, Yinli Qiu, Minquan Yu, Xiangqing Xu, Xin Liu, Bi-Feng Liu, Liangren Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Guisen Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (22)
                                     , 10017-10039. <a href="https://doi.org/10.1021/acs.jmedchem.8b01096" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01096</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01096%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BFused%252BTricyclic%252BHeterocycle%252BPiperazine%252B%252528Piperidine%252529%252BDerivatives%252BAs%252BPotential%252BMultireceptor%252BAtypical%252BAntipsychotics%26aulast%3DCao%26aufirst%3DXudong%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D12072018%26date%3D09112018%26date%3D01112018%26volume%3D61%26issue%3D22%26spage%3D10017%26epage%3D10039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Natascha  Nebel</span>, <span class="hlFld-ContribAuthor ">Brigitte  Strauch</span>, <span class="hlFld-ContribAuthor ">Simone  Maschauer</span>, <span class="hlFld-ContribAuthor ">Roman  Lasch</span>, <span class="hlFld-ContribAuthor ">Hannelore  Rampp</span>, <span class="hlFld-ContribAuthor ">Stefanie K.  Fehler</span>, <span class="hlFld-ContribAuthor ">Leonard R.  Bock</span>, <span class="hlFld-ContribAuthor ">Harald  Hübner</span>, <span class="hlFld-ContribAuthor ">Peter  Gmeiner</span>, <span class="hlFld-ContribAuthor ">Markus R.  Heinrich</span>, and <span class="hlFld-ContribAuthor ">Olaf  Prante</span>  . </span><span class="cited-content_cbyCitation_article-title">[18F]Fluorophenylazocarboxylates: Design and Synthesis of Potential Radioligands for Dopamine D3 and μ-Opioid Receptor. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2017,</strong> <em>2 </em>
                                    (12)
                                     , 8649-8659. <a href="https://doi.org/10.1021/acsomega.7b01374" title="DOI URL">https://doi.org/10.1021/acsomega.7b01374</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.7b01374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.7b01374%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3D%25255B18F%25255DFluorophenylazocarboxylates%25253A%252BDesign%252Band%252BSynthesis%252Bof%252BPotential%252BRadioligands%252Bfor%252BDopamine%252BD3%252Band%252B%2525CE%2525BC-Opioid%252BReceptor%26aulast%3DNebel%26aufirst%3DNatascha%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D14092017%26date%3D16112017%26date%3D31122017%26volume%3D2%26issue%3D12%26spage%3D8649%26epage%3D8659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrés  Charris-Molina</span>, <span class="hlFld-ContribAuthor ">Juan-Carlos  Castillo</span>, <span class="hlFld-ContribAuthor ">Mario  Macías</span>, and <span class="hlFld-ContribAuthor ">Jaime  Portilla</span>  . </span><span class="cited-content_cbyCitation_article-title">One-Step Synthesis of Fully Functionalized Pyrazolo[3,4-b]pyridines via Isobenzofuranone Ring Opening. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>82 </em>
                                    (23)
                                     , 12674-12681. <a href="https://doi.org/10.1021/acs.joc.7b02471" title="DOI URL">https://doi.org/10.1021/acs.joc.7b02471</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.7b02471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.7b02471%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DOne-Step%252BSynthesis%252Bof%252BFully%252BFunctionalized%252BPyrazolo%25255B3%25252C4-b%25255Dpyridines%252Bvia%252BIsobenzofuranone%252BRing%252BOpening%26aulast%3DCharris-Molina%26aufirst%3DAndr%25C3%25A9s%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D29092017%26date%3D20112017%26date%3D01122017%26date%3D10112017%26volume%3D82%26issue%3D23%26spage%3D12674%26epage%3D12681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Barbara  Männel</span>, <span class="hlFld-ContribAuthor ">Mariama  Jaiteh</span>, <span class="hlFld-ContribAuthor ">Alexey  Zeifman</span>, <span class="hlFld-ContribAuthor ">Alena  Randakova</span>, <span class="hlFld-ContribAuthor ">Dorothee  Möller</span>, <span class="hlFld-ContribAuthor ">Harald  Hübner</span>, <span class="hlFld-ContribAuthor ">Peter  Gmeiner</span>, and <span class="hlFld-ContribAuthor ">Jens  Carlsson</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure-Guided Screening for Functionally Selective D2 Dopamine Receptor Ligands from a Virtual Chemical Library. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2017,</strong> <em>12 </em>
                                    (10)
                                     , 2652-2661. <a href="https://doi.org/10.1021/acschembio.7b00493" title="DOI URL">https://doi.org/10.1021/acschembio.7b00493</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.7b00493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.7b00493%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DStructure-Guided%252BScreening%252Bfor%252BFunctionally%252BSelective%252BD2%252BDopamine%252BReceptor%252BLigands%252Bfrom%252Ba%252BVirtual%252BChemical%252BLibrary%26aulast%3DM%25C3%25A4nnel%26aufirst%3DBarbara%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D15062017%26date%3D28082017%26date%3D19092017%26date%3D20102017%26date%3D28082017%26volume%3D12%26issue%3D10%26spage%3D2652%26epage%3D2661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deborah  Wenk</span>, <span class="hlFld-ContribAuthor ">Vladimir  Ignatchenko</span>, <span class="hlFld-ContribAuthor ">Andrew  Macklin</span>, <span class="hlFld-ContribAuthor ">Harald  Hübner</span>, <span class="hlFld-ContribAuthor ">Peter  Gmeiner</span>, <span class="hlFld-ContribAuthor ">Dorothée  Weikert</span>, <span class="hlFld-ContribAuthor ">Monika  Pischetsrieder</span>, <span class="hlFld-ContribAuthor ">Thomas  Kislinger</span>. </span><span class="cited-content_cbyCitation_article-title">Functionally selective activation of the dopamine receptor D2 is mirrored by the protein expression profiles. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-021-83038-x" title="DOI URL">https://doi.org/10.1038/s41598-021-83038-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-021-83038-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-021-83038-x%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DFunctionally%252Bselective%252Bactivation%252Bof%252Bthe%252Bdopamine%252Breceptor%252BD2%252Bis%252Bmirrored%252Bby%252Bthe%252Bprotein%252Bexpression%252Bprofiles%26aulast%3DWenk%26aufirst%3DDeborah%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marta  Sanchez-Soto</span>, <span class="hlFld-ContribAuthor ">Ravi Kumar  Verma</span>, <span class="hlFld-ContribAuthor ">Blair K. A.  Willette</span>, <span class="hlFld-ContribAuthor ">Elizabeth C.  Gonye</span>, <span class="hlFld-ContribAuthor ">Annah M.  Moore</span>, <span class="hlFld-ContribAuthor ">Amy E.  Moritz</span>, <span class="hlFld-ContribAuthor ">Comfort A.  Boateng</span>, <span class="hlFld-ContribAuthor ">Hideaki  Yano</span>, <span class="hlFld-ContribAuthor ">R. Benjamin  Free</span>, <span class="hlFld-ContribAuthor ">Lei  Shi</span>, <span class="hlFld-ContribAuthor ">David R.  Sibley</span>. </span><span class="cited-content_cbyCitation_article-title">A structural basis for how ligand binding site changes can allosterically regulate GPCR signaling and engender functional selectivity. </span><span class="cited-content_cbyCitation_journal-name">Science Signaling</span><span> <strong>2020,</strong> <em>13 </em>
                                    (617)
                                     , eaaw5885. <a href="https://doi.org/10.1126/scisignal.aaw5885" title="DOI URL">https://doi.org/10.1126/scisignal.aaw5885</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/scisignal.aaw5885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fscisignal.aaw5885%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Signaling%26atitle%3DA%252Bstructural%252Bbasis%252Bfor%252Bhow%252Bligand%252Bbinding%252Bsite%252Bchanges%252Bcan%252Ballosterically%252Bregulate%252BGPCR%252Bsignaling%252Band%252Bengender%252Bfunctional%252Bselectivity%26aulast%3DSanchez-Soto%26aufirst%3DMarta%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D617%26spage%3Deaaw5885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kim A.  Neve</span>. </span><span class="cited-content_cbyCitation_article-title">Dopamine Receptors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.1016/B978-0-12-819460-7.00119-5" title="DOI URL">https://doi.org/10.1016/B978-0-12-819460-7.00119-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-819460-7.00119-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-819460-7.00119-5%26sid%3Dliteratum%253Aachs%26atitle%3DDopamine%252BReceptors%26aulast%3DNeve%26aufirst%3DKim%2BA.%26date%3D2020%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BLife%252BSciences%26date%3D2020%26volume%3D108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marlene  Jacobson</span>, <span class="hlFld-ContribAuthor ">Wayne  Childers</span>, <span class="hlFld-ContribAuthor ">Magid  Abou‐Gharbia</span>. </span><span class="cited-content_cbyCitation_article-title">Dopamine D
              2
              Partial Agonists – Discovery, Evolution, and Therapeutic Potential. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 83-130. <a href="https://doi.org/10.1002/9783527814695.ch4" title="DOI URL">https://doi.org/10.1002/9783527814695.ch4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527814695.ch4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527814695.ch4%26sid%3Dliteratum%253Aachs%26atitle%3DDopamine%252BD%252B2%252BPartial%252BAgonists%252B%2525E2%252580%252593%252BDiscovery%25252C%252BEvolution%25252C%252Band%252BTherapeutic%252BPotential%26aulast%3DJacobson%26aufirst%3DMarlene%26date%3D2019%26date%3D2019%26spage%3D83%26epage%3D130%26pub%3DWiley%26atitle%3DSuccessful%252BDrug%252BDiscovery%26aulast%3DFischer%26aufirst%3DJ%25C3%25A1nos%26date%3D2019%26date%3D2019%26volume%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meridith T.  Robins</span>, <span class="hlFld-ContribAuthor ">Terrance  Chiang</span>, <span class="hlFld-ContribAuthor ">Jennifer N.  Berry</span>, <span class="hlFld-ContribAuthor ">Mee Jung  Ko</span>, <span class="hlFld-ContribAuthor ">Jiwon E.  Ha</span>, <span class="hlFld-ContribAuthor ">Richard M.  van Rijn</span>. </span><span class="cited-content_cbyCitation_article-title">Behavioral Characterization of β-Arrestin 1 Knockout Mice in Anxiety-Like and Alcohol Behaviors. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Behavioral Neuroscience</span><span> <strong>2018,</strong> <em>12 </em><a href="https://doi.org/10.3389/fnbeh.2018.00054" title="DOI URL">https://doi.org/10.3389/fnbeh.2018.00054</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fnbeh.2018.00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffnbeh.2018.00054%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Behavioral%2520Neuroscience%26atitle%3DBehavioral%252BCharacterization%252Bof%252B%2525CE%2525B2-Arrestin%252B1%252BKnockout%252BMice%252Bin%252BAnxiety-Like%252Band%252BAlcohol%252BBehaviors%26aulast%3DRobins%26aufirst%3DMeridith%2BT.%26date%3D2018%26date%3D2018%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lani S.  Chun</span>, <span class="hlFld-ContribAuthor ">Rakesh H.  Vekariya</span>, <span class="hlFld-ContribAuthor ">R. Benjamin  Free</span>, <span class="hlFld-ContribAuthor ">Yun  Li</span>, <span class="hlFld-ContribAuthor ">Da-Ting  Lin</span>, <span class="hlFld-ContribAuthor ">Ping  Su</span>, <span class="hlFld-ContribAuthor ">Fang  Liu</span>, <span class="hlFld-ContribAuthor ">Yoon  Namkung</span>, <span class="hlFld-ContribAuthor ">Stephane A.  Laporte</span>, <span class="hlFld-ContribAuthor ">Amy E.  Moritz</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Aubé</span>, <span class="hlFld-ContribAuthor ">Kevin J.  Frankowski</span>, <span class="hlFld-ContribAuthor ">David R.  Sibley</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Activity Investigation of a G Protein-Biased Agonist Reveals Molecular Determinants for Biased Signaling of the D2 Dopamine Receptor. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Synaptic Neuroscience</span><span> <strong>2018,</strong> <em>10 </em><a href="https://doi.org/10.3389/fnsyn.2018.00002" title="DOI URL">https://doi.org/10.3389/fnsyn.2018.00002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fnsyn.2018.00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffnsyn.2018.00002%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Synaptic%2520Neuroscience%26atitle%3DStructure-Activity%252BInvestigation%252Bof%252Ba%252BG%252BProtein-Biased%252BAgonist%252BReveals%252BMolecular%252BDeterminants%252Bfor%252BBiased%252BSignaling%252Bof%252Bthe%252BD2%252BDopamine%252BReceptor%26aulast%3DChun%26aufirst%3DLani%2BS.%26date%3D2018%26date%3D2018%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Barbara  Männel</span>, <span class="hlFld-ContribAuthor ">Harald  Hübner</span>, <span class="hlFld-ContribAuthor ">Dorothée  Möller</span>, <span class="hlFld-ContribAuthor ">Peter  Gmeiner</span>. </span><span class="cited-content_cbyCitation_article-title">β-Arrestin biased dopamine D2 receptor partial agonists: Synthesis and pharmacological evaluation. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (20)
                                     , 5613-5628. <a href="https://doi.org/10.1016/j.bmc.2017.08.037" title="DOI URL">https://doi.org/10.1016/j.bmc.2017.08.037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2017.08.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2017.08.037%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3D%2525CE%2525B2-Arrestin%252Bbiased%252Bdopamine%252BD2%252Breceptor%252Bpartial%252Bagonists%25253A%252BSynthesis%252Band%252Bpharmacological%252Bevaluation%26aulast%3DM%25C3%25A4nnel%26aufirst%3DBarbara%26date%3D2017%26volume%3D25%26issue%3D20%26spage%3D5613%26epage%3D5628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/medium/jm-2017-003633_0002.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00363&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/medium/jm-2017-003633_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Previously Described β-Arrestin-Biased Agonists <b>1</b>–<b>3</b> with Partial Agonist Characteristics at D<sub>2</sub>R</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00363&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/medium/jm-2017-003633_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 2. Formal Structural Hybridization of the D<sub>2</sub>R Partial Agonist Aripiprazole and the Known β<sub>2</sub>-AR Agonists Procaterol and <b>4</b>, Leading to Novel Dopaminergics</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00363&amp;id=cht2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/medium/jm-2017-003633_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0006.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Heterocyclic Aromatic Piperazine and Homopiperazine Head Groups<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00363&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) DBU, benzyl bromide, isopropyl alcohol, rt, 1.5 h (70–88%); (b) Br<sub>2</sub>, AcOH, rt, 4 h (53–84%); (c) K<sub>2</sub>CO<sub>3</sub>, benzyl bromide, DMF, 50 °C, 24 h or rt, 2 h (57–91%); (d) Pd<sub>2</sub>(dba)<sub>3</sub> or Pd(OAc)<sub>2</sub>, <i>rac</i>-BINAP, NaO<sup><i>t</i></sup>Bu, 1-boc-piperazine or 1-boc-homopiperazine, toluene, 85 °C, 115 °C or reflux, 24–48 h (63–73%); (e) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h (51–97%); (f) Br<sub>2</sub>, THF, 0 °C, 2 h, then rt, 16 h (47%); (g) Pd<sub>2</sub>(dba)<sub>3</sub> or Pd(OAc)<sub>2</sub>, <i>rac</i>-BINAP, Cs<sub>2</sub>CO<sub>3</sub>, 1-boc-piperazine or 1-boc-homopiperazine, toluene, 85 °C or reflux, 24–72 h (38–66%); (h) Br<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 5 h (55–75%).</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/medium/jm-2017-003633_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0007.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Full-Length Dopaminergics<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00363&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 7-(4-bromobutoxy)-3,4-dihydroquinolin-2(1<i>H</i>)-one, NaI, acetonitrile, reflux 30 min, then addition of triethylamine in acetonitrile, 80 °C, 16 h (45–74%); (b) 5-(4-bromobutoxy)-pyrazolo[1,5-<i>a</i>]pyridine, NaI, acetonitrile, reflux 30 min, then addition of triethylamine in acetonitrile, 80 °C, 16 h (65–77%); (c) 10% Pd/C in acetic acid/methanol, rt, 4 h (63–79%) or TFA in toluene, reflux, 8 h (57–79%) or MsOH in toluene, reflux, 3 h (48–59%).</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/medium/jm-2017-003633_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0008.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Heteroarylpiperazines with Alternate Appendages<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00363&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 4-(3-(1-butyl-1<i>H</i>-1,2,3-triazol-4-yl)propoxy)-<i>N</i>-(3-oxopropyl)-3-methoxybenzamide or 4-(3-(1-butyl-1<i>H</i>-1,2,3-triazol-4-yl)propoxy)-<i>N</i>-(4-oxobutyl)-3-methoxybenzamide, NaBH(OAc)<sub>3</sub>, dichloroethane, rt, 6 h (80–89%); (b) MsOH in toluene, reflux, 3 h (43–74%).</p></p></figure><figure data-id="fig1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/medium/jm-2017-003633_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Dose–response curves at D<sub>2S</sub>R and metabolic stability of target compounds <b>13a</b>,<b>b</b> and <b>17a</b>. (a–c) Dose–response curves for D<sub><b>2S</b></sub>R-mediated activation of Gα<sub>o1</sub> (gray) and the recruitment of β-arrestin-2 in absence (blue) or presence (orange) of GRK2. (d) Bias factors for D<sub>2S</sub>R activation were calculated using the operational model of agonism. Positive values for ΔΔlog(τ/<i>K</i><sub>A</sub>) indicate a preference for β-arrestin-2 recruitment. (e) Metabolic stability of <b>13a</b> and <b>17a</b> assessed in rat liver microsomes: distribution between metabolized substrate, substrate nonspecifically bound to matrix, and the remaining fraction after 60 min of incubation. (f) Inhibition of hERG tail currents by <b>13a</b> was measured to estimate susceptibility of cardiotoxicity. Data represent mean ± SEM of at least three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.7b00363/20170602/images/large/jm-2017-003633_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00363&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i80">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55242" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55242" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 68 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Beaulieu, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espinoza, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainetdinov, R. R.</span><span> </span><span class="NLM_article-title">Dopamine Receptors – Iuphar Review 13</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">172</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span><span class="refDoi"> DOI: 10.1111/bph.12906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1111%2Fbph.12906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=25671228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWlsLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=1-23&author=J.-M.+Beaulieuauthor=S.+Espinozaauthor=R.+R.+Gainetdinov&title=Dopamine+Receptors+%E2%80%93+Iuphar+Review+13&doi=10.1111%2Fbph.12906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine receptors - IUPHAR Review 13</span></div><div class="casAuthors">Beaulieu, Jean-Martin; Espinoza, Stefano; Gainetdinov, Raul R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-23</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The variety of physiol. functions controlled by dopamine in the brain and periphery is mediated by the D1, D2, D3, D4 and D5 dopamine GPCRs.  Drugs acting on dopamine receptors are significant tools for the management of several neuropsychiatric disorders including schizophrenia, bipolar disorder, depression and Parkinson's disease.  Recent investigations of dopamine receptor signalling have shown that dopamine receptors, apart from their canonical action on cAMP-mediated signalling, can regulate a myriad of cellular responses to fine-tune the expression of dopamine-assocd. behaviors and functions.  Such signalling mechanisms may involve alternate G protein coupling or non-G protein mechanisms involving ion channels, receptor tyrosine kinases or proteins such as β-arrestins that are classically involved in GPCR desensitization.  Another level of complexity is the growing appreciation of the physiol. roles played by dopamine receptor heteromers.  Applications of new in vivo techniques have significantly furthered the understanding of the physiol. functions played by dopamine receptors.  Here we provide an update of the current knowledge regarding the complex biol., signalling, physiol. and pharmacol. of dopamine receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1fpdKAWrR5rVg90H21EOLACvtfcHk0lg8sOYNw5J5aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWlsLjJ&md5=7f15533abc8fb6aa76a4ec41072b6219</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1111%2Fbph.12906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12906%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DJ.-M.%26aulast%3DEspinoza%26aufirst%3DS.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26atitle%3DDopamine%2520Receptors%2520%25E2%2580%2593%2520Iuphar%2520Review%252013%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D1%26epage%3D23%26doi%3D10.1111%2Fbph.12906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Chaudhuri, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schapira, A. H. V.</span><span> </span><span class="NLM_article-title">Non-Motor Symptoms of Parkinson’s Disease: Dopaminergic Pathophysiology and Treatment</span> <span class="citation_source-journal">Lancet Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">464</span><span class="NLM_x">–</span> <span class="NLM_lpage">474</span><span class="refDoi"> DOI: 10.1016/S1474-4422(09)70068-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1016%2FS1474-4422%2809%2970068-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=19375664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVajsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=464-474&author=K.+R.+Chaudhuriauthor=A.+H.+V.+Schapira&title=Non-Motor+Symptoms+of+Parkinson%E2%80%99s+Disease%3A+Dopaminergic+Pathophysiology+and+Treatment&doi=10.1016%2FS1474-4422%2809%2970068-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment</span></div><div class="casAuthors">Chaudhuri, K. Ray; Schapira, Anthony H. V.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">464-474</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Several studies, including work from the Parkinson's disease (PD) non-motor group and others, have established that the non-motor symptoms of PD are common, occur across all stages of PD, are under-reported, and are a key determinant of quality of life.  Research suggests that the non-motor symptoms of the disease are frequently unrecognized by clinicians and remain untreated.  Even when identified, there is a common perception that many of these symptoms are untreatable.  The role of dopaminergic drugs in treating the various non-motor problems of PD, although clin. recognized, has received little attention.  In this Review, we investigate the dopaminergic basis of the range of non-motor symptoms that occur in PD such as depression, apathy, sleep disorders (including rapid-eye movement sleep behavior disorder), and erectile dysfunction.  We discuss the evidence that these symptoms are treatable, at least in part, with various dopaminergic strategies and, where relevant, we also refer to the use of deep-brain stimulation of appropriate targets in the brain.  This Review provides a comprehensive overview of the management of this challenging aspect of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH0aCFNtuE7rVg90H21EOLACvtfcHk0lg8sOYNw5J5aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVajsb0%253D&md5=30e08b16ec451f1240d43101601388da</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2809%2970068-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252809%252970068-7%26sid%3Dliteratum%253Aachs%26aulast%3DChaudhuri%26aufirst%3DK.%2BR.%26aulast%3DSchapira%26aufirst%3DA.%2BH.%2BV.%26atitle%3DNon-Motor%2520Symptoms%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%253A%2520Dopaminergic%2520Pathophysiology%2520and%2520Treatment%26jtitle%3DLancet%2520Neurol.%26date%3D2009%26volume%3D8%26spage%3D464%26epage%3D474%26doi%3D10.1016%2FS1474-4422%2809%2970068-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Oertel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulz, J. B.</span><span> </span><span class="NLM_article-title">Current and Experimental Treatments of Parkinson Disease: A Guide for Neuroscientists</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">139</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">337</span><span class="refDoi"> DOI: 10.1111/jnc.13750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1111%2Fjnc.13750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=27577098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVaku7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2016&pages=325-337&author=W.+Oertelauthor=J.+B.+Schulz&title=Current+and+Experimental+Treatments+of+Parkinson+Disease%3A+A+Guide+for+Neuroscientists&doi=10.1111%2Fjnc.13750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Current and experimental treatments of Parkinson disease: A guide for neuroscientists</span></div><div class="casAuthors">Oertel, Wolfgang; Schulz, Joerg B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">S1</span>),
    <span class="NLM_cas:pages">325-337</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Over a period of more than 50 years, the symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been optimized using pharmacotherapy, deep brain stimulation, and physiotherapy.  The arsenal of pharmacotherapies includes L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine.  In the later course of the disease, motor complications occur, at which stage different oral formulations of L-Dopa or dopamine agonists with long half-life, a transdermal application or parenteral pumps for continuous drug supply can be subscribed.  Alternatively, the patient is offered deep brain stimulation of the subthalamic nucleus (STN) or the internal part of the globus pallidus (GPi).  For a more efficacious treatment of motor complications, new formulations of L-Dopa, dopamine agonists, and amantadine as well as new MAO-B and COMT inhibitors are currently tested in clin. trials, and some of them already yielding pos. results in phase 3 trials.  In addn., nondopaminergic agents have been tested in the early clin. phase for the treatment of motor fluctuations and dyskinesia, including adenosine A2A antagonists (istradefylline, preladenant, and tozadenant) and modulators of the metabolic glutamate receptor 5 (mGluR5 - mavoglurant) and serotonin (eltoprazine) receptors.  Recent clin. trials testing coenzyme Q10, the dopamine agonist pramipexole, creatine monohydrate, pioglitazone, or AAV-mediated gene therapy aimed at increasing expression of neurturin, did not prove efficacious.  Treatment with nicotine, caffeine, inosine (a precursor of urate), and isradipine (a dihydropyridine calcium channel blocker), as well as active and passive immunization against α-synuclein and inhibitors or modulators of α-synuclein-aggregation are currently studied in clin. trials.  However, to date, no disease-modifying treatment is available.  The authors here review the current status of treatment options for motor and nonmotor symptoms, and discuss current investigative strategies for disease modification.  This review provides basic insights, mainly addressing basic scientists and nonspecialists.  It stresses the need to intensify therapeutic PD research and points out reasons why the translation of basic research to disease-modifying therapies has been unsuccessful so far.  The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy.  For a more efficacious treatment of motor complications, new formulations of L-Dopa, dopamine agonists, and amantadine as well as new MAO-B and COMT inhibitors are currently tested in clin. trials.  Nondopaminergic agents have been tested in the early clin. phase for the treatment of motor fluctuations and dyskinesia.  Recent clin. trials testing coenzyme Q10, the dopamine agonist pramipexole, creatine monohydrate, pioglitazone, or AAV-mediated gene therapy aimed at increasing expression of neurturin, did not prove efficacious.  Treatment with nicotine, caffeine, and isradipine - a dihydropyridine calcium channel blocker - as well as active and passive immunization against α-synuclein and inhibitors of α-synuclein-aggregation are currently studied in clin. trials.  However, to date, no disease-modifying treatment is available for PD.  The authors here review the current status of treatment options and investigative strategies for both motor and nonmotor symptoms.  This review stresses the need to intensify therapeutic PD research and points out reasons why the translation of basic research to disease-modifying therapies has been unsuccessful so far.  This article is part of a.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOoeI0DPzjZ7Vg90H21EOLACvtfcHk0lg8sOYNw5J5aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVaku7vI&md5=da131e76891960bf56133449592627c7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fjnc.13750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.13750%26sid%3Dliteratum%253Aachs%26aulast%3DOertel%26aufirst%3DW.%26aulast%3DSchulz%26aufirst%3DJ.%2BB.%26atitle%3DCurrent%2520and%2520Experimental%2520Treatments%2520of%2520Parkinson%2520Disease%253A%2520A%2520Guide%2520for%2520Neuroscientists%26jtitle%3DJ.%2520Neurochem.%26date%3D2016%26volume%3D139%26spage%3D325%26epage%3D337%26doi%3D10.1111%2Fjnc.13750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Cilia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akpalu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarfo, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cham, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amboni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cereda, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akassi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pezzoli, G.</span><span> </span><span class="NLM_article-title">The Modern Pre-Levodopa Era of Parkinson’s Disease: Insights into Motor Complications from Sub-Saharan Africa</span> <span class="citation_source-journal">Brain</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">2731</span><span class="NLM_x">–</span> <span class="NLM_lpage">2742</span><span class="refDoi"> DOI: 10.1093/brain/awu195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1093%2Fbrain%2Fawu195" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2014&pages=2731-2742&author=R.+Ciliaauthor=A.+Akpaluauthor=F.+S.+Sarfoauthor=M.+Chamauthor=M.+Amboniauthor=E.+Ceredaauthor=M.+Fabbriauthor=P.+Adjeiauthor=J.+Akassiauthor=A.+Bonettiauthor=G.+Pezzoli&title=The+Modern+Pre-Levodopa+Era+of+Parkinson%E2%80%99s+Disease%3A+Insights+into+Motor+Complications+from+Sub-Saharan+Africa&doi=10.1093%2Fbrain%2Fawu195"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawu195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawu195%26sid%3Dliteratum%253Aachs%26aulast%3DCilia%26aufirst%3DR.%26aulast%3DAkpalu%26aufirst%3DA.%26aulast%3DSarfo%26aufirst%3DF.%2BS.%26aulast%3DCham%26aufirst%3DM.%26aulast%3DAmboni%26aufirst%3DM.%26aulast%3DCereda%26aufirst%3DE.%26aulast%3DFabbri%26aufirst%3DM.%26aulast%3DAdjei%26aufirst%3DP.%26aulast%3DAkassi%26aufirst%3DJ.%26aulast%3DBonetti%26aufirst%3DA.%26aulast%3DPezzoli%26aufirst%3DG.%26atitle%3DThe%2520Modern%2520Pre-Levodopa%2520Era%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%253A%2520Insights%2520into%2520Motor%2520Complications%2520from%2520Sub-Saharan%2520Africa%26jtitle%3DBrain%26date%3D2014%26volume%3D137%26spage%3D2731%26epage%3D2742%26doi%3D10.1093%2Fbrain%2Fawu195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Fahn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oakes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoulson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieburtz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olanow, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanner, C.</span><span> </span><span class="NLM_article-title">Levodopa and the Progression of Parkinson’s Disease</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">351</span><span class="NLM_x">, </span> <span class="NLM_fpage">2498</span><span class="NLM_x">–</span> <span class="NLM_lpage">2508</span><span class="refDoi"> DOI: 10.1056/NEJMoa033447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1056%2FNEJMoa033447" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=15590952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVGksbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2004&pages=2498-2508&author=S.+Fahnauthor=D.+Oakesauthor=I.+Shoulsonauthor=K.+Kieburtzauthor=A.+Rudolphauthor=A.+Langauthor=C.+W.+Olanowauthor=C.+Tanner&title=Levodopa+and+the+Progression+of+Parkinson%E2%80%99s+Disease&doi=10.1056%2FNEJMoa033447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Levodopa and the progression of Parkinson's disease</span></div><div class="casAuthors">Fahn, S.; Oakes, D.; Shoulson, I.; Kieburtz, K.; Rudolph, A.; Marek, K.; Seibyl, J.; Lang, A.; Olanow, C. W.; Tanner, C.; Schifitto, G.; Zhao, H.; Reyes, L.; Shinaman, A.; Comella, C.; Goetz, C.; Blasucci, L.; Samanta, J.; Stacy, M.; Williamson, K.; Harringan, M.; Greene, P.; Ford, B.; Moskowitz, C.; Truong, D.; Pathak, M.; Jankovic, J.; Ondo, W.; Atassi, F.; Hunter, C.; Jacques, C.; Friedman, J. H.; Lannon, M.; Russell, D. S.; Jennings, D.; Fussell, B.; Standaert, D.; Schwarzschild, M. A.; Growdon, J.; Tennis, M.; Gauthier, S.; Panisset, M.; Hall, J.; Gancher, S.; Hammerstad, J.; Stone, C.; Alexander-Brown, B.; Factor, S.; Molho, E.; Brown, D.; Evans, S.; Clark, J.; Manyam, B.; Simpson, P.; Wulbrecht, B.; Whetteckey, J.; Martin, W.; Roberts, T.; King, P.; Hauser, R.; Zesiewicz, T.; Gauger, L.; Trugman, J.; Wooten, G. F.; Rost-Ruffner, E.; Perlmutter, J.; Racette, B.; Suchowersky, O.; Ranawaya, R.; Wood, S.; Pantella, C.; Kurlan, R.; Richard, I.; Pearson, N.; Caviness, J.; Adler, C.; Lind, M.; Simuni, T.; Siderowf, A.; Colcher, A.; Lloyd, M.; Weiner, W.; Shulman, L.; Koller, W.; Lyons, K.; Feldman, R.; St.-Halaire, M.-H.; Ellias, S.; Thomas, C.-A.; Juncos, J.; Watts, R.; Partlow, A.; Tetrud, J.; Togasaki, D. M.; Welsh, M.; Stewart, T.; Mark, M. H.; Sage, J. I.; Caputo, D.; Gould, H.; Rao, J.; McKendrick, A.; Brin, M.; Danisi, F.; Benabou, R.; Hubble, J.; Paulson, G.; Reider, C.; Birnbaum, A.; Miyasaki, J.; Johnston, L.; So, J.; Pahwa, R.; Dubinsky, R.; Wszolek, Z.; Uitti, R.; Turk, M.; Tuite, P.; Rottenberg, D.; Hansen, J.; Serrano Ramos, C.; Waters, C.; Lews, M.; Welsh, M.; Kawai, C.; O'Brien, C.; Kumar, R.; Seeberger, L.; Judd, D.; Mendis, T.; Barclay, C. L.; Grimes, D. A.; Sutherland, L.; Dawson, T.; Reich, S.; Dunlop, R.; Albin, R.; Frey, K.; Wernette, K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2498-2508</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Despite the known benefit of levodopa in reducing the symptoms of Parkinson's disease, concern has been expressed that its use might hasten neurodegeneration.  This study assessed the effect of levodopa on the rate of progression of Parkinson's disease.  In this randomized, double-blind, placebo-controlled trial, we evaluated 361 patients with early Parkinson's disease who were assigned to receive carbidopa-levodopa at a daily dose of 37.5 and 150 mg, 75 and 300 mg, or 150 and 600 mg, resp., or a matching placebo for a period of 40 wk, and then to undergo withdrawal of treatment for 2 wk.  The primary outcome was a change in scores on the Unified Parkinson's Disease Rating Scale (UPDRS) between baseline and 42 wk.  Neuroimaging studies of 142 subjects were performed at baseline and at week 40 to assess striatal dopamine-transporter d. with the use of iodine-123-labeled 2-β3-carboxymethoxy-3-β-(4-iodophenyl)tropane ([123I]β-CIT) uptake.  The severity of parkinsonism increased more in the placebo group than in all the groups receiving levodopa: the mean difference between the total score on the UPDRS at baseline and at 42 wk was 7.8 units in the placebo group, 1.9 units in the group receiving levodopa at a dose of 150 mg daily, 1.9 in those receiving 300 mg daily, and -1.4 in those receiving 600 mg daily (P<0.001).  In contrast, in a substudy of 116 patients the mean percent decline in the [123I]β-CIT uptake was significantly greater with levodopa than placebo (-6 percent among those receiving levodopa at 150 mg daily, -4 percent in those receiving it at 300 mg daily, and-7.2 percent among those receiving it at 600 mg daily, as compared with -1.4 percent among those receiving placebo; 19 patients with no dopaminergic deficits on the baseline scans were excluded from the anal.) (P=0.036).  The subjects receiving the highest dose of levodopa had significantly more dyskinesia, hypertonia, infection, headache, and nausea than those receiving placebo.  The clin. data suggest that levodopa either slows the progression of Parkinson's disease or has a prolonged effect on the symptoms of the disease.  In contrast, the neuroimaging data suggest either that levodopa accelerates the loss of nigrostriatal dopamine nerve terminals or that its pharmacol. effects modify the dopamine transporter.  The potential long-term effects of levodopa on Parkinson's disease remain uncertain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3aL483WQB3bVg90H21EOLACvtfcHk0lioV0sNQIHPCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVGksbnE&md5=812566c1dec6affaf62025942c23b516</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa033447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa033447%26sid%3Dliteratum%253Aachs%26aulast%3DFahn%26aufirst%3DS.%26aulast%3DOakes%26aufirst%3DD.%26aulast%3DShoulson%26aufirst%3DI.%26aulast%3DKieburtz%26aufirst%3DK.%26aulast%3DRudolph%26aufirst%3DA.%26aulast%3DLang%26aufirst%3DA.%26aulast%3DOlanow%26aufirst%3DC.%2BW.%26aulast%3DTanner%26aufirst%3DC.%26atitle%3DLevodopa%2520and%2520the%2520Progression%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D351%26spage%3D2498%26epage%3D2508%26doi%3D10.1056%2FNEJMoa033447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Jenner, P.</span><span> </span><span class="NLM_article-title">Molecular Mechanisms of L-DOPA-Induced Dyskinesia</span> <span class="citation_source-journal">Nat. Rev. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">665</span><span class="NLM_x">–</span> <span class="NLM_lpage">677</span><span class="refDoi"> DOI: 10.1038/nrn2471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1038%2Fnrn2471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=18714325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVSjurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=665-677&author=P.+Jenner&title=Molecular+Mechanisms+of+L-DOPA-Induced+Dyskinesia&doi=10.1038%2Fnrn2471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of L-DOPA-induced dyskinesia</span></div><div class="casAuthors">Jenner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">665-677</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Dyskinesia is a treatment-limiting side effect of dopaminergic replacement therapies in Parkinson's disease.  Here Jenner discusses what we know about the mol. causes of dyskinesia induction and expression, highlighting recent findings that suggest that altered glutamatergic transmission might be important.  L-DOPA (L-3,4-dihydroxyphenylalanine) remains the most effective drug for the treatment of Parkinson's disease.  However, chronic use causes dyskinesia, a complex motor phenomenon that consists of two components: the execution of involuntary movements in response to drug administration, and the 'priming' phenomenon that underlies these movements' establishment and persistence.  A reinterpretation of recent data suggests that priming for dyskinesia results from nigral denervation and the loss of striatal dopamine input, which alters glutamatergic synaptic connectivity in the striatum.  The subsequent response of the abnormal basal ganglia to dopaminergic drugs dets. the manner and timing of dyskinesia expression.  The combination of nigral denervation and drug treatment establishes inappropriate signaling between the motor cortex and the striatum, leading to persistent dyskinesia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-pdXwQI94e7Vg90H21EOLACvtfcHk0lioV0sNQIHPCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVSjurvP&md5=5dac15ce126371908eef79c093420b67</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrn2471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn2471%26sid%3Dliteratum%253Aachs%26aulast%3DJenner%26aufirst%3DP.%26atitle%3DMolecular%2520Mechanisms%2520of%2520L-DOPA-Induced%2520Dyskinesia%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2008%26volume%3D9%26spage%3D665%26epage%3D677%26doi%3D10.1038%2Fnrn2471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Bezard, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brotchie, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, C. E.</span><span> </span><span class="NLM_article-title">Pathophysiology of Levodopa-Induced Dyskinesia: Potential for New Therapies</span> <span class="citation_source-journal">Nat. Rev. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">588</span><span class="refDoi"> DOI: 10.1038/35086062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1038%2F35086062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=11484001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmtVaqtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=577-588&author=E.+Bezardauthor=J.+M.+Brotchieauthor=C.+E.+Gross&title=Pathophysiology+of+Levodopa-Induced+Dyskinesia%3A+Potential+for+New+Therapies&doi=10.1038%2F35086062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Pathophysiology of levodopa-induced dyskinesia: potential for new therapies</span></div><div class="casAuthors">Bezard, Erwan; Brotchie, Jonathan M.; Gross, Christian E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">577-588</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  Involuntary movements - or dyskinesias - are a debilitating complication of levodopa therapy for Parkinson's disease, and is experienced in most patients.  Despite the importance of this problem, little was known about the cause of dyskinesia until recently; however, this situation has changed significantly in the past few years.  Our increased understanding of levodopa-induced dyskinesia is not only valuable for improving patient care, but also in providing us with new insights into the functional organization of the basal ganglia and motor systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWYg9R_A809LVg90H21EOLACvtfcHk0lioV0sNQIHPCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmtVaqtbY%253D&md5=bafffabb855b5a952871105b38a84e91</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2F35086062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35086062%26sid%3Dliteratum%253Aachs%26aulast%3DBezard%26aufirst%3DE.%26aulast%3DBrotchie%26aufirst%3DJ.%2BM.%26aulast%3DGross%26aufirst%3DC.%2BE.%26atitle%3DPathophysiology%2520of%2520Levodopa-Induced%2520Dyskinesia%253A%2520Potential%2520for%2520New%2520Therapies%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2001%26volume%3D2%26spage%3D577%26epage%3D588%26doi%3D10.1038%2F35086062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Reiter, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shukla, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefkowitz, R. J.</span><span> </span><span class="NLM_article-title">Molecular Mechanism of Beta-Arrestin-Biased Agonism at Seven-Transmembrane Receptors</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span><span class="refDoi"> DOI: 10.1146/annurev.pharmtox.010909.105800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1146%2Fannurev.pharmtox.010909.105800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=21942629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsV2nt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=179-197&author=E.+Reiterauthor=S.+Ahnauthor=A.+K.+Shuklaauthor=R.+J.+Lefkowitz&title=Molecular+Mechanism+of+Beta-Arrestin-Biased+Agonism+at+Seven-Transmembrane+Receptors&doi=10.1146%2Fannurev.pharmtox.010909.105800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors</span></div><div class="casAuthors">Reiter, Eric; Ahn, Seungkirl; Shukla, Arun K.; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">179-197</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The concept of biased agonism has recently come to the fore with the realization that seven-transmembrane receptors (7TMRs, also known as G protein-coupled receptors, or GPCRs) activate complex signaling networks and can adopt multiple active conformations upon agonist binding.  As a consequence, the "efficacy" of receptors, which was classically considered linear, is now recognized as pluridimensional.  Biased agonists selectively stabilize only a subset of receptor conformations induced by the natural "unbiased" ligand, thus preferentially activating certain signaling mechanisms.  Such agonists thus reveal the intriguing possibility that one can direct cellular signaling with unprecedented precision and specificity and support the notion that biased agonists may identify new classes of therapeutic agents that have fewer side effects.  This review focuses on one particular class of biased ligands that has the ability to alter the balance between G protein-dependent and β-arrestin-dependent signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB-dMKnViGurVg90H21EOLACvtfcHk0lhfi3xg3HPsWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsV2nt74%253D&md5=05065a33108ddeebc36923b3cc821037</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.010909.105800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.010909.105800%26sid%3Dliteratum%253Aachs%26aulast%3DReiter%26aufirst%3DE.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DShukla%26aufirst%3DA.%2BK.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DMolecular%2520Mechanism%2520of%2520Beta-Arrestin-Biased%2520Agonism%2520at%2520Seven-Transmembrane%2520Receptors%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2012%26volume%3D52%26spage%3D179%26epage%3D197%26doi%3D10.1146%2Fannurev.pharmtox.010909.105800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Peterson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pack, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkins, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urs, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bass, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lichtarge, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span> </span><span class="NLM_article-title">Elucidation of G-Protein and B-Arrestin Functional Selectivity at the Dopamine D2 Receptor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">7097</span><span class="NLM_x">–</span> <span class="NLM_lpage">7102</span><span class="refDoi"> DOI: 10.1073/pnas.1502742112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1073%2Fpnas.1502742112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=7097-7102&author=S.+M.+Petersonauthor=T.+F.+Packauthor=A.+D.+Wilkinsauthor=N.+M.+Ursauthor=D.+J.+Urbanauthor=C.+E.+Bassauthor=O.+Lichtargeauthor=M.+G.+Caron&title=Elucidation+of+G-Protein+and+B-Arrestin+Functional+Selectivity+at+the+Dopamine+D2+Receptor&doi=10.1073%2Fpnas.1502742112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1502742112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1502742112%26sid%3Dliteratum%253Aachs%26aulast%3DPeterson%26aufirst%3DS.%2BM.%26aulast%3DPack%26aufirst%3DT.%2BF.%26aulast%3DWilkins%26aufirst%3DA.%2BD.%26aulast%3DUrs%26aufirst%3DN.%2BM.%26aulast%3DUrban%26aufirst%3DD.%2BJ.%26aulast%3DBass%26aufirst%3DC.%2BE.%26aulast%3DLichtarge%26aufirst%3DO.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26atitle%3DElucidation%2520of%2520G-Protein%2520and%2520B-Arrestin%2520Functional%2520Selectivity%2520at%2520the%2520Dopamine%2520D2%2520Receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D7097%26epage%3D7102%26doi%3D10.1073%2Fpnas.1502742112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Urban, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Zastrow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spedding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailman, R. B.</span><span> </span><span class="NLM_article-title">Functional Selectivity and Classical Concepts of Quantitative Pharmacology</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">320</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span><span class="refDoi"> DOI: 10.1124/jpet.106.104463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1124%2Fjpet.106.104463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=16803859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsFersw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=2007&pages=1-13&author=J.+D.+Urbanauthor=W.+P.+Clarkeauthor=M.+von+Zastrowauthor=D.+E.+Nicholsauthor=B.+Kobilkaauthor=H.+Weinsteinauthor=J.+A.+Javitchauthor=B.+L.+Rothauthor=A.+Christopoulosauthor=P.+M.+Sextonauthor=K.+J.+Millerauthor=M.+Speddingauthor=R.+B.+Mailman&title=Functional+Selectivity+and+Classical+Concepts+of+Quantitative+Pharmacology&doi=10.1124%2Fjpet.106.104463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Functional selectivity and classical concepts of quantitative pharmacology</span></div><div class="casAuthors">Urban, Jonathan D.; Clarke, William P.; von Zastrow, Mark; Nichols, David E.; Kobilka, Brian; Weinstein, Harel; Javitch, Jonathan A.; Roth, Bryan L.; Christopoulos, Arthur; Sexton, Patrick M.; Miller, Keith J.; Spedding, Michael; Mailman, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">320</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The concept of intrinsic efficacy has been enshrined in pharmacol. for half of a century, yet recent data have revealed that many ligands can differentially activate signaling pathways mediated via a single G protein-coupled receptor in a manner that challenges the traditional definition of intrinsic efficacy.  Some terms for this phenomenon include functional selectivity, agonist-directed trafficking, and biased agonism.  At the extreme, functionally selective ligands may be both agonists and antagonists at different functions mediated by the same receptor.  Data illustrating this phenomenon are presented from serotonin, opioid, dopamine, vasopressin, and adrenergic receptor systems.  A variety of mechanisms may influence this apparently ubiquitous phenomenon.  It may be initiated by differences in ligand-induced intermediate conformational states, as shown for the β2-adrenergic receptor.  Subsequent mechanisms that may play a role include diversity of G proteins, scaffolding and signaling partners, and receptor oligomers.  Clearly, expanded research is needed to elucidate the proximal (e.g., how functionally selective ligands cause conformational changes that initiate differential signaling), intermediate (mechanisms that translate conformation changes into differential signaling), and distal mechanisms (differential effects on target tissue or organism).  Besides the heuristically interesting nature of functional selectivity, there is a clear impact on drug discovery, because this mechanism raises the possibility of selecting or designing novel ligands that differentially activate only a subset of functions of a single receptor, thereby optimizing therapeutic action.  It also may be timely to revise classic concepts in quant. pharmacol. and relevant pharmacol. conventions to incorporate these new concepts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5GzdtvWZRkbVg90H21EOLACvtfcHk0lhfi3xg3HPsWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsFersw%253D%253D&md5=54465473b5996d0755baeee89eeb0ba9</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.104463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.104463%26sid%3Dliteratum%253Aachs%26aulast%3DUrban%26aufirst%3DJ.%2BD.%26aulast%3DClarke%26aufirst%3DW.%2BP.%26aulast%3Dvon%2BZastrow%26aufirst%3DM.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DKobilka%26aufirst%3DB.%26aulast%3DWeinstein%26aufirst%3DH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DMiller%26aufirst%3DK.%2BJ.%26aulast%3DSpedding%26aufirst%3DM.%26aulast%3DMailman%26aufirst%3DR.%2BB.%26atitle%3DFunctional%2520Selectivity%2520and%2520Classical%2520Concepts%2520of%2520Quantitative%2520Pharmacology%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D320%26spage%3D1%26epage%3D13%26doi%3D10.1124%2Fjpet.106.104463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Neve, K. A.</span><span> </span><span class="NLM_article-title">Functional Selectivity of G Protein-Coupled Receptor Ligands—New Opportunities for Drug Discovery</span>. In  <span class="citation_source-book">The Receptors</span>, <span class="NLM_edition">1st</span> ed.; <span class="NLM_contrib-group">Neve, K. A.</span>, Ed.; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">Totowa, NJ</span>;<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=25-40&author=K.+A.+Neveauthor=K.+A.+Neve&title=The+Receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DNeve%26aufirst%3DK.%2BA.%26atitle%3DFunctional%2520Selectivity%2520of%2520G%2520Protein-Coupled%2520Receptor%2520Ligands%25E2%2580%2594New%2520Opportunities%2520for%2520Drug%2520Discovery%26btitle%3DThe%2520Receptors%26aulast%3DNeve%26aufirst%3DK.%2BA.%26pub%3DHumana%2520Press%26date%3D2009%26spage%3D25%26epage%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Urs, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bido, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daigle, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bass, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainetdinov, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bezard, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span> </span><span class="NLM_article-title">Targeting B-Arrestin2 in the Treatment of L-DOPA–Induced Dyskinesia in Parkinson’s Disease</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">E2517</span><span class="NLM_x">–</span> <span class="NLM_lpage">E2526</span><span class="refDoi"> DOI: 10.1073/pnas.1502740112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1073%2Fpnas.1502740112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=E2517-E2526&author=N.+M.+Ursauthor=S.+Bidoauthor=S.+M.+Petersonauthor=T.+L.+Daigleauthor=C.+E.+Bassauthor=R.+R.+Gainetdinovauthor=E.+Bezardauthor=M.+G.+Caron&title=Targeting+B-Arrestin2+in+the+Treatment+of+L-DOPA%E2%80%93Induced+Dyskinesia+in+Parkinson%E2%80%99s+Disease&doi=10.1073%2Fpnas.1502740112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1502740112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1502740112%26sid%3Dliteratum%253Aachs%26aulast%3DUrs%26aufirst%3DN.%2BM.%26aulast%3DBido%26aufirst%3DS.%26aulast%3DPeterson%26aufirst%3DS.%2BM.%26aulast%3DDaigle%26aufirst%3DT.%2BL.%26aulast%3DBass%26aufirst%3DC.%2BE.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26aulast%3DBezard%26aufirst%3DE.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26atitle%3DTargeting%2520B-Arrestin2%2520in%2520the%2520Treatment%2520of%2520L-DOPA%25E2%2580%2593Induced%2520Dyskinesia%2520in%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3DE2517%26epage%3DE2526%26doi%3D10.1073%2Fpnas.1502740112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Ahmed, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berthet, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bychkov, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porras, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bioulac, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carl, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloch, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kook, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubert, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dovero, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doudnikoff, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurevich, V. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurevich, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bezard, E.</span><span> </span><span class="NLM_article-title">Lentiviral Overexpression of GRK6 Alleviates L-DOPA–Induced Dyskinesia in Experimental Parkinson’s Disease</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">28ra28</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3000664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1126%2Fscitranslmed.3000664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=20410529" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=28ra28&author=M.+R.+Ahmedauthor=A.+Berthetauthor=E.+Bychkovauthor=G.+Porrasauthor=Q.+Liauthor=B.+H.+Bioulacauthor=Y.+T.+Carlauthor=B.+Blochauthor=S.+Kookauthor=I.+Aubertauthor=S.+Doveroauthor=E.+Doudnikoffauthor=V.+V.+Gurevichauthor=E.+V.+Gurevichauthor=E.+Bezard&title=Lentiviral+Overexpression+of+GRK6+Alleviates+L-DOPA%E2%80%93Induced+Dyskinesia+in+Experimental+Parkinson%E2%80%99s+Disease&doi=10.1126%2Fscitranslmed.3000664"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3000664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3000664%26sid%3Dliteratum%253Aachs%26aulast%3DAhmed%26aufirst%3DM.%2BR.%26aulast%3DBerthet%26aufirst%3DA.%26aulast%3DBychkov%26aufirst%3DE.%26aulast%3DPorras%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DBioulac%26aufirst%3DB.%2BH.%26aulast%3DCarl%26aufirst%3DY.%2BT.%26aulast%3DBloch%26aufirst%3DB.%26aulast%3DKook%26aufirst%3DS.%26aulast%3DAubert%26aufirst%3DI.%26aulast%3DDovero%26aufirst%3DS.%26aulast%3DDoudnikoff%26aufirst%3DE.%26aulast%3DGurevich%26aufirst%3DV.%2BV.%26aulast%3DGurevich%26aufirst%3DE.%2BV.%26aulast%3DBezard%26aufirst%3DE.%26atitle%3DLentiviral%2520Overexpression%2520of%2520GRK6%2520Alleviates%2520L-DOPA%25E2%2580%2593Induced%2520Dyskinesia%2520in%2520Experimental%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2010%26volume%3D2%26spage%3D28ra28%26doi%3D10.1126%2Fscitranslmed.3000664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Allen, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yost, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sassano, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yadav, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span> </span><span class="NLM_article-title">Discovery of Beta-Arrestin-Biased Dopamine D2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">18488</span><span class="NLM_x">–</span> <span class="NLM_lpage">18493</span><span class="refDoi"> DOI: 10.1073/pnas.1104807108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1073%2Fpnas.1104807108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=22025698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFymtLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=18488-18493&author=J.+A.+Allenauthor=J.+M.+Yostauthor=V.+Setolaauthor=X.+Chenauthor=M.+F.+Sassanoauthor=M.+Chenauthor=S.+Petersonauthor=P.+N.+Yadavauthor=X.+P.+Huangauthor=B.+Fengauthor=N.+H.+Jensenauthor=X.+Cheauthor=X.+Baiauthor=S.+V.+Fryeauthor=W.+C.+Wetselauthor=M.+G.+Caronauthor=J.+A.+Javitchauthor=B.+L.+Rothauthor=J.+Jin&title=Discovery+of+Beta-Arrestin-Biased+Dopamine+D2+Ligands+for+Probing+Signal+Transduction+Pathways+Essential+for+Antipsychotic+Efficacy&doi=10.1073%2Fpnas.1104807108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy</span></div><div class="casAuthors">Allen, John A.; Yost, Julianne M.; Setola, Vincent; Chen, Xin; Sassano, Maria F.; Chen, Meng; Peterson, Sean; Yadav, Prem N.; Huang, Xi-Ping; Feng, Bo; Jensen, Niels H.; Che, Xin; Bai, Xu; Frye, Stephen V.; Wetsel, William C.; Caron, Marc G.; Javitch, Jonathan A.; Roth, Bryan L.; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">18488-18493, S18488/1-S18488/15</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Elucidating the key signal transduction pathways essential for both antipsychotic efficacy and side-effect profiles is essential for developing safer and more effective therapies.  Recent work has highlighted noncanonical modes of dopamine D2 receptor (D2R) signaling via β-arrestins as being important for the therapeutic actions of both antipsychotic and antimanic agents.  We thus sought to create unique D2R agonists that display signaling bias via β-arrestinergic signaling.  Through a robust diversity-oriented modification of the scaffold represented by aripiprazole (1), we discovered UNC9975 (2), UNC0006 (3); and UNC9994 (4) as unprecedented β-arrestin-biased D2R ligands.  These compds. also represent unprecedented β-arrestin-biased ligands for a Gi-coupled G protein-coupled receptor (GPCR).  Significantly, UNC9975, UNC0006, and UNC9994 are simultaneously antagonists of Gi-regulated cAMP prodn. and partial agonists for D2R/β-arrestin-2 interactions.  Importantly, VNC9975 displayed potent antipsychotic-like activity without inducing motoric side effects in inbred C57BL/6 mice in vivo.  Genetic deletion of β-arrestin-2 simultaneously attenuated the antipsychotic actions of UNC9975 and transformed it into a typical antipsychotic .drug with a high propensity to induce catalepsy.  Similarly, the antipsychotic-like activity displayed by UNC9994, an extremely β-arrestin-biased D2R agonist, in wild-type mice was completely abolished in β-arrestin-2 knockout mice.  Taken together, our results suggest that β-arrestin signaling and recruitment can be simultaneously a significant contributor to antipsychotic efficacy and protective against motoric side effects.  These functionally selective, β-arrestin-biased D2R ligands represent valuable chem. probes for further investigations of D2R signaling in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr87mjP6jm447Vg90H21EOLACvtfcHk0lgVte24tb2y8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFymtLzK&md5=d5b06e4ac4d2cc4cd04fd1de760ec628</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1104807108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1104807108%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26aulast%3DYost%26aufirst%3DJ.%2BM.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DPeterson%26aufirst%3DS.%26aulast%3DYadav%26aufirst%3DP.%2BN.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DChe%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DX.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520Beta-Arrestin-Biased%2520Dopamine%2520D2%2520Ligands%2520for%2520Probing%2520Signal%2520Transduction%2520Pathways%2520Essential%2520for%2520Antipsychotic%2520Efficacy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D18488%26epage%3D18493%26doi%3D10.1073%2Fpnas.1104807108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Weichert, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruse, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manglik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Covalent Agonists for Studying G Protein-Coupled Receptor Activation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">10744</span><span class="NLM_x">–</span> <span class="NLM_lpage">10748</span><span class="refDoi"> DOI: 10.1073/pnas.1410415111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1073%2Fpnas.1410415111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=25006259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyqtbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=10744-10748&author=D.+Weichertauthor=A.+C.+Kruseauthor=A.+Manglikauthor=C.+Hillerauthor=C.+Zhangauthor=H.+H%C3%BCbnerauthor=B.+K.+Kobilkaauthor=P.+Gmeiner&title=Covalent+Agonists+for+Studying+G+Protein-Coupled+Receptor+Activation&doi=10.1073%2Fpnas.1410415111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent agonists for studying G protein-coupled receptor activation</span></div><div class="casAuthors">Weichert, Dietmar; Kruse, Andrew C.; Manglik, Aashish; Hiller, Christine; Zhang, Cheng; Huebner, Harald; Kobilka, Brian K.; Gmeiner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">10744-10748</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Structural studies on G protein-coupled receptors (GPCRs) provide important insights into the architecture and function of these important drug targets.  However, the crystn. of GPCRs in active states is particularly challenging, requiring the formation of stable and conformationally homogeneous ligand-receptor complexes.  Native hormones, neurotransmitters, and synthetic agonists that bind with low affinity are ineffective at stabilizing an active state for crystallogenesis.  To promote structural studies on the pharmacol. highly relevant class of aminergic GPCRs, the authors here present the development of covalently binding mol. tools activating Gs-, Gi-, and Gq-coupled receptors.  The covalent agonists are derived from the monoamine neurotransmitters noradrenaline, dopamine, serotonin, and histamine, and they were accessed using a general and versatile synthetic strategy.  The authors demonstrate that the tool compds. presented herein display an efficient covalent binding mode and that the resp. covalent ligand-receptor complexes activate G proteins comparable to the natural neurotransmitters.  A crystal structure of the β2-adrenoreceptor in complex with a covalent noradrenaline analog and a conformationally selective antibody (nanobody) verified that these agonists can be used to facilitate crystallogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqbJHK2UMj1rVg90H21EOLACvtfcHk0lgVte24tb2y8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyqtbnN&md5=a131bb7711d9a1826c77c3b598dee470</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1410415111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1410415111%26sid%3Dliteratum%253Aachs%26aulast%3DWeichert%26aufirst%3DD.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DHiller%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DCovalent%2520Agonists%2520for%2520Studying%2520G%2520Protein-Coupled%2520Receptor%2520Activation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D10744%26epage%3D10748%26doi%3D10.1073%2Fpnas.1410415111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Ring, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manglik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruse, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enos, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span> </span><span class="NLM_article-title">Adrenaline-Activated Structure of Beta2-Adrenoceptor Stabilized by an Engineered Nanobody</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">502</span><span class="NLM_x">, </span> <span class="NLM_fpage">575</span><span class="NLM_x">–</span> <span class="NLM_lpage">579</span><span class="refDoi"> DOI: 10.1038/nature12572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1038%2Fnature12572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=24056936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFSlsLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=502&publication_year=2013&pages=575-579&author=A.+M.+Ringauthor=A.+Manglikauthor=A.+C.+Kruseauthor=M.+D.+Enosauthor=W.+I.+Weisauthor=K.+C.+Garciaauthor=B.+K.+Kobilka&title=Adrenaline-Activated+Structure+of+Beta2-Adrenoceptor+Stabilized+by+an+Engineered+Nanobody&doi=10.1038%2Fnature12572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Adrenaline-activated structure of β2-adrenoceptor stabilized by an engineered nanobody</span></div><div class="casAuthors">Ring, Aaron M.; Manglik, Aashish; Kruse, Andrew C.; Enos, Michael D.; Weis, William I.; Garcia, K. Christopher; Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">502</span>
        (<span class="NLM_cas:issue">7472</span>),
    <span class="NLM_cas:pages">575-579</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) are integral membrane proteins that play an essential role in human physiol., yet the mol. processes through which they bind to their endogenous agonists and activate effector proteins remain poorly understood.  So far, it has not been possible to capture an active-state GPCR bound to its native neurotransmitter.  Crystal structures of agonist-bound GPCRs have relied on the use of either exceptionally high-affinity agonists or receptor stabilization by mutagenesis.  Many natural agonists such as adrenaline, which activates the β2-adrenoceptor (β2AR), bind with relatively low affinity, and they are often chem. unstable.  Here, using directed evolution, the authors engineered a high-affinity conformationally selective single-domain camelid antibody fragment (nanobody; Nb6B9) that stabilized the active state of human β2AR, and used this to obtain crystal structures of the activated receptor bound to multiple ligands.  The authors present structures of the active-state human β2AR bound to 3 chem. distinct agonists: (1) the ultrahigh-affinity agonist BI167107; (2) the high-affinity catecholamine agonist, hydroxybenzylisoproterenol; and (3) the low-affinity endogenous agonist, adrenaline.  The crystal structures revealed a highly conserved overall ligand recognition and activation mode despite diverse ligand chem. structures and affinities that ranged from 100 nM to ∼80 pM.  Overall, the adrenaline-bound receptor structure was similar to the others, but it had substantial rearrangements in extracellular loop 3 and the extracellular tip of transmembrane helix 6.  These structures also revealed a water-mediated H-bond between 2 conserved Tyr residues, which appeared to stabilize the active state of the β2AR and related GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAp0VskflwWbVg90H21EOLACvtfcHk0lidwzQTUxknNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFSlsLzP&md5=c5b844a0a86ee0a74843588a4a363592</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnature12572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12572%26sid%3Dliteratum%253Aachs%26aulast%3DRing%26aufirst%3DA.%2BM.%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26aulast%3DEnos%26aufirst%3DM.%2BD.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DGarcia%26aufirst%3DK.%2BC.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DAdrenaline-Activated%2520Structure%2520of%2520Beta2-Adrenoceptor%2520Stabilized%2520by%2520an%2520Engineered%2520Nanobody%26jtitle%3DNature%26date%3D2013%26volume%3D502%26spage%3D575%26epage%3D579%26doi%3D10.1038%2Fnature12572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Rasmussen, S. G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fung, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casarosa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chae, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVree, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbaum, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thian, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konetzki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunahara, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gellman, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pautsch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyaert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span> </span><span class="NLM_article-title">Structure of a Nanobody-Stabilized Active State of the B2 Adrenoceptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">469</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span><span class="refDoi"> DOI: 10.1038/nature09648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1038%2Fnature09648" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=469&publication_year=2011&pages=175-180&author=S.+G.+F.+Rasmussenauthor=H.-J.+Choiauthor=J.+J.+Fungauthor=E.+Pardonauthor=P.+Casarosaauthor=P.+S.+Chaeauthor=B.+T.+DeVreeauthor=D.+M.+Rosenbaumauthor=F.+S.+Thianauthor=T.+S.+Kobilkaauthor=A.+Schnappauthor=I.+Konetzkiauthor=R.+K.+Sunaharaauthor=S.+H.+Gellmanauthor=A.+Pautschauthor=J.+Steyaertauthor=W.+I.+Weisauthor=B.+K.+Kobilka&title=Structure+of+a+Nanobody-Stabilized+Active+State+of+the+B2+Adrenoceptor&doi=10.1038%2Fnature09648"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnature09648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09648%26sid%3Dliteratum%253Aachs%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%2BF.%26aulast%3DChoi%26aufirst%3DH.-J.%26aulast%3DFung%26aufirst%3DJ.%2BJ.%26aulast%3DPardon%26aufirst%3DE.%26aulast%3DCasarosa%26aufirst%3DP.%26aulast%3DChae%26aufirst%3DP.%2BS.%26aulast%3DDeVree%26aufirst%3DB.%2BT.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DKonetzki%26aufirst%3DI.%26aulast%3DSunahara%26aufirst%3DR.%2BK.%26aulast%3DGellman%26aufirst%3DS.%2BH.%26aulast%3DPautsch%26aufirst%3DA.%26aulast%3DSteyaert%26aufirst%3DJ.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DStructure%2520of%2520a%2520Nanobody-Stabilized%2520Active%2520State%2520of%2520the%2520B2%2520Adrenoceptor%26jtitle%3DNature%26date%3D2011%26volume%3D469%26spage%3D175%26epage%3D180%26doi%3D10.1038%2Fnature09648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Warne, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moukhametzianov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nehme, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leslie, A. G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schertler, G. F. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tate, C. G.</span><span> </span><span class="NLM_article-title">The Structural Basis for Agonist and Partial Agonist Action on a B1-Adrenergic Receptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">469</span><span class="NLM_x">, </span> <span class="NLM_fpage">241</span><span class="NLM_x">–</span> <span class="NLM_lpage">244</span><span class="refDoi"> DOI: 10.1038/nature09746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1038%2Fnature09746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=21228877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvFelsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=469&publication_year=2011&pages=241-244&author=T.+Warneauthor=R.+Moukhametzianovauthor=J.+G.+Bakerauthor=R.+Nehmeauthor=P.+C.+Edwardsauthor=A.+G.+W.+Leslieauthor=G.+F.+X.+Schertlerauthor=C.+G.+Tate&title=The+Structural+Basis+for+Agonist+and+Partial+Agonist+Action+on+a+B1-Adrenergic+Receptor&doi=10.1038%2Fnature09746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis for agonist and partial agonist action on a β1-adrenergic receptor</span></div><div class="casAuthors">Warne, Tony; Moukhametzianov, Rouslan; Baker, Jillian G.; Nehme, Rony; Edwards, Patricia C.; Leslie, Andrew G. W.; Schertler, Gebhard F. X.; Tate, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">469</span>
        (<span class="NLM_cas:issue">7329</span>),
    <span class="NLM_cas:pages">241-244</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">β-Adrenergic receptors (βARs) are G-protein-coupled receptors (GPCRs) that activate intracellular G proteins upon binding catecholamine agonist ligands such as adrenaline and noradrenaline.  Synthetic ligands have been developed that either activate or inhibit βARs for the treatment of asthma, hypertension or cardiac dysfunction.  These ligands are classified as either full agonists, partial agonists or antagonists, depending on whether the cellular response is similar to that of the native ligand, reduced or inhibited, resp.  However, the structural basis for these different ligand efficacies is unknown.  Here we present four crystal structures of the thermostabilized turkey (Meleagris gallopavo) β1-adrenergic receptor (β1AR-m23) bound to the full agonists carmoterol and isoprenaline and the partial agonists salbutamol and dobutamine.  In each case, agonist binding induces a 1 Å contraction of the catecholamine-binding pocket relative to the antagonist bound receptor.  Full agonists can form hydrogen bonds with two conserved serine residues in transmembrane helix 5 (Ser5.42 and Ser5.46), but partial agonists only interact with Ser5.42 (superscripts refer to Ballesteros-Weinstein numbering).  The structures provide an understanding of the pharmacol. differences between different ligand classes, illuminating how GPCRs function and providing a solid foundation for the structure-based design of novel ligands with predictable efficacies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2EWXHDM88tLVg90H21EOLACvtfcHk0lidwzQTUxknNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvFelsw%253D%253D&md5=aa7fa20ff770ea13d97f0cf39311a1ea</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnature09746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09746%26sid%3Dliteratum%253Aachs%26aulast%3DWarne%26aufirst%3DT.%26aulast%3DMoukhametzianov%26aufirst%3DR.%26aulast%3DBaker%26aufirst%3DJ.%2BG.%26aulast%3DNehme%26aufirst%3DR.%26aulast%3DEdwards%26aufirst%3DP.%2BC.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DSchertler%26aufirst%3DG.%2BF.%2BX.%26aulast%3DTate%26aufirst%3DC.%2BG.%26atitle%3DThe%2520Structural%2520Basis%2520for%2520Agonist%2520and%2520Partial%2520Agonist%2520Action%2520on%2520a%2520B1-Adrenergic%2520Receptor%26jtitle%3DNature%26date%3D2011%26volume%3D469%26spage%3D241%26epage%3D244%26doi%3D10.1038%2Fnature09746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Weichert, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Structure-Guided Development of Dual B2 Adrenergic/Dopamine D2 Receptor Agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2641</span><span class="NLM_x">–</span> <span class="NLM_lpage">2653</span><span class="refDoi"> DOI: 10.1016/j.bmc.2016.04.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1016%2Fj.bmc.2016.04.028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=2641-2653&author=D.+Weichertauthor=M.+Stanekauthor=H.+H%C3%BCbnerauthor=P.+Gmeiner&title=Structure-Guided+Development+of+Dual+B2+Adrenergic%2FDopamine+D2+Receptor+Agonists&doi=10.1016%2Fj.bmc.2016.04.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.04.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.04.028%26sid%3Dliteratum%253Aachs%26aulast%3DWeichert%26aufirst%3DD.%26aulast%3DStanek%26aufirst%3DM.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DStructure-Guided%2520Development%2520of%2520Dual%2520B2%2520Adrenergic%252FDopamine%2520D2%2520Receptor%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D2641%26epage%3D2653%26doi%3D10.1016%2Fj.bmc.2016.04.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Beattie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruce, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlton, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuenoud, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairhurst, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fozard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janus, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosethorne, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandham, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sykes, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trifilieff, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissler, E.</span><span> </span><span class="NLM_article-title">An Investigation into the Structure–Activity Relationships Associated with the Systematic Modification of the B2-Adrenoceptor Agonist Indacaterol</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">6280</span><span class="NLM_x">–</span> <span class="NLM_lpage">6285</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.07.096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1016%2Fj.bmcl.2012.07.096" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6280-6285&author=D.+Beattieauthor=D.+Beerauthor=M.+E.+Bradleyauthor=I.+Bruceauthor=S.+J.+Charltonauthor=B.+M.+Cuenoudauthor=R.+A.+Fairhurstauthor=D.+Farrauthor=J.+R.+Fozardauthor=D.+Janusauthor=E.+M.+Rosethorneauthor=D.+A.+Sandhamauthor=D.+A.+Sykesauthor=A.+Trifilieffauthor=K.+L.+Turnerauthor=E.+Wissler&title=An+Investigation+into+the+Structure%E2%80%93Activity+Relationships+Associated+with+the+Systematic+Modification+of+the+B2-Adrenoceptor+Agonist+Indacaterol&doi=10.1016%2Fj.bmcl.2012.07.096"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.07.096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.07.096%26sid%3Dliteratum%253Aachs%26aulast%3DBeattie%26aufirst%3DD.%26aulast%3DBeer%26aufirst%3DD.%26aulast%3DBradley%26aufirst%3DM.%2BE.%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DCuenoud%26aufirst%3DB.%2BM.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DFarr%26aufirst%3DD.%26aulast%3DFozard%26aufirst%3DJ.%2BR.%26aulast%3DJanus%26aufirst%3DD.%26aulast%3DRosethorne%26aufirst%3DE.%2BM.%26aulast%3DSandham%26aufirst%3DD.%2BA.%26aulast%3DSykes%26aufirst%3DD.%2BA.%26aulast%3DTrifilieff%26aufirst%3DA.%26aulast%3DTurner%26aufirst%3DK.%2BL.%26aulast%3DWissler%26aufirst%3DE.%26atitle%3DAn%2520Investigation%2520into%2520the%2520Structure%25E2%2580%2593Activity%2520Relationships%2520Associated%2520with%2520the%2520Systematic%2520Modification%2520of%2520the%2520B2-Adrenoceptor%2520Agonist%2520Indacaterol%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6280%26epage%3D6285%26doi%3D10.1016%2Fj.bmcl.2012.07.096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Yoshizaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanimura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yabuuchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span> </span><span class="NLM_article-title">Sympathomimetic Amines Having a Carbostyril Nucleus</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1138</span><span class="NLM_x">–</span> <span class="NLM_lpage">1142</span><span class="refDoi"> DOI: 10.1021/jm00231a011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00231a011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1976&pages=1138-1142&author=S.+Yoshizakiauthor=K.+Tanimuraauthor=S.+Tamadaauthor=Y.+Yabuuchiauthor=K.+Nakagawa&title=Sympathomimetic+Amines+Having+a+Carbostyril+Nucleus&doi=10.1021%2Fjm00231a011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm00231a011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00231a011%26sid%3Dliteratum%253Aachs%26aulast%3DYoshizaki%26aufirst%3DS.%26aulast%3DTanimura%26aufirst%3DK.%26aulast%3DTamada%26aufirst%3DS.%26aulast%3DYabuuchi%26aufirst%3DY.%26aulast%3DNakagawa%26aufirst%3DK.%26atitle%3DSympathomimetic%2520Amines%2520Having%2520a%2520Carbostyril%2520Nucleus%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1976%26volume%3D19%26spage%3D1138%26epage%3D1142%26doi%3D10.1021%2Fjm00231a011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Yoshizaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manabe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tei, S.</span><span> </span><span class="NLM_article-title">Isomers of Erythro-5-(1-Hydroxy-2-Isopropylaminobutyl)-8-Hydroxycarbostyril, a New Bronchodilator</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1103</span><span class="NLM_x">–</span> <span class="NLM_lpage">1104</span><span class="refDoi"> DOI: 10.1021/jm00218a024</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00218a024" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1977&pages=1103-1104&author=S.+Yoshizakiauthor=Y.+Manabeauthor=S.+Tamadaauthor=K.+Nakagawaauthor=S.+Tei&title=Isomers+of+Erythro-5-%281-Hydroxy-2-Isopropylaminobutyl%29-8-Hydroxycarbostyril%2C+a+New+Bronchodilator&doi=10.1021%2Fjm00218a024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm00218a024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00218a024%26sid%3Dliteratum%253Aachs%26aulast%3DYoshizaki%26aufirst%3DS.%26aulast%3DManabe%26aufirst%3DY.%26aulast%3DTamada%26aufirst%3DS.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DTei%26aufirst%3DS.%26atitle%3DIsomers%2520of%2520Erythro-5-%25281-Hydroxy-2-Isopropylaminobutyl%2529-8-Hydroxycarbostyril%252C%2520a%2520New%2520Bronchodilator%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1977%26volume%3D20%26spage%3D1103%26epage%3D1104%26doi%3D10.1021%2Fjm00218a024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Bouyssou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoenke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolf, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lustenberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pestel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sieger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lotz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heine, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Büttner, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konetzki, I.</span><span> </span><span class="NLM_article-title">Discovery of Olodaterol, a Novel Inhaled B2-Adrenoceptor Agonist with a 24 H Bronchodilatory Efficacy</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1410</span><span class="NLM_x">–</span> <span class="NLM_lpage">1414</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.12.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1016%2Fj.bmcl.2009.12.087" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1410-1414&author=T.+Bouyssouauthor=C.+Hoenkeauthor=K.+Rudolfauthor=P.+Lustenbergerauthor=S.+Pestelauthor=P.+Siegerauthor=R.+Lotzauthor=C.+Heineauthor=F.+H.+B%C3%BCttnerauthor=A.+Schnappauthor=I.+Konetzki&title=Discovery+of+Olodaterol%2C+a+Novel+Inhaled+B2-Adrenoceptor+Agonist+with+a+24+H+Bronchodilatory+Efficacy&doi=10.1016%2Fj.bmcl.2009.12.087"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.12.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.12.087%26sid%3Dliteratum%253Aachs%26aulast%3DBouyssou%26aufirst%3DT.%26aulast%3DHoenke%26aufirst%3DC.%26aulast%3DRudolf%26aufirst%3DK.%26aulast%3DLustenberger%26aufirst%3DP.%26aulast%3DPestel%26aufirst%3DS.%26aulast%3DSieger%26aufirst%3DP.%26aulast%3DLotz%26aufirst%3DR.%26aulast%3DHeine%26aufirst%3DC.%26aulast%3DB%25C3%25BCttner%26aufirst%3DF.%2BH.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DKonetzki%26aufirst%3DI.%26atitle%3DDiscovery%2520of%2520Olodaterol%252C%2520a%2520Novel%2520Inhaled%2520B2-Adrenoceptor%2520Agonist%2520with%2520a%252024%2520H%2520Bronchodilatory%2520Efficacy%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1410%26epage%3D1414%26doi%3D10.1016%2Fj.bmcl.2009.12.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Hoenke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouyssou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tautermann, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolf, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konetzki, I.</span><span> </span><span class="NLM_article-title">Use of 5-Hydroxy-4H-Benzo[1,4]Oxazin-3-Ones as Beta2-Adrenoceptor Agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6640</span><span class="NLM_x">–</span> <span class="NLM_lpage">6644</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1016%2Fj.bmcl.2009.10.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6640-6644&author=C.+Hoenkeauthor=T.+Bouyssouauthor=C.+S.+Tautermannauthor=K.+Rudolfauthor=A.+Schnappauthor=I.+Konetzki&title=Use+of+5-Hydroxy-4H-Benzo%5B1%2C4%5DOxazin-3-Ones+as+Beta2-Adrenoceptor+Agonists&doi=10.1016%2Fj.bmcl.2009.10.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DHoenke%26aufirst%3DC.%26aulast%3DBouyssou%26aufirst%3DT.%26aulast%3DTautermann%26aufirst%3DC.%2BS.%26aulast%3DRudolf%26aufirst%3DK.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DKonetzki%26aufirst%3DI.%26atitle%3DUse%2520of%25205-Hydroxy-4H-Benzo%255B1%252C4%255DOxazin-3-Ones%2520as%2520Beta2-Adrenoceptor%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6640%26epage%3D6644%26doi%3D10.1016%2Fj.bmcl.2009.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Rosenbaum, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aragao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arlow, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devree, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunahara, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chae, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gellman, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dror, R. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caffrey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span> </span><span class="NLM_article-title">Structure and Function of an Irreversible Agonist-Beta(2) Adrenoceptor Complex</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">469</span><span class="NLM_x">, </span> <span class="NLM_fpage">236</span><span class="NLM_x">–</span> <span class="NLM_lpage">240</span><span class="refDoi"> DOI: 10.1038/nature09665</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1038%2Fnature09665" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=21228876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvFehsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=469&publication_year=2011&pages=236-240&author=D.+M.+Rosenbaumauthor=C.+Zhangauthor=J.+A.+Lyonsauthor=R.+Hollauthor=D.+Aragaoauthor=D.+H.+Arlowauthor=S.+G.+Rasmussenauthor=H.+J.+Choiauthor=B.+T.+Devreeauthor=R.+K.+Sunaharaauthor=P.+S.+Chaeauthor=S.+H.+Gellmanauthor=R.+O.+Drorauthor=D.+E.+Shawauthor=W.+I.+Weisauthor=M.+Caffreyauthor=P.+Gmeinerauthor=B.+K.+Kobilka&title=Structure+and+Function+of+an+Irreversible+Agonist-Beta%282%29+Adrenoceptor+Complex&doi=10.1038%2Fnature09665"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and function of an irreversible agonist-β2 adrenoceptor complex</span></div><div class="casAuthors">Rosenbaum, Daniel M.; Zhang, Cheng; Lyons, Joseph A.; Holl, Ralph; Aragao, David; Arlow, Daniel H.; Rasmussen, Soren G. F.; Choi, Hee-Jung; DeVree, Brian T.; Sunahara, Roger K.; Chae, Pil Seok; Gellman, Samuel H.; Dror, Ron O.; Shaw, David E.; Weis, William I.; Caffrey, Martin; Gmeiner, Peter; Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">469</span>
        (<span class="NLM_cas:issue">7329</span>),
    <span class="NLM_cas:pages">236-240</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) are eukaryotic integral membrane proteins that modulate biol. function by initiating cellular signaling in response to chem. diverse agonists.  Despite recent progress in the structural biol. of GPCRs, the mol. basis for agonist binding and allosteric modulation of these proteins is poorly understood.  Structural knowledge of agonist-bound states is essential for deciphering the mechanism of receptor activation, and for structure-guided design and optimization of ligands.  However, the crystn. of agonist-bound GPCRs has been hampered by modest affinities and rapid off-rates of available agonists.  Using the inactive structure of the human β2 adrenergic receptor (β2AR) as a guide, we designed a β2AR agonist that can be covalently tethered to a specific site on the receptor through a disulfide bond.  The covalent β2AR-agonist complex forms efficiently, and is capable of activating a heterotrimeric G protein.  We crystd. a covalent agonist-bound β2AR-T4L fusion protein in lipid bilayers through the use of the lipidic mesophase method, and detd. its structure at 3.5 Å resoln.  A comparison to the inactive structure and an antibody-stabilized active structure (companion paper) shows how binding events at both the extracellular and intracellular surfaces are required to stabilize an active conformation of the receptor.  The structures are in agreement with long-timescale (up to 30 μs) mol. dynamics simulations showing that an agonist-bound active conformation spontaneously relaxes to an inactive-like conformation in the absence of a G protein or stabilizing antibody.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3cxTxwHig_rVg90H21EOLACvtfcHk0lhajl0HcZ1vpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvFehsQ%253D%253D&md5=8629b93e43fb692395e2aa6f8bb011a9</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnature09665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09665%26sid%3Dliteratum%253Aachs%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLyons%26aufirst%3DJ.%2BA.%26aulast%3DHoll%26aufirst%3DR.%26aulast%3DAragao%26aufirst%3DD.%26aulast%3DArlow%26aufirst%3DD.%2BH.%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%26aulast%3DChoi%26aufirst%3DH.%2BJ.%26aulast%3DDevree%26aufirst%3DB.%2BT.%26aulast%3DSunahara%26aufirst%3DR.%2BK.%26aulast%3DChae%26aufirst%3DP.%2BS.%26aulast%3DGellman%26aufirst%3DS.%2BH.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DCaffrey%26aufirst%3DM.%26aulast%3DGmeiner%26aufirst%3DP.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DStructure%2520and%2520Function%2520of%2520an%2520Irreversible%2520Agonist-Beta%25282%2529%2520Adrenoceptor%2520Complex%26jtitle%3DNature%26date%3D2011%26volume%3D469%26spage%3D236%26epage%3D240%26doi%3D10.1038%2Fnature09665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCorvy, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span> </span><span class="NLM_article-title">Discovery of G Protein-Biased D2 Dopamine Receptor Partial Agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">10601</span><span class="NLM_x">–</span> <span class="NLM_lpage">10618</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01208</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01208" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOqs7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10601-10618&author=X.+Chenauthor=J.+D.+McCorvyauthor=M.+G.+Fischerauthor=K.+V.+Butlerauthor=Y.+Shenauthor=B.+L.+Rothauthor=J.+Jin&title=Discovery+of+G+Protein-Biased+D2+Dopamine+Receptor+Partial+Agonists&doi=10.1021%2Facs.jmedchem.6b01208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of G Protein-Biased D2 Dopamine Receptor Partial Agonists</span></div><div class="casAuthors">Chen, Xin; McCorvy, John D.; Fischer, Matthew G.; Butler, Kyle V.; Shen, Yudao; Roth, Bryan L.; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10601-10618</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Biased ligands (also known as functionally selective ligands) of G protein-coupled receptors are valuable tools for dissecting the roles of G protein-dependent and independent signaling pathways in health and disease.  Biased ligands have also been increasingly pursued by the biomedical community as promising therapeutics with improved efficacy and reduced side effects compared with unbiased ligands.  The authors previously discovered first-in-class β-arrestin-biased agonists of dopamine D2 receptor (D2R) by extensively exploring multiple regions of aripiprazole, a balanced D2R agonist.  In the authors' continuing efforts to identify biased agonists of D2R, the authors unexpectedly discovered a G protein-biased agonist of D2R, compd. 1 (5-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-methylbenzo[d]thiazole), which is the first G protein-biased D2R agonist from the aripiprazole scaffold.  The authors designed and synthesized novel analogs to explore two regions of 1 and conducted structure-functional selectivity relationship (SFSR) studies.  Here the authors report the discovery of 1, findings from the authors' SFSR studies, and characterization of novel G protein-biased D2R agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeKlhGCqSPxLVg90H21EOLACvtfcHk0lhajl0HcZ1vpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOqs7vK&md5=81b1435b1ae82438aa3f270f7ee4f853</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01208%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DFischer%26aufirst%3DM.%2BG.%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520G%2520Protein-Biased%2520D2%2520Dopamine%2520Receptor%2520Partial%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10601%26epage%3D10618%26doi%3D10.1021%2Facs.jmedchem.6b01208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sassano, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span> </span><span class="NLM_article-title">Structure-Functional Selectivity Relationship Studies of Beta-Arrestin-Biased Dopamine D(2) Receptor Agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7141</span><span class="NLM_x">–</span> <span class="NLM_lpage">7153</span><span class="refDoi"> DOI: 10.1021/jm300603y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300603y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWhsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7141-7153&author=X.+Chenauthor=M.+F.+Sassanoauthor=L.+Zhengauthor=V.+Setolaauthor=M.+Chenauthor=X.+Baiauthor=S.+V.+Fryeauthor=W.+C.+Wetselauthor=B.+L.+Rothauthor=J.+Jin&title=Structure-Functional+Selectivity+Relationship+Studies+of+Beta-Arrestin-Biased+Dopamine+D%282%29+Receptor+Agonists&doi=10.1021%2Fjm300603y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Functional Selectivity Relationship Studies of β-Arrestin-Biased Dopamine D2 Receptor Agonists</span></div><div class="casAuthors">Chen, Xin; Sassano, Maria F.; Zheng, Lianyou; Setola, Vincent; Chen, Meng; Bai, Xu; Frye, Stephen V.; Wetsel, William C.; Roth, Bryan L.; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7141-7153</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Functionally selective G protein-coupled receptor (GPCR) ligands, which differentially modulate canonical and noncanonical signaling, are extremely useful for elucidating key signal transduction pathways essential for both the therapeutic actions and side effects of drugs.  However, few such ligands have been created, and very little purposeful attention has been devoted to studying what we term: "structure-functional selectivity relationships" (SFSR).  We recently disclosed the first β-arrestin-biased dopamine D2 receptor (D2R) agonists UNC9975 (44) and UNC9994 (36), which have robust in vivo antipsychotic drug-like activities.  Here we report the first comprehensive SFSR studies focused on exploring four regions of the aripiprazole scaffold, which resulted in the discovery of these β-arrestin-biased D2R agonists.  These studies provide a successful proof-of-concept for how functionally selective ligands can be discovered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwoG1fasQ6GLVg90H21EOLACvtfcHk0lhoqPKarYtAmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWhsbfK&md5=00b0613e62ce7b5a4c98cb5212fea3b5</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm300603y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300603y%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DBai%26aufirst%3DX.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DStructure-Functional%2520Selectivity%2520Relationship%2520Studies%2520of%2520Beta-Arrestin-Biased%2520Dopamine%2520D%25282%2529%2520Receptor%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7141%26epage%3D7153%26doi%3D10.1021%2Fjm300603y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Möller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kling, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skultety, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leuner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Functionally Selective Dopamine D2, D3 Receptor Partial Agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4861</span><span class="NLM_x">–</span> <span class="NLM_lpage">4875</span><span class="refDoi"> DOI: 10.1021/jm5004039</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5004039" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4861-4875&author=D.+M%C3%B6llerauthor=R.+C.+Klingauthor=M.+Skultetyauthor=K.+Leunerauthor=H.+H%C3%BCbnerauthor=P.+Gmeiner&title=Functionally+Selective+Dopamine+D2%2C+D3+Receptor+Partial+Agonists&doi=10.1021%2Fjm5004039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm5004039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5004039%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25B6ller%26aufirst%3DD.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DSkultety%26aufirst%3DM.%26aulast%3DLeuner%26aufirst%3DK.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DFunctionally%2520Selective%2520Dopamine%2520D2%252C%2520D3%2520Receptor%2520Partial%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4861%26epage%3D4875%26doi%3D10.1021%2Fjm5004039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Möller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uzuneser, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skultety, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huth, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plouffe, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alzheimer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedland, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouvier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-<i>a</i>]Pyridine Substructure</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2908</span><span class="NLM_x">–</span> <span class="NLM_lpage">2929</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01857</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01857" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A280%3ADC%252BC1czhs1Ojsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2908-2929&author=D.+M%C3%B6llerauthor=A.+Banerjeeauthor=T.+C.+Uzuneserauthor=M.+Skultetyauthor=T.+Huthauthor=B.+Plouffeauthor=H.+H%C3%BCbnerauthor=C.+Alzheimerauthor=K.+Friedlandauthor=C.+P.+M%C3%BCllerauthor=M.+Bouvierauthor=P.+Gmeiner&title=Discovery+of+G+Protein-Biased+Dopaminergics+with+a+Pyrazolo%5B1%2C5-a%5DPyridine+Substructure&doi=10.1021%2Facs.jmedchem.6b01857"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure</span></div><div class="casAuthors">Moller Dorothee; Banerjee Ashutosh; Skultety Marika; Hubner Harald; Gmeiner Peter; Uzuneser Taygun C; Muller Christian P; Huth Tobias; Alzheimer Christian; Plouffe Bianca; Bouvier Michel; Friedland Kristina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2908-2929</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">1,4-Disubstituted aromatic piperazines are privileged structural motifs recognized by aminergic G protein-coupled receptors.  Connection of a lipophilic moiety to the arylpiperazine core by an appropriate linker represents a promising concept to increase binding affinity and to fine-tune functional properties.  In particular, incorporation of a pyrazolo[1,5-a]pyridine heterocyclic appendage led to a series of high-affinity dopamine receptor partial agonists.  Comprehensive pharmacological characterization involving BRET biosensors, binding studies, electrophysiology, and complementation-based assays revealed compounds favoring activation of G proteins (preferably Go) over β-arrestin recruitment at dopamine D2 receptors.  The feasibility to design G protein-biased partial agonists as putative novel therapeutics was demonstrated for the representative 2-methoxyphenylpiperazine 16c, which unequivocally displayed antipsychotic activity in vivo.  Moreover, combination of the pyrazolo[1,5-a]pyridine appendage with a 5-hydroxy-N-propyl-2-aminotetraline unit led to balanced or G protein-biased dopaminergic ligands depending on the stereochemistry of the headgroup, illustrating the complex structure-functional selectivity relationships at dopamine D2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSsvEaQplNsM25P7XSLhESfW6udTcc2eYbBgFw7MOmu7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czhs1Ojsw%253D%253D&md5=208855de29fed6b821fd6e4a5bfb412f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01857%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25B6ller%26aufirst%3DD.%26aulast%3DBanerjee%26aufirst%3DA.%26aulast%3DUzuneser%26aufirst%3DT.%2BC.%26aulast%3DSkultety%26aufirst%3DM.%26aulast%3DHuth%26aufirst%3DT.%26aulast%3DPlouffe%26aufirst%3DB.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DAlzheimer%26aufirst%3DC.%26aulast%3DFriedland%26aufirst%3DK.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BP.%26aulast%3DBouvier%26aufirst%3DM.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520G%2520Protein-Biased%2520Dopaminergics%2520with%2520a%2520Pyrazolo%255B1%252C5-a%255DPyridine%2520Substructure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2908%26epage%3D2929%26doi%3D10.1021%2Facs.jmedchem.6b01857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Weichert, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kling, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Molecular Determinants of Biased Agonism at the Dopamine D2 Receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">2703</span><span class="NLM_x">–</span> <span class="NLM_lpage">2717</span><span class="refDoi"> DOI: 10.1021/jm501889t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501889t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjslelsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2703-2717&author=D.+Weichertauthor=A.+Banerjeeauthor=C.+Hillerauthor=R.+C.+Klingauthor=H.+H%C3%BCbnerauthor=P.+Gmeiner&title=Molecular+Determinants+of+Biased+Agonism+at+the+Dopamine+D2+Receptor&doi=10.1021%2Fjm501889t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Determinants of Biased Agonism at the Dopamine D2 Receptor</span></div><div class="casAuthors">Weichert, Dietmar; Banerjee, Ashutosh; Hiller, Christine; Kling, Ralf C.; Huebner, Harald; Gmeiner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2703-2717</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of biased (functionally selective) ligands provides a formidable challenge in medicinal chem.  In an effort to learn to design functionally selective mol. tools for the highly therapeutically relevant dopamine D2 receptor, we synthesized a collection of agonists based on structurally distinct head groups derived from canonical or atypical dopaminergic pharmacophores.  The test compds. feature a long lipophilic appendage that was shown to mediate biased signaling.  By employing functional assays and mol. dynamics simulations, we could show that atypical dopamine surrogates of type 1 and 2 promote biased signaling, while ligands built from classical dopaminergic head groups (type 3 and 4) typically elicit more balanced signaling profiles.  Besides this, we found a strong influence of the stereochem. of type 4 aminotetraline-derived agonists on functional selectivity at D2 receptors.  Whereas the (S)-enantiomer behaved as a full agonist, the biased ligand (R)-4 induced poor G protein coupling but substantial β-arrestin recruitment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLUr0k5gvdy7Vg90H21EOLACvtfcHk0lhoqPKarYtAmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjslelsrc%253D&md5=cdf8f3ed9dff5f14ae06dbbc227fb14a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm501889t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501889t%26sid%3Dliteratum%253Aachs%26aulast%3DWeichert%26aufirst%3DD.%26aulast%3DBanerjee%26aufirst%3DA.%26aulast%3DHiller%26aufirst%3DC.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DMolecular%2520Determinants%2520of%2520Biased%2520Agonism%2520at%2520the%2520Dopamine%2520D2%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2703%26epage%3D2717%26doi%3D10.1021%2Fjm501889t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Pisani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giangreco, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolotti, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanachi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cellamare, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carotti, A.</span><span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of Coumarin Derivatives Tethered to an Edrophonium-Like Fragment as Highly Potent and Selective Dual Binding Site Acetylcholinesterase Inhibitors</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1616</span><span class="NLM_x">–</span> <span class="NLM_lpage">1630</span><span class="refDoi"> DOI: 10.1002/cmdc.201000210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1002%2Fcmdc.201000210" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=1616-1630&author=L.+Pisaniauthor=M.+Cattoauthor=I.+Giangrecoauthor=F.+Leonettiauthor=O.+Nicolottiauthor=A.+Stefanachiauthor=S.+Cellamareauthor=A.+Carotti&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+Coumarin+Derivatives+Tethered+to+an+Edrophonium-Like+Fragment+as+Highly+Potent+and+Selective+Dual+Binding+Site+Acetylcholinesterase+Inhibitors&doi=10.1002%2Fcmdc.201000210"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000210%26sid%3Dliteratum%253Aachs%26aulast%3DPisani%26aufirst%3DL.%26aulast%3DCatto%26aufirst%3DM.%26aulast%3DGiangreco%26aufirst%3DI.%26aulast%3DLeonetti%26aufirst%3DF.%26aulast%3DNicolotti%26aufirst%3DO.%26aulast%3DStefanachi%26aufirst%3DA.%26aulast%3DCellamare%26aufirst%3DS.%26aulast%3DCarotti%26aufirst%3DA.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520Coumarin%2520Derivatives%2520Tethered%2520to%2520an%2520Edrophonium-Like%2520Fragment%2520as%2520Highly%2520Potent%2520and%2520Selective%2520Dual%2520Binding%2520Site%2520Acetylcholinesterase%2520Inhibitors%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D1616%26epage%3D1630%26doi%3D10.1002%2Fcmdc.201000210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Cerqueira, N. M. F. S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliveira-Campos, A. M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coelho, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Carvalho, L. H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guglielmetti, R.</span><span> </span><span class="NLM_article-title">Synthesis of Photochromic Dyes Based on Annulated Coumarin Systems</span> <span class="citation_source-journal">Helv. Chim. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">442</span><span class="NLM_x">–</span> <span class="NLM_lpage">450</span><span class="refDoi"> DOI: 10.1002/1522-2675(200202)85:2<442::AID-HLCA442>3.0.CO;2-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1002%2F1522-2675%28200202%2985%3A2%3C442%3A%3AAID-HLCA442%3E3.0.CO%3B2-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2002&pages=442-450&author=N.+M.+F.+S.+A.+Cerqueiraauthor=A.+M.+F.+Oliveira-Camposauthor=P.+J.+Coelhoauthor=L.+H.+M.+de+Carvalhoauthor=A.+Samatauthor=R.+Guglielmetti&title=Synthesis+of+Photochromic+Dyes+Based+on+Annulated+Coumarin+Systems&doi=10.1002%2F1522-2675%28200202%2985%3A2%3C442%3A%3AAID-HLCA442%3E3.0.CO%3B2-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2F1522-2675%28200202%2985%3A2%3C442%3A%3AAID-HLCA442%3E3.0.CO%3B2-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1522-2675%2528200202%252985%253A2%253C442%253A%253AAID-HLCA442%253E3.0.CO%253B2-9%26sid%3Dliteratum%253Aachs%26aulast%3DCerqueira%26aufirst%3DN.%2BM.%2BF.%2BS.%2BA.%26aulast%3DOliveira-Campos%26aufirst%3DA.%2BM.%2BF.%26aulast%3DCoelho%26aufirst%3DP.%2BJ.%26aulast%3Dde%2BCarvalho%26aufirst%3DL.%2BH.%2BM.%26aulast%3DSamat%26aufirst%3DA.%26aulast%3DGuglielmetti%26aufirst%3DR.%26atitle%3DSynthesis%2520of%2520Photochromic%2520Dyes%2520Based%2520on%2520Annulated%2520Coumarin%2520Systems%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D2002%26volume%3D85%26spage%3D442%26epage%3D450%26doi%3D10.1002%2F1522-2675%28200202%2985%3A2%3C442%3A%3AAID-HLCA442%3E3.0.CO%3B2-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Mewshaw, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornby, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spangler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scerni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schechter, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andree, T. H.</span><span> </span><span class="NLM_article-title">Studies toward the Discovery of the Next Generation of Antidepressants. 3. Dual 5-HT1A and Serotonin Transporter Affinity within a Class of <i>N</i>-Aryloxyethylindolylalkylamines</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">3823</span><span class="NLM_x">–</span> <span class="NLM_lpage">3842</span><span class="refDoi"> DOI: 10.1021/jm0304010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0304010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=3823-3842&author=R.+E.+Mewshawauthor=D.+Zhouauthor=P.+Zhouauthor=X.+Shiauthor=G.+Hornbyauthor=T.+Spanglerauthor=R.+Scerniauthor=D.+Smithauthor=L.+E.+Schechterauthor=T.+H.+Andree&title=Studies+toward+the+Discovery+of+the+Next+Generation+of+Antidepressants.+3.+Dual+5-HT1A+and+Serotonin+Transporter+Affinity+within+a+Class+of+N-Aryloxyethylindolylalkylamines&doi=10.1021%2Fjm0304010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm0304010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0304010%26sid%3Dliteratum%253Aachs%26aulast%3DMewshaw%26aufirst%3DR.%2BE.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DHornby%26aufirst%3DG.%26aulast%3DSpangler%26aufirst%3DT.%26aulast%3DScerni%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DSchechter%26aufirst%3DL.%2BE.%26aulast%3DAndree%26aufirst%3DT.%2BH.%26atitle%3DStudies%2520toward%2520the%2520Discovery%2520of%2520the%2520Next%2520Generation%2520of%2520Antidepressants.%25203.%2520Dual%25205-HT1A%2520and%2520Serotonin%2520Transporter%2520Affinity%2520within%2520a%2520Class%2520of%2520N-Aryloxyethylindolylalkylamines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D3823%26epage%3D3842%26doi%3D10.1021%2Fjm0304010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Chung, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bian, Z.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A. S.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J. C.-O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, P. H.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chui, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, K.-H.</span><span> </span><span class="NLM_article-title">Development of 8-Benzyloxy-Substituted Quinoline Ethers and Evaluation of Their Antimicrobial Activities</span> <span class="citation_source-journal">Med. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1568</span><span class="NLM_x">–</span> <span class="NLM_lpage">1577</span><span class="refDoi"> DOI: 10.1007/s00044-014-1217-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1007%2Fs00044-014-1217-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVKmt7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=1568-1577&author=P.-Y.+Chungauthor=R.+Gambariauthor=Y.-X.+Chenauthor=C.-H.+Chengauthor=Z.-X.+Bianauthor=A.+S.-C.+Chanauthor=J.+C.-O.+Tangauthor=P.+H.-M.+Leungauthor=C.-H.+Chuiauthor=K.-H.+Lam&title=Development+of+8-Benzyloxy-Substituted+Quinoline+Ethers+and+Evaluation+of+Their+Antimicrobial+Activities&doi=10.1007%2Fs00044-014-1217-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Development of 8-benzyloxy-substituted quinoline ethers and evaluation of their antimicrobial activities</span></div><div class="casAuthors">Chung, Po-Yee; Gambari, Roberto; Chen, Yi-Xin; Cheng, Chor-Hing; Bian, Zhao-Xiang; Chan, Albert Sun-Chi; Tang, Johnny Cheuk-On; Leung, Polly Hang-Mei; Chui, Chung-Hin; Lam, Kim-Hung</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1568-1577</span>CODEN:
                <span class="NLM_cas:coden">MCREEB</span>;
        ISSN:<span class="NLM_cas:issn">1054-2523</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Boston</span>)
        </div><div class="casAbstract">FR OLA series of 8-benzyloxy-substituted quinoline ethers (2a-n) compds. was synthesized.  All synthesized compds. were screened in vitro for their preliminary antimicrobial activities against two Gram-neg. bacteria (Pseudomonas aeruginosa and Escherichia coli), two Gram-pos. bacteria (Staphylococcus aureus and Staphylococcus epidermidis), and a fungal species (Aspergillus niger).  Among all the synthesized compds., compd. 2e showed a significant growth inhibitory activity with an MIC value 3.125 μg/mL which was comparable to 8-hydroxyquinoline (2.5 μg/mL) and terbinafine (1.25 μg/mL) against A. niger.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok3erKcuEWL7Vg90H21EOLACvtfcHk0ljE5MBs5leUrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVKmt7bP&md5=5f57cfa77ee5df368525af0c87ca3e34</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs00044-014-1217-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00044-014-1217-4%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DP.-Y.%26aulast%3DGambari%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.-X.%26aulast%3DCheng%26aufirst%3DC.-H.%26aulast%3DBian%26aufirst%3DZ.-X.%26aulast%3DChan%26aufirst%3DA.%2BS.-C.%26aulast%3DTang%26aufirst%3DJ.%2BC.-O.%26aulast%3DLeung%26aufirst%3DP.%2BH.-M.%26aulast%3DChui%26aufirst%3DC.-H.%26aulast%3DLam%26aufirst%3DK.-H.%26atitle%3DDevelopment%2520of%25208-Benzyloxy-Substituted%2520Quinoline%2520Ethers%2520and%2520Evaluation%2520of%2520Their%2520Antimicrobial%2520Activities%26jtitle%3DMed.%2520Chem.%2520Res.%26date%3D2015%26volume%3D24%26spage%3D1568%26epage%3D1577%26doi%3D10.1007%2Fs00044-014-1217-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Manninen, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omar, W. A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heiskanen, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemmetyinen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hormi, O. E. O.</span><span> </span><span class="NLM_article-title">Synthesis and Characterization of Tris-(5-Amino-8-Hydroxyquinoline)Aluminum Complexes and Their Use as Anode Buffer Layers in Inverted Organic Solar Cells</span> <span class="citation_source-journal">J. Mater. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">22971</span><span class="NLM_x">–</span> <span class="NLM_lpage">22982</span><span class="refDoi"> DOI: 10.1039/c2jm35292c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1039%2Fc2jm35292c" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=22971-22982&author=V.+M.+Manninenauthor=W.+A.+E.+Omarauthor=J.+P.+Heiskanenauthor=H.+J.+Lemmetyinenauthor=O.+E.+O.+Hormi&title=Synthesis+and+Characterization+of+Tris-%285-Amino-8-Hydroxyquinoline%29Aluminum+Complexes+and+Their+Use+as+Anode+Buffer+Layers+in+Inverted+Organic+Solar+Cells&doi=10.1039%2Fc2jm35292c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1039%2Fc2jm35292c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2jm35292c%26sid%3Dliteratum%253Aachs%26aulast%3DManninen%26aufirst%3DV.%2BM.%26aulast%3DOmar%26aufirst%3DW.%2BA.%2BE.%26aulast%3DHeiskanen%26aufirst%3DJ.%2BP.%26aulast%3DLemmetyinen%26aufirst%3DH.%2BJ.%26aulast%3DHormi%26aufirst%3DO.%2BE.%2BO.%26atitle%3DSynthesis%2520and%2520Characterization%2520of%2520Tris-%25285-Amino-8-Hydroxyquinoline%2529Aluminum%2520Complexes%2520and%2520Their%2520Use%2520as%2520Anode%2520Buffer%2520Layers%2520in%2520Inverted%2520Organic%2520Solar%2520Cells%26jtitle%3DJ.%2520Mater.%2520Chem.%26date%3D2012%26volume%3D22%26spage%3D22971%26epage%3D22982%26doi%3D10.1039%2Fc2jm35292c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Oshiro, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurahashi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tottori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uwahodo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishi, T.</span><span> </span><span class="NLM_article-title">Novel Antipsychotic Agents with Dopamine Autoreceptor Agonist Properties: Synthesis and Pharmacology of 7-[4-(4-Phenyl-1-Piperazinyl)Butoxy]-3,4-Dihydro-2(1<i>H</i>)-Quinolinone Derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">658</span><span class="NLM_x">–</span> <span class="NLM_lpage">667</span><span class="refDoi"> DOI: 10.1021/jm940608g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm940608g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADyaK1cXosFaqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=658-667&author=Y.+Oshiroauthor=S.+Satoauthor=N.+Kurahashiauthor=T.+Tanakaauthor=T.+Kikuchiauthor=K.+Tottoriauthor=Y.+Uwahodoauthor=T.+Nishi&title=Novel+Antipsychotic+Agents+with+Dopamine+Autoreceptor+Agonist+Properties%3A+Synthesis+and+Pharmacology+of+7-%5B4-%284-Phenyl-1-Piperazinyl%29Butoxy%5D-3%2C4-Dihydro-2%281H%29-Quinolinone+Derivatives&doi=10.1021%2Fjm940608g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Antipsychotic Agents with Dopamine Autoreceptor Agonist Properties: Synthesis and Pharmacology of 7-[4-(4-Phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone Derivatives</span></div><div class="casAuthors">Oshiro, Yasuo; Sato, Seiji; Kurahashi, Nobuyuki; Tanaka, Tatsuyoshi; Kikuchi, Tetsuro; Tottori, Katsura; Uwahodo, Yasufumi; Nishi, Takao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">658-667</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To develop a novel antipsychotic agent which is an agonist of dopamine (DA) autoreceptors and an antagonist of postsynaptic DA receptors, a series of 7-[4-[4-(substituted phenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinones was synthesized and their dual activities were examd.  The postsynaptic DA receptor antagonistic activities of the compds. were evaluated by their ability to inhibit stereotypy induced by apomorphine in mice, and the autoreceptor agonist activities were detd. by their effects on the γ-butyrolactone (GBL)-induced increase in L-dihydroxyphenylalanine (DOPA) synthesis in the mouse brain.  Many compds. inhibited the stereotypic behavior, and several compds. reversed the GBL-induced increase in the DOPA synthesis.  Among them, 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone (aripiprazole, OPC-14597) (I) had these 2 activities.  This compd. reversed the GBL-induced DOPA synthesis (ED50 values of 5.1 μmol/kg po) and inhibited the APO induced stereotypy (ED50 values of 0.6 mmol/kg po).  I induced catalepsy at 10-fold higher dose than that required for the antagonism of APO-induced stereotypy (ED50 value of 7.8 μmol/kg oral).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnD8-A-QQlZLVg90H21EOLACvtfcHk0lh9VYPmHRBh5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXosFaqtw%253D%253D&md5=02ff3a24cc876f68419f60acc4bae45e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm940608g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm940608g%26sid%3Dliteratum%253Aachs%26aulast%3DOshiro%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DKurahashi%26aufirst%3DN.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DKikuchi%26aufirst%3DT.%26aulast%3DTottori%26aufirst%3DK.%26aulast%3DUwahodo%26aufirst%3DY.%26aulast%3DNishi%26aufirst%3DT.%26atitle%3DNovel%2520Antipsychotic%2520Agents%2520with%2520Dopamine%2520Autoreceptor%2520Agonist%2520Properties%253A%2520Synthesis%2520and%2520Pharmacology%2520of%25207-%255B4-%25284-Phenyl-1-Piperazinyl%2529Butoxy%255D-3%252C4-Dihydro-2%25281H%2529-Quinolinone%2520Derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D658%26epage%3D667%26doi%3D10.1021%2Fjm940608g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Gmeiner, P.; Huebner, H.; Skultety, M.</span><span> </span><span class="NLM_article-title">Preparation of Indolizines and Aza-Analog Derivatives Thereof as CNS Active Compounds</span>. WO2008113559A2,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=P.+Gmeiner&author=H.+Huebner&author=M.+Skultety&title=Preparation+of+Indolizines+and+Aza-Analog+Derivatives+Thereof+as+CNS+Active+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DPreparation%2520of%2520Indolizines%2520and%2520Aza-Analog%2520Derivatives%2520Thereof%2520as%2520CNS%2520Active%2520Compounds%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Kühhorn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Götz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whistler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Development of a Bivalent Dopamine D(2) Receptor Agonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7911</span><span class="NLM_x">–</span> <span class="NLM_lpage">7919</span><span class="refDoi"> DOI: 10.1021/jm2009919</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2009919" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlWrs7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7911-7919&author=J.+K%C3%BChhornauthor=A.+G%C3%B6tzauthor=H.+H%C3%BCbnerauthor=D.+Thompsonauthor=J.+Whistlerauthor=P.+Gmeiner&title=Development+of+a+Bivalent+Dopamine+D%282%29+Receptor+Agonist&doi=10.1021%2Fjm2009919"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Bivalent Dopamine D2 Receptor Agonist</span></div><div class="casAuthors">Kuehhorn, Julia; Goetz, Angela; Huebner, Harald; Thompson, Dawn; Whistler, Jennifer; Gmeiner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7911-7919</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bivalent D2 agonists may function as useful mol. probes for the discovery of novel neurol. therapeutics.  On the basis of our recently developed bivalent dopamine D2 receptor antagonists of type 1, the bivalent agonist 2 was synthesized when a spacer built from 22 atoms was employed.  Compared to the monovalent control compd. 6 contg. a capped spacer, the bis-aminoindane deriv. 2 revealed substantial steepening of the competition curve, indicating a bivalent binding mode.  Dimer-specific Hill slopes were not a result of varying functional properties because both the dopaminergic 2 and the monovalent control agent 6 proved to be D2 agonists substantially inhibiting cAMP accumulation and inducing D2 receptor internalization.  Investigation of the heterobivalent ligands 8 and 9, contg. an agonist and a phenylpiperazine-based antagonist pharmacophore, revealed moderate steepening of the displacement curves and antagonist to very weak partial agonist properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKk6sjty41_LVg90H21EOLACvtfcHk0lh9VYPmHRBh5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlWrs7fP&md5=c814855234dd17049cfab52f53a85ae7</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm2009919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2009919%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25BChhorn%26aufirst%3DJ.%26aulast%3DG%25C3%25B6tz%26aufirst%3DA.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DThompson%26aufirst%3DD.%26aulast%3DWhistler%26aufirst%3DJ.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DDevelopment%2520of%2520a%2520Bivalent%2520Dopamine%2520D%25282%2529%2520Receptor%2520Agonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7911%26epage%3D7919%26doi%3D10.1021%2Fjm2009919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Tabor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisenburger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purkayastha, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaindl, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grömer, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornhuber, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tschammer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birdsall, N. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mashanov, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandoghdar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Visualization and Ligand-Induced Modulation of Dopamine Receptor Dimerization at the Single Molecule Level</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">33233</span><span class="refDoi"> DOI: 10.1038/srep33233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1038%2Fsrep33233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=27615810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWnu7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=33233&author=A.+Taborauthor=S.+Weisenburgerauthor=A.+Banerjeeauthor=N.+Purkayasthaauthor=J.+M.+Kaindlauthor=H.+H%C3%BCbnerauthor=L.+Weiauthor=T.+W.+Gr%C3%B6merauthor=J.+Kornhuberauthor=N.+Tschammerauthor=N.+J.+M.+Birdsallauthor=G.+I.+Mashanovauthor=V.+Sandoghdarauthor=P.+Gmeiner&title=Visualization+and+Ligand-Induced+Modulation+of+Dopamine+Receptor+Dimerization+at+the+Single+Molecule+Level&doi=10.1038%2Fsrep33233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Visualization and ligand-induced modulation of dopamine receptor dimerization at the single molecule level</span></div><div class="casAuthors">Tabor, Alina; Weisenburger, Siegfried; Banerjee, Ashutosh; Purkayastha, Nirupam; Kaindl, Jonas M.; Huebner, Harald; Wei, Luxi; Groemer, Teja W.; Kornhuber, Johannes; Tschammer, Nuska; Birdsall, Nigel J. M.; Mashanov, Gregory I.; Sandoghdar, Vahid; Gmeiner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">33233</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs), including dopamine receptors, represent a group of important pharmacol. targets.  An increased formation of dopamine receptor D2 homodimers has been suggested to be assocd. with the pathophysiol. of schizophrenia.  Selective labeling and ligand-induced modulation of dimerization may therefore allow the investigation of the pathophysiol. role of these dimers.  Using TIRF microscopy at the single mol. level, transient formation of homodimers of dopamine receptors in the membrane of stably transfected CHO cells has been obsd.  The equil. between dimers and monomers was modulated by the binding of ligands; whereas antagonists showed a ratio that was identical to that of unliganded receptors, agonist-bound D2 receptor-ligand complexes resulted in an increase in dimerization.  Addn. of bivalent D2 receptor ligands also resulted in a large increase in D2 receptor dimers.  A phys. interaction between the protomers was confirmed using high resoln. cryogenic localization microscopy, with ca. 9 nm between the centers of mass.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0U-LA35caB7Vg90H21EOLACvtfcHk0lgNfKy69r8G1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWnu7fJ&md5=03a23cdbee9605ce1fc9cf6bff103713</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fsrep33233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep33233%26sid%3Dliteratum%253Aachs%26aulast%3DTabor%26aufirst%3DA.%26aulast%3DWeisenburger%26aufirst%3DS.%26aulast%3DBanerjee%26aufirst%3DA.%26aulast%3DPurkayastha%26aufirst%3DN.%26aulast%3DKaindl%26aufirst%3DJ.%2BM.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DGr%25C3%25B6mer%26aufirst%3DT.%2BW.%26aulast%3DKornhuber%26aufirst%3DJ.%26aulast%3DTschammer%26aufirst%3DN.%26aulast%3DBirdsall%26aufirst%3DN.%2BJ.%2BM.%26aulast%3DMashanov%26aufirst%3DG.%2BI.%26aulast%3DSandoghdar%26aufirst%3DV.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DVisualization%2520and%2520Ligand-Induced%2520Modulation%2520of%2520Dopamine%2520Receptor%2520Dimerization%2520at%2520the%2520Single%2520Molecule%2520Level%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D33233%26doi%3D10.1038%2Fsrep33233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Ohno, Y.</span><span> </span><span class="NLM_article-title">Therapeutic Role of 5-HT1A Receptors in the Treatment of Schizophrenia and Parkinson’s Disease</span> <span class="citation_source-journal">CNS Neurosci. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">65</span><span class="refDoi"> DOI: 10.1111/j.1755-5949.2010.00211.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1111%2Fj.1755-5949.2010.00211.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=21091640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVCnurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=58-65&author=Y.+Ohno&title=Therapeutic+Role+of+5-HT1A+Receptors+in+the+Treatment+of+Schizophrenia+and+Parkinson%E2%80%99s+Disease&doi=10.1111%2Fj.1755-5949.2010.00211.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease</span></div><div class="casAuthors">Ohno, Yukihiro</div><div class="citationInfo"><span class="NLM_cas:title">CNS Neuroscience & Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-65</span>CODEN:
                <span class="NLM_cas:coden">CNTNAB</span>;
        ISSN:<span class="NLM_cas:issn">1755-5930</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  5-HT1A receptors have long been implicated in the pathogenesis and treatment of anxiety and depressive disorders.  Recently, several lines of studies have revealed new insights into the therapeutic role of 5-HT1A receptors in treating schizophrenia and Parkinson's disease.  Specifically, 5-HT1A receptors seem to be a promising target for alleviating antipsychotic-induced extrapyramidal side effects (EPS) and cognitive/affective disorders in schizophrenia.  In the treatment of patients with Parkinson's disease, 5-HT1A agonists are expected to improve not only affective symptoms (e.g., anxiety and depression), but also the core parkinsonian symptoms as well as antiparkinsonian agents-induced side effects (e.g., L-DOPA-induced dyskinesia).  Here, the therapeutic mechanisms mediated by 5-HT1A receptors in schizophrenia and Parkinson's disease are reviewed.  This evidence should encourage discovery of new 5-HT1A ligands, which can resolve the unmet clin. needs in the current therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMhhzTRrq3R7Vg90H21EOLACvtfcHk0lgNfKy69r8G1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVCnurc%253D&md5=d70ebb228afb20826693e9ed48d287c2</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1111%2Fj.1755-5949.2010.00211.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1755-5949.2010.00211.x%26sid%3Dliteratum%253Aachs%26aulast%3DOhno%26aufirst%3DY.%26atitle%3DTherapeutic%2520Role%2520of%25205-HT1A%2520Receptors%2520in%2520the%2520Treatment%2520of%2520Schizophrenia%2520and%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DCNS%2520Neurosci.%2520Ther.%26date%3D2011%26volume%3D17%26spage%3D58%26epage%3D65%26doi%3D10.1111%2Fj.1755-5949.2010.00211.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Lohse, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benovic, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Codina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefkowitz, R. J.</span><span> </span><span class="NLM_article-title">Beta-Arrestin: A Protein That Regulates Beta-Adrenergic Receptor Function</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">248</span><span class="NLM_x">, </span> <span class="NLM_fpage">1547</span><span class="NLM_x">–</span> <span class="NLM_lpage">1550</span><span class="refDoi"> DOI: 10.1126/science.2163110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1126%2Fscience.2163110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=2163110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADyaK3cXlvVKktLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=248&publication_year=1990&pages=1547-1550&author=M.+J.+Lohseauthor=J.+L.+Benovicauthor=J.+Codinaauthor=M.+G.+Caronauthor=R.+J.+Lefkowitz&title=Beta-Arrestin%3A+A+Protein+That+Regulates+Beta-Adrenergic+Receptor+Function&doi=10.1126%2Fscience.2163110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">β-Arrestin:  a protein that regulates β-adrenergic receptor function</span></div><div class="casAuthors">Lohse, Martin J.; Benovic, Jeffrey L.; Codina, Juan; Caron, Marc G.; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">248</span>
        (<span class="NLM_cas:issue">4962</span>),
    <span class="NLM_cas:pages">1547-50</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Homologous or agonist-specific desensitization of β-adrenergic receptors is thought to be mediated by a specific kinase, the β-adrenergic receptor kinase (βARK).  However, recent data suggest that a cofactor is required for this kinase to inhibit receptor function.  The cDNA for such a cofactor was cloned and found to encode a 418-amino acid protein homologous to the retinal protein arrestin.  The protein, termed β-arrestin, was expressed and partially purified.  It inhibited the signaling function of βARK-phosphorylated β-adrenergic receptors by >75%, but not that of rhodopsin.  It is proposed that β-arrestin in concert with βARK effects homologous desensitization of β-adrenergic receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPkPorBQRSCrVg90H21EOLACvtfcHk0lgNfKy69r8G1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXlvVKktLk%253D&md5=57d5471cdc1ae51a2ba4a83360accc65</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1126%2Fscience.2163110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.2163110%26sid%3Dliteratum%253Aachs%26aulast%3DLohse%26aufirst%3DM.%2BJ.%26aulast%3DBenovic%26aufirst%3DJ.%2BL.%26aulast%3DCodina%26aufirst%3DJ.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DBeta-Arrestin%253A%2520A%2520Protein%2520That%2520Regulates%2520Beta-Adrenergic%2520Receptor%2520Function%26jtitle%3DScience%26date%3D1990%26volume%3D248%26spage%3D1547%26epage%3D1550%26doi%3D10.1126%2Fscience.2163110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Lefkowitz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenoy, S. K.</span><span> </span><span class="NLM_article-title">Transduction of Receptor Signals by Beta-Arrestins</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">308</span><span class="NLM_x">, </span> <span class="NLM_fpage">512</span><span class="NLM_x">–</span> <span class="NLM_lpage">517</span><span class="refDoi"> DOI: 10.1126/science.1109237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1126%2Fscience.1109237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=15845844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtlOjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2005&pages=512-517&author=R.+J.+Lefkowitzauthor=S.+K.+Shenoy&title=Transduction+of+Receptor+Signals+by+Beta-Arrestins&doi=10.1126%2Fscience.1109237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Transduction of Receptor Signals by β-Arrestins</span></div><div class="casAuthors">Lefkowitz, Robert J.; Shenoy, Sudha K.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">5721</span>),
    <span class="NLM_cas:pages">512-517</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  The transmission of extracellular signals to the interior of the cell is a function of plasma membrane receptors, of which the seven transmembrane receptor family is by far the largest and most versatile.  Classically, these receptors stimulate heterotrimeric G proteins, which control rates of generation of diffusible second messengers and entry of ions at the plasma membrane.  Recent evidence, however, indicates another previously unappreciated strategy used by the receptors to regulate intracellular signaling pathways.  They direct the recruitment, activation, and scaffolding of cytoplasmic signaling complexes via two multifunctional adaptor and transducer mols., β-arrestins 1 and 2.  This mechanism regulates aspects of cell motility, chemotaxis, apoptosis, and likely other cellular functions through a rapidly expanding list of signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk2fXdqgYhC7Vg90H21EOLACvtfcHk0lgNfKy69r8G1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtlOjtLs%253D&md5=ed070237312d050e5d5ec437b3adc76c</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1126%2Fscience.1109237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1109237%26sid%3Dliteratum%253Aachs%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DShenoy%26aufirst%3DS.%2BK.%26atitle%3DTransduction%2520of%2520Receptor%2520Signals%2520by%2520Beta-Arrestins%26jtitle%3DScience%26date%3D2005%26volume%3D308%26spage%3D512%26epage%3D517%26doi%3D10.1126%2Fscience.1109237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Urs, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, J. P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span> </span><span class="NLM_article-title">Deletion of Gsk3β in D2r-Expressing Neurons Reveals Distinct Roles for B-Arrestin Signaling in Antipsychotic and Lithium Action</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">20732</span><span class="NLM_x">–</span> <span class="NLM_lpage">20737</span><span class="refDoi"> DOI: 10.1073/pnas.1215489109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1073%2Fpnas.1215489109" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=20732-20737&author=N.+M.+Ursauthor=J.+C.+Snyderauthor=J.+P.+R.+Jacobsenauthor=S.+M.+Petersonauthor=M.+G.+Caron&title=Deletion+of+Gsk3%CE%B2+in+D2r-Expressing+Neurons+Reveals+Distinct+Roles+for+B-Arrestin+Signaling+in+Antipsychotic+and+Lithium+Action&doi=10.1073%2Fpnas.1215489109"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1215489109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1215489109%26sid%3Dliteratum%253Aachs%26aulast%3DUrs%26aufirst%3DN.%2BM.%26aulast%3DSnyder%26aufirst%3DJ.%2BC.%26aulast%3DJacobsen%26aufirst%3DJ.%2BP.%2BR.%26aulast%3DPeterson%26aufirst%3DS.%2BM.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26atitle%3DDeletion%2520of%2520Gsk3%25CE%25B2%2520in%2520D2r-Expressing%2520Neurons%2520Reveals%2520Distinct%2520Roles%2520for%2520B-Arrestin%2520Signaling%2520in%2520Antipsychotic%2520and%2520Lithium%2520Action%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D20732%26epage%3D20737%26doi%3D10.1073%2Fpnas.1215489109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Lane, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powney, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, G.</span><span> </span><span class="NLM_article-title">G Protein Coupling and Ligand Selectivity of the D2L and D3 Dopamine Receptors</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">325</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">330</span><span class="refDoi"> DOI: 10.1124/jpet.107.134296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1124%2Fjpet.107.134296" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=18218829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktFGjur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=325&publication_year=2008&pages=319-330&author=J.+R.+Laneauthor=B.+Powneyauthor=A.+Wiseauthor=S.+Reesauthor=G.+Milligan&title=G+Protein+Coupling+and+Ligand+Selectivity+of+the+D2L+and+D3+Dopamine+Receptors&doi=10.1124%2Fjpet.107.134296"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">G protein coupling and ligand selectivity of the D2L and D3 dopamine receptors</span></div><div class="casAuthors">Lane, J. Robert; Powney, Ben; Wise, Alan; Rees, Stephen; Milligan, Graeme</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">325</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">319-330</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The human dopamine D2L receptor couples promiscuously to multiple members of the Gαi/o subfamily.  Despite the high homol. of the D2L and D3 receptors, the G protein coupling specificity of the human D3 receptor is less clearly characterized.  The primary aim of this study, then, was the parallel characterization of the G protein coupling specificity of the D2L and D3 receptors.  By using both receptor-G protein fusion proteins and stable cell lines in which pertussis toxin-resistant mutants of individual Gαi-family G proteins were expressed in an inducible fashion, we demonstrated highly selective coupling of the D3 receptor to Gαo1.  Furthermore, by using the fusion proteins to ensure identical stoichiometry of receptor to G protein for each pairing, a range of ligands displayed higher potency and, for partial agonists, higher efficacy at the D3 receptor when coupled to Gαo1 compared with the D2L receptor.  The second aim of this study was to investigate the mol. basis of the above differential G protein coupling specificity.  The importance of a 12-amino acid sequence from the C-terminal end of the third intracellular loop of the D2L receptor in providing promiscuity in G protein coupling was demonstrated using a chimeric D3/D2 receptor in which the equiv. region of the D3 receptor was exchanged for this sequence.  This chimera displayed D3-like affinity for [3H]spiperone and potency for agonists but gained D2-like ability to couple to each of Gαi1-3 as well as Gαo1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxa1ewwkwA2bVg90H21EOLACvtfcHk0lhPD2rn0y_yow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktFGjur0%253D&md5=dd55e53f17554e5fdf1740b788b9028c</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.134296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.134296%26sid%3Dliteratum%253Aachs%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DPowney%26aufirst%3DB.%26aulast%3DWise%26aufirst%3DA.%26aulast%3DRees%26aufirst%3DS.%26aulast%3DMilligan%26aufirst%3DG.%26atitle%3DG%2520Protein%2520Coupling%2520and%2520Ligand%2520Selectivity%2520of%2520the%2520D2L%2520and%2520D3%2520Dopamine%2520Receptors%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D325%26spage%3D319%26epage%3D330%26doi%3D10.1124%2Fjpet.107.134296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Strange, P. G.</span><span> </span><span class="NLM_article-title">Use of the Gtpγs Binding Assay for Analysis of Ligand Potency and Efficacy at G Protein-Coupled Receptors</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">161</span><span class="NLM_x">, </span> <span class="NLM_fpage">1238</span><span class="NLM_x">–</span> <span class="NLM_lpage">1249</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00963.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1111%2Fj.1476-5381.2010.00963.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=20662841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFWhsr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2010&pages=1238-1249&author=P.+G.+Strange&title=Use+of+the+Gtp%CE%B3s+Binding+Assay+for+Analysis+of+Ligand+Potency+and+Efficacy+at+G+Protein-Coupled+Receptors&doi=10.1111%2Fj.1476-5381.2010.00963.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors</span></div><div class="casAuthors">Strange, Philip G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1238-1249</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  In this review I consider assays for G protein-coupled receptor (GPCR) activity based on the binding of labeled analogs of GTPγS ([35S]GTPγS or Eu-GTPγS) to G proteins in tissues (GTPγS binding assays).  Such assays provide convenient measures of GPCR activity close to the receptor in the signaling cascade.  In order to set up a GTPγS binding assay, the requirements of the assay must be considered.  These are tissue source, GTPγS analog, G protein, GDP, Mg2+/Na+ ions, saponin, incubation time.  The assay, once optimized, can be used to generate concn./response curves for GPCRs signaling via Gi/o proteins (or to other G proteins with a modified assay) and actions of agonists, inverse agonists and antagonists may, in principle, be assessed.  For agonists and inverse agonists, data for the maximal agonist effect, the concn. of ligand giving a half-maximal response and the Hill coeff. may be derived.  For antagonists, data for the equil. dissocn. const. can be obtained.  The mechanistic basis of the assay is considered.  Although the assay can be used to profile ligands, under the conditions it is used, it may not be measuring the same event that dets. GPCR action in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonpFh81URvabVg90H21EOLACvtfcHk0lhPD2rn0y_yow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFWhsr3K&md5=8fa11a4e869eec381bae3880f4051dc2</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00963.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00963.x%26sid%3Dliteratum%253Aachs%26aulast%3DStrange%26aufirst%3DP.%2BG.%26atitle%3DUse%2520of%2520the%2520Gtp%25CE%25B3s%2520Binding%2520Assay%2520for%2520Analysis%2520of%2520Ligand%2520Potency%2520and%2520Efficacy%2520at%2520G%2520Protein-Coupled%2520Receptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D161%26spage%3D1238%26epage%3D1249%26doi%3D10.1111%2Fj.1476-5381.2010.00963.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Gazi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickolls, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strange, P. G.</span><span> </span><span class="NLM_article-title">Functional Coupling of the Human Dopamine D2 Receptor with Galphai1, Galphai2, Galphai3, and Galphao G Proteins: Evidence for Agonist Regulation of G Protein Selectivity</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">775</span><span class="NLM_x">–</span> <span class="NLM_lpage">786</span><span class="refDoi"> DOI: 10.1038/sj.bjp.0705116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1038%2Fsj.bjp.0705116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=12642378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisFegs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2003&pages=775-786&author=L.+Gaziauthor=S.+Nickollsauthor=P.+G.+Strange&title=Functional+Coupling+of+the+Human+Dopamine+D2+Receptor+with+Galphai1%2C+Galphai2%2C+Galphai3%2C+and+Galphao+G+Proteins%3A+Evidence+for+Agonist+Regulation+of+G+Protein+Selectivity&doi=10.1038%2Fsj.bjp.0705116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Functional coupling of the human dopamine D2 receptor with Gαi1, Gαi2, Gαi3 and Gαo G proteins: Evidence for agonist regulation of G protein selectivity</span></div><div class="casAuthors">Gazi, Lucien; Nickolls, Sarah A.; Strange, Philip G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">775-786</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The human dopamine D2long (D2L) receptor was expressed with four different G proteins in Sf9 cells using the baculovirus expression system.  When co-expressed with Gi/Go G proteins (Gi1α, Gi2α, Gi3α, or Goα, plus Gβ1 and Gγ2), the receptor displayed a high-affinity binding site for the agonists (dopamine and NPA), which was sensitive to GTP (100 μM), demonstrating interaction between the receptor and the different G proteins.  The receptor to G protein ratio (R:G ratio) was evaluated using [3H]-spiperone satn. binding (R) and [35S]-GTPγS satn. binding (G).  R:G ratios of 1:12, 1:3, 1:14 and 1:5 were found for Gi1, Gi2, Gi3, and Go prepns., resp.  However, when R:G ratios of 1:2 and 1:12 were compared for Gi2 and Go, no difference was found for the stimulation of [35S]-GTPγS binding.  Several agonists were tested for their ability to stimulate [35S]-GTPγS binding to membranes co-expressing the receptor and various G proteins.  All the compds. tested showed agonist activity in prepns. expressing Gi3 and Go.  However, for Gi2 and Gi1 prepns., compds. such as S-(-)-3-PPP and p-tyramine were unable to stimulate [35S]-GTPγS binding.  Most of the compds. showed higher relative efficacies (compared to dopamine) and higher potencies in the prepn. expressing Go.  Comparison of the effects of different agonists in the different prepns. showed that each agonist differentially activates the four G proteins.  We conclude that the degree of selectivity of G protein activation by the D2L receptor can depend on the conformation of the receptor stabilized by an agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSCewgdeU6SbVg90H21EOLACvtfcHk0li4QLc45j_tgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisFegs7s%253D&md5=f0417b2243b11377ab4df51a98aebaff</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0705116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0705116%26sid%3Dliteratum%253Aachs%26aulast%3DGazi%26aufirst%3DL.%26aulast%3DNickolls%26aufirst%3DS.%26aulast%3DStrange%26aufirst%3DP.%2BG.%26atitle%3DFunctional%2520Coupling%2520of%2520the%2520Human%2520Dopamine%2520D2%2520Receptor%2520with%2520Galphai1%252C%2520Galphai2%252C%2520Galphai3%252C%2520and%2520Galphao%2520G%2520Proteins%253A%2520Evidence%2520for%2520Agonist%2520Regulation%2520of%2520G%2520Protein%2520Selectivity%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2003%26volume%3D138%26spage%3D775%26epage%3D786%26doi%3D10.1038%2Fsj.bjp.0705116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Jiang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spicher, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulay, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birnbaumer, L.</span><span> </span><span class="NLM_article-title">Most Central Nervous System D2 Dopamine Receptors Are Coupled to Their Effectors by Go</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">3577</span><span class="NLM_x">–</span> <span class="NLM_lpage">3582</span><span class="refDoi"> DOI: 10.1073/pnas.051632598</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1073%2Fpnas.051632598" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=3577-3582&author=M.+Jiangauthor=K.+Spicherauthor=G.+Boulayauthor=Y.+Wangauthor=L.+Birnbaumer&title=Most+Central+Nervous+System+D2+Dopamine+Receptors+Are+Coupled+to+Their+Effectors+by+Go&doi=10.1073%2Fpnas.051632598"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1073%2Fpnas.051632598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.051632598%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DM.%26aulast%3DSpicher%26aufirst%3DK.%26aulast%3DBoulay%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DBirnbaumer%26aufirst%3DL.%26atitle%3DMost%2520Central%2520Nervous%2520System%2520D2%2520Dopamine%2520Receptors%2520Are%2520Coupled%2520to%2520Their%2520Effectors%2520by%2520Go%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2001%26volume%3D98%26spage%3D3577%26epage%3D3582%26doi%3D10.1073%2Fpnas.051632598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Lohse, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, C.</span><span> </span><span class="NLM_article-title">Arrestin Interactions with G Protein-Coupled Receptors</span> <span class="citation_source-journal">Handb. Exp. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">219</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">56</span><span class="refDoi"> DOI: 10.1007/978-3-642-41199-1_2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1007%2F978-3-642-41199-1_2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=24292823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFOhurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=219&publication_year=2014&pages=15-56&author=M.+J.+Lohseauthor=C.+Hoffmann&title=Arrestin+Interactions+with+G+Protein-Coupled+Receptors&doi=10.1007%2F978-3-642-41199-1_2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Arrestin Interactions with G Protein-Coupled Receptors</span></div><div class="casAuthors">Lohse, Martin J.; Hoffmann, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">219</span>
        (<span class="NLM_cas:issue">Arrestins</span>),
    <span class="NLM_cas:pages">15-56</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">1865-0325</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) are the primary interaction partners for arrestins.  The visual arrestins, arrestin 1 and arrestin 4, physiol. bind to only very few receptors, i.e., rhodopsin and the color opsins, resp.  In contrast, the ubiquitously expressed nonvisual variants β-arrestin 1 and 2 bind to a large no. of receptors in a fairly nonspecific manner.  This binding requires two triggers, agonist activation and receptor phosphorylation by a G-protein-coupled receptor kinase (GRK).  These two triggers are mediated by two different regions of the arrestins, the "phosphorylation sensor" in the core of the protein and a less well-defined "activation sensor.".  Binding appears to occur mostly in a 1:1 stoichiometry, involving the N-terminal domain of GPCRs, but in addn. a second GPCR may loosely bind to the C-terminal domain when active receptors are abundant.  Arrestin binding initially uncouples GPCRs from their G-proteins.  It stabilizes receptors in an active conformation and also induces a conformational change in the arrestins that involves a rotation of the two domains relative to each other plus changes in the polar core.  This conformational change appears to permit the interaction with further downstream proteins.  The latter interaction, demonstrated mostly for β-arrestins, triggers receptor internalization as well as a no. of nonclassical signaling pathways.  Open questions concern the exact stoichiometry of the interaction, possible specificity with regard to the type of agonist and of GRK involved, selective regulation of downstream signaling (=biased signaling), and the options to use these mechanisms as therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2hOyPIZgUfLVg90H21EOLACvtfcHk0li4QLc45j_tgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFOhurk%253D&md5=dd72458eea9257ac6fcca239265740d8</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-41199-1_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-41199-1_2%26sid%3Dliteratum%253Aachs%26aulast%3DLohse%26aufirst%3DM.%2BJ.%26aulast%3DHoffmann%26aufirst%3DC.%26atitle%3DArrestin%2520Interactions%2520with%2520G%2520Protein-Coupled%2520Receptors%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2014%26volume%3D219%26spage%3D15%26epage%3D56%26doi%3D10.1007%2F978-3-642-41199-1_2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Urs, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gee, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pack, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCorvy, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evron, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguiz, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borrelli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span> </span><span class="NLM_article-title">Distinct Cortical and Striatal Actions of a B-Arrestin–Biased Dopamine D2 Receptor Ligand Reveal Unique Antipsychotic-Like Properties</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">E8178</span><span class="NLM_x">–</span> <span class="NLM_lpage">E8186</span><span class="refDoi"> DOI: 10.1073/pnas.1614347113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1073%2Fpnas.1614347113" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=E8178-E8186&author=N.+M.+Ursauthor=S.+M.+Geeauthor=T.+F.+Packauthor=J.+D.+McCorvyauthor=T.+Evronauthor=J.+C.+Snyderauthor=X.+Yangauthor=R.+M.+Rodriguizauthor=E.+Borrelliauthor=W.+C.+Wetselauthor=J.+Jinauthor=B.+L.+Rothauthor=P.+O%E2%80%99Donnellauthor=M.+G.+Caron&title=Distinct+Cortical+and+Striatal+Actions+of+a+B-Arrestin%E2%80%93Biased+Dopamine+D2+Receptor+Ligand+Reveal+Unique+Antipsychotic-Like+Properties&doi=10.1073%2Fpnas.1614347113"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1614347113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1614347113%26sid%3Dliteratum%253Aachs%26aulast%3DUrs%26aufirst%3DN.%2BM.%26aulast%3DGee%26aufirst%3DS.%2BM.%26aulast%3DPack%26aufirst%3DT.%2BF.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DEvron%26aufirst%3DT.%26aulast%3DSnyder%26aufirst%3DJ.%2BC.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DBorrelli%26aufirst%3DE.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DP.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26atitle%3DDistinct%2520Cortical%2520and%2520Striatal%2520Actions%2520of%2520a%2520B-Arrestin%25E2%2580%2593Biased%2520Dopamine%2520D2%2520Receptor%2520Ligand%2520Reveal%2520Unique%2520Antipsychotic-Like%2520Properties%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3DE8178%26epage%3DE8186%26doi%3D10.1073%2Fpnas.1614347113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Peterson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pack, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span> </span><span class="NLM_article-title">Receptor, Ligand and Transducer Contributions to Dopamine D2 Receptor Functional Selectivity</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0141637</span><span class="refDoi"> DOI: 10.1371/journal.pone.0141637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1371%2Fjournal.pone.0141637" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0141637&author=S.+M.+Petersonauthor=T.+F.+Packauthor=M.+G.+Caron&title=Receptor%2C+Ligand+and+Transducer+Contributions+to+Dopamine+D2+Receptor+Functional+Selectivity&doi=10.1371%2Fjournal.pone.0141637"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0141637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0141637%26sid%3Dliteratum%253Aachs%26aulast%3DPeterson%26aufirst%3DS.%2BM.%26aulast%3DPack%26aufirst%3DT.%2BF.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26atitle%3DReceptor%252C%2520Ligand%2520and%2520Transducer%2520Contributions%2520to%2520Dopamine%2520D2%2520Receptor%2520Functional%2520Selectivity%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0141637%26doi%3D10.1371%2Fjournal.pone.0141637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Lipinski, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominy, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, P. J.</span><span> </span><span class="NLM_article-title">Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span><span class="refDoi"> DOI: 10.1016/S0169-409X(00)00129-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1016%2FS0169-409X%2800%2900129-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=11259830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2001&pages=3-26&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+Computational+Approaches+to+Estimate+Solubility+and+Permeability+in+Drug+Discovery+and+Development+Settings&doi=10.1016%2FS0169-409X%2800%2900129-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-26</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is greater than 500 and the calcd. Log P (CLogP) is greater than 5 (or MlogP >4.15).  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYDqa02g16urVg90H21EOLACvtfcHk0liuwKzDlJ_0JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D&md5=c60bb89da68f051c0ee7ac4c0468a0e4</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2800%2900129-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252800%252900129-0%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520Computational%2520Approaches%2520to%2520Estimate%2520Solubility%2520and%2520Permeability%2520in%2520Drug%2520Discovery%2520and%2520Development%2520Settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2001%26volume%3D46%26spage%3D3%26epage%3D26%26doi%3D10.1016%2FS0169-409X%2800%2900129-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Prachayasittikul, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prachayasittikul, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruchirawat, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prachayasittikul, V.</span><span> </span><span class="NLM_article-title">8-Hydroxyquinolines: A Review of Their Metal Chelating Properties and Medicinal Applications</span> <span class="citation_source-journal">Drug Des., Dev. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1157</span><span class="NLM_x">–</span> <span class="NLM_lpage">1178</span><span class="refDoi"> DOI: 10.2147/DDDT.S49763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.2147%2FDDDT.S49763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=24115839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A280%3ADC%252BC2c3hsFGjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=1157-1178&author=V.+Prachayasittikulauthor=S.+Prachayasittikulauthor=S.+Ruchirawatauthor=V.+Prachayasittikul&title=8-Hydroxyquinolines%3A+A+Review+of+Their+Metal+Chelating+Properties+and+Medicinal+Applications&doi=10.2147%2FDDDT.S49763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications</span></div><div class="casAuthors">Prachayasittikul Veda; Prachayasittikul Supaluk; Ruchirawat Somsak; Prachayasittikul Virapong</div><div class="citationInfo"><span class="NLM_cas:title">Drug design, development and therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1157-78</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Metal ions play an important role in biological processes and in metal homeostasis.  Metal imbalance is the leading cause for many neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. 8-Hydroxyquinoline (8HQ) is a small planar molecule with a lipophilic effect and a metal chelating ability.  As a result, 8HQ and its derivatives hold medicinal properties such as antineurodegenerative, anticancer, antioxidant, antimicrobial, anti-inflammatory, and antidiabetic activities.  Herein, diverse bioactivities of 8HQ and newly synthesized 8HQ-based compounds are discussed together with their mechanisms of actions and structure-activity relationships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSIgm-NVygKbTQLBVDQn4bCfW6udTcc2ea0TKCVEkX3ALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3hsFGjug%253D%253D&md5=f94aea2e89099f930db6b55bfeca418e</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S49763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S49763%26sid%3Dliteratum%253Aachs%26aulast%3DPrachayasittikul%26aufirst%3DV.%26aulast%3DPrachayasittikul%26aufirst%3DS.%26aulast%3DRuchirawat%26aufirst%3DS.%26aulast%3DPrachayasittikul%26aufirst%3DV.%26atitle%3D8-Hydroxyquinolines%253A%2520A%2520Review%2520of%2520Their%2520Metal%2520Chelating%2520Properties%2520and%2520Medicinal%2520Applications%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2013%26volume%3D7%26spage%3D1157%26epage%3D1178%26doi%3D10.2147%2FDDDT.S49763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Swart, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oelen, W. E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruins, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tepper, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Zeeuw, R. A.</span><span> </span><span class="NLM_article-title">Determination of the Dopamine D2 Agonist N-0923 and Its Major Metabolites in Perfused Rat Livers by HPLC-UV-Atmospheric Pressure Ionization Mass Spectrometry</span> <span class="citation_source-journal">J. Anal. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">71</span><span class="NLM_x">–</span> <span class="NLM_lpage">77</span><span class="refDoi"> DOI: 10.1093/jat/18.2.71</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1093%2Fjat%2F18.2.71" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=7911536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADyaK2cXis1Snur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1994&pages=71-77&author=P.+J.+Swartauthor=W.+E.+M.+Oelenauthor=A.+P.+Bruinsauthor=P.+G.+Tepperauthor=R.+A.+de+Zeeuw&title=Determination+of+the+Dopamine+D2+Agonist+N-0923+and+Its+Major+Metabolites+in+Perfused+Rat+Livers+by+HPLC-UV-Atmospheric+Pressure+Ionization+Mass+Spectrometry&doi=10.1093%2Fjat%2F18.2.71"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of the dopamine D2 agonist N-0923 and its major metabolites in perfused rat livers by HPLC-UV-atmospheric pressure ionization mass spectrometry</span></div><div class="casAuthors">Swart, P. J.; Oelen, W. E. M.; Bruins, A. P.; Tepper, P. G.; de Zeeuw, R. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Analytical Toxicology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">71-7</span>CODEN:
                <span class="NLM_cas:coden">JATOD3</span>;
        ISSN:<span class="NLM_cas:issn">0146-4760</span>.
    </div><div class="casAbstract">The metab. of the dopamine D2 agonist N-0923 (I) was investigated by an in vitro isolated liver perfusion.  Detg. the metabolic profile and identity of the different metabolites was achieved by using high-performance liq. chromatog. with UV detection, combined with atm. pressure ionization mass spectrometry.  Using this technique, no extensive sample cleanup is required, and the studies can be performed without radioactivity.  In addn. to previously obsd. metabolites, nine new metabolic products were identified.  All metabolites were exclusively excreted into the bile, except for the despropyl metabolite which was also detectable in the perfusate.  5-O-glucuronidation and N-depropylation followed by 5-O-glucuronidation are the most important metabolic routes.  N-dealkylation of the thienylethyl group followed by 5-O-glucuronidation and sulfation is a second major metabolic pathway.  Catechol formation of the despropyl metabolite with or without subsequent conjugation was not found.  Catechol formation of the desthienylethyl metabolite occurred, but only its glucuronide conjugates were found.  This study complements previous results of in vivo metabolic studies using the radiolabeled racemate N-0437, and it explains differences in bile excretion during isolated liver perfusions using N-0923 and radiolabeled N-0923.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4kyBKN-uXgrVg90H21EOLACvtfcHk0liuwKzDlJ_0JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1Snur4%253D&md5=28080e2120ab1e129dd35a1b4ea7afb3</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1093%2Fjat%2F18.2.71&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjat%252F18.2.71%26sid%3Dliteratum%253Aachs%26aulast%3DSwart%26aufirst%3DP.%2BJ.%26aulast%3DOelen%26aufirst%3DW.%2BE.%2BM.%26aulast%3DBruins%26aufirst%3DA.%2BP.%26aulast%3DTepper%26aufirst%3DP.%2BG.%26aulast%3Dde%2BZeeuw%26aufirst%3DR.%2BA.%26atitle%3DDetermination%2520of%2520the%2520Dopamine%2520D2%2520Agonist%2520N-0923%2520and%2520Its%2520Major%2520Metabolites%2520in%2520Perfused%2520Rat%2520Livers%2520by%2520HPLC-UV-Atmospheric%2520Pressure%2520Ionization%2520Mass%2520Spectrometry%26jtitle%3DJ.%2520Anal.%2520Toxicol.%26date%3D1994%26volume%3D18%26spage%3D71%26epage%3D77%26doi%3D10.1093%2Fjat%2F18.2.71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of in Vitro Half-Life Approach and Nonspecific Binding to Microsomes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1350</span><span class="NLM_x">–</span> <span class="NLM_lpage">1359</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10534321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=1350-1359&author=R.+S.+Obach&title=Prediction+of+Human+Clearance+of+Twenty-Nine+Drugs+from+Hepatic+Microsomal+Intrinsic+Clearance+Data%3A+An+Examination+of+in+Vitro+Half-Life+Approach+and+Nonspecific+Binding+to+Microsomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1350-1359</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Twenty-nine drugs of disparate structures and physicochem. properties were used in an examn. of the capability of human liver microsomal lability data ("in vitro T1/2" approach) to be useful in the prediction of human clearance.  Addnl., the potential importance of nonspecific binding to microsomes in the in vitro incubation milieu for the accurate prediction of human clearance was investigated.  The compds. examd. demonstrated a wide range of microsomal metabolic labilities with scaled intrinsic clearance values ranging from less than 0.5 mL/min/kg to 189 mL/min/kg.  Microsomal binding was detd. at microsomal protein concns. used in the lability incubations.  For the 29 compds. studied, unbound fractions in microsomes ranged from 0.11 to 1.0.  Generally, basic compds. demonstrated the greatest extent of binding and neutral and acidic compds. the least extent of binding.  In the projection of human clearance values, basic and neutral compds. were well predicted when all binding considerations (blood and microsome) were disregarded, however, including both binding considerations also yielded reasonable predictions.  Including only blood binding yielded very poor projections of human clearance for these two types of compds.  However, for acidic compds., disregarding all binding considerations yielded poor predictions of human clearance.  It was generally most difficult to accurately predict clearance for this class of compds.; however the accuracy was best when all binding considerations were included.  Overall, inclusion of both blood and microsome binding values gave the best agreement between in vivo clearance values and clearance values projected from in vitro intrinsic clearance data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWp2hUTOxyubVg90H21EOLACvtfcHk0liUJeA3DXixnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D&md5=7804cd4dfb131caac45aff9b7a1df901</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DPrediction%2520of%2520Human%2520Clearance%2520of%2520Twenty-Nine%2520Drugs%2520from%2520Hepatic%2520Microsomal%2520Intrinsic%2520Clearance%2520Data%253A%2520An%2520Examination%2520of%2520in%2520Vitro%2520Half-Life%2520Approach%2520and%2520Nonspecific%2520Binding%2520to%2520Microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1999%26volume%3D27%26spage%3D1350%26epage%3D1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Peters, S. A.</span><span> </span><span class="NLM_article-title">Appendix I</span>. In  <span class="citation_source-book">Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations: Principles, Methods, and Applications in the Pharmaceutical Industry</span>, <span class="NLM_edition">1st</span> ed.; <span class="NLM_publisher-name">John Wiley & Sons</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">421</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1002%2F9781118140291.app1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=407-421&author=S.+A.+Peters&title=Physiologically-Based+Pharmacokinetic+%28PBPK%29+Modeling+and+Simulations%3A+Principles%2C+Methods%2C+and+Applications+in+the+Pharmaceutical+Industry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1002%2F9781118140291.app1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118140291.app1%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DS.%2BA.%26atitle%3DAppendix%2520I%26btitle%3DPhysiologically-Based%2520Pharmacokinetic%2520%2528PBPK%2529%2520Modeling%2520and%2520Simulations%253A%2520Principles%252C%2520Methods%252C%2520and%2520Applications%2520in%2520the%2520Pharmaceutical%2520Industry%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%26date%3D2012%26spage%3D407%26epage%3D421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Recanatini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poluzzi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, F.</span><span> </span><span class="NLM_article-title">Qt Prolongation through hERG K+ Channel Blockade: Current Knowledge and Strategies for the Early Prediction During Drug Development</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">133</span><span class="NLM_x">–</span> <span class="NLM_lpage">166</span><span class="refDoi"> DOI: 10.1002/med.20019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1002%2Fmed.20019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=15389727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitlWhs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=133-166&author=M.+Recanatiniauthor=E.+Poluzziauthor=M.+Masettiauthor=A.+Cavalliauthor=F.+De+Ponti&title=Qt+Prolongation+through+hERG+K%2B+Channel+Blockade%3A+Current+Knowledge+and+Strategies+for+the+Early+Prediction+During+Drug+Development&doi=10.1002%2Fmed.20019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">QT prolongation through hERG K+ channel blockade: current knowledge and strategies for the early prediction during drug development</span></div><div class="casAuthors">Recanatini, Maurizio; Poluzzi, Elisabetta; Masetti, Matteo; Cavalli, Andrea; de Ponti, Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-166</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Prolongation of the QT interval of the ECG is a typical effect of Class III antiarrhythmic drugs, achieved through blockade of potassium channels.  In the past decade, evidence has accrued that several classes of drugs used for non-cardiovascular indications may prolong the QT interval with the same mechanism (namely, human ether-a-go-go-related gene (hERG) K+ channel blockade).  The great interest in QT prolongation is because of several reasons.  First, drug-induced QT prolongation increases the likelihood of a polymorphous ventricular arrhythmia (namely, torsades de pointes, TdP), which may cause syncope and degenerate into ventricular fibrillation and sudden death.  Second, the fact that several classes of drugs, such as antihistamines, fluoroquinolones, macrolides, and neuroleptics may cause the long QT syndrome (LQTS) raises the question whether this is a class effect (e.g., shared by all agents of a given pharmacol. class) or a specific effect of single agents within a class.  There is now consensus that, in most cases, only a few agents within a therapeutic class share the ability to significantly affect hERG K+ channels.  These compds. should be identified as early as possible during drug development.  Third, QT prolongation and interaction with hERG K+ channels have become surrogate markers of cardiotoxicity and have received increasing regulatory attention.  This review briefly outlines the mechanisms leading to QT prolongation and the different strategies that can be followed to predict this unwanted effect.  In particular, it will focus on the approaches recently proposed for the in silico screening of new compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO7B-6DBAFeLVg90H21EOLACvtfcHk0liUJeA3DXixnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitlWhs7Y%253D&md5=aa5aea37c667b4f35546259cc2593c6d</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1002%2Fmed.20019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20019%26sid%3Dliteratum%253Aachs%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DPoluzzi%26aufirst%3DE.%26aulast%3DMasetti%26aufirst%3DM.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DDe%2BPonti%26aufirst%3DF.%26atitle%3DQt%2520Prolongation%2520through%2520hERG%2520K%252B%2520Channel%2520Blockade%253A%2520Current%2520Knowledge%2520and%2520Strategies%2520for%2520the%2520Early%2520Prediction%2520During%2520Drug%2520Development%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2005%26volume%3D25%26spage%3D133%26epage%3D166%26doi%3D10.1002%2Fmed.20019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Raschi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceccarini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Recanatini, M.</span><span> </span><span class="NLM_article-title">Herg-Related Drug Toxicity and Models for Predicting hERG Liability and QT Prolongation</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1005</span><span class="NLM_x">–</span> <span class="NLM_lpage">1021</span><span class="refDoi"> DOI: 10.1517/17425250903055070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1517%2F17425250903055070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=19572824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVWhsLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=1005-1021&author=E.+Raschiauthor=L.+Ceccariniauthor=F.+De+Pontiauthor=M.+Recanatini&title=Herg-Related+Drug+Toxicity+and+Models+for+Predicting+hERG+Liability+and+QT+Prolongation&doi=10.1517%2F17425250903055070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">hERG-related drug toxicity and models for predicting hERG liability and QT prolongation</span></div><div class="casAuthors">Raschi, Emanuel; Ceccarini, Luisa; De Ponti, Fabrizio; Recanatini, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1005-1021</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: hERG K+ channels have been recognized as a primary antitarget in safety pharmacol.  Their blockade, caused by several drugs with different therapeutic indications, may lead to QT prolongation and, eventually, to potentially fatal arrhythmia, namely torsade de pointes.  Therefore, a no. of preclin. models have been developed to predict hERG liability early in the drug development process.  Objective: The aim of this review is to outline the present state of the art on drug-induced hERG blockade, providing insights on the predictive value of in vitro and in silico models for hERG liability.  Methods: On the basis of latest reports, high-throughput preclin. models have been discussed outlining advantages and limitations.  Conclusion: Although no single model has an abs. value, an integrated risk assessment is recommended to predict the pro-arrhythmic risk of a given drug.  This prediction requires expertise from different areas and should encompass emerging issues such as interference with hERG trafficking and QT shortening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCQa-hX-BiQ7Vg90H21EOLACvtfcHk0liUJeA3DXixnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVWhsLnK&md5=93e148db825611c7e086f75e50b8953c</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1517%2F17425250903055070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425250903055070%26sid%3Dliteratum%253Aachs%26aulast%3DRaschi%26aufirst%3DE.%26aulast%3DCeccarini%26aufirst%3DL.%26aulast%3DDe%2BPonti%26aufirst%3DF.%26aulast%3DRecanatini%26aufirst%3DM.%26atitle%3DHerg-Related%2520Drug%2520Toxicity%2520and%2520Models%2520for%2520Predicting%2520hERG%2520Liability%2520and%2520QT%2520Prolongation%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2009%26volume%3D5%26spage%3D1005%26epage%3D1021%26doi%3D10.1517%2F17425250903055070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Sanguinetti, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitcheson, J. S.</span><span> </span><span class="NLM_article-title">Predicting Drug–hERG Channel Interactions That Cause Acquired Long QT Syndrome</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span><span class="refDoi"> DOI: 10.1016/j.tips.2005.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1016%2Fj.tips.2005.01.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=119-124&author=M.+C.+Sanguinettiauthor=J.+S.+Mitcheson&title=Predicting+Drug%E2%80%93hERG+Channel+Interactions+That+Cause+Acquired+Long+QT+Syndrome&doi=10.1016%2Fj.tips.2005.01.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2005.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2005.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DSanguinetti%26aufirst%3DM.%2BC.%26aulast%3DMitcheson%26aufirst%3DJ.%2BS.%26atitle%3DPredicting%2520Drug%25E2%2580%2593hERG%2520Channel%2520Interactions%2520That%2520Cause%2520Acquired%2520Long%2520QT%2520Syndrome%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2005%26volume%3D26%26spage%3D119%26epage%3D124%26doi%3D10.1016%2Fj.tips.2005.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Poluzzi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raschi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moretti, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, F.</span><span> </span><span class="NLM_article-title">Drug-Induced Torsades De Pointes: Data Mining of the Public Version of the FDA Adverse Event Reporting System (AERS)</span> <span class="citation_source-journal">Pharmacoepidemiol. Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">512</span><span class="NLM_x">–</span> <span class="NLM_lpage">518</span><span class="refDoi"> DOI: 10.1002/pds.1746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1002%2Fpds.1746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=19358226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFCks7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=512-518&author=E.+Poluzziauthor=E.+Raschiauthor=U.+Morettiauthor=F.+De+Ponti&title=Drug-Induced+Torsades+De+Pointes%3A+Data+Mining+of+the+Public+Version+of+the+FDA+Adverse+Event+Reporting+System+%28AERS%29&doi=10.1002%2Fpds.1746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS)</span></div><div class="casAuthors">Poluzzi, Elisabetta; Raschi, Emanuel; Moretti, Ugo; De Ponti, Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacoepidemiology and Drug Safety</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">512-518</span>CODEN:
                <span class="NLM_cas:coden">PDSAEA</span>;
        ISSN:<span class="NLM_cas:issn">1053-8569</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">To investigate spontaneous reports of TdP present in the public version of the FDA Adverse Event Reporting System (AERS) in the light of what is already known on their TdP-liability.  Reports of TdP from Jan. 2004 through Dec. 2007 were retrieved from the public version of the AERS database.  All reports were selected from REACTION files and the relevant suspected and/or interacting drugs were identified from DRUG files.  Qual. anal. was performed by the case/non-case method.  Cases were represented by TdP reports, whereas non-cases were all reports of adverse drug reactions other than TdP.  Quant. anal. was assessed by calcg. the crude and adjusted reporting odds ratio (ROR), as a measure of disproportionality, with the 95% confidence interval.  Reports of TdP were 1665 over a 4-yr period, involving 376 active substances.  Thirty-five drugs with at least 10 reports were identified: amiodarone and methadone were assocd. with the highest no. of cases (113 and 83 resp.) and most of the other reports were ascribable to antibacterials, antidepressants and antipsychotics; remarkable differences in no. of cases and ROR were present among agents within each therapeutic class.  A disproportionate reporting was also obsd. for other compds. such as donepezil, famotidine and mitoxantrone.  Large spontaneous reporting databases represent an important source for signal detection of rare adverse drug reactions (ADR), such as TdP.  The no. of reports assocd. to donepezil, famotidine and mitoxantrone could be considered unexpected on the basis of current evidence and needs further investigations on their true TdP-liability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcqqV3h5uS37Vg90H21EOLACvtfcHk0ljX4Ks3xxhHYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFCks7k%253D&md5=c43280d022cc8bf6f24bde78fad69544</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fpds.1746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpds.1746%26sid%3Dliteratum%253Aachs%26aulast%3DPoluzzi%26aufirst%3DE.%26aulast%3DRaschi%26aufirst%3DE.%26aulast%3DMoretti%26aufirst%3DU.%26aulast%3DDe%2BPonti%26aufirst%3DF.%26atitle%3DDrug-Induced%2520Torsades%2520De%2520Pointes%253A%2520Data%2520Mining%2520of%2520the%2520Public%2520Version%2520of%2520the%2520FDA%2520Adverse%2520Event%2520Reporting%2520System%2520%2528AERS%2529%26jtitle%3DPharmacoepidemiol.%2520Drug%2520Saf.%26date%3D2009%26volume%3D18%26spage%3D512%26epage%3D518%26doi%3D10.1002%2Fpds.1746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Löber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tschammer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Recent Advances in the Search for D3- and D4-Selective Drugs: Probes, Models and Candidates</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">148</span><span class="NLM_x">–</span> <span class="NLM_lpage">157</span><span class="refDoi"> DOI: 10.1016/j.tips.2010.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1016%2Fj.tips.2010.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=21232805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A280%3ADC%252BC3M3ktVWnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=148-157&author=S.+L%C3%B6berauthor=H.+H%C3%BCbnerauthor=N.+Tschammerauthor=P.+Gmeiner&title=Recent+Advances+in+the+Search+for+D3-+and+D4-Selective+Drugs%3A+Probes%2C+Models+and+Candidates&doi=10.1016%2Fj.tips.2010.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the search for D3- and D4-selective drugs: probes, models and candidates</span></div><div class="casAuthors">Lober Stefan; Hubner Harald; Tschammer Nuska; Gmeiner Peter</div><div class="citationInfo"><span class="NLM_cas:title">Trends in pharmacological sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">148-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dopamine D(2)-like receptors (including D(2), D(3) and D(4)) belong to the 'rhodopsin-like' family of G protein-coupled receptors (GPCRs), which represent the largest group of targets for bioactive molecules.  Due to their high sequence similarity, the design of subtype-selective ligands requires rational and effective strategies.  The general formula of 1,4-disubstituted aromatic piperidines and piperazines (1,4-DAPs) was extracted from classical dopaminergic drugs.  The biological properties of this compound family are encoded by an aromatic head group that controls intrinsic activity, an amine moiety and a lipophilic appendage.  D(3)- and D(4)-selective molecular probes and drug candidates were generated from the general formula of 1,4-DAP.  Formal structural rearrangement led to investigational drugs beyond the 1,4-DAP structure.  The very recent publication of the X-ray crystal structure of D(3) should facilitate efficient discovery of unprecedented chemotypes.  However, the development of D(3)-selective agonists, functionally selective ligands and the exploitation of homo- and heteromers remain challenging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJYDidIFGFwMjl5L8hwNX0fW6udTcc2eYUic9EtF2gG7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3ktVWnsg%253D%253D&md5=9b688525eaa75c6d965b634617c16d70</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2010.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2010.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6ber%26aufirst%3DS.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DTschammer%26aufirst%3DN.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DRecent%2520Advances%2520in%2520the%2520Search%2520for%2520D3-%2520and%2520D4-Selective%2520Drugs%253A%2520Probes%252C%2520Models%2520and%2520Candidates%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2011%26volume%3D32%26spage%3D148%26epage%3D157%26doi%3D10.1016%2Fj.tips.2010.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Hiller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kling, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinemann, F. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Functionally Selective Dopamine D2/D3 Receptor Agonists Comprising an Enyne Moiety</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5130</span><span class="NLM_x">–</span> <span class="NLM_lpage">5141</span><span class="refDoi"> DOI: 10.1021/jm400520c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400520c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC3sXoslSqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5130-5141&author=C.+Hillerauthor=R.+C.+Klingauthor=F.+W.+Heinemannauthor=K.+Meyerauthor=H.+H%C3%BCbnerauthor=P.+Gmeiner&title=Functionally+Selective+Dopamine+D2%2FD3+Receptor+Agonists+Comprising+an+Enyne+Moiety&doi=10.1021%2Fjm400520c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Functionally Selective Dopamine D2/D3 Receptor Agonists Comprising an Enyne Moiety</span></div><div class="casAuthors">Hiller, Christine; Kling, Ralf C.; Heinemann, Frank W.; Meyer, Karsten; Huebner, Harald; Gmeiner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5130-5141</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonracemic ethynylcyclohexynylamines I and ent-I {R = 1,1'-biphenyl-4-yl, pyrazolo[1,5-a]pyridin-2-yl, pyrazolo[1,5-a]pyridin-3-yl, 4-[3-(1-butyl-1,2,3-triazol-4-yloxy)propoxy]-3-methoxyphenyl, benzo[b]thiophene-2-yl, ferrocenyl} were prepd. as dopamine receptor agonists with atypical catechol isosteres; their selectivities for dopamine receptors and for activating receptors through G-protein subunits Go and Gi and the metabolic stability of rac-I (R = 4-PhC6H4) were detd.  The ethynylcyclohexynylamines bound to D2-like receptors with high affinities.  Ent-I (R = pyrazolo[1,5-a]pyridin-2-yl) selectively activated D2slow-promoted Go activation over Gi coupling; the most significant functional bias obsd. was for ent-I {R = 4-[3-(1-butyl-1,2,3-triazol-4-yloxy)propoxy]-3-methoxyphenyl} which selectively activated Go over Gi coupling at D2long receptors.  Functional selectivity for β-arrestin recruitment over Gi activation was obsd. for I (R = 1,1'-biphenyl-4-yl) and ent-I (R = benzothiophene-2-yl), while ent-I (R = pyrazolo[1,5-a]pyridin-2-yl) preferred β-arrestin recruitment compared to Go coupling.  The structure of a nonracemic N-(ethynylcyclohexenyl)dinitrobenzamide was detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXn2SrS-IBCrVg90H21EOLACvtfcHk0ljX4Ks3xxhHYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXoslSqtr4%253D&md5=3855de949f505a83ed3aa561ca182e75</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm400520c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400520c%26sid%3Dliteratum%253Aachs%26aulast%3DHiller%26aufirst%3DC.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DHeinemann%26aufirst%3DF.%2BW.%26aulast%3DMeyer%26aufirst%3DK.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DFunctionally%2520Selective%2520Dopamine%2520D2%252FD3%2520Receptor%2520Agonists%2520Comprising%2520an%2520Enyne%2520Moiety%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5130%26epage%3D5141%26doi%3D10.1021%2Fjm400520c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Tschammer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elsner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehrlich, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuster, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kühhorn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whistler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Highly Potent 5-Aminotetrahydropyrazolopyridines: Enantioselective Dopamine D3 Receptor Binding, Functional Selectivity, and Analysis of Receptor-Ligand Interactions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2477</span><span class="NLM_x">–</span> <span class="NLM_lpage">2491</span><span class="refDoi"> DOI: 10.1021/jm101639t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101639t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2477-2491&author=N.+Tschammerauthor=J.+Elsnerauthor=A.+Goetzauthor=K.+Ehrlichauthor=S.+Schusterauthor=M.+Rubergauthor=J.+K%C3%BChhornauthor=D.+Thompsonauthor=J.+Whistlerauthor=H.+H%C3%BCbnerauthor=P.+Gmeiner&title=Highly+Potent+5-Aminotetrahydropyrazolopyridines%3A+Enantioselective+Dopamine+D3+Receptor+Binding%2C+Functional+Selectivity%2C+and+Analysis+of+Receptor-Ligand+Interactions&doi=10.1021%2Fjm101639t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm101639t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101639t%26sid%3Dliteratum%253Aachs%26aulast%3DTschammer%26aufirst%3DN.%26aulast%3DElsner%26aufirst%3DJ.%26aulast%3DGoetz%26aufirst%3DA.%26aulast%3DEhrlich%26aufirst%3DK.%26aulast%3DSchuster%26aufirst%3DS.%26aulast%3DRuberg%26aufirst%3DM.%26aulast%3DK%25C3%25BChhorn%26aufirst%3DJ.%26aulast%3DThompson%26aufirst%3DD.%26aulast%3DWhistler%26aufirst%3DJ.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DHighly%2520Potent%25205-Aminotetrahydropyrazolopyridines%253A%2520Enantioselective%2520Dopamine%2520D3%2520Receptor%2520Binding%252C%2520Functional%2520Selectivity%252C%2520and%2520Analysis%2520of%2520Receptor-Ligand%2520Interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2477%26epage%3D2491%26doi%3D10.1021%2Fjm101639t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Lowry, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosebrough, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farr, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randall, R. J.</span><span> </span><span class="NLM_article-title">Protein Measurement with the Folin Phenol Reagent</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1951</span><span class="NLM_x">, </span> <span class="NLM_volume">193</span><span class="NLM_x">, </span> <span class="NLM_fpage">265</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1016%2FS0021-9258%2819%2952451-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=14907713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADyaG38XhsVyrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=1951&pages=265-275&author=O.+H.+Lowryauthor=N.+J.+Rosebroughauthor=A.+L.+Farrauthor=R.+J.+Randall&title=Protein+Measurement+with+the+Folin+Phenol+Reagent"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Protein measurement with the Folin phenol reagent</span></div><div class="casAuthors">Lowry, Oliver H.; Rosebrough, Nira J.; Farr, A. Lewis; Randall, Rose J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1951</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">265-75</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">cf. C.A. 41, 1271h.  Proteins were detd. with the Folin phenol reagent after alk. Cu treatment.  The method is as sensitive as with Nessler reagent, yet requires no digestion.  It is 10-20 times more sensitive than detn. of the ultraviolet absorption at λ = 280 mμ and is more specific.  It is several fold more sensitive than the ninhydrin reaction and 100 times more sensitive than the biuret reaction.  Two major disadvantages are: the amt. of color varies with different proteins; the color is not strictly proportional to concn.  Few substances cause serious interference.  Uric acid, guanine, and xanthine react with Folin reagent.  The method is useful for following enzyme fractionation, detg. mixed tissue proteins, detn. of very small amts. of protein, or detg. highly dild. protein, or protein in colored solns. or in the presence of N-contg. material.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHNRKGd34F8LVg90H21EOLACvtfcHk0lizt2og-sZjqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG38XhsVyrsw%253D%253D&md5=19d36395fad7dd87661caa3d2b97640d</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2819%2952451-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252819%252952451-6%26sid%3Dliteratum%253Aachs%26aulast%3DLowry%26aufirst%3DO.%2BH.%26aulast%3DRosebrough%26aufirst%3DN.%2BJ.%26aulast%3DFarr%26aufirst%3DA.%2BL.%26aulast%3DRandall%26aufirst%3DR.%2BJ.%26atitle%3DProtein%2520Measurement%2520with%2520the%2520Folin%2520Phenol%2520Reagent%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1951%26volume%3D193%26spage%3D265%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haubmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Utz, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Conjugated Enynes as Nonaromatic Catechol Bioisosteres: Synthesis, Binding Experiments and Computational Studies of Novel Dopamine Receptor Agonists Recognizing Preferentially the D3 Subtype</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">756</span><span class="NLM_x">–</span> <span class="NLM_lpage">762</span><span class="refDoi"> DOI: 10.1021/jm991098z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm991098z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=756-762&author=H.+H%C3%BCbnerauthor=C.+Haubmannauthor=W.+Utzauthor=P.+Gmeiner&title=Conjugated+Enynes+as+Nonaromatic+Catechol+Bioisosteres%3A+Synthesis%2C+Binding+Experiments+and+Computational+Studies+of+Novel+Dopamine+Receptor+Agonists+Recognizing+Preferentially+the+D3+Subtype&doi=10.1021%2Fjm991098z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjm991098z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm991098z%26sid%3Dliteratum%253Aachs%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DHaubmann%26aufirst%3DC.%26aulast%3DUtz%26aufirst%3DW.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DConjugated%2520Enynes%2520as%2520Nonaromatic%2520Catechol%2520Bioisosteres%253A%2520Synthesis%252C%2520Binding%2520Experiments%2520and%2520Computational%2520Studies%2520of%2520Novel%2520Dopamine%2520Receptor%2520Agonists%2520Recognizing%2520Preferentially%2520the%2520D3%2520Subtype%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D756%26epage%3D762%26doi%3D10.1021%2Fjm991098z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Black, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leff, P.</span><span> </span><span class="NLM_article-title">Operational Models of Pharmacological Agonism</span> <span class="citation_source-journal">Proc. R. Soc. London, Ser. B</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">220</span><span class="NLM_x">, </span> <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">162</span><span class="refDoi"> DOI: 10.1098/rspb.1983.0093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1098%2Frspb.1983.0093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=6141562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADyaL2cXmtFaqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=220&publication_year=1983&pages=141-162&author=J.+W.+Blackauthor=P.+Leff&title=Operational+Models+of+Pharmacological+Agonism&doi=10.1098%2Frspb.1983.0093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Operational models of pharmacological agonism</span></div><div class="casAuthors">Black, J. W.; Leff, P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Royal Society of London, Series B:  Biological Sciences</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">220</span>
        (<span class="NLM_cas:issue">1219</span>),
    <span class="NLM_cas:pages">141-62</span>CODEN:
                <span class="NLM_cas:coden">PRLBA4</span>;
        ISSN:<span class="NLM_cas:issn">0080-4649</span>.
    </div><div class="casAbstract">A general, operational model is presented which explicitly describes pharmacol. agonism in terms of 3 parameters: an agonist-receptor dissocn. const., the total receptor concn. [Ro], and a parameter (KE) which defines the transduction of the agonist-receptor complex into pharmacol. effect.  The ratio RO/KE, the transducer ratio (τ), is a logical definition for the efficacy of an agonist in a system.  The model provides a chem. definition of intrinsic efficacy, making this parameter exptl. accessible in principle.  Alternate models are compared and contrasted with regard to their practical and conceptual utilities in exptl. pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonpXVldFQ_nbVg90H21EOLACvtfcHk0lizt2og-sZjqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXmtFaqtA%253D%253D&md5=a0421df9c56495d48d076010acf44b65</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1098%2Frspb.1983.0093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frspb.1983.0093%26sid%3Dliteratum%253Aachs%26aulast%3DBlack%26aufirst%3DJ.%2BW.%26aulast%3DLeff%26aufirst%3DP.%26atitle%3DOperational%2520Models%2520of%2520Pharmacological%2520Agonism%26jtitle%3DProc.%2520R.%2520Soc.%2520London%252C%2520Ser.%2520B%26date%3D1983%26volume%3D220%26spage%3D141%26epage%3D162%26doi%3D10.1098%2Frspb.1983.0093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Namkung, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radresa, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armando, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devost, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beautrait, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Gouill, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laporte, S. A.</span><span> </span><span class="NLM_article-title">Quantifying Biased Signaling in GPCRs Using BRET-Based Biosensors</span> <span class="citation_source-journal">Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span><span class="refDoi"> DOI: 10.1016/j.ymeth.2015.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1016%2Fj.ymeth.2015.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=25890247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslehsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2016&pages=5-10&author=Y.+Namkungauthor=O.+Radresaauthor=S.+Armandoauthor=D.+Devostauthor=A.+Beautraitauthor=C.+Le+Gouillauthor=S.+A.+Laporte&title=Quantifying+Biased+Signaling+in+GPCRs+Using+BRET-Based+Biosensors&doi=10.1016%2Fj.ymeth.2015.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Quantifying biased signaling in GPCRs using BRET-based biosensors</span></div><div class="casAuthors">Namkung, Yoon; Radresa, Olivier; Armando, Sylvain; Devost, Dominic; Beautrait, Alexandre; Le Gouill, Christian; Laporte, Stephane A.</div><div class="citationInfo"><span class="NLM_cas:title">Methods (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5-10</span>CODEN:
                <span class="NLM_cas:coden">MTHDE9</span>;
        ISSN:<span class="NLM_cas:issn">1046-2023</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">There has been a growing appreciation that G protein-coupled receptor (GPCR) functional selectivity (viz. biased signaling), in particular between G protein- and β-arrestin-dependent signaling, can be achieved with specific ligands, and that such directed signaling represents a promising avenue for improving drug efficacy and therapy.  Thus, for any given GPCRs it is important to define means to pharmacol. characterize and classify drugs for their propensity to bias signaling.  Here we describe an exptl. protocol and step-by-step approach to assess functional selectivity between Gαq and β-arrestin-dependent responses using the prototypical angiotensin II (AngII) type 1 receptor (AT1R) expressed in HEK 293 cells.  The protocol describes the expression of Bioluminescence Resonance Energy Transfer (BRET) sensors for either Gαq or β-arrestin with AT1R, and the use of the operational model of pharmacol. agonism to quantify ligand bias.  Such methods are equally applicable to other GPCRs and their downstream signaling effectors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoisQm2sSQfUbVg90H21EOLACvtfcHk0lizt2og-sZjqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslehsLo%253D&md5=3734d70788ffaa1faeb348d608d2c126</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.ymeth.2015.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymeth.2015.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DNamkung%26aufirst%3DY.%26aulast%3DRadresa%26aufirst%3DO.%26aulast%3DArmando%26aufirst%3DS.%26aulast%3DDevost%26aufirst%3DD.%26aulast%3DBeautrait%26aufirst%3DA.%26aulast%3DLe%2BGouill%26aufirst%3DC.%26aulast%3DLaporte%26aufirst%3DS.%2BA.%26atitle%3DQuantifying%2520Biased%2520Signaling%2520in%2520GPCRs%2520Using%2520BRET-Based%2520Biosensors%26jtitle%3DMethods%26date%3D2016%26volume%3D92%26spage%3D5%26epage%3D10%26doi%3D10.1016%2Fj.ymeth.2015.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">van der Westhuizen, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breton, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouvier, M.</span><span> </span><span class="NLM_article-title">Quantification of Ligand Bias for Clinically Relevant B2-Adrenergic Receptor Ligands: Implications for Drug Taxonomy</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">492</span><span class="NLM_x">–</span> <span class="NLM_lpage">509</span><span class="refDoi"> DOI: 10.1124/mol.113.088880</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1124%2Fmol.113.088880" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2014&pages=492-509&author=E.+T.+van+der+Westhuizenauthor=B.+Bretonauthor=A.+Christopoulosauthor=M.+Bouvier&title=Quantification+of+Ligand+Bias+for+Clinically+Relevant+B2-Adrenergic+Receptor+Ligands%3A+Implications+for+Drug+Taxonomy&doi=10.1124%2Fmol.113.088880"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1124%2Fmol.113.088880&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.113.088880%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BWesthuizen%26aufirst%3DE.%2BT.%26aulast%3DBreton%26aufirst%3DB.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DBouvier%26aufirst%3DM.%26atitle%3DQuantification%2520of%2520Ligand%2520Bias%2520for%2520Clinically%2520Relevant%2520B2-Adrenergic%2520Receptor%2520Ligands%253A%2520Implications%2520for%2520Drug%2520Taxonomy%26jtitle%3DMol.%2520Pharmacol.%26date%3D2014%26volume%3D85%26spage%3D492%26epage%3D509%26doi%3D10.1124%2Fmol.113.088880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Manglik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aryal, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCorvy, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dengler, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corder, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kling, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernat, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sassano, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giguère, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Löber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherrer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span> </span><span class="NLM_article-title">Structure-Based Discovery of Opioid Analgesics with Reduced Side Effects</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">537</span><span class="NLM_x">, </span> <span class="NLM_fpage">185</span><span class="NLM_x">–</span> <span class="NLM_lpage">190</span><span class="refDoi"> DOI: 10.1038/nature19112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=10.1038%2Fnature19112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=27533032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlKmsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=537&publication_year=2016&pages=185-190&author=A.+Manglikauthor=H.+Linauthor=D.+K.+Aryalauthor=J.+D.+McCorvyauthor=D.+Denglerauthor=G.+Corderauthor=A.+Levitauthor=R.+C.+Klingauthor=V.+Bernatauthor=H.+H%C3%BCbnerauthor=X.-P.+Huangauthor=M.+F.+Sassanoauthor=P.+M.+Gigu%C3%A8reauthor=S.+L%C3%B6berauthor=D.+Duanauthor=G.+Scherrerauthor=B.+K.+Kobilkaauthor=P.+Gmeinerauthor=B.+L.+Rothauthor=B.+K.+Shoichet&title=Structure-Based+Discovery+of+Opioid+Analgesics+with+Reduced+Side+Effects&doi=10.1038%2Fnature19112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based discovery of opioid analgesics with reduced side effects</span></div><div class="casAuthors">Manglik, Aashish; Lin, Henry; Aryal, Dipendra K.; McCorvy, John D.; Dengler, Daniela; Corder, Gregory; Levit, Anat; Kling, Ralf C.; Bernat, Viachaslau; Hubner, Harald; Huang, Xi-Ping; Sassano, Maria F.; Giguere, Patrick M.; Lober, Stefan; Da Duan; Scherrer, Gregory; Kobilka, Brian K.; Gmeiner, Peter; Roth, Bryan L.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">537</span>
        (<span class="NLM_cas:issue">7619</span>),
    <span class="NLM_cas:pages">185-190</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Morphine is an alkaloid from the opium poppy used to treat pain.  The potentially lethal side effects of morphine and related opioids-which include fatal respiratory depression-are thought to be mediated by μ-opioid-receptor (μOR) signalling through the β-arrestin pathway or by actions at other receptors.  Conversely, G-protein μOR signalling is thought to confer analgesia.  Here we computationally dock over 3 million mols. against the μOR structure and identify new scaffolds unrelated to known opioids.  Structure-based optimization yields PZM21-a potent Gi activator with exceptional selectivity for μOR and minimal β-arrestin-2 recruitment.  Unlike morphine, PZM21 is more efficacious for the affective component of analgesia vs. the reflexive component and is devoid of both respiratory depression and morphine-like reinforcing activity in mice at equi-analgesic doses.  PZM21 thus serves as both a probe to disentangle μOR signalling and a therapeutic lead that is devoid of many of the side effects of current opioids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiCff2w3U8iLVg90H21EOLACvtfcHk0lhkR1VG-DkrTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlKmsbvI&md5=b8bb2d8575dadf4a6dc74d94c26d2c1a</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fnature19112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19112%26sid%3Dliteratum%253Aachs%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DAryal%26aufirst%3DD.%2BK.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DDengler%26aufirst%3DD.%26aulast%3DCorder%26aufirst%3DG.%26aulast%3DLevit%26aufirst%3DA.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DBernat%26aufirst%3DV.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DGigu%25C3%25A8re%26aufirst%3DP.%2BM.%26aulast%3DL%25C3%25B6ber%26aufirst%3DS.%26aulast%3DDuan%26aufirst%3DD.%26aulast%3DScherrer%26aufirst%3DG.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DGmeiner%26aufirst%3DP.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DStructure-Based%2520Discovery%2520of%2520Opioid%2520Analgesics%2520with%2520Reduced%2520Side%2520Effects%26jtitle%3DNature%26date%3D2016%26volume%3D537%26spage%3D185%26epage%3D190%26doi%3D10.1038%2Fnature19112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i76"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00363">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_26858"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00363">10.1021/acs.jmedchem.7b00363</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Supplementary figures, data from functional assays, <sup>1</sup>H and <sup>13</sup>C NMR spectra (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00363/suppl_file/jm7b00363_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00363/suppl_file/jm7b00363_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00363/suppl_file/jm7b00363_si_001.pdf">jm7b00363_si_001.pdf (2.92 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00363/suppl_file/jm7b00363_si_002.csv">jm7b00363_si_002.csv (1.42 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00363&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-11%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00363%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00363" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66798a32dd0dd1fb","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
